CA2948488A1

CA2948488A1 - Expansion of definitive endoderm lineage cells

Info

Publication number: CA2948488A1
Application number: CA2948488A
Authority: CA
Inventors: Alireza Rezania
Original assignee: Janssen Biotech Inc
Current assignee: Janssen Biotech Inc
Priority date: 2008-04-24
Filing date: 2009-04-22
Publication date: 2009-10-29
Also published as: EP2669366A3; EP2669366B1; EP3327114A1; US7939322B2; CA2722619C; PL2283113T3; EP2669366A2; BRPI0911599A2; ES2663421T3; EP2283113B1; RU2010147817A; KR20100134127A; KR101690773B1; KR101832902B1; ZA201008391B; KR102057056B1; AU2009239442A1; CN102083965B; CA2722619A1; WO2009132063A2

Abstract

The present invention is directed to pluripotent cells that can be readily expanded in culture on tissue culture substrate that is not pre-treated with protein or an extracellular matrix, and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent cell line from human embryonic stem cells.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DENIANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

PLURIPOTENT CELLS
This patent application is a divisional application of Canadian patent application 2,722,619 filed April 22, 2009 FIELD OF THE INVENTION
[0001] The present invention is directed to pluripotent stem cells that can be readily expanded in culture on tissue culture polystyrene and do not require a feeder cell line. The present invention also provides methods to derive the pluripotent stem cell line from human embryonic stem cells.
BACKGROUND

[0002] Advances in cell-replacement therapy for Type I diabetes mellitus and a shortage of transplantable islets of Langerhans have focused interest on developing sources of insulin-producing cells, or 0 cells, appropriate for engraftment. One approach is the generation of functional p cells from pluripotent stem cells, such as, for example, embryonic stem cells.

[0003] In vertebrate embryonic development, a pluripotent cell gives rise to a group of cells comprising three germ layers (ectoderm, mesoderm, and endoderm) in a process known as gastrulation. Tissues such as, for example, thyroid, thymus, pancreas, gut, and liver, will develop from the endoderm, via an intermediate stage. The intermediate stage in this process is the formation of definitive endoderm. Definitive endoderm cells express a number of markers, such as, HNF-3 beta, GATA-4, Mix11, CXCR4 and SOX-17.

[0004] Formation of the pancreas arises from the differentiation of definitive endoderm into pancreatic endoderm. Cells of the pancreatic endoderm express the pancreatic-duodenal homeobox gene, PDX-1. In the absence of PDX-1, the pancreas fails to develop beyond the formation of ventral and dorsal buds. Thus, PDX-1 expression marks a critical step in pancreatic organogenesis. The mature pancreas contains, among other cell types, exocrine tissue and endocrine tissue. Exocrine and endocrine tissues arise from the differentiation of pancreatic endoderm.

[0005] Cells bearing the features of islet cells have reportedly been derived from embryonic cells of the mouse. For example, Lumelsky etal. (Science 292:1389, 2001) report differentiation of mouse embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Soria et al. (Diabetes 49:157, 2000) report that insulin-secreting cells derived from mouse embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice.

[0006] In one example, Hon i et al. (PNAS 99: 16105, 2002) disclose that treatment of mouse embryonic stem cells with inhibitors of phosphoinositide 3-kinase (LY294002) produced cells that resembled 13 cells.

[0007] In another example, Blyszczuk et al. (PNAS 100:998, 2003) reports the generation of insulin-producing cells from mouse embryonic stem cells constitutively expressing Pax4.

[0008] Micallef et al. reports that retinoic acid can regulate the commitment of embryonic stem cells to form PDX-1 positive pancreatic endoderm. Retinoic acid is most effective at inducing PDX-1 expression when added to cultures at day 4 of embryonic stem cell differentiation during a period corresponding to the end of gastrulation in the embryo (Diabetes 54:301, 2005).

[0009] Miyazaki et al. reports a mouse embryonic stem cell line over-expressing PDX-1.
Their results show that exogenous PDX-1 expression clearly enhanced the expression of insulin, somatostatin, glucokinase, neurogenin3, P48, Pax6, and HNF6 genes in the resulting differentiated cells (Diabetes 53: 1030, 2004).

[0010] Skoudy et al. reports that activin-A (a member of the TGFI3 superfamily) upregulates the expression of exocrine pancreatic genes (p48 and amylase) and endocrine genes (PDX-1, insulin, and glucagon) in mouse embryonic stem cells. The maximal effect was observed using 1nM activin-A. They also observed that the expression level of insulin and PDX-1 mRNA was not affected by retinoic acid; however, 3nM FGF-7 treatment resulted in an increased level of the transcript for PDX-1 (Biochem.
J. 379:
749, 2004).

[0011] Shiraki et al. studied the effects of growth factors that specifically enhance differentiation of embryonic stem cells into PDX-1 positive cells. They observed that TG932 reproducibly yielded a higher proportion of PDX-1 positive cells (Genes Cells.
2005 Jun; 10(6): 503-16.).

[0012] Gordon et al. demonstrated the induction of brachyury+/HNF-3 beta+
endoderm cells from mouse embryonic stem cells in the absence of serum and in the presence of activin along with an inhibitor of Wnt signaling (US2006/0003446A1).

[0013] Gordon et al. (PNAS, Vol 103, page 16806, 2006) states "Wnt and TGF-beta/nodal/
activin signaling simultaneously were required for the generation of theanterior primitive streak".

[0014] However, the mouse model of embryonic stem cell development may not exactly mimic the developmental program in higher mammals, such as, for example, humans.

[0015] Thomson et al. isolated embryonic stem cells from human blastocysts (Science 282:114, 1998). Concurrently, Gearhart and coworkers derived human embryonic germ (hEG) cell lines from fetal gonadal tissue (Shamblott et al., Proc. Natl.
Acad. Sci.
USA 95:13726, 1998). Unlike mouse embryonic stem cells, which can be prevented from differentiating simply by culturing with Leukemia Inhibitory Factor (LIF), human embryonic stem cells must be maintained under very special conditions (U.S.
Pat. No.
6,200,806; WO 99/20741; WO 01/51616).

[0016] D'Amour et al. describes the production of enriched cultures of human embryonic stem cell-derived definitive endoderm in the presence of a high concentration of activin and low serum (D'Amour KA et al. 2005). Transplanting these cells under the kidney capsule of mice resulted in differentiation into more mature cells with characteristics of some endodermal organs. Human embryonic stem cell-derived definitive endoderm cells can be further differentiated into PDX-1 positive cells after addition of FGF-10 (US 2005/0266554A1).

[0017] D'Amour et al. (Nature Biotechnology - 24, 1392 - 1401 (2006)) states "We have developed a differentiation process that converts human embryonic stem (hES) cells to endocrine cells capable of synthesizing the pancreatic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin. This process mimics in vivo pancreatic organogenesis by directing cells through stages resembling definitive endoderm, gut-tube endoderm, pancreatic endoderm and endocrine precursor en route to cells that express endocrine hormones".

[0018] In another example, Fisk eta!, reports a system for producing pancreatic islet cells from human embryonic stem cells (US2006/0040387A1). In this case, the differentiation pathway was divided into three stages. Human embryonic stem cells were first differentiated to endoderm using a combination of n-butyrate and activin-A.
The cells were then cultured with TGFB antagonists such as Noggin in combination with EGF or betacellulin to generate PDX-1 positive cells. The terminal differentiation was induced by nicotinamide.

[0019] In one example, Benvenistry et al. states: "We conclude that over-expression of PDX-1 enhanced expression of pancreatic enriched genes, induction of insulin expression may require additional signals that are only present in vivo" (Benvenistry et al, Stem Cells 2006; 24:1923-1930).

[0020] Current methods to culture human embryonic stem cells requires the use of either extracellular matrix proteins or a fibroblast feeder layer, or the addition of exogenous growth factors, such as, for example, bFGF.

[0021] In one example, Cheon eta! (BioReprod DOI:
10.1095/biolreprod.105.046870, October 19, 2005) disclose a feeder-free, serum-free culture system in which embryonic stem cells are maintained in unconditioned serum replacement (SR) medium supplemented with different growth factors capable of triggering embryonic stem cell self-renewal.

[0022] In another example, Levenstein et al (Stem Cells 24: 568-574, 2006) disclose methods for the long-term culture of human embryonic stem cells in the absence of fibroblasts or conditioned medium, using media supplemented with bFGF.

[0023] In another example, US20050148070 discloses a method of culturing human embryonic stem cells in defined media without serum and without fibroblast feeder cells, the method comprising: culturing the stem cells in a culture medium containing albumin, amino acids, vitamins, minerals, at least one transferrin or transferrin substitute, at least one insulin or insulin substitute, the culture medium essentially free of mammalian fetal serum and containing at least about 100 ng/ml of a fibroblast growth factor capable of activating a fibroblast growth factor signaling receptor, wherein the growth factor is supplied from a source other than just a fibroblast feeder layer, the medium supported the proliferation of stem cells in an undifferentiated state without feeder cells or conditioned medium.

[0024] In another example, 1JS20050233446 discloses a defined media useful in culturing stem cells, including undifferentiated primate primordial stem cells. In solution, the media is substantially isotonic as compared to the stem cells being cultured.
In a given culture, the particular medium comprises a base medium and an amount of each of bFGF, insulin, and ascorbic acid necessary to support substantially undifferentiated growth of the primordial stem cells.

[0025] In another example, US6800480 states "In one embodiment, a cell culture medium for growing primate-derived primordial stem cells in a substantially undifferentiated state is provided which includes a low osmotic pressure, low endotoxin basic medium that is effective to support the growth of primate-derived primordial stem cells. The basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate selected from the group consisting of feeder cells and an extracellular matrix component derived from feeder cells.
The medium further includes nonessential amino acids, an anti-oxidant, and a first growth factor selected from the group consisting of nucleosides and a pyruvate salt."

[0026] In another example, US20050244962 states: "In one aspect the invention provides a method of culturing primate embryonic stem cells. One cultures the stem cells in a culture essentially free of mammalian fetal serum (preferably also essentially free of any animal serum) and in the presence of fibroblast growth factor that is supplied from a source other than just a fibroblast feeder layer. In a preferred form, the fibroblast feeder layer, previously required to sustain a stem cell culture, is rendered unnecessary by the addition of sufficient fibroblast growth factor."

[0027] In a further example, W02005065354 discloses a defined, isotonic culture medium that is essentially feeder-free and serum-free, comprising: a. a basal medium; b.
an amount of bFGF sufficient to support growth of substantially undifferentiated mammalian stem cells; c. an amount of insulin sufficient to support growth of substantially undifferentiated mammalian stem cells; and d. an amount of ascorbic acid sufficient to support growth of substantially undifferentiated mammalian stem cells.

[0028] In another example, W02005086845 discloses a method for maintenance of an undifferentiated stem cell, said method comprising exposing a stem cell to a member of the transforming growth factor-beta (TGF[3) family of proteins, a member of the fibroblast growth factor (FGF) family of proteins, or nicotinamide (NIC) in an amount sufficient to maintain the cell in an undifferentiated state for a sufficient amount of time to achieve a desired result.

[0029] Additionally, formation of pancreatic endocrine cells, pancreatic hormone expressing cells, or pancreatic hormone secreting cells from human embryonic cells may require genetic manipulation of the human embryonic stem cells. Transfection of human embryonic stem cells using traditional techniques, such as, for example, lipofectamine or electroporation is inefficient

[0030] W02007027157 discloses a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew.
Preferably, the method selects against somatic cells based on their inability to self renew.
Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells.
Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line.

[0031] Therefore, there still remains a significant need to develop conditions for establishing pluripotent stem cell lines that can be expanded to address the current clinical needs, while retaining the potential to differentiate into pancreatic endocrine cells, pancreatic hormone expressing cells, or pancreatic hormone secreting cells.

SUMMARY

[0032] The present disclosure provides a cell population with characteristics of human embryonic stem cells, that can be readily expanded in culture, in low serum, that requires no feeder cell line or a coating of complex matrix proteins, can be passaged in single cell suspension, can be transfected with a very high efficiency, and cultured under hypoxic conditions. This combination of unique attributes separates the cells described from the prior art.

[0033] In one embodiment, a method for deriving a population of cells comprising cells expressing pluripotency markers, comprises the steps of:
a. Obtaining cells, and b. Culturing the cells under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix prior to culturing the cells.

[0034] The cells may be human embryonic stem cells, or they may be cells expressing markers characteristic of the definitive endoderm lineage. The human embryonic stem cells may be cultured in normoxic conditions prior to culturing the cells on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
Alternatively, the human embryonic stem cells may be cultured in hypoxic conditions.

[0035] The human embryonic stem cells may be cultured in normoxic conditions prior to culturing the cells on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, and treated with a Rho kinase inhibitor.
Alternatively, the human embryonic stem cells may be cultured in hypoxic conditions, and treated with a Rho kinase inhibitor.

[0036] The cells expressing markers characteristic of the definitive endoderm lineage may be cultured in normoxic conditions prior to culturing the cells on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
Alternatively, the cells expressing markers characteristic of the definitive endoderm lineage may be cultured in hypoxic conditions.

[0037] In one embodiment, there is disclosed a method for deriving a population of cells comprising cells expressing pluripotency markers, comprising the steps of:
a. Culturing human embryonic stem cells, b. Differentiating the human embryonic stem cells into cells expressing markers characteristic of definitive endoderm cells, and c. Removing the cells, and subsequently culturing them under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix prior to culturing the cells.

[0038] The cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, activin-A, and a Wnt ligand. Alternatively, the cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pretreated with a protein or an extracellular matrix, in medium containing serum, activin-A, a Wnt ligand, and IGF-1.

[0039] The cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, a Rho kinase inhibitor, activin-A, and a Wnt ligand. Alternatively, the cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pretreated with a protein or an extracellular matrix, in medium containing serum, a Rho kinase inhibitor, activin-A, a Wnt ligand, and IGF-1.

[0040] In one embodiment, there is disclosed a method for deriving a population of cells comprising cells expressing pluripotency markers, comprising the steps of:
a. Culturing human embryonic stem cells, and b. Removing the cells, and subsequently culturing them under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.

[0041] The cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, activin-A, and a Wnt ligand. Alternatively, the cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pretreated with a protein or an extracellular matrix, in medium containing serum, activin-A, a Wnt ligand, and IGF-1.

[0042] The cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, a Rho kinase inhibitor, activin-A, and a Wnt ligand. Alternatively, the cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pretreated with a protein or an extracellular matrix, in medium containing serum, a Rho kinase inhibitor, activin-A, a Wnt ligand, and IGF-1.

[0043] The cells expressing pluripotency markers derived by the methods of the present disclosure are capable of expansion in culture under hypoxic conditions, on tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
In one embodiment, there is disclosed a method to expand cells expressing markers characteristic of the definitive endoderm lineage, comprising the steps of culturing the cells under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix. In one embodiment, the cells expressing markers characteristic of the definitive endoderm lineage are derived from pluripotent cells formed by the methods of the present invention.

[0044] The cells may be cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, activin-A, a Wnt ligand, and a GSK-3B inhibitor.
BRIEF DESCRIPTION OF THE FIGURES

[0045] Figure 1 shows the expression of CXCR4 (CD 184, Y-axis) and CD9 (X-axis) in cells from the human embryonic stem cell line H9 at passage 54 that have been differentiated into definitive endoderm following treatment with low serum +Activin-A + WNT-for 4 days.

[0046] Figure 2 shows the real-time PCR analysis of cells from the human embryonic stem cell line H9 at passage 54 at day 4 and 6 of the definitive endoderm differentiation protocol outlined in Example 5. Panel a) depicts expression of AFP, Bry, CXCR4, GSC, and SOX-7. Panel b) depicts the expression of SOX-17, GATA-4, and HNF-3 beta.
[0048] Figure 3 shows the isolation protocol used to derive EXPRES cells from embryonic stem cells according to the methods of the present invention.
[0049] Figure 4 shows the morphology of expanded EXPRES cells at PO, at day 11, that were cultured in 2% FBS + DMEM-F12 + 100 ng/ml of Activin-A (Panel a) or 2% FBS +
DMEM-F12 + 100 ng/ml of Activin-A + 20 ng/ml of WNT-3A (Panel b). Panel c shows the morphology of the EXPRES cells at passage 3.
[0050] Figure 5 shows the real-time PCR analysis of expanded EXPRES cells cultured in 2-5% FBS + DMEM-F12 + 100 ng/ml of Activin-A + 20 ng/ml of WNT-3A for three passages. Panel a) depicts expression of AFP, Bry, CXCR4, GSC, and SOX-7.
Panel b) depicts the expression of SOX-17, GATA-4, and HNF-3 beta.
[0051] Figure 6 shows the effect of the addition of Wnt-3A on gene expression in EXPRES
cells. Panel a) depicts real-time PCR expression of SOX-17, GATA-4, and HNF-3 beta. Panel b) depicts real-time PCR expression of AFP, Bry, CXCR4, GSC, and SOX-7.
[0052] Figure 7 shows the effect of IGF-1, Wnt-3A and activin-A on gene expression in EXPRES cells. Panel a) depicts real-time PCR expression of SOX-17, GATA-4, HNF-3 beta, Bry, CXCR4, and GSC. Panel b) depicts real-time PCR expression of and SOX-7 and AFP. Panel c) depicts real-time PCR expression of OCT-4.
[0053] Figure 8 shows the morphology of expanded EXPRES cells derived from the human embryonic stem cell line H9 at passage 54, cultured in a) 2% FBS +DMEM-F12 +

ng/ml of AA + 20 ng/ml of WNT-3A, b) 2% FBS + DMEMF12 + 100 ng/ml of AA, c) 2% FBS + DMEM-F12 + 50 ng/ml of IGF-I.
[0054] Figure 9 shows the expansion potential of EXPRES 01 and 02 cells cultured on tissue culture polystyrene under hypoxic conditions. EXPRES 01 was cultured in 2% FBS
+
DM-F12 + 100 ng/ml of AA + 20 ng/ml of WNT-3A + 50 ng/ml of IGF-I and EXPRES
02 cells were cultured in 2% FBS + DM-F12 + 100 ng/ml of AA +20 ng/ml of WNT-3A.

[0055] Figure 10 shows the morphology of EXPRES cells derived from single cell suspension of undifferentiated ES cells on TCPS (tissue culture polystyrene) in DM-F12 +
2% FBS
+ 100 ng/ml AA + 20 ng/ml WNT3A + 50 ng/ml of IGF-I.
[0056] Figure 11 shows the protein expression as determined by FACS in EXPRES 01 cells at passage 24 cells. Panel a) shows the expression levels of E-cadherin, panel b) shows the expression levels of CXCR4, panel c) shows the expression levels of CD9, panel d) shows the expression levels of CDI17, panel e) shows the expression levels of CD30, panel 0 shows the expression levels of L1F receptor, panel g) shows the expression levels of TRA 1-60, panel h) shows the expression levels of TRA 1-81, panel i) shows the expression levels of SSEA-1, panel j) shows the expression levels of SSEA-3, panel k) shows the expression levels of SSEA-4, and Panel 1) shows the expression levels of CD56.
[0057] Figure 12 shows the protein expression as determined by FACS in EXPRES 02 at passage 21 cells. Panel a) shows the expression levels of E-cadherin, panel b) shows the expression levels of CXCR4, panel c) shows the expression levels of CD9, panel d) shows the expression levels of CD117, panel e) shows the expression levels of CD30, panel f) shows the expression levels of LIF receptor, panel g) shows the expression levels of TRA 1-60, panel h) shows the expression levels of TRA 1-81, panel i) shows the expression levels of S SEA-1, panel j) shows the expression levels of SSEA-3, panel k) shows the expression levels of SSEA-4, and panel 1) shows the expression levels of CD56.
[0058] Figure 13 shows immuno fluorescent images of EXPRES 01 at passage 10 cultured in 2% FBS + DMEM-F12 + 100 ng/ml of AA + 20 ng/ml of WNT-3A + 50 ng/ml of IGF-I. Panel a) DAPI image for panel b, panel b) Nanog, panel c) DAPI and Oct-4 co-staining, panel d) DAPI image for panel e, panel e) SOX-2, and panel f) DAPI
and HNF-3 beta co-staining.
[0059] Figure 14 shows immuno fluorescent images of EXPRES 02 at passage 9 cultured in 2% FBS + DMEM-F12 + 100 ng/ml of AA +20 ng/ml of WNT-3A. Panel a) DAPI
image for panel b, panel b) HNf3B, panel c) DAPI image for panel d, panel d) OCT-4, panel e) DAPI image for panel f, panel 1) SOX-2, panel g) DAPI image for panel h, panel h) NANOG.

[0060] Figure 15 shows gene expression as determined by real-time PCR for cells, EXPRES 02 cells, EB derived from H9 cells, SA002 cultured on MATRIGELTm in MEF-CM, and undifferentiated H9 cells cultured on MATRIGEL in MEFCM. All the expression levels are normalized to undifferentiated H9 cells. Panel a) shows SOX-1 expression, panel b) shows FOXD3, MY0D1, POU5F1, and ZFP42 expression, panel c) shows ABCG2, Connexin 43, Connexin 45, and cytokeratin 15 expression, panel d) shows nestin, SOX-2, UTF1, and vimentin, panel e) shows GATA-2, Brachyury, TERT, and tubulin-beta III expression, panel 0 shows CFC1, and GATA-expression, Panel g) shows AFP and FOXA2 expression, and Panel h) shows IPF1A
and MSX1 expression.
[0061] Figure 16 shows the expression, as determined by FACS of CXCR4 (Y-axis) and CD9 (x-axis) in a) EXPRES 01 cells passage 5 cells cultured on tissue culture polystyrene in growth media and then switched to DMEM-F12 + 0.5% FBS + 100 ng/ml of activin-A

and 20 ng/ml of WNT3A for 2 days followed by additional 2 days in DMEM-F12 +
2%
FBS + 100 ng/ml of activin-A, b) EXPRES 02 cells passage 4 cells cultured on tissue culture polystyrene in growth media and then switched to DMEM-F12 + 0.5% FBS +

100 ng/ml of activin-A and 20 ng/ml of WNT3A for 2 days followed by additional days in DMEM-F12 + 2% FBS + 100 ng/ml of activin-A.
[0062] Figure 17 shows gene expression as determined by real-time PCR in a) cells and b) EXPRES 02 cells treated with low serum plus AA + WNT3a.
[0063] Figure 18 shows immuno fluorescent images of EXPRES 01 cells at passage 5 cultured in 2% FBS + DMEM-F12 + 100 ng/ml of AA + 20 ng/ml of WNT-3A + 50 ng/ml of IGF-I and then switched to DMEM-F12 + 0.5% FBS + 100 ng/ml of activin-A and 20 ng/ml of WNT3A for 2 days, followed by additional 2 days in DMEM-F12 + 2% FBS
+ 100 ng/ml of activin-A. Panel a) DAPI image for panel b, panel b) GATA-4, panel c) DAPI image for panel d, panel d) SOX-17, panel e) DAPI image for panel f, panel 0 I-INF-3 beta, panel g) DAPI image for panel h, and panel h) OCT-4.
[0064] Figure 19 shows immuno fluorescent images of EXPRES 02 cells at passage 4 cultured in 2% FBS + DMEM-F12 + 100 ng/ml of AA + 20 ng/ml of WNT-3A and then switched to DMEM-F12 + 0.5% FBS + 100 ng/ml of activin-A and 20 ng/ml of WNT3A for 2 days followed by additional 2 days in DMEM-F12 + 2% FBS + 100 ng/ml of activin-A. Panel a) DAPI image for panel b, panel b) GATA-4, panel c) DAPI
image for panel d, panel d) SOX-17, panel e) DAPI image for panel f, panel f) beta, panel g) DAPI image for panel h, and panel h) OCT-4.
[0065] Figure 20 shows protein expression as determined by FACS of CXCR4 (Y-axis) and CD9 (x-axis) for a) EXPRES 01 cells at passage 19 cells and b) EXPRES 02 cells at passage 14 cells cultured on tissue culture polystyrene in growth media and then switched to DMEM-F12 + 0.5% FBS + 100 ng/ml of activin-A + 100 nM GSK-3B
inhibitor IX, and 20 ng/ml of WNT3A for 4days.
[0066] Figure 21 shows immuno fluorescent images of EXPRES 01 cells at passage 19 cultured in 2% FBS + DMEM-F12 + 100 nWm1 of AA + 20 ng/ml of WNT-3A + 50 ng/ml of IGF-I and EXPRES 02 cells at passage 14 cultured in 2% FBS + DMEM-F12 + 100 ng/ml of AA + 20 ng/ml of WNT-3A and then switched to DMEM-F12 + 0.5%
FBS + 100 ng/ml of activin-A + 100 nM GSK-3B inhibitor IX, and 20 ng/ml of WNT3A for 5days. Panel a) DAPI image for panel b, panel b) HNF-3 beta, panel c) DAPI image for panel d, panel d) GATA-4, panel e) DAPI image for panel f, panel f) SOX-17, panel g)DAPI image for panel h, panel h) HNF-3 beta, Panel i) DAPI
image for panel j, panel j) GATA-4, panel k)DAPI image for panel 1, panel 1) SOX-17.
[0067] Figure 22 shows gene expression as determined by real-time PCR data for a) EXPRES
01 and EXPRES 02 cells treated with low serum plus AA + WNT3a + GSK-3B IX
inhibitor for 5 days. Panel a depicts expression of AFP, Brachyury, CDX2, Moxl, OCT3/4, SOX-7, and ZIC1 and panel b shows expression levels of CXCR4, GATA-4, Goosecoid, HNf3B, and SOX-17.
[0068] Figure 23 shows gene expression as determined by real-time PCR for cells seeded at 5000-40000 cells/cm2 on tissue culture polystyrene in growth media and then switched to DMEM-F12 + 0.5% FBS + 100 ng/ml AA + 20 ng/ml WNT3A + 100 nM GSK-3B inhibitor IX for four days under hypoxic conditions. Panel a depicts expression levels of AFP, Brachyury, SOX-7, and OTX2. Panel b depicts expression levels of CXCR4, HNF-3 beta, GATA-4, SOX-17, Cerb, and GSC.
[0069] Figure 24 shows the results of a telomere length assay in low telomere control cells (lane 1), EXPRES 01 cells at passage 24 (lane 2), EXPRES 02 cells at passage 17 (lane 3), undifferentiated cells from the human embryonic stem cell line H1 at passage 40 (lane 4), and high telomere length control cells (lane 5).
[0070] Figure 25 shows gene expression as determined by real-time PCR data for EXPRES 01 cells at passage 21 that have been differentiated to foregut endoderm cells (S3), pancreatic endoderm cells (S4), and pancreatic endocrine cells (S5).
[0071] Figure 26 shows immuno fluorescent images of EXPRES 01 at passage 35 cultured according to Example 18. Panel a) DAPI image for panel b, panel b) Anti-1 trypsin, panel c) HNF-3 beta and Albumin, panel d) Albumin and DAPI, panel e) DAPI
image for panel f, panel f) PDX-1, panel g) DAPI image for panel h, panel h) SOX-17, panel i) DAPI image for panel j, panel j) CDX-2.
[0072] Figure 27 shows scatter plots of microarray data comparing, panel a) EXPRES 01 cells (y-axis) to undifferentiated cells from the human embryonic stem cell line H9 (x-axis), panel b) EXPRES 02 cells (y-axis) to undifferentiated cells from the human embryonic stem cell line H9 (x-axis), panel c) EXPRES 01 cells (y-axis) to EXPRES 02 cells (x-axis), panel d) EXPRES 01 cells (y-axis) to cells from the human embryonic stem cell line H9 that have been differentiated into definitive endoderm (x-axis), panel e) EXPRES 02 cells (y-axis) to cells from the human embryonic stem cell line H9 that have been differentiated into definitive endoderm (x-axis), panel f) undifferentiated cells from the human embryonic stem cell line H9 (y-axis) to cells from the human embryonic stem cell line H9 that have been differentiated into definitive endoderm (x-axis).
[0073] Figure 28 shows the morphology of EB bodies formed by EXPRES 01 cells.
[0074] Figure 29 shows gene expression as determined by real-time PCR for cells of the EXPRES 01 cell line, cells of the EXPRES 02 cell line, and cells from the human embryonic stem cell line H9 at passage 43, following five weeks of transplantation beneath the kidney capsule of NOD-SCID mice. Panels a-c, show mesoderm markers.
Panels f & g show ectoderm markers. Panels h & i show endoderm markers. Panel j shows extra embryonic endoderm markers. Panels k-m show pluripotency markers.
[0075] Figure 30 shows the proliferation and cell cycle status of EXPRES 03 cells, as determined by BRDU incorporation. EXPRES 03 cells were cultured in 2%

FBS/DMEM/F12, supplemented with, panel a) activin-A (100 ng/ml) and wnt3a (20ng/m1), panel b) Activin-A (100 ng/ml) and wnt3a (20ng/m1) and IGF
(50nh/m1).
Other cells shown include, panel c) hES cells (H9p43), panel d) Amniotic Fluid Cells (AFDX002) and panel e) mitomycin treated MEF cells. Panel f) shows the frequency of cells in S-phase, G1 and G2/M-phases of cell cycle for different cell populations studied.
[0076] Figure 31 shows the transfection efficiency and expression of EGFP
in EXPRES 01 cells and human embryonic stem cells plated either as single cell dispersions or cell clusters. Cells were analyzed 24 hrs later by fluorescence microscopy and flow cytometry. Panel A) shows data obtained from EXPRES 01 cells. Panel B) shows data obtained from single cell dispersions of human embryonic stem cells and Panel C) shows data obtained from cell clusters of human embryonic stem cells.
[0077] Figure 32 shows average OD readings representing dehydrogenase enzyme activity versus cell number as measured by MTS assay for a) EXPRES 01 cells cultured in atmospheric oxygen (approximately 21%), b) EXPRES 01 cells cultured in 3% 02, c) EXPRES 02 cells cultured in atmospheric oxygen (approximately 21%), d) EXPRES
02 cells cultured in 3% 02 conditions.
[0078] Figure 33 shows gene expression as determined by real-time PCR for cells seeded at 10000 cells/cm2 on tissue culture polystyrene in DMEMF12 +
0.5%
FBS + 100 ng/ml AA + 20 ng/ml WNT3A + 100 nM GSK-3B inhibitor IX.. Panel a depicts expression levels of AFP, Brachyury, SOX-7, and OTX2. Panel b depicts expression levels of CXCR4, HNF-3 beta, GATA-4, SOX-17, Cerl, and GSC.
[0079] Figure 34 shows protein expression of CXCR4 (Y-axis) and CD9 (x-axis), as determined by FACS for EXPRES 01 P27 cells cultured on tissue culture polystyrene in DMEM-F12 + 0.5% FBS + 100 ng/ml AA +20 ng/ml WNT3A + 100 nM GSK-3B
inhibitor IX for three passages.
[0080] Figure 35 shows the effects of siRNA transfection on the expression of GSK-3B and beta-catenin. EXPRES cells were analyzed by fluorescence microscopy and quantitative RT-PCR methods. A) Fluorescence microscopy of cells transfected with i) CY3 labeled siRNA and ii) Fluorescein labeled siRNA. B) Target gene knockdown expressed as % remaining activity in cells transfected with i) GSK3b and ii) Beta-catenin siRNA oligo sequences.
[0081] Figure 36 shows the karyotype of two cell lines derived by methods of the present invention. Panel a: EXPRES 01 cell line. Panel b: EXPRES 02 cell line.
[0082] Figure 37 shows the morphology of EXPRES 15 cells at passage 0 after 24h culture in a) 2% FBS + DM-F12 + 100 ng/ml of activin-A+ 20 ng/ml of WNT-3A + 50 ng/ml IGF orb) 2% FBS + DM-F12 + 100 ng/ml of Activin-A+ 20 ng/ml of WNT-3A + 50 ng/ml IGF + 10 [IM of the Rho kinase inhibitor Y-27632.
[0083] Figure 38 shows the karyotype of EXPRES 15 cells cultured in 2% FBS
+ DM-F12 +
100 ng/ml of Activin-A+ 20 ng/ml of WNT-3A + 50 ng/ml IGF + 10 p1\4 of the Rho kinase inhibitor Y-27632 for 12 passages.
[0084] Figure 39 shows the proliferation as determined by A490 of EXPRES 11 cells cultured in basal media supplemented with IGF, activin-A, Wnt3A, and GSK inhibitor IX
at the concentrations indicated at 24 h (panel a), 48 h (panel b), and 96 h (panel c).
DETAILED DESCRIPTION
[0085] For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the following subsections that describe or illustrate certain features, embodiments, or applications of the present invention.
Definitions [0086] Stem cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self renewing progenitors, non-renewing progenitors, and terminally differentiated cells.
Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
[0087] Stem cells are classified by their developmental potential as: (1) totipotent, meaning able to give rise to all embryonic and extraembryonic cell types; (2) pluripotent, meaning able to give rise to all embryonic cell types; (3) multipotent, meaning able to give rise to a subset of cell lineages, but all within a particular tissue, organ, or physiological system (for example, hematopoietic stem cells (HSC) can produce progeny that include HSC (self- renewal), blood cell restricted oligopotent progenitors and all cell types and elements (e.g., platelets) that are normal components of the blood); (4) oligopotent, meaning able to give rise to a more restricted subset of cell lineages than multipotent stem cells; and (5) unipotent, meaning able to give rise to a single cell lineage (e.g. , spermatogenic stem cells).
[0088] Differentiation is the process by which an unspecialized ("uncommitted") or less specialized cell acquires the features of a specialized cell such as, for example, a nerve cell or a muscle cell. A differentiated or differentiation-induced cell is one that has taken on a more specialized ("committed") position within the lineage of a cell. The term "committed", when applied to the process of differentiation, refers to a cell that has proceeded in the differentiation pathway to a point where, under normal circumstances, it will continue to differentiate into a specific cell type or subset of cell types, and cannot, under normal circumstances, differentiate into a different cell type or revert to a less differentiated cell type. De-differentiation refers to the process by which a cell reverts to a less specialized (or committed) position within the lineage of a cell. As used herein, the lineage of a cell defines the heredity of the cell, i.e., which cells it came from and what cells it can give rise to. The lineage of a cell places the cell within a hereditary scheme of development and differentiation. A lineage-specific marker refers to a characteristic specifically associated with the phenotype of cells of a lineage of interest and can be used to assess the differentiation of an uncommitted cell to the lineage of interest.
[0089] "AFP" or "alpha-fetoprotein protein" as used herein, refers to an antigen produced at the onset of liver development. AFP may also be expressed in extraembryonic cells.
[0090] "Albumin" is a soluble monomeric protein that makes up about half of all serum proteins in adults.
[0091] "f3-cell lineage" refer to cells with positive gene expression for the transcription factor PDX-1 and at least one of the following transcription factors: NGN-3, Nkx2.2, Nkx6.1, NeuroD, Is1-1, HNF-3 beta, MAFA, Pax4, and Pax6. Cells expressing markers characteristic of the r3 cell lineage include 13 cells.
[0092] "Brachyury", as used herein, is a T-box gene family member. It is the marker for primitive streak and mesoderm cells.
[0093] "Cells expressing markers characteristic of the definitive endoderm lineage" as used herein refer to cells expressing at least one of the following markers: SOX-17, GATA-4, HNF-3 beta, GSC, Cerl, Nodal, FGF8, Brachyury, Mix-like homeobox protein, FGF4 CD48, eomesodermin (EOMES), DKK4, FGF17, GATA-6, CXCR4, C-Kit, CD99, or OTX2. Cells expressing markers characteristic of the definitive endoderm lineage include primitive streak precursor cells, primitive streak cells, mesendoderm cells and definitive endoderm cells.
[0094] "c-Kit" and "CD117" both refer to a cell surface receptor tyrosine kinase having a sequence disclosed in Genbank Accession No. X06182, or a naturally occurring variant sequence thereof (e.g., allelic variant).
[0095] "CD99" as used herein refers to the protein encoded by the gene wit the accession number NM _002414.
[0096] "Cells expressing markers characteristic of the pancreatic endoderm lineage" as used herein refer to cells expressing at least one of the following markers: PDX-1, HNF-lbeta, PTF-1 alpha, HNF-6, or HB9. Cells expressing markers characteristic of the pancreatic endoderm lineage include pancreatic endoderm cells.
[0097] "Cells expressing markers characteristic of the pancreatic endocrine lineage" as used herein refer to cells expressing at least one of the following markers: NGN-3, NeuroD, Islet-1, PDX-1, NKX6.1, Pax-4, Ngn-3, or PTF-1 alpha. Cells expressing markers characteristic of the pancreatic endocrine lineage include pancreatic endocrine cells, pancreatic hormone expressing cells, and pancreatic hormone secreting cells, and cells of the 3-cell lineage.
[0098] "Cerl" or "Cerebrus" as used herein is a member of the cysteine knot superfamily of proteins.

[0099] "CXCR4" as used herein refers to the stromal cell-derived factor 1 (SDF-1) receptor, also known as "LESTR" or "fusin". In the gastrulating mouse embryo, CXCR4 is expressed in the definitive endoderm and mesoderm but not in extraembryonic endoderm.
[0100] "Definitive endoderm" as used herein refers to cells which bear the characteristics of cells arising from the epiblast during gastrulation and which form the gastrointestinal tract and its derivatives. Definitive endoderm cells express the following markers:
HNF-3 beta, GATA-4, SOX-17, Cerberus, OTX2, goosecoid, C-Kit, CD99, and Mix11.
[0101] "Extraembryonic endoderm" as used herein refers to a population of cells expressing at least one of the following markers: SOX-7, AFP, and SPARC.
[0102] "FGF-2", "FGF-4" "FGF-8" "FGF-10", and "FGF-17" as used herein, are members of the fibroblast growth factor family.
[0103] "GATA-4" and "GATA-6" are members of the GATA transcription factor family. This family of transcription factors is induced by TGF43 signaling, and contribute to the maintenance of early endoderm markers.
[0104] "GLUT-2", as used herein, refers to the glucose transporter molecule that is expressed in numerous fetal and adult tissues, including pancreas, liver, intestine, brain, and kidney.
[0105] "Goosecoid" or "GSC" as used herein, refers to a homeodomain transcription factor expressed in the dorsal lip of the blastopore.
[0106] "HB9" as used herein, refers to the homeobox gene 9.
[0107] "HNF-1 alpha", "HNF-1 beta", "HNF-3 beta", and "HNF-6" belong to the hepatic nuclear factor family of transcription factors, which is characterized by a highly conserved DNA binding domain and two short earboxy-terminal domains.
[0108] "Islet-1" or "Is1-1" as used herein is a member of the LIM/homeodomain family of transcription factors, and is expressed in the developing pancreas.

[0109] "MafA" as used herein is a transcription factor expressed in the pancreas, and controls the expression of genes involved in insulin biosynthesis and secretion.
[0110] "Markers" as used herein, are nucleic acid or polypeptide molecules that are differentially expressed in a cell of interest. In this context, differential expression means an increased level for a positive marker and a decreased level for a negative marker. The detectable level of the marker nucleic acid or polypeptide is sufficiently higher or lower in the cells of interest compared to other cells, such that the cell of interest can be identified and distinguished from other cells using any of a variety of methods known in the art.
[0111] "Mesendoderm cell" as used herein refers to a cell expressing at least one of the following markers: CD48, eomesodermin (EOMES), SOX-17, DKK4, HNF-3 beta, GSC, FGF17, GATA-6.
[0112] "Mix11" as used herein refers to a homeobox gene, which is marker for the cells in the primitive streak, mesoderm, and endoderm.
[0113] "NeuroD" as used herein is basic helix-loop-helix (bHLH) transcription factor implicated in neurogenesis.
[0114] "NGN-3" as used herein, is a member of the neurogenin family of basic loophelix-loop transcription factors.
[0115] "Nkx-2.2" and "Nkx-6.1" as used herein are members of the NIcx transcription factor family.
[0116] "Nodal" as used herein, is a member of the TGF beta superfamily of proteins.
[0117] "Oct-4" is a member of the POU-domain transcription factor and is widely regarded as a hallmark of pluripotent stem cells. The relationship of Oct-4 to pluripotent stem cells is indicated by its tightly restricted expression to undifferentiated pluripotent stem cells.
Upon differentiation to somatic lineages, the expression of Oct-4 disappears rapidly.
[0118] "Pancreatic endocrine cell", or "pancreatic hormone expressing cell"
as used herein refers to a cell capable of expressing at least one of the following hormones:
insulin, glucagon, somatostatin, and pancreatic polypeptide.

[0119] "Pancreatic hormone secreting cell" as used herein refers to a cell capable of secreting at least one of the following hormones: insulin, glucagon, somatostatin, and pancreatic polypeptide.
[0120] "Pax-4" and "Pax-6" as used herein are pancreatic 13 cell specific transcription factors that are implicated in islet development.
[0121] "PDX-1" as used herein refers to a homeodomain transcription factor implicated in pancreas development.
[0122] "Pre-primitive streak cell" as used herein refers to a cell expressing at least one of the following markers: Nodal, or FGF8 [0123] "Primitive streak cell" as used herein refers to a cell expressing at least one of the following markers: Brachyury, Mix-like homeobox protein, or FGF4.
[0124] "PTF-1 alpha" as used herein refers to a basic helix-loop-helix protein of 48 kD that is a sequence-specific DNA-binding subunit of the trimeric pancreas transcription factor-1 (PTF1).
[0125] "SOX-1", "SOX-2", "SOX-7", and "SOX-17"as used herein, are a members of the SOX transcription factor family, and are implicated in embryogenesis.
[0126] "SPARC" as used herein is also known as "secreted protein acidic and rich in cysteine".
[0127] "SSEA-1" (Stage Specific Embryonic Antigen-1) is a glycolipid surface antigen present on the surface of murine teratocarcinoma stem cells (EC), murine and human embryonic germ cells (EG), and murine embryonic stem cells (ES).
[0128] "SSEA-3" (Stage Specific Embryonic Antigen-3) is a glycolipid surface antigen present on the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG), and human embryonic stem cells (ES).
[0129] "SSEA-4" (Stage Specific Embryonic Antigen-4) is a glycolipid surface antigen present on the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG), and human embryonic stem cells (ES).

[0130] "TRA1-60" is a keratin sulfate related antigen that is expressed on the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG), and human embryonic stem cells (ES).
[0131] "TRA1-81" is a keratin sulfate related antigen that is expressed on the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG), and human embryonic stem cells (ES).
[0132] "TRA2-49" is an alkaline phosphatase isozyme expressed on the surface of human teratocarcinoma stem cells (EC) and human embryonic stem cells (ES).
[0133] "UTF-1" as used herein, refers a transcriptional co-activator expressed in pluripotent embryonic stem cells and extra-embryonic cells.
[0134] "Zicl" as used herein is a member of the Zic transcription factor family. Zicl regulates the expression of neural and neural crest-specific genes and is expressed in the cells of the dorsal neural tube and the premigratory neural crest Method to derive cells expressing pluripotency markers [0135] The present invention provides a cell population with characteristics of human embryonic stem cells, that can be readily expanded in culture, in low serum, that requires no feeder cell line or a coating of complex matrix proteins, can be passaged in single cell suspension, can be transfected with a very high efficiency, and cultured under hypoxic conditions. This combination of unique attributes separates the cells described in the present invention from the prior art.
[0136] In one embodiment, the present invention provides a method for deriving a population of cells comprising cells expressing pluripotency markers, comprising the steps of:
a. Obtaining cells, and b. Culturing the cells under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix prior to culturing the cells.

[0137] The cells may be human embryonic stem cells, or they may be cells expressing markers characteristic of the definitive endoderm lineage. The human embryonic stem cells may be cultured in normoxic conditions prior to culturing the cells on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
Alternatively, the human embryonic stem cells may be cultured in hypoxic conditions.
[0138] The cells expressing markers characteristic of the definitive endoderm lineage may be cultured in normoxic conditions prior to culturing the cells on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
Alternatively, the cells expressing markers characteristic of the definitive endoderm lineage may be cultured in hypoxic conditions.
[0139] In one embodiment, the present invention provides a method for deriving a population of cells comprising cells expressing pluripotency markers, comprising the steps of:
a. Culturing human embryonic stem cells, b. Differentiating the human embryonic stem cells into cells expressing markers characteristic of definitive endoderm cells, and c. Removing the cells, and subsequently culturing them under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix prior to culturing the cells.
[0140] In one embodiment, the present invention provides a method for deriving a population of cells comprising cells expressing pluripotency markers, comprising the steps of:
a. Culturing human embryonic stem cells, and b. Removing the cells, and subsequently culturing them under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.

Cell culture under hypoxic conditions on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix [0141] In one embodiment, the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not coated with an extracellular matrix for about 1 to about 20 days. In an alternate embodiment, the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not coated with an extracellular matrix for about 5 to about 20 days. In an alternate embodiment, the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not coated with an extracellular matrix for about 15 days.
[0142] In one embodiment, the hypoxic condition is about 1% 02 to about 20%
02. In an alternate embodiment, the hypoxic condition is about 2% 02 to about 10% 02. In an alternate embodiment, the hypoxic condition is about 3% 02.
[0143] The cells may be cultured, under hypoxic conditions on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum, activin-A, and a Wnt ligand. Alternatively, the medium may also contain IGF-1.
[0144] The culture medium may have a serum concentration in the range of about 2% to about 5%. In an alternate embodiment, the serum concentration may be about 2%.
[0145] Activin-A may be used at a concentration from about lpg/ml to about 100 g/ml. In an alternate embodiment, the concentration may be about lpg/ml to about 1 1g/ml.
In another alternate embodiment, the concentration may be about lpg/ml to about 10Ong/ml. In another alternate embodiment, the concentration may be about 5Ong/m1 to about 10Ong/ml. In another alternate embodiment, the concentration may be about 1 0Ong/ml.
[0146] The Wnt ligand may be selected from the group consisting of Wnt-1, Wnt-3a, Wnt-5a and Wnt-7a. In one embodiment, the Wnt ligand is Wnt-1. In an alternate embodiment, the Wnt ligand is Wnt-3 a.
[0147] The Wnt ligand may be used at a concentration of about lng/ml to about 1000ng/ml. In an alternate embodiment, the Wnt ligand may be used at a concentration of about lOng/m1 to about 10Ong/ml. In one embodiment, the concentration of the Wnt ligand is about 2Ong/ml.

[0148] IGF-1 may be used at a concentration of about lng/ml to about 10Ong/ml. In an alternate embodiment, the IGF-Imay be used at a concentration of about lOng/m1 to about 10Ong/ml. In one embodiment, the concentration of IGF-1 is about 5Ong/ml.
[0149] The cells expressing pluripotency markers derived by the methods of the present invention are capable of expansion in culture under hypoxic conditions, on tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.
[0150] The cells expressing pluripotency markers derived by the methods of the present invention express at least one of the following pluripotency markers selected from the group consisting of: ABCG2, cripto, FoxD3, Connexin43, Connexin45, Oct4, SOX-2, Nanog, hTERT, UTF-1, ZFP42, SSEA-3, SSEA-4, Tral -60, and Tral-81.
[0151] In one embodiment, the cells expressing pluripotency markers derived by the methods of the present invention are capable of expressing markers characteristic of pre-primitive streak cells.
[0152] In one embodiment, the cells expressing pluripotency markers derived by the methods of the present invention are capable of expressing markers characteristic of primitive streak cells.
[0153] In one embodiment, the cells expressing pluripotency markers derived by the methods of the present invention are capable of expressing markers characteristic of mesendoderm cells.
[0154] In one embodiment, the cells expressing pluripotency markers derived by the methods of the present invention are capable of expressing markers characteristic of definitive endoderm cells.
Further differentiation of cells expressing pluripotency markers derived by the methods of the present invention [0155] Cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage by any method in the art.

[0156] For example, cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in D'Amour et al, Nature Biotechnology 23, 1534 - 1541 (2005).
[0157] For example, cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in Shinozaki et al, Development 131, 1651 - 1662 (2004).
[0158] For example, cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in McLean et al, Stem Cells 25, 29 - 38 (2007).
[0159] For example, cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in D'Amour et al, Nature Biotechnology 24, 1392 - 1401 (2006).
[0160] For example, cells expressing pluripotency markers derived by the methods of the present invention may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage by culturing the pluripotent stem cells in medium containing activin-A in the absence of serum, then culturing the cells with activin-A
and serum, and then culturing the cells with activin-A and serum of a different concentration. An example of this method is disclosed in D'Amour et al, Nature Biotechnology, 23, 1534-1541, 2005.
Further differentiation of cells expressing markers characteristic of the definitive endoderm lineage [0161] Cells expressing markers characteristic of the definitive endoderm lineage may be differentiated into cells expressing markers characteristic of the pancreatic endoderm lineage by any method in the art.

[0162] For example, cells expressing markers characteristic of the definitive endoderm lineage may be differentiated into cells expressing markers characteristic of the pancreatic endoderm lineage according to the methods disclosed in D'Amour et al, Nature Biotechnology 24, 1392 - 1401 (2006).
[0163] For example, cells expressing markers characteristic of the definitive endoderm lineage are further differentiated into cells expressing markers characteristic of the pancreatic endoderm lineage, by treating the cells expressing markers characteristic of the definitive endoderm lineage with a fibroblast growth factor and KAAD-cyclopamine, then removing the medium containing the fibroblast growth factor and KAAD-cyclopamine and subsequently culturing the cells in medium containing retinoic acid, a fibroblast growth factor and KAAD-cyclopamine. An example of this method is disclosed in D' Amour eta!, Nature Biotechnology, 24: 1392-1401, (2006).
Further differentiation of cells expressing markers characteristic of the pancreatic endoderm lineage [0164] Cells expressing markers characteristic of the pancreatic endoderm lineage may be differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage by any method in the art.
[0165] For example, cells expressing markers characteristic of the pancreatic endoderm lineage may be differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage according to the methods disclosed in D'Amour eta!, Nature Biotechnology 24, 1392 - 1401 (2006).
[0166] Without being subject to limitation, the following sections contain examples of methods to obtain cells that are suitable starting materials for forming cells expressing pluripotency markers and markers characteristic of the definitive endoderm lineage according to the methods of the present invention.
Isolation, expansion and culture of human embryonic stem cells [0167] Characterization of human embiyonic stem cells: Human embryonic stem cells may express one or more of the stage-specific embryonic antigens (SSEA) 3 and 4, and markers detectable using antibodies designated Tra-1-60 and Tra-1-81 (Thomson et al., Science 282:1145, 1998). Differentiation of human embryonic stem cells in vitro results in the loss of SSEA-4, Tra- 1-60, and Tra-1-81 expression (if present) and increased expression of SSEA-1. Undifferentiated human embryonic stem cells typically have alkaline phosphatase activity, which can be detected by fixing the cells with 4% paraformaldehyde, and then developing with Vector Red as a substrate, as described by the manufacturer (Vector Laboratories, Burlingame Calif.).
Undifferentiated pluripotent stem cells also typically express Oct-4 and TERT, as detected by RT-PCR.
[0168] Another desirable phenotype of propagated human embryonic stem cells is a potential to differentiate into cells of all three germinal layers: endoderm, mesoderm, and ectoderm tissues. Pluripotency of human embryonic stem cells can be confirmed, for example, by injecting cells into SOD mice, fixing the teratomas that form using 4%
paraformaldehyde, and then examining them histologically for evidence of cell types from the three germ layers. Alternatively, pluripotency may be determined by the creation of embryoid bodies and assessing the embryoid bodies for the presence of markers associated with the three germinal layers.
[0169] Propagated human embryonic stem cell lines may be karyotyped using a standard G-banding technique and compared to published karyotypes of the corresponding primate species. It is desirable to obtain cells that have a "normal karyotype", which means that the cells are euploid, wherein all human chromosomes are present and not noticeably altered.
[0170] Sources of human embryonic stem cells: Types of human embryonic stem cells that may be used include established lines of human embryonic cells derived from tissue formed after gestation, including pre-embryonic tissue (such as, for example, a blastocyst), embryonic tissue, or fetal tissue taken any time during gestation, typically but not necessarily before approximately 10-12 weeks gestation. Non-limiting examples are established lines of human embryonic stem cells or human embryonic germ cells, such as, for example the human embryonic stem cell lines HI, H7, and H9 (WiCell). Also contemplated is use of the compositions of this disclosure during the initial establishment or stabilization of such cells, in which case the source cells would be primary pluripotent cells taken directly from the source tissues. Also suitable are cells taken from a pluripotent stem cell population already cultured in the absence of feeder cells. Also suitable are mutant human embryonic stem cell lines, such as, for example, BGOlv (BresaGen, Athens, GA).
[0171] In one embodiment, Human embryonic stem cells are prepared as described by Thomson etal. (U.S. Pat. No. 5,843,780; Science 282:1145, 1998; Curr. Top.
Dev.
Biol. 38:133 ff., 1998; Proc. Natl. Acad. Sci. U.S.A. 92:7844, 1995).
[0172] Culture of human embryonic stem cells: In one embodiment, human embryonic stem cells are cultured in a culture system that is essentially free of feeder cells, but nonetheless supports proliferation of human embryonic stem cells without undergoing substantial differentiation. The growth of human embryonic stem cells in feeder-free culture without differentiation is supported using a medium conditioned by culturing previously with another cell type. Alternatively, the growth of human embryonic stem cells in feeder-free culture without differentiation is supported using a chemically defined medium.
[0173] In an alternate embodiment, human embryonic stem cells are initially cultured layer of feeder cells that support the human embryonic stem cells in various ways. The human embryonic are then transferred to a culture system that is essentially free of feeder cells, but nonetheless supports proliferation of human embryonic stem cells without undergoing substantial differentiation.
[0174] Examples of conditioned media suitable for use in the present invention are disclosed in US20020072117, US6642048, W02005014799, and Xu et al (Stem Cells 22: 972-980, 2004).
[0175] An example of a chemically defined medium suitable for use in the present invention may be found in US20070010011.
[0176] Suitable culture media may be made from the following components, such as, for example, Dulbecco's modified Eagle's medium (DMEM), Gibco # 11965-092;
Knockout Dulbecco's modified Eagle's medium (KO DMEM), Gibco # 10829-018;
Ham's F12/50% DMEM basal medium; 200 mM L-glutamine, Gibco #15039-027; non-essential amino acid solution, Gibco 11140-050;13- mercaptoethanol, Sigma #
M7522;
human recombinant basic fibroblast growth factor (bFGF), Gibco # 13256-029.

[0177] In one embodiment, the human embryonic stem cells are plated onto a suitable culture substrate that is treated prior to treatment according to the methods of the present invention. In one embodiment, the treatment is an extracellular matrix component, such as, for example, those derived from basement membrane or that may form part of adhesion molecule receptor-ligand couplings. In one embodiment, the suitable culture substrate is MATRIGEL (Becton Dickenson). MATRIGEL is a soluble preparation from Engelbreth-Holm-Swarm tumor cells that gels at room temperature to form a reconstituted basement membrane.
[0178] Other extracellular matrix components and component mixtures are suitable as an alternative. This may include laminin, fibronectin, proteoglycan, entactin, heparan sulfate, and the like, alone or in various combinations.
[0179] The human embryonic stem cells are plated onto the substrate in a suitable distribution and in the presence of a medium that promotes cell survival, propagation, and retention of the desirable characteristics. All these characteristics benefit from careful attention to the seeding distribution and can readily be determined by one of skill in the art.
[0180] The human embryonic stem cells are then removed from the treated tissue culture substrate and plated onto a non-treated tissue culture substrate, prior to treatment according to the methods of the present invention to form cells expressing pluripotency markers and markers characteristic of the definitive endoderm lineage.
Differentiation of human embryonic stem cells into cells expressing markers characteristic of the definitive endoderm lineage [0181] Human embryonic stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage by any method in the art.
The cells expressing markers characteristic of the definitive endoderm lineage are suitable for treating according to the methods of the present invention.
[0182] For example, human embryonic stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in D'Amour et al, Nature Biotechnology 23, 1534¨ 1541 (2005).

[0183] For example, human embryonic stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in Shinozaki et al, Development 131, 1651 - 1662 (2004).
[0184] For example, human embryonic stem cells may be differentiated into cells expressing markers characteristic of the definitive endoderm lineage according to the methods disclosed in McLean et al, Stem Cells 25, 29 - 38 (2007).
Differentiation of human embryonic stem cells cultured on an extracellular matrix into cells expressing markers characteristic of the definitive endoderm lineage [0185] In one embodiment, the present invention provides a method for differentiating human embryonic stem cells expressing markers characteristic of the definitive endoderm lineage, comprising the steps of:
a. Plating the human embryonic stem cells on a tissue culture substrate coated with an extracellular matrix, and b. Culturing the human embryonic stem cells with activin-A and a Wnt ligand.
[0186] The cells expressing markers characteristic of the definitive endoderm lineage are then subsequently treated by the methods of the present invention to form cells expressing pluripotency markers and markers characteristic of the definitive endoderm lineage.
[0187] Culturing the human embryonic stem cells with activin-A and a Wnt ligand may be performed in a single culture medium. Alternatively, culturing the human embryonic stem cells with activin-A and a Wnt ligand may be performed in more than one culture media. In one embodiment, culturing the human embryonic stem cells with activin-A
and a Wnt ligand is performed in two culture media.
[0188] Extracellular Matrix: In one aspect of the present invention, the human embryonic stem cells are cultured and differentiated on a tissue culture substrate coated with an extracellular matrix. The extracellular matrix may be a solubilized basement membrane preparation extracted from mouse sarcoma cells (which is sold by BD
Biosciences under the trade name MATRIGEL). Alternatively, the extracellular matrix may be growth factor-reduced MATRIGEL. Alternatively, the extracellular matrix may fibronectin. In an alternate embodiment, the human embryonic stem cells are cultured and differentiated on tissue culture substrate coated with human serum.
[0189] The extracellular matrix may be diluted prior to coating the tissue culture substrate.
Examples of suitable methods for diluting the extracellular matrix and for coating the tissue culture substrate may be found in Kleinman, H.K., et al., Biochemistry 25:312 (1986), and Hadley, M.A., et al., J.Cell.Biol. 101:1511 (1985).
[0190] In one embodiment, the extracellular matrix is MATRIGEL. In one embodiment, the tissue culture substrate is coated with MATRIGEL at a 1:10 dilution. In an alternate embodiment, the tissue culture substrate is coated with MATRIGEL at a 1:15 dilution.
In an alternate embodiment, the tissue culture substrate is coated with MATRIGEL at a 1:30 dilution. In an alternate embodiment, the tissue culture substrate is coated with MATRIGEL at a 1:60 dilution.
[0191] In one embodiment, the extracellular matrix is growth factor-reduced MATRIGEL. In one embodiment, the tissue culture substrate is coated with growth factor-reduced MATRIGEL at a 1:10 dilution. In an alternate embodiment, the tissue culture substrate is coated with growth factor-reduced MATRIGEL at a 1:15 dilution. In an alternate embodiment, the tissue culture substrate is coated with growth factor-reduced MATRIGEL at a 1:30 dilution. In an alternate embodiment, the tissue culture substrate is coated with growth factor reduced MATRIGEL at a 1:60 dilution.
[0192] Differentiation of human embryonic stem cells into cells expressing markers characteristic of the definitive endoderm lineage on an extracellular matrix, using a single culture medium: In one embodiment, the present invention provides a method for differentiating human embryonic stem cells expressing markers characteristic of the definitive endoderm lineage, comprising the steps of:
a. Plating the human embryonic stem cells on a tissue culture substrate coated with an extracellular matrix, and b. Culturing the human embryonic stem cells with activin-A and a Wnt ligand.
[0193] The culture medium should contain sufficiently low concentrations of certain factors to allow the differentiation of human embryonic stem cells to definitive endoderm, such as, for example insulin and IGF (as disclosed in W02006020919). This may be achieved by lowing the serum concentration, or alternatively, by using chemically defined media that lacks insulin and IGF. Examples of chemically defined media are disclosed in Wiles eta! (Exp Cell Res. 1999 Feb 25; 247(1): 241-8.).
[0194] The culture medium may have a serum concentration in the range of about 0% to about 10%. In an alternate embodiment, the concentration may be in the range of about 0%
to about 5%. In an alternate embodiment, the concentration may be in the range of about 0% to about 2%. In an alternate embodiment, the concentration may be about 2%.
[0195] The time of culturing with activin-A and a Wnt ligand may range from about 1 day to about 7 days. In an alternate embodiment, the time of culturing may range from about 1 day to about 3 days. In an alternate embodiment, the time of culturing may be about 3 days.
[0196] Activin-A may be used at any concentration suitable to cause differentiation of the human embryonic stem cells. The concentration maybe from about lpg/ml to about 100 g/ml. In an alternate embodiment, the concentration may be about lpg/ml to about In/mi. In another alternate embodiment, the concentration may be about lpg/ml to about 10Ong/ml. In another alternate embodiment, the concentration may be about 5Ong/m1 to about 10Ong/ml. In another alternate embodiment, the concentration may be about 10Ong/ml.
[0197] The choice of the Wnt ligand may be optimized to improve the efficiency of the differentiation process. The Wnt ligand may be selected from the group consisting of Wnt-1, Wnt-3a, Wnt-5a and Wnt-7a. In one embodiment, the Wnt ligand is Wnt-I.
In an alternate embodiment, the Wnt ligand is Wnt-3a.
[0198] The Wnt ligand may be at a concentration of about lng/ml to about 1000ng/ml. In an alternate embodiment, the concentration may be about lOng/m1 to about 10Ong/ml.
[0199] The single culture medium may also contain a GSK-3B inhibitor. The inhibitor may be selected from the group consisting of GSK-3B inhibitor IX and GSK-3B inhibitor XI. In one embodiment, the GSK-3B inhibitor is GSK-3B inhibitor IX.

[0200] When culturing human embryonic stem cells with a GSK-3B inhibitor, the concentration of the GSK-3B inhibitor may be from about 1nM to about 1000nM.
In an alternate embodiment, the human embryonic stem cells are cultured with the GSK-3B inhibitor at a concentration of about lOnM to about 100nM.
[0201] The single culture medium may also contain at least one other additional factor that may enhance the formation of cells expressing markers characteristic of the definitive endoderm lineage from human embryonic stem cells. Alternatively, the at least one other additional factor may enhance the proliferation of the ells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention. Further, the at least one other additional factor may enhance the ability of the cells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention to form other cell types, or improve the efficiency of any other additional differentiation steps.
[0202] The at least one additional factor may be, for example, nicotinamide, members of TGF-13 family, including TGF-f31, 2, and 3, serum albumin, members of the fibroblast growth factor family, platelet-derived growth factor-AA, and ¨BB, platelet rich plasma, insulin growth factor (IGF-I, II), growth differentiation factor (GDF-5, -6, -8, -10, 11), glucagon like peptide-I and II (GLP-I and II), GLP-1 and GLP-2 mimetobody, Exendin-4, retinoic acid, parathyroid hormone, insulin, progesterone, aprotinin, hydrocortisone, ethanolamine, beta mercaptoethanol, epidermal growth factor (EGF), gastrin I and II, copper chelators such as, for example, triethylene pentamine, forskolin, Na-Butyrate, activin, betacellulin, ITS, noggin, neurite growth factor, nodal, valporic acid, trichostatin A, sodium butyrate, hepatocyte growth factor (HGF), sphingosine 1, VEGF, MG132 (EMD, CA), N2 and B27 supplements (Gibco, CA), steroid alkaloid such as, for example, cyclopamine (EMD, CA), keratinocyte growth factor (KGF), Dicickopf protein family, bovine pituitary extract, islet neogenesis-associated protein (INGAP), Indian hedgehog, sonic hedgehog, proteasome inhibitors, notch pathway inhibitors, sonic hedgehog inhibitors, or combinations thereof.
[0203] The at least one other additional factor may be supplied by conditioned media obtained from pancreatic cells lines such as, for example, PANC-1 (ATCC No: CRL-1469), CAPAN-1 (ATCC No: HTB-79), BxPC-3 (ATCC No: CRL-1687), HPAF-II (ATCC

No: CRL-1997), hepatic cell lines such as, for example, HepG2 (ATCC No: HTB-8065), and intestinal cell lines such as, for example, FHs 74 (ATCC No: CCL-241).
[0204] Differentiation of human embryonic stem cells into cells expressing markers characteristic of the definitive endoderm lineage on an extracellular matrix, using two culture media: Differentiation of human embryonic stem cells into cells of a definitive endoderm lineage may be accomplished by culturing the human embryonic stem cells with activin-A and a Wnt ligand using two culture media. Thus, the differentiation of the human embryonic stem cells may be accomplished as follows:
a. Plating the human embryonic stem cells on a tissue culture substrate coated with an extracellular matrix, b. Culturing the human embryonic stem cells with activin-A and a Wnt ligand in a first culture medium, and c. Culturing the human embryonic stem cells with activin-A in a second culture medium.
[0205] The first culture medium may contain serum at a low concentration, and the second culture medium may contain serum at a higher concentration than the first culture medium.
[0206] The second culture medium may contain a Wnt ligand.
[0207] First Culture Medium: The first culture medium should contain sufficiently low concentrations of certain factors to allow the differentiation of human embryonic stem cells into cells expressing markers characteristic of the definitive endoderm lineage, such as, for example insulin and IGF (as disclosed in W02006020919). This may be achieved by lowing the serum concentration, or alternatively, by using chemically defined media that lacks insulin and IGF. Examples of chemically defined media are disclosed in Wiles et al (Exp Cell Res. 1999 Feb 25; 247(1):241-8.).
[0208] In the first culture medium there may be a lower concentration of serum, relative to the second culture medium. Increasing the serum concentration in the second culture medium increases the survival of the cells, or, alternatively, may enhance the proliferation of the cells. The serum concentration of the first medium may be in the range of about 0% to about 10%. Alternatively, the serum concentration of the first medium may be in the range of about 0% to about 2%. Alternatively, the serum concentration of the first medium may be in the range of about 0% to about 1%.

Alternatively, the serum concentration of the first medium may be about 0.5%.
[0209] When culturing the human embryonic stem cells with activin-A and a Wnt ligand using at least two culture media, the time of culturing in the first culture medium may range from about 1 day to about 3 days.
[0210] Activin-A may be used at any concentration suitable to cause differentiation of the human embryonic stem cells. The concentration maybe from about lpg/m1 to about 100 g/ml. In an alternate embodiment, the concentration may be about lpg/ml to about lug/ml. In another alternate embodiment, the concentration may be about lpg/ml to about 10Ong/ml. In another alternate embodiment, the concentration may be about 5Ong/m1 to about 10Ong/ml. In another alternate embodiment, the concentration may be about 10Ong/ml.
[0211] The choice of the Wnt ligand may be optimized to improve the efficiency of the differentiation process. The Wnt ligand may be selected from the group consisting of Wnt-1, Wnt-3a, Wnt-5a and Wnt-7a. In one embodiment, the Wnt ligand is Wnt-1.
In an alternate embodiment, the Wnt ligand is Wnt-3a.
[0212] The Wnt ligand may be at a concentration of about lng/ml to about 1000ng/ml. In an alternate embodiment, the concentration may be about lOng/m1 to about 10Ong/ml.
[0213] The first culture medium may also contain a GSK-3B inhibitor. The GSK-3B inhibitor may be added to the first culture medium, to the second culture medium, or to both the first and second culture media.
[0214] The GSK-3B inhibitor may be selected from the group consisting of GSK-3B inhibitor IX and GSK-3B inhibitor XI. In one embodiment, the GSK-3B inhibitor is GSK-3B
inhibitor IX.
[0215] When culturing human embryonic stem cells with a GSK-3B inhibitor, the concentration of the GSK-3B inhibitor may be from about 1nM to about 1000nM.
In an alternate embodiment, the human embryonic stem cells are cultured with the GSK-3B inhibitor at a concentration of about lOnM to about 100nM.
[0216] The first culture medium may also contain at least one other additional factor that may enhance the formation of cells expressing markers characteristic of the definitive endoderm lineage from human embryonic stem cells. Alternatively, the at least one other additional factor may enhance the proliferation of the cells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention. Further, the at least one other additional factor may enhance the ability of the cells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention to form other cell types, or improve the efficiency of any other additional differentiation steps.
[0217] The at least one additional factor may be, for example, nicotinamide, members of the TGF-p family, including TGF-131, 2, and 3, serum albumin, members of the fibroblast growth factor family, platelet-derived growth factor-AA, and ¨BB, platelet rich plasma, insulin growth factor (IGF-I, II), growth differentiation factor (GDF-5, -6, -8, -10, 11), glucagon like peptide-I and II (GLP-I and II), GLP-1 and GLP-2 mimetobody, Exendin-4, retinoic acid, parathyroid hormone, insulin, progesterone, aprotinin, hydrocortisone, ethanolamine, beta mercaptoethanol, epidermal growth factor (EGF), gastrin I and II, copper chelators such as, for example, triethylene pentamine, forskolin, Na-Butyrate, activin, betacellulin, ITS, noggin, neurite growth factor, nodal, valporic acid, trichostatin A, sodium butyrate, hepatocyte growth factor (HGF), sphingosine-1, VEGF, MG132 (EMD, CA), N2 and B27 supplements (Gibco, CA), steroid alkaloid such as, for example, cyclopamine (EMD, CA), keratinocyte growth factor (KGF), Dicldcopf protein family, bovine pituitary extract, islet neogenesis-associated protein (INGAP), Indian hedgehog, sonic hedgehog, proteasome inhibitors, notch pathway inhibitors, sonic hedgehog inhibitors, or combinations thereof.
[0218] The at least one other additional factor may be supplied by conditioned media obtained from pancreatic cells lines such as, for example, PANC-1 (ATCC No: CRL-1469), CAPAN-1 (ATCC No: HTB-79), BxP C-3 (ATCC No: CRL-1687), HPAF-II (ATCC
No: CRL-1997), hepatic cell lines such as, for example, HepG2 (ATCC No: HTB-8065), and intestinal cell lines such as, for example, FHs 74 (ATCC No: CCL-241).

[0219] Second Culture Medium: The second culture medium should contain certain factors, such as, for example, insulin and IGF (as disclosed in W02006020919), at a sufficient concentration to promote the survival of the cultured cells. This may be achieved by increasing the serum concentration, or, alternatively, by using chemically defined media where the concentrations of insulin and IGF are increased relative to the first culture medium. Examples of chemically defined media are disclosed in Wiles et al (Exp Cell Res. 1999 Feb 25; 247(1): 241-8.).
[0220] In a second culture medium having higher concentrations of serum, the serum concentration of the second culture medium may be in the range about 0.5% to about 10%. Alternatively, the serum concentration of the second culture medium may be in the range of about 0.5% to about 5%. Alternatively, the serum concentration of the second culture medium may be in the range of about 0.5% to about 2%.
Alternatively, the serum concentration of the second culture medium may be about 2%. When culturing human embryonic stem cells with the second culture medium, the time of culturing may range from about 1 day to about 4 days.
[0221] Similar to the first culture medium, Activin-A may be used at any concentration suitable to cause differentiation of the human embryonic stem cells. The concentration maybe from about lpg/ml to about 1004g/ml. In an alternate embodiment, the concentration may be about lpg/ml to about 1 g/ml. In another alternate embodiment, the concentration may be about lpg/ml to about 10Ong/ml. In another alternate embodiment, the concentration may be about 5Ong/m1 to about 10Ong/ml. In another alternate embodiment, the concentration may be about 10Ong/ml.
[0222] The Wnt ligand may be at a concentration of about ing/m1 to about 1000ng/ml. In an alternate embodiment, the concentration may be about lOng/m1 to about 10Ong/ml.
[0223] The Wnt ligand may be selected from the group consisting of Wnt-1, Wnt-3a, Wnt-5a and Wnt-7a. In one embodiment, the Wnt ligand is Wnt-1. In an alternate embodiment, the Wnt ligand is Wnt-3a.
[0224] The second culture medium may also contain a GSK-3B inhibitor. The inhibitor may be added to the first culture medium, to the second culture medium, or to both the first and second culture media.

[0225] The GSK-3B inhibitor may be selected from the group consisting of GSK-3B inhibitor IX and GSK-3B inhibitor XI. In one embodiment, the GSK-3B inhibitor is GSK-3B
inhibitor IX.
[0226] When culturing human embryonic stem cells with a GSK-3B inhibitor, the concentration of the GSK-3B inhibitor may be from about 1nM to about 1000nM.
In an alternate embodiment, the human embryonic stem cells are cultured with the GSK-3B inhibitor at a concentration of about lOnM to about 100nM.
[0227] Similar to the first culture medium, the second culture medium may also contain at least one other additional factor that may enhance the formation of cells expressing markers characteristic of the definitive endoderm lineage from human embryonic stem cells. Alternatively, the at least one other additional factor may enhance the proliferation of the cells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention. Further, the at least one other additional factor may enhance the ability of the cells expressing markers characteristic of the definitive endoderm lineage formed by the methods of the present invention to form other cell types, or improve the efficiency of any other additional differentiation steps.
[0228] The at least one additional factor may be, for example, nicotinamide, members of the TGF-13 family, including TGF-131, 2, and 3, serum albumin, members of the fibroblast growth factor family, platelet-derived growth factor-AA, and ¨BB, platelet rich plasma, insulin growth factor (IGF-I, II), growth differentiation factor (GDF-5, -6, -8, -10, 11), glucagon like peptide-I and 11 (GLP-I and II), GLP-1 and GLP-2 mimetobody, Exendin-4, retinoic acid, parathyroid hormone, insulin, progesterone, aprotinin, hydrocortisone, ethanolamine, beta mercaptoethanol, epidermal growth factor (EGF), gastrin I and II, copper chelators such as, for example, triethylene pentamine, forskolin, Na-Butyrate, activin, betacellulin, ITS, noggin, neurite growth factor, nodal, valporic acid, trichostatin A, sodium butyrate, hepatocyte growth factor (HGF), sphingosine-1, VEGF, MG132 (EMD, CA), N2 and B27 supplements (Gibco, CA), steroid alkaloid such as, for example, cyclopamine (EMD, CA), keratinocyte growth factor (KGF), Dicldcopf protein family, bovine pituitary extract, islet neogenesis-associated protein (INGAP), Indian hedgehog, sonic hedgehog, proteasome inhibitors, notch pathway inhibitors, sonic hedgehog inhibitors, or combinations thereof.
[0229] The at least one other additional factor may be supplied by conditioned media obtained from pancreatic cells lines such as, for example, PANC-1 (ATCC No: CRL-1469), CAPAN-1 (ATCC No: HTB-79), BxPC-3 (ATCC No: CRL-1687), HPAF-II (ATCC
No: CRL-1997), hepatic cell lines such as, for example, HepG2 (ATCC No: HTB-8065), and intestinal cell lines such as, for example, FHs 74 (ATCC No: CCL-241).
[0230] The present invention is further illustrated, but not limited by, the following examples.
Example 1 Human Embryonic Stem Cell Culture [0231] Stem cells are undifferentiated cells defined by their ability at the single cell level to both self-renew and differentiate to produce progeny cells, including self renewing progenitors, non-renewing progenitors, and terminally differentiated cells.
Stem cells are also characterized by their ability to differentiate in vitro into functional cells of various cell lineages from multiple germ layers (endoderm, mesoderm and ectoderm), as well as to give rise to tissues of multiple germ layers following transplantation and to contribute substantially to most, if not all, tissues following injection into blastocysts.
[0232] The human embryonic stem cell lines H1, H7 and H9 were obtained from WiCell Research Institute, Inc., (Madison, WI) and cultured according to instructions provided by the source institute. Briefly, cells were cultured on mouse embryonic fibroblast (MEF) feeder cells in ES cell medium consisting of DMEM/F12 (Invitrogen/GIBCO) supplemented with 20% knockout serum replacement, 100 nM MEM nonessential amino acids, 0.5 mM beta-mercaptoethanol, 2mM L-glutamine with 4ng/m1 human basic fibroblast growth factor (bFGF) (all from Invitrogen/GIBCO). MEF cells, derived from E13 to 13.5 mouse embryos, were purchased from Charles River. MEF

cells were expanded in DMEM medium supplemented with 10% FBS (Hyclone), 2mM
glutamine, and 100 mM MEM nonessential amino acids. Sub-confluent MEF cell cultures were treated with 10p.g/m1 mitomycin C (Sigma, St. Louis, MO) for 3h to arrest cell division, then trypsinized and plated at 2x104/cm2 on 0.1% bovine gelatin-coated dishes. MEF cells from passage two through four were used as feeder layers.

Human embryonic stem cells plated on MEF cell feeder layers were cultured at 37 C in an atmosphere of 5% CO2 within a humidified tissue culture incubator. When confluent (approximately 5-7 days after plating), human embryonic stem cells were treated with 1mg/m1 collagenase type IV (Invitrogen/GIBCO) for 5-10 min and then gently scraped off the surface using a 5-ml pipette. Cells were centrifuged at 900 rpm for 5 min, and the pellet was resuspended and re-plated at a 1:3 to 1:4 ratio of cells in fresh culture medium.
[0233] In parallel, H1, H7, and H9 human embryonic stem cells were also seeded on plates coated with a 1:30 dilution of growth factor reduced MATRIGEL (BD Biosciences) and cultured in MEF-conditioned media supplemented with 8 ng/ml bFGF. The cells cultured on MATRIGEL were routinely passaged with collagenase IV
(Invitrogen/GIBCO), DispaseTM (BD Biosciences) or LIBERASE enzyme. Some of the human embryonic stem cell cultures were incubated under hypoxic conditions (approximately 3% 02).
Example 2 Fluorescence-Activated Cell Sorting (FACS) Analysis [0234] Adhered human embryonic stem cells were removed from culture plates by a five-minute incubation with TrypLETm Express solution (Invitrogen, CA). Released cells were resuspended in human embryonic stem cell culture medium and recovered by centrifugation, followed by washing and resuspending the cells in a staining buffer consisting of 2% BSA, 0.05% sodium azide in PBS (Sigma, MO). As appropriate, the cells were Fe-receptor blocked for 15 minutes using a 0.1% y¨globulin (Sigma) solution. Aliquots (approximately 1x105 cells) were incubated with either phycoerythirin (PE) or allophycocyanin (APC) conjugated monoclonal antibodies (5 11.1 antibody per 1x106 cells), as indicated in Table IA, or with an unconjugated primary antibody. Controls included appropriate isotype matched antibodies, unstained cells, and cells stained only with secondary conjugated antibody. All incubations with antibodies were performed for 30 mins at 4 C, after which the cells were washed with the staining buffer. Samples that were stained with unconjugated primary antibodies were incubated for an additional 30 mins at 4 C with secondary conjugated PE
or ¨
APC labeled antibodies. See Table IB for a list of secondary antibodies used.
Washed cells were pelleted and resuspended in the staining buffer, and the cell surface molecules were identified using a FACS Array (BD Biosciences) instrument, collecting at least 10,000 events.
Example 3 Immunocytochemistry [0235] Adhered cells were fixed with 4% paraformaldheyde for 20 min at room temperature.
Fixed cells were blocked for 1 h at room temperature with PBS/0.1%BSA/10%
normal chick serum /0.5% TritonTm X-100 and then incubated overnight with primary antibodies in PBS/0.1%BSA/10% normal chick serum at 4 C. The list of primary antibodies and their working dilutions are shown in Table IA. After three washes in PBS/0.1% BSA, fluorescent secondary antibodies (Table IB) at a 1:100 dilution in PBS were incubated with cells for 1 h at room temperature to allow binding.
Control samples included reactions where the primary antibody was omitted or where the primary antibody was replaced with corresponding matched negative control immunoglobulins at the same concentration as the primary antibodies. Stained samples were rinsed; a drop of PROLONG (Invitrogen, CA) containing diamidino-2-phenylindole, dihydrochloride (DAPI) was added to each sample to counter-stain the nucleus and to function as an anti-fade reagent. Images were acquired using a Nikon Confocal Eclipse C-1 inverted microscope (Nikon, Japan) and a 10-60X
objective.
Example 4 PCR Analysis of ES Derived-Cells [0236] RNA extraction, purification, and cDNA synthesis: RNA samples were purified by binding to a silica-gel membrane (Rneasy Mini Kit, Qiagen, CA) in the presence of an ethanol-containing, high-salt buffer followed by washing to remove contaminants. The RNA was further purified using a TURBO DNA-free kit (Ambion, INC), and high-quality RNA was then eluted in water. Yield and purity were assessed by A260 and A280 readings on a spectrophotometer. CDNA copies were made from purified RNA
using an ABI (ABI, CA) high capacity cDNA archive kit.

[0237] Real-time PCR amplification and quantitative analysis: Unless otherwise stated, all reagents were purchased from Applied Biosystems. Real-time PCR reactions were performed using the ABI PRISM 7900 Sequence Detection System. TAQMANO
UNIVERSAL PCR MASTER MIX (ABI, CA) was used with 20 ng of reverse transcribed RNA in a total reaction volume of 20 pl Each cDNA sample was run in duplicate to correct for pipetting errors. Primers and FAM-labeled TAQMAN
probes were used at concentrations of 200 nM. The level of expression for each target gene was normalized using a human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) endogenous control previously developed by Applied Biosystems. Primer and probe sets are listed in Table II. SOX-17 primers were designed using the PRIMERS
program (ABI, CA) and were the following sequences: SOX-17:
TGGCGCAGCAGATACCA, AGCGCCTTCCACGACTTG, and CCAGCATCTTGCTCAACTCGGCG. After an initial incubation at 50 C for 2 min followed by 95 C for 10 min, samples were cycled 40 times in two stages - a denaturation step at 95 C for 15 sec followed by an annealing/extension step at 60 C
for 1 min. Data analysis was carried out using GENEAMP07000 Sequence Detection System software. For each primer/probe set, a Ct value was determined as the cycle number at which the fluorescence intensity reached a specific value in the middle of the exponential region of amplification. Relative gene expression levels were calculated using the comparative Ct method. Briefly, for each cDNA sample, the endogenous control Ct value was subtracted from the gene of interest Ct to give the delta Ct value (ACt). The normalized amount of target was calculated as 2-ACt, assuming amplification to be 100% efficiency. Final data were expressed relative to a calibrator sample.
Example 5 Differentiation of Human Embryonic Stem Cells Cultured on Tissue Culture Substrate Coated with MATRIGEL to Definitive Endoderm (DE) [02381 Cells from the human embryonic stem cell line H9 at passage 54 were cultured under hypoxic conditions (approximately 3% 02) and plated on MATRIGEL (1:30 dilution) coated dishes were exposed to DMEM/F12 medium supplemented with 0.5% FBS, 20 ng/ml WNT-3a (Catalog# 1324-WN-002, R&D Systems, MN), and 100 ng/ml Activin-A (R&D Systems, MN) for two days followed by treatment with DMEM/F12 media supplemented with 2% FBS and 100 ng/m1Activin-A (AA) for an additional 3-4 days.
Figure 1 depicts the expression of CXCR4 by FACS at day 4. Figure 2 displays the real-time PCR data for cultures of cells from the human embryonic stem cell line H9 treated with low serum + AA + WNT3A at days 4 and 6. This protocol resulted in significant upregulation of definitive endoderm markers. This procedure will be further referred to as the DE (Definite Endoderm) protocol.
Example 6 Isolation and Expansion of Human Embryonic Stem Cell Derived Cells Differentiated to the Definitive Endoderm Stage [0239] Cells from the human embryonic stem cell lines HI and H9 various passages (Passage 30-54) were cultured under hypoxic conditions (approximately 3% 02) for at least three passages. The cells were cultured in MEF-CM supplemented with 8 ng/ml of bFGF
and plated on MATRIGEL coated plates according to Example 1. The cells were exposed to the DE protocol outlined in Example 5. At days 3-6, the cultures were exposed to TrypLETm Express solution (Invitrogen, CA) for 5 mins. Released cells were resuspended in DMEM-F12 + 2% FBS medium, recovered by centrifugation, and counted using a hemocytometer. The released cells were seeded at 1000-10,000 cells/cm2 on tissue culture polystyrene (TCPS) treated flasks and cultured in DMEM-F12 + 2% FBS + 100 ng/ml activin-A + 20 ng/ml WNT-3A under hypoxic conditions (approximately 3% 02) at 37 C in standard tissue culture incubator. The TCPS
flalcs were not coated with MATRIGEL or other extracellular matrix proteins. The media was changed daily. In some cultures, the media was further supplemented with ng/ml of IGF-I (insulin growth factor-I from R&D Systems, MN) or 1X ITS
(Insulin, transferrin, and selenium from Invitrogen, Ca). In some of the culture conditions the basal media (DM-F12 + 2% FBS) was further supplemented with 0.1 mM
mercaptoethanol (Invitrogen, CA) and non-essential amino acids (1X, NEAA from Invitrogen, CA). The first passage cells are referred to as Pl. In parallel, similar cultures were established under normoxic conditions (approximately 21% 02).
The outline of this isolation procedure is depicted in Figure 3.

[0240] Following 5-15 days of culturing, distinct cell colonies appeared surrounded by a large number of enlarged cells that appear to be in senescence (Figure 4a-b). At approximately 50-60% continency, the cultures were passaged by exposure to TrypLETm Express solution for 5 mins at room temperature. The released cells were resuspended in DMEM-F12 + 2% FBS medium, recovered by centrifugation, and seeded at 10,000 cells/cm2 on tissue culture polystyrene (TCPS) treated flasks in DMEM-F12 + 2%FBS + 100 ng/ml activin-A + 20 ng/ml WNT-3A +/- 50 ng/ml of IGF-I. This media will be further referred to as the "growth media". Figure 4 c depicts the morphology of cells at passage 3 seeded at 10,000 cells/cm2. At passage 3 (panel c) following the initial isolation, the cells appeared to have a uniform epithelial-like morphology with a large nucleus to cytoplasm ratio.
[0241] In some cultures the growth media was further supplemented with 1X
NEAA plus 0.1 mM mercaptoethanol. Following three to four passages, the attached cells appeared to have a uniform morphology with a large nucleus to cytoplasm ratio. Parallel cultures established under normoxic conditions failed to show robust colony formation by attached cells. Following 2-3 passages, the cultures established under normoxic conditions were abandoned due to poor growth rate.
Example 7 Role of activin-A, WNT3A, and IGF-I in Expansion and Maintenance of DE
Markers Following Multiple Passages 102421 Cultures derived from the parental human embryonic stem cell line H9 according to the methods described in Example 6 were passaged every 4-7 days. Figure 5 depicts real-time PCR results for the expanded cells cultured in 2% FBS + DMEM-F12 + 100 ng/ml of activin-A + 20 of WNT3A for three passages. This data is for a line isolated at day6 of the DE protocol outlined in Example 5. There is a clear decrease in DE
markers, such as SOX-17 and HNF-3 beta following each passage. As shown in Figure 6, addition of WNT3A to the growth media containing activin-A led to a significant boost in the expression of DE markers. However, addition of 50 ng/ml of IGF-I and withdrawal of Activin-A and WNT-3A (Figure 7 a-c) led to a precipitous drop in the expression of DE markers along with OCT-4 and an increase in expression of visceral endoderm markers, such as SOX-7 and APP. Figure 8 a-c depicts the morphology of expanded cells derived from H9p54 at passage 5 cultured in a) 2% FBS + DMF12 +

100 ng/ml of activin-A + 20 ng/ml of WNT-3A, b) 2% FBS + DM-F12 + 100 ng/ml of activin-A, c) 2% FBS + DM-F12 + 50 ng/ml of IGF-I. Morphology of cells cultured in the presence of activin-A or activin-A + WNT3A were very similar and distinct from morphology of cells cultured in 2% FBS + IGF-I.
Example 8 Expansion Potential of Human Embryonic Stem Cell Derived Cells Differentiated to the Definitive Endoderm stage [0243] Cultures established from the parental human embryonic stem cell line H9 according to the methods described in Example 6 were passaged every 4-5 days when the growth media contained 50 ng/ml of IGF-I or ITS. However, cultures fed with growth media lacking the IGF or ITS supplements showed slower growth rate and were passaged every 5-7 days. The population doubling time of cells fed with growth media +

ng/ml of IGF-I was approximately 55 hrs where as the population doubling time of cultures fed only with the growth media was approximately 75 hrs. The cell population expanded according to Example 6 will be referred to as EXPRES cells (EXpandable PRE-primitive Streak cells). Table III lists various EXPRES cells established according to methods outlined in Example 6. The expansion potential of two cell lines (EXPRES 01 and 02) is depicted in Figure 9.
Example 9 Derivation of EXPRES Cells from Suspensions of Single Human Embryonic Stem Cells [0244] Cells from the human embryonic stem cell lines HI P33 and H9 P45 were cultured under hypoxic conditions (approximately 3% 02) for at least three passages.
The cells were cultured in MEF-CM supplemented with 8 ng/ml of bFGF and plated on MATRIGEL coated plates according to Example 1. At approximately 60%
confluency, the cultures were exposed to TrypLETm Express solution (Invitrogen, CA) for 5 mins. Released cells were resuspended in DMEM-F12 + 2% FBS medium, recovered by centrifugation, and counted using a hemocytometer. The released cells were seeded at 1000 to 10,000 cells/cm2 on tissue culture polystyrene (TCPS) treated flasks and cultured in DM-F12 + 2% FBS + 100 ng/ml activin-A + 20 ng/ml WNT-3A

+ 50 ng/ml of IGF-I + 0.1 mM mercaptoethanol (Invitrogen, CA) and non-essential amino acids (1X, NEAA from Invitrogen, CA) under hypoxic conditions (approximately 3% 02) at 37 C in a standard tissue culture incubator. The TCPS
flasks were not coated with MATRIGEL or other extarcellular matrix proteins.
The media was changed daily. The first passage cells are referred to as Pl. In parallel, similar cultures were established under normoxic conditions (approximately 21%
02).
Cultures established under atmospheric conditions did not result in colony formation and there was poor cell proliferation. However, cultures established under hypoxic conditions resulted in formation of many colonies (Figure 10) resembling embryonic stem cell colonies cultured on MATRIGEL or on MEF feeders. These cultures closely resemble the properties of EXPRES cells isolated during ES to DE
differentiation.
Example 10 Expression of Cell Surface Proteins by EXPRES Cells [0245] The cell lines EXPRES 01 and EXPRES 02 were evaluated for expression of various cell-surface markers including markers associated with pluripotency. Cells from EXPRES 01 were evaluated at passages 9 to 24. Cells from EXPRES 02 were evaluated at passages 7 to 20. Both lines exhibited strong expression of pluripotency markers typically assigned to undifferentiated human embryonic stem cells.
However, the EXPRES 02 line showed a higher percentage of expression of differentiation markers, such as CXCR4, LIE receptor, and NCAM as compared to the EXPRES 01 line. Representative FACS plots are depicted in Figure 11 for EXPRES 01 P24 and in Figure 12 for EXPRES 02 P21 line. Table IV lists the mean expression levels along with the ranges (in brackets) of the evaluated cell surface markers from three different experiments.
Example 11 Expression of Pluripotency Associated Markers by EXPRES Cells- Immuno fluorescent (IF) Staining [0246] EXPRES 01 and 02 cells maintained in their respective growth media were stained for pluripotency-associated markers using methods outlined in Example 3. Figure 13

47 depicts IF images for OCT-4, Nanog, SOX-2, and HNF-3 beta for EXPRES 01 P10 cells cultured in 2% FBS + DM-F12 + 100 ng/ml activin-A + 20 ng/ml WNT3A + 50 ng/ml IGF-1. Figure 14 depicts IF images for OCT-4, Nanog, SOX-2, and HNF-3 beta for EXPRES 02 passage 9 cells cultured in 2% FBS + DM-F12 + 100 ng/ml activin-A
+ 20 ng/ml WNT3A. EXPRES 01 cells strongly stain positive for OCT-4, Nanog, and SOX-2 and weakly for HNF-3 beta. However, EXPRES 02 cells show stronger expression for HNF-3 beta and weaker expression of OCT-4, NANOG, and SOX-2.
Example 12 Expression of Definitive Endoderm and Undifferentiated Embryonic Stem Cell Markers by Real Time PCR
[0247] Real-time PCR analysis of embryonic markers (POU5F1, SOX-2, UTF1, ZFP42, Connexin43, Connexin45, FOXD3), extraembryonic markers (AFP, KRT15), ectoderm markers (SOX-1, TUBB3, NEST1N), endoderm markers (FOXA2, IPF1, KRT15, GATA-4), and mesoderm markers (GATA-4, GATA-2, MYOD, MSX1, CFC1, ABCG2) expressed by EXPRES 01 passage 11 and EXPRES 02passage 7 lines cultured in their respective growth media is depicted in Figure 15 a-h. All of the data is normalized to fold change with respect to undifferentiated cells from the human embryonic stem cell line H9, cultured in MEF-CM on MATRIGEL coated plates. As a control, EB bodies were formed from H9 cells using standard methods of collagenase digestion and seeding on non-treated surfaces in DMEM-F12 + 20 % FBS for approximately 10 days. Gene expression of various germ layers was upregulated by EB bodies as compared to undifferentiated ES cells. Another reference RNA was collected from undifferentiated SA002 line (Cellartis, Sweden) cultured on MATRIGEL in MEF-CM. As expected gene expression of various germ layers was strongly upregulated by EB bodies as compared to EXPRES 01, EXPRES 02, SA002, and H9 lines. Both EXPRES 01 and 02 lines showed expression of FOXA2 as compared to undifferentiated SA002 and H9 lines. Neither of the EXPRES lines exhibited strong expression of extra embryonic, mesoderm or ectoderm markers.
Furthermore, expression of embryonic markers by EXPRES cells was similar to the SA002 and H9 reference cell lines.
Example 13

48 Various Growth Media Useful for Expansion of EXPRES Cells [02481 EXPRES cells have been successfully cultured in the following media compositions for at least 2-30 passages:
1. DM-F12 + 2% FBS + 100 ng/ml AA + 20 ng/ml WNT-3A
2. DM-F12 + 2% FBS + 100 ng/ml AA + 20 ng/ml WNT-3A +50 ng/ml IGF-I
3. DM-F12 + 2% FBS + 100 ng/ml AA + 20 ng/ml WNT-3A + 10 ng/ml IGF-I
4. DM-F12 + 2% FBS +50 ng/ml AA +20 ng/ml WNT-3A +50 ng,/m1IGF-I
5. DM-F12 + 2% FBS + 50 ng/ml AA + 10 ng/ml WNT-3A + 50 ng/ml IGF-I
6. DM-F12 + 2% FBS +50 ng/ml AA + 20 ng/ml WNT-3A + 10 ng/ml IGF-I
7. DM-F12 + 2% FBS + 100 ng/ml AA + 10 ng/ml WNT-3A + 10 ng/ml IGF-I
8. HEScGRO defined media (Chemicon, CA) The basal component of the above listed media may be replaced with similar media such as, RPMI, DMEM, CRML, Knockout TmDMEM, and F12.
Example 14 Differentiation of EXPRES Cells Cultured on Tissue Culture Substrate to Definitive Endoderm (DE) cells [02491 EXPRES 01 cells at passage 5 and EXPRES 02 cells at passage 4, cultured on TCPS in their respective media were exposed to DMEM/F12 medium supplemented with 0.5%
FBS, 20 ng/ml WNT-3a, and 100 ng/ml activin-A (R&D Systems, MN) for two days followed by treatment with DMEM/F12 media supplemented with 2% FBS and 100 ng/ml activin-A (AA) for an additional 3-5 days. Figure 16 depicts the expression of CXCR4 by FACS at days 4 for EXPRES 01 cells (Figure 16 a, approximately 17%
CXCR4 positive) and EXPRES 02 cells (Figure 16b, approximately 40% CXCR4 positive). Figure 17 displays the real-time PCR data for EXPRES 01 cell (Figure 17a) and EXPRES 02 cell (Figure 17b) cultures treated with low serum + AA + WNT3A
at

49 days 2-5. Figures 18 and 19 depict immunofluoresence images of EXPRES 01 and cells, respectively, treated with the same treatment mentioned above for 4 days.
Overall EXPRES 02 cells appear to show a stronger expression of DE markers as compared to EXPRES 01 cells. As evident by FACS, immuno staining, and PCR
data, lowering of serum concentration and removal of IGF did enhance the expression of DE
markers. However, the overall expression level of DE markers such as CXCR4 and HNF-3 beta was lower than what we have routinely observed in undifferentiated human ES cultures differentiated to the DE stage.
[0250] In order to enhance expression of DE markers, the DE differentiation protocol was changed to the following: EXPRES 01 cells at passage 19 and EXPRES 02 cells at passage 14 cultured on TCPS in their respective media were exposed to DMEM/F12 medium supplemented with 0.5% FBS, 20 ng,/m1WNT-3a, 100 ng/ml activin-A, and 100 nM GSK-3B inhibitor IX (Catalog# 361550, Calbiochem, CA) for 4 to 5 days.
Figure 20 depicts the expression of CXCR4 by FACS at days 4 for EXPRES 01 (Figure 20 a, approximately 57% CXCR4 positive) and EXPRES 02 (Figure 20b, approximately 86% CXCR4 positive). Figure 21 depicts the corresponding immuno fluorescent images at day 5 for EXPRES 01 cells (panels a-f) and EXPRES 02 cells (panels g-l) cells differentiated to the DE stage. Figure 22 displays the real-time PCR
data for EXPRES 01 (Figure 22a) and EXPRES 02 (Figure 22b).
Example 15 Effect of Seeding Density on the Differentiation of EXPRES 01 Cells to DE
[0251] EXPRES 01 P31 cells were seeded at 5000, 10000, 20000, or 40000 cells/cm2 on TCPS
plates in DM-F12 + 2% FBS + 0.1 mM mercaptoethanol + lx, NEAA + 100 ng/ml activin-A + 20 ng/ml WNT3A under hypoxic conditions (approximately 3% 02) at C in standard tissue culture incubator. Following two days post seeding, the media was switched to DMEM-F12 +0.5% FBS + 100 ng/ml activin-A +20 ngiml WNT3A +
100 nM GSK-3B inhibitor IX for four days under hypoxic conditions (approximately 3% 02) at 37 C in standard tissue culture incubator. Figure 23 depicts the real-time PCR analysis of definitive endoderm markers at day 4 of differentiation. It appears that a seeding density of at least 10000-20000 cells/cm2 is required for the robust formation of definitive endoderm.

Example 16 Telomere Length of EXPRES Cells [0252] The telomere length of two EXPRES lines isolated according to Example 5 along with undifferentiated cells from the human embryonic stem cell line HI was analyzed by using the Telo TAGGG Telomere Length Assay (Roche, IN) and following the manufacturer's instruction. Figure 24 depicts the telomere length for EXPRES
01 cells at P24, EXPRES 02 cells at P17, H1 cells at P40, high and low telomere controls provided by the kit, along with the scale marker. Both lines appear to have shorter telomere length than undifferentiated ES cells.
Example 17 Further Differentiation of EXPRES Cells Cultured on Tissue Culture Substrate to Pancreatic Endoderm [0253] EXPRES 01 cells at passage 21 underwent a 5 day differentiation by treatment with 10Ong/m1 activin-A, lOng/m1 of Wnt3a, and 100 nM GSK3beta inhibitor IX in 0.5%

FBS, DMEM:F12 media. Cells were analyzed by FACS and showed 80% of the cells were positive for CXCR4. The cells were then treated for 3 days in each of the following steps: 2%FBS DMEM:F12 containing 5Ong/m1FGF-10, and 0.25p.M
KAAD-Cyclopamine (Calbiochem, CA); followed by, 1%B27 DMEM, low glucose containing 50 ng/ml FGF-10, 0.251.IM KAAD-Cyclopamine and liuM Retinoic Acid (Sigma, MO); followed by, 1%B27 DMEM, low glucose containing 11.1M DAPT
(Calbiochem, CA) plus 50 ng/ml Exendin4 (Sigma, MO); and lastly followed by, 1%
B27 DMEM CMRL containing 50ng/m1 each of IGF, HGF and Exendin4. Samples were taken at the end of each step, and RNA was extracted for the cells. Q-RT
PCR
was conducted for the markers shown. As depicted in Figure 25, Insulin levels were increased 100 fold over untreated cells and PDX-1 levels were also increased over 1000 fold.
Example 18 Further Differentiation of EXPRES Cells Cultured on Tissue Culture Substrate to Foregut Endoderm [0254] EXPRES01 cells at passage 35 underwent a 5 day differentiation by treatment with 10Ong/m1 activin-A, 20ng/m1 of Wnt3a, and 100 nM GSK3beta inhibitor IX in 0.5%

FBS, DMEM:F12 media. Cells were analyzed by FACS and showed approximately 70% of the cells were positive for CXCR4. The cells were then treated for in each of the following steps: 2%FBS DMEM:F12 containing 5Ong/m1FGF-10, and 0.25p.M
KAAD-Cyclopamine (Calbiochem, CA) for 3 days; Step3, 1%B27 DMEM, low glucose containing 50 ng/ml FGF-10, 0.25 M KAAD-Cyclopamine and luM Retinoic Acid (Sigma, MO) for 4 days; and Step 4, 1%B27 DMEM, low glucose containing DAFT (Calbiochem, CA) plus 50 ng/ml Exendin4 (Sigma, MO) for 4 days.. This protocol is based on a prior publication by D'Amour et al (Nature Biotech, 24, 1392, 2006). Cells were fixed at end of stage 4 and stained for PDX-1, HNF-3 beta, SOX-17, Albumin, anti-trypsin, and CDX-2. As depicted in Figure 26, EXPRES cells can be readily differentiated to foregut endoderm as measured by expression of PDX-1 (approximately 20% of culture stained positive), HNF-3 beta (approximately 90%

positive), albumin (approximately 5% positive), anti-1- Trypsin (approximately 70%
positive), SOX-17 (approximately 70%), and CDX-2 (approximately 5% positive).
Example 19 Microarray Analysis of EXPRES Cells Versus Undifferentiated Human Embryonic Stem Cells [0255] Total RNA was isolated from cultures of the human embryonic stem cell line H9,at passage 44, EXPRES 01 Pll and EXPRES 02 P7 using an RNeasy mini kit (Qiagen):
All groups contained three biological replicates and each biological replicate was repeated on two separate gene chips. Sample preparation, hybridization, and image analysis were performed according to the Affymetrix Human Genome U133 Plus 2.0 Array. Following normalization and a log transformation, data analysis was performed using OmniViz software (MA) and GENESIFTER (VizXLabs, WA). Significant differences in gene expression between the samples were evaluated using analysis of variance and an F-test with adjusted P-value (Benjamini and Hochberg correction) of less than or equal to 0.05. Only genes with a present call in at least one group were included in the analysis. Table V lists the mean normalized log-transformed signal intensity of genes showing at least 5-fold difference between groups (undifferentiated ES, EXPRES 01 and EXPRES 02 cells) along with the adjusted P-value for each gene.
Genes representing primitive streak or definite endoderm are highlighted in bold. Only the top 200 genes that are upregulated or down regulated are shown in Table V.
Example 20 Microarray Analysis of EXPRES Cells Differentiated to the DE Stage Versus Human Embryonic Stem Cells Differentiated to the DE Stage [0256] Total RNA was isolated from the following cultures using an RNeasy mini kit (Qiagen): A) H9P33 cells cultured on MATRIGEL-coated plates (1:30 dilution) and exposed to DMEM/F12 medium supplemented with 0.5% FBS and 100 ng/ml Activin-A and 20 ng/ml of wnt3A for two days followed by treatment with DMEM/F12 medium supplemented with 2% FBS and 100 ng/ml Activin-A (AA) for an additional three days; B) EXPRES 01 P24 cells cultured on TCPS and exposed to DMEM/F12 medium supplemented with 0.5% FBS, 100 ng/ml Activin-A, 20 ng/ml of WNT3A, and 100 nm GSK-3B IX inhibitor (Catalog# 361550, Calbiochem, CA) for five days C) EXPRES02 P17 cells cultured on TCPS and exposed to DMEM/F12 medium supplemented with 0.5% FBS, 100 ng/ml Activin-A, 20 ng/ml of WNT3A, and 100 nm GSK-3B IX inhibitor (Catalog# 361550, Calbiochem, CA) for five days, D) H9P39 cells cultured on MATRIGEL-coated plates (1:30 dilution) and exposed to medium supplemented with 0.5% FBS and 100 ng/ml Activin-A and 20 ng/ml of wnt3A for two days followed by treatment with DMEM/F12 medium supplemented with 2% FBS and 100 ng/ml Activin-A (AA) for an additional two days RNA
samples were collected from group D at 2hrs, 6hrs, 24 hrs, 30 hrs, 48 hrs, 72 hrs, and 96 hrs.
EXPRES 01 and 02 cultured in their respective growth media were also included as controls. All groups contained three biological replicates and each biological replicate was repeated on two separate gene chips.
10257] Sample preparation, hybridization, and image analysis were performed according to the Affymetrix Human Genome U133 Plus 2.0 Array. Following normalization and a log transformation, data analysis was performed using OmniViz software (MA) and GENES1FTER (VizXLabs, WA). Significant differences in gene expression between the samples were evaluated using analysis of variance and an F-test with adjusted P-value (Benjamini and Hochberg correction) of less than or equal to 0.05. Only genes with a present call in at least one group were included in the analysis. Table VI lists the mean normalized log-transformed signal intensity of genes showing at least 5-fold between group A, group B, group C, and group D at various time points along with the adjusted P-value for each gene. Only the top 200 genes that are upregulated or down regulated are shown in Table VI. Genes representing primitive streak or definite endoderm are highlighted in bold. Table VII lists the correlation coefficient for each comparison group. Scatter plots corresponding to the correlation coefficients are depicted in Figure 27. The global expression profile of EXPRES 01 cells appear to resemble the expression profile of samples at 30 hrs or less of the DE stage, whereas the EXPRES 02 cells appear to resemble the expression profile of samples at greater than 48 hrs of the DE stage.
Example 21 Formation of Embryoid Bodies and Differentiation to Various Lineages [0258] EXPRES 01 passage 27 cultures were removed as single cells using TrypLETm Express solution, spun at 200g for 4 mins, and resuspended in DMEM-F12 + 20% FBS. The cell suspension was seeded on low adhesion Petri dishes. 3-4 days post seeding, embryoid body (EB) like structures were formed (Figure 28). Treatment of the cultures with DMEM-F12 + 2% FBS + 1 micro molar retinoic acid induced expression of ectoderm markers, such as NeuroD.
Example 22 Formation of Teratomas in the Kidney Capsules of NOD-SCID Mice [0259] Undifferentiated cells from the human embryonic stem cell line H9 at passage 42, EXSPRES 01 Passage 30, and EXPRES 02 P22 cells were released from cultures using TRYPLE, washed in basal media, and then suspended in DMEM-F12 basal media.
Approximately 1x106 undifferentiated H9 P42, 1.5 million EXPRES 01 and 02 cells were injected into the kidney capsule of six week old NOD-SCID mice. Five weeks following transplantation, the animals were sacrificed; kidneys were excised and fixed in formalin or placed in lysis buffer to collect RNA for subsequent PCR
analysis.
Figure 29 depicts expression of markers characteristic of mesoderm, ectoderm, endoderm, extraembryonic visceral endoderm, and pluripotency markers for collected samples. Similar to H9 line, both EXPRES lines show strong expression of all germ layers along with extra embryonic endoderm.
Example 23 Proliferation And Cell Cycle Analysis of EXPRES 03 cells [0260] Human embryonic stem cells have a unique cell cycle status that is distinguishable from other somatic cells, characterized by high proportion of cells in S-Phase, and shortened or truncated Gap phases (GI and G2). The cell cycle control mechanisms in hES cells may be functionally linked to their self-renewal and pluripotency capacity of these cells, and may be different from control mechanism in their differentiated/committed counterparts. These experiments were designed to determine the cells cycle nature of EXPRES cells that have been shown to express many of the markers of pluripotency hES cells.
[0261] Methods: Cells were seeded at 5,000-10,000 cells /cm2 in Cell Bind tissue culture flasks (Coming) and cultured for 2-4 days. EXPRES 03 cells were cultured either in growth medium containing 2% FBS inDMEM/F12 and Activin-A (100 ng/ml), wnt3a (10-20 ng/ml) and IGF (50 ng/ml). For comparative proliferation analysis, IGF
was sometimes omitted from the growth factor cocktail. Cell proliferation was analyzed using the APC BRDU Flow kit according to the Manufacturer's recommendations (BD
Biosciences, San Diego, CA). Briefly, cells were pulsed with BRDU for 1-2 hrs at the end of culture period, released using Tryple E Express and counted. Cells were fixed in BD Cytofix/Cytosperm Buffer, incubated for 30 min, followed by incubation with BD
Cytoperm buffer for 10 minutes on ice. Cells were then treated with DNAse for 1 hr at 37 C to expose incorporated BRDU, followed by staining with APC conjugated anti-BRDU antibody. For cell cycle analysis, cells were stained with 7AAD, and analyzed on FACS Array.
[0262] Results: Similar to the highly hES cells, EXPRES 03 cells retained a highly proliferation rate, as shown by the high percentage of cells that in S-phase determined by their capacity to incorporate BRDU in culture. The frequency of cells in S-Phase was typically greater than 45% (range 40-60%), similar to hES cells (Figure 30 a-c).
Although the number of EXPRES 03 cells grown in the presence of IGF were 2-3 times the number of cells grown in absence of IGF after 3-4 days, there was only marginal differences in frequency of cells in S-phase when cell were exposed to BRDU
for 1 hour or more (Figure 30 1). This high frequency of cell in S-phase and cell cycle structure is unlike that observed in somatic cells, as shown here for human amniotic fluid cells (AFDX002) (Figure 30 d). Furthermore, mitomycin treated cells Mouse Embryo Fibroblast (MEF, Figure 30 e) do not proceed into S-phase but show apparent accumulation in the G2/M phase (64%), which may be related to the inability of mitomycin treated cells to separate the DNA strands at mitosis.
Example 24 Transfection Efficiency of ES cells vs EXPRES cells [0263] A major limitation of genetic manipulation of hES is their relative resistance to conventional methods of transfection and viral transduction. In addition to their highly proliferative rates, EXPRES cells are easy to transfect in vitro. To compare transfection efficiency, in EXPRES and hES cells were transfected in culture with EGFP and analyzed by fluorescence microscopy and flow cytometric methods.
[0264] Methods: EXPRES 01 cells were seeded on human fibronectin coated (lOug/m1) 6 well tissue culture plates in growth medium comprising 2% FBS in DMEM/F12, Activin-A
(100 ng/ml), wnt3a (10-20 ng/ml) and IGF (50 ng/ml). For cell clusters hES
cell were passaged by routine methods using collagenase into MATRIGEL coated 6 well culture plates, and grown in MEF conditioned hES medium. For single cells, hES cells were passaged by exposing cells to TRYPLE for 3 minutes at 37 C, followed by plating onto MATRIGEL coated 6 well culture plates. When cells achieved desired confluency (70-80%), cells were transfected with Lipofectamine 2000 according to the manufacturer's recommendations (Invitrogen, Carlsbad, CA). Briefly, 4 ug of DNA
was diluted into 2501.11 Opti-MEM I Reduced serum medium. Five microliters of Lipofectamine 200 was mixed into total of 250 Opti-MEM I medium for 5 minutes and gently mixed with diluted DNA. The DNA/Lipofectamine complexes were allowed to form at room temperature for 20 minutes, and then added to the respective wells with gentle swirling motions o f the plates for gentle mixing. Cells were incubated in presence of complexes for another 24 hrs followed by complete change of medium. Cells were analyzed by fluorescence microscopy and flow cytometry 48 hrs following transfection.
[0265] Results: The uptake and expression of eGFP was compared by transfection of EXPRES 01 cells and hES cells plated as single cell dispersion or cell clusters, and analyzed 48 hrs later. EXPRES 01 cell showed the highest level of eGFP protein expression, with 75% of cell expressing eGFP by flow cytometric analysis (Figure 31).
In contrast, hES were more resistant to transfection, with only 3% of cell expressing eGFP protein by FACS when cell clusters were used. Preparing a single cell dispersion of hES enhanced the level of DNA uptake and eGFP expression to about 20 %, but which is still by about three fold less the expression in EXPRES 01 cells.
Example 25 EXPRES Cells as a Versatile Tool for Screening [0266] EXPRES cells were grown in DMEM:F12 medium containing 2% PBS, 10Ong/m1 recombinant human Activin-A (R&D Systems), and 2Ong,/m1 recombinant mouse Wnt3a (R&D Systems). Growth medium for EXPRES 01 cells also contained 5Ong/m1 recombinant human IGF-1 (R&D Systems). Both cell lines were routinely grown at 37 C in an atmosphere of low oxygen (3%) and 5% CO2. EXPRES 01 and EXPRES
02 cells were released from culture as a single cell suspension using TrypLE
enzymatic digestion (Invitrogen, CA) then washed and counted to determine accurate cell numbers and viability (>95%). Aliquots ranging from 1,250 to 80,000 cells were distributed into human fibronectin-coated wells of a 96-well plate (Corning-Costar) in a final volume of 100 IA culture medium. Control wells were also fibronectin-coated and contained an equivalent volume of culture medium without cells. Plates were allowed to equilibrate overnight in a humidified chamber incubated under standard low oxygen, 5% CO2 at 37 C. During this time, the cells attached as monolayer cultures with varying degrees of conflueney dependent upon the initial seeding density. After overnight culture, 200 of MTS reagent (CellTiter 96 Aqueous Assay; Promega) was added to each well.
MTS
is reduced to formazan and can be used as a measure of dehydrogenase enzyme activity directly proportional to the number of live cells. One plate was returned to low oxygen culture while an identical parallel plate was incubated in normal oxygen (20%). After 4 hours, absorbance was read at 490nm on a spectrophormetric plate reader (Molecular Devices). Statistical calculations for mean OD, standard deviation, and percent coefficient of variation (CV) were determined for replicate sample sets within each plate and then compared to similar wells between both plates.
[0267] Standard deviation and percent coefficient of variation values demonstrate that EXPRES cells can be evenly distributed between wells for high plating efficiency and good well-to-well reproducibility (Table VM a-f). As seen with average 0D490 readings for equivalent numbers of cells, the EXPRES 01 line has a higher metabolic activity than the EXPRES 02 line. For each EXPRES line, percent CV values between the two plates suggest there are no differences in metabolic activity for parallel conditions regardless of atmospheric oxygen levels in this short-term assay.
Optimal cell numbers per well within the linear range for this assay were determined by graphing average OD readings (Figure 32): less than 20,000 cells/well for and less than 40,000 cells/well for EXPRES 02. Again, atmospheric differences in oxygen levels did not affect optimal cell number results in this short-term assay. These results suggest that EXPRES cells are amenable to screening protocols that can measure toxicological effects of various agents on cell proliferation and/or metabolic rate.
Example 26 Expansion of DE-like Cells Derived from EXPRES Cells [0268] Previous examples establish that EXPRES cells can be derived from embryonic stem cells and can be readily expanded on TCPS in various growth media. Most of these media formulation contain IGF as a supplement or insulin/IGF in 2% FBS used in the growth media. These factors have been shown to inhibit DE related genes through the PI-3 kinase pathway (Stem cells, 25:29-38, 2007). An alternative media was formulated based on DM-F12 + 0.5% FBS + 100 ng/ml AA + 20 ng/ml WNT3A + 100 nM GSK-3B inhibitor IX (further referred to as "growth media for DE cells").
EXPRES 01 at passage 27 cells cultured in the above media were able to propagate at the same rate as cells cultured in DM-F12 + 2% FBS + 100 ng/ml AA + 20 ng/ml WNT3A + 50 ng/ml IGF-I. Furthermore, cells cultured in the growth media for DE

cells expressed strong DE markers by real-time PCR (Figure 33) through three passages. Approximately 72% of cells expressed CXCR4 (Figure 34).

Example 27 siRNA Knockdown of Target Genes in EXPRES cells [0269] Efficient knockdown of target genes in human embryonic stem cells using siRNA is severely limited by the ability to achieve high levels of transfection in human embryonic stem cells grown as cluster colonies. EXPRES cells are easily transfected with siRNA using conventional methods, and thus offer a valuable system to screen siRNA oligo sequences, as well as evaluate the role played by targeted genes.
[0270] Methods: EXPRES 03 cells were seeded on fibronectin coated (104g/m1) 6 well tissue culture plates in growth medium comprising 2% FBS in DMEM/F12, Activin-A (100 ng/ml), wnt3a (10-20 ng,/m1) and IGF (50 ng/ml). For 6 well plates, 200,000 cells were seeded 24 hrs prior to transfection with the siRNA oligo sequences.
[0271] To evaluate target gene knockdown, cells at 70-80% confluency cells were transfected using Lipofectamine 2000 according to the manufacturer's recommendations (Ambion (Applied Biosystems), Foster City, CA). Briefly, the appropriate amount of siRNA was diluted into 250 ul Opti-MEM I Reduced serum medium to achieve a final concentration of 100 nmol. Five microlitres of Lipofectamine 2000 was diluted in 250 p.1 Opti-MEM I medium and incubated for 5 minutes. The complexes were incubated for 15-20 min at room temperature, and then added to the cells with gentle swirling motions of the plates for gentle mixing. Cells were incubated in presence of siRNA for another 24 hrs followed by complete change of medium. Cells were visualized with fluorescence microscopy 24-48 hrs following transfection, and RNA harvested for analysis of target gene knockdown by quantitative RT-PCR methods. The following pre-validated siRNA oligo sequences, purchased from Ambion were tested: Beta-catenin (Id. No. 42816) and GSK3b (Id. No. 42839).
[0272] Results: Fluorescence microscopy revealed a very high level of siRNA
uptake by EXPRES cells (>80%) when using fluorescently labeled siRNA (Figure 35). RNA
harvested from the cells was analyzed by PCR for target gene knockdown, and compared with control siRNA oligo transfected cells. Beta-catenin and GSK3b siRNA
oligos achieved very high levels of gene knockdown in EXPRES cells, with greater than 93% gene knockdown. Other non-validated oligo sequences to other gene targets eg Hes-1, Oct-4 achieved lower and variable levels of target gene knockdown..
Specificity of oligo sequences was verified by analysis of other gene transcripts, which did not show any appreciable knockdown.
Example 28 Cytokine Antibody Array analysis for EXPRES 01 and 02 lines [0273] EXPRES 01 and 02 lines at passage 22 and 23, respectively, were grown to approximately 70% confluency in their respective media and then cell lystaes was collected using mammalian cell lysis kit (Sigma-Aldrich, MO). Cytokine array analysis was completed using Cytokine Array panels provided by RayBiotech, GA
(http://www.raybiotech.com/). Table IX a-c lists cytokine, cytokine and growth factor receptor expression following normalization of the data and background subtraction.
For each panel, positive and negative controls are also included. The panels were run for two different samples per cell type.
Example 29 Karyotype Analysis The karyotype of EXPRES 01 cells at passage 20 and EXPRES 02 cells at passage was determined by G-band analysis. Cytogenetic analysis was performed on twenty-one G-banded cells from EXPRES 01 and on twenty G-banded cells from EXPRES 02.

Half of the G-banded EXPRES 01 cells showed a normal 46XX karyotype while the rest showed abnormal karyotype such as trisomy 17. The EXPRES 02 line also showed a chromosome rearrangement with a duplication of almost all of the chromosome short-arm.
Example 30 Derivation of EXPRES Cells from a Suspension of Single Human Embryonic Stem Cells in the Presence of a Rho-Kinase (ROCK) Inhibitor [0274] Cells from the human embryonic stem cell line H9 at passage 35 lines were cultured under hypoxic conditions (approximately 3% 02) for at least three passages.
The cells were cultured in MEF-CM supplemented with 8 nginal of bFGF and plated on MATRIGEL coated plates according to Example 1. At approximately 60%
confluency, the cultures were exposed to TrypLETm Express solution (Invitrogen, CA) for 5 mins. Released cells were resuspended in DM-F12 + 2% FBS medium, recovered by centrifugation, and counted using a hemocytometer. The released cells were seeded at 1000-10,000 cells/cm2 on tissue culture polystyrene (TCPS) flasks and cultured in DM-F12 + 2% FBS + 100 ng/ml activin-A +20 ng/ml WNT-3A + 50 ng/ml of IGF-I +
0.1 mM mercaptoethanol (Invitrogen, CA), non-essential amino acids (1X, NEAA
from Invitrogen, CA) +/- 10 l_tm ROCK inhibitor (Y-27632, Calbiochem, CA) under hypoxic conditions (approximately 3% 02) at 37 C in a standard tissue culture incubator. The TCPS flalcs were not coated with MATRIGEL or other extracellular matrix proteins.
The media was changed daily. The first passage cells are referred to as Pl. As shown in Figure 37, 24 hrs after seeding, addition of the ROCK inhibitor resulted in a significantly larger number of attached cells as compared to cultures derived in the absence of the ROCK inhibitor. EXPRES cells derived using the ROCK inhibitor, Y27632 were designated as EXPRES 15.
Example 31 Karyotype Analysis [0275] The karyotype of EXPRES 15 cells at passage 5 and 12 were determined by G-band analysis. Cytogenetic analysis was performed on twenty-one G-banded cells from EXPRES 15 all of the cells showed a normal 46XX karyotype (Figure 38). FISH
analysis of chromosomes 12 and 17 also showed that all cells demonstrated a normal signal pattern for the ETV6 BAP (TEL) gene located on chromosome 12 and all cells demonstrated a normal signal pattern for the Her2/neu gene and 17 centromere on chromosome 17.
Example 32 EXPRES Cells can be Maintained in Media Containing a Range of Concentrations of IGF, WNT3A, activin-A, and GSK-3B inhibitors [0276] EXPRES 11 cells were grown in DMEM/F12 (Invitrogen) containing 2%
FBS, 10Ong/m1 activin-A, 2Ong/m1 Wnt3a and 5Ong/m1IGF. At 80% confluency, cells were passed using TrypLE Express (Invitrogen) into 96-well plates at a density of cells/well in DMEM/F12 containing 2% FBS. Cells were allowed to adhere to the substrate for 1 hour in a humidified incubator held at 37 C with 5% CO2, prior to the addition of activin-A ranging from 50 to 10Ong/ml, Wnt3a ranging from 10 to 2Ong/ml, IGF ranging from 10 to 5Ong/ml, and 50 to 100 nM GSK-3B inhibitor (IX). At 24, and 96 hours, cell viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Briefly, MTS reagent was added to the 96-well plates and allowed to incubate with the cells for 1-4 hours and then reading the absorbance at 490nm on a plate reader. The absorbance reading was directly proportional to the number of living cells. Figure 39 a-c shows the absorbance readings at a) 24 hrs, b) 48 hrs, and c) 96 hrs post seeding.
[0277]
Although the various aspects of the invention have been illustrated above by reference to examples and preferred embodiments, it will be appreciated that the scope of the invention is defined not by the foregoing description but by the following claims properly construed under principles of patent law.

Table IA: List of primary antibodies used for FACS and immuno staining analysis.
Antibody Supplier Isotype Catalog#
SSEA-1 Chemicon (CA) Mouse IgM MAB4301 SSEA-3 Chemicon (CA) Mouse IgG3 MAB4303 SSEA-4 Chemicon (CA) Rat IgM MAB1435 TRA 1-60 Chemicon (CA) Mouse IgM MAB4360 TRA 1-81 Chemicon (CA) Mouse IgM MAB4381 TRA 1-85 Chemicon (CA) Mouse IgG1 MAB4385 ¨AP R&D Systems Mouse IgG1 FAB1448A
(MN) ¨HNF3f3 R&D Systems Goat IgG AF2400 PDX1 Santa Cruz Goat IgG
Biotechnology, INC
(CA) sc-14664 GATA4 R&D Systems Goat IgG AF2606 Sox 17 R&D Systems Goat IgG AF1924 CD 9 BD Bioscience Mouse IgG1 341647 (CA) CXCR4 R&D Systems Mouse IgG2A FAB170A
SOX2 R&D Systems Goat IgG AF2018 Nanog R&D Systems Goat IgG AF1997 ¨OCT4 R&D Systems Goat IgG AF1759 Gata6 R&D Systems Goat IgG AF1700 E,c ad R&D Systems Mouse IgG MAB1838 Ncam R&D Systems Mouse IgG MAB777 HNFlb R&D Systems Goat IgG AF3330 ¨13-catenin R&D Systems Mouse IgG

HNFla BD Bioscience Mouse IgG

¨CD99 Invitrogen (CA) Mouse IgG

¨Cerebus Santa Cruz Goat IgG
Biotechnology, INC

Hex Santa Cruz Goat IgG
Biotechnology, INC

AFP R&D Systems Mouse IgG

Antitrypsin DAKO (CA) Rabbit islet 1 R&D Systems Goat IgG

_ Table TB: List of secondary conjugated antibodies used for FACS and immuno staining analysis.
Secondary Conjugated Supplier Dilution Antibody Goat Anti-Mouse IgG APC Jackson ImmunoResearch 1:200 conjugated (PA) Goat Anti-Mouse IgG PE Jackson ImmunoResearch 1:200 conjugated (PA) Donkey anti-rabbit PE or ¨ Jackson ImmunoResearch 1:200 APC conjugated (PA) Donkey anti-goat PE or ¨ Jackson ImmunoResearch 1:200 APC conjugated (PA) Goat anti-mouse IgM PE SouthernBiotech (AL) 1:200 Goat anti-Rat IgM PE SouthemBiotech (AL) 1:200 Goat anti-mouse IgG3 PE SouthemBiotech (AL) 1:200 Table II List of primers used for real-time PCR analysis using TAQMAN probes Primer/Probe Catalog Number 18s 4310893E
ABCG2 Hs00184979 m1 AchE Hs00241307 m1 AFP Hs00173490 m1 ALB Hs00609411 m1 alpha-antitrypsin Hs02384981 m1 Amylase Hs00420710_g 1 AP Hs00240993 m1 Atoh 1 Hs00944192 s1 B3Tubulin Hs00964962_g1 B-Catenin Hs99999168 m1 Barx1 Hs00222053 m1 Brachyury (T) Hs00610080 m1 CCK Hs00174937 m1 Cdx1 Hs00156451 m1 Cdx2 Hs00230919 m1 CEBPa Hs00269972 s1 CEBPb Hs00942496 s1 Cerberus Hs00193796 m1 CFC1(Cripto) Hs00414425 m1 CGA Hs00174938 m1 CK19 (KRT19) Hs00761767 s1 CLDN4 (claudin4) Hs00533616 s1 C-Myc Binding Protein Hs00429315_g 1 Connexin32 (GJB-1) Hs00939759 s1 Connexin45 Hs00271416 s1 CTNNI31 Hs00170025 m1 CXCR4 Hs00237052 m1 Cylcin-D1 Hs00277039 ml Dapper1 (DACT-1) Hs00420410 m1 DKK1 Hs00183740 m1 DKK4 Hs00205290 ml Endoglin Hs00164438 m1 Exo1 Hs00243513 m1 F3 Hs00175225 m1 FAH Hs00164611 m1 FGF4 Hs00173564 m1 FGF10 Hs00610298 m1 FGFR1 Hs00241111 m1 FGFR3 Hs00179839 m1 FGFR4 Hs00242558 m1 Flk1 Hs00911705_g1 FOXA1 Hs00270129 m1 FOXA3 Hs00270130 m1 FOXD3 Hs00255287 s1 FOXF1 Hs00230962 m1 GAPDH (human) 4310884E
Gastrin Hs00174945 m1 GATA1 Hs00231112 m1 GATA4 Hs00171403 m1 GATA5 Hs00388359 ml GATA6 Hs00232018 m1 GCK Hs00175951 m1 GFAP Hs00157674 ml GIP Hs00175030 m1 Gil Hs01110766 m1 Glucagon Hs00174967 _m1 Glut-2 Hs00165775 _m1 Goosecoid Hs00418279 _m1 GS Hs00374213 _m1 Handy1 Hs00231848 m1 HB9 Hs00232128 _m1 Hes1 Hs00172878 ml Hexl Hs00172696 ml HEYL Hs00232718 m1 HHIP (hedgehog interacting protein) Hs01011009_ m1 hHIF1a Hs00153153 m1 _ HNF1 Hs00167041 m1 _ HNFla Hs00167041 _m1 HNF1B Hs00172123_ m1 HNF3B Hs00232764 m1 HNF4a Hs00230853 m1 HNF6 (onecut) Hs00413554 _m1 HoxB1 Hs00157973 m1 IBSP Hs00173720_ m1 Insulin II Hs00355773 m1 Islet-1 Hs00158126 m1 Jagged-1 (JAG1) Hs00164982 m1 KDR Hs00176676_ m1 KRT15 Hs00267035 m1 MafA Hs00999118 m1 MAML1 Hs00207373_ m1 Map2 Hs00159041 _m1 MapK14 Hs00176247_ m1 MapK8 Hs00177083 m1 MBP (myelin basic protein) Hs00921945_ m1 Mix11 Hs00430824_g 1 MMP1 (matrix metalloprotease1) Hs00233958_ m1 MOX1 Hs00793059_ m1 MSX1 Hs00427183_ m1 Mucinl Hs00904328 m1 Mucin2 Hs00159374_ m1 Myf5 Hs00271574_ m1 MyoD1 Hs00159528_ m1 N-Cadherin (CDH2) Hs00169953_ m1 N-Cam1 Hs00169851 m1 NEFH Hs00606024_ m1 NEFL Hs00196245 m1 Nestin Hs00707120_ s1 NeuroD1 Hs00159598_ m1 Ngn3 Hs00360700_q 1 Nkx2.1 Hs00163037_ m1 Nkx2.2 Hs00159616_ m1 Nkx6.1 Hs00232355_ m1 Notch1 Hs01062014_ m1 NTS Hs00175048_m1 02 Hs00377820 ml 0ct3/4 Hs00742896 sl OTX2 Hs00222238 ml Pax3 Hs00240950 ml Pax4 Hs00173014 ml Pax6 Hs00240871 ml Pax8 Hs00247586 ml Pax9 Hs00196354 ml PDX-1 (IPF1) Hs00236830 ml Ptch (Patched) Hs00970985 ml PTFla Hs00603586_ql PYY Hs01062281 ml RA receptor alpha Hs00230907 ml =
RALDH Hs01125173 ml RBPSUH Hs00794653 ml Rexl (ZFP42) Hs00399279 ml SCGB1 Hs00171092 ml Secretin Hs00360814_ql sFRP Hs00610060 ml sFRP5 Hs00169366 ml SHH Hs00179843 ml SLC5A8 Hs01068911 ml Snail Hs00195591 ml Snai2 Hs00161904_ml Somatostatin Hs00174949 ml Soxl Hs00534426 sl Sox10 Hs00366918 ml Sox17 see "Soxl 7" iab Sox2 Hs00602736 sl Sox3 Hs00271627 sl Sox7 Hs00846731 sl Sox9 Hs00165814 ml Sparc Hs00234160 ml SP-C Hs00161628 ml TBX6 Hs00365539¨ml Tart Hs00162669 ml THBD Hs00264920 sl Twistl Hs00361186 ml UtF1 Hs00747497_ql Vim Hs00185584 ml Wnt3a (human) Hs01055707 ml Wnt3a (mouse) Mm00437337 ml WT1 Hs01103754 ml Zicl Hs00604749 ml Zic2 Hs00600845_ml Table III List of EXPRES lines generated from 111 & 119 parent lines ID# ES Day of derivation Media used to propagate cells Parent during DE
line, differentiation Passage number EXPRES 01 H9P54 Day 4 Growth media + 50 ng/m1IGF-I
EXPRES 02 H9P54 Day 6 DM-F12+ 2% FBS +100 ng/ml AA +20 ng/ml WNT-3A (growth media) EXPRES 03 H9P39 Day 3 Growth media + 50 ng/ml IGF-I
EXPRES 04 H9P39 Day 4 Growth media + 50 ng/ml IGF-I
EXPRES 05 H9P39 Day 5 Growth media + 50 ng/ml IGF-I
EXPRES 06 H9P49 Day 5 Growth media EXPRES 07 HIPS Day 5 Growth media EXPRES 08 H1P39 Day 4 Growth media + 50 ng/ml IGF-I + 0.1mM
mercaptoethanol EXPRES 09 H1P39 Day 6 Growth media + 50 ng/ml IGF-I + 0.1mM
mercaptoethanol EXPRES 10 H1P49 Day 4 Growth media EXPRES 11 H9P30 Day 4 Growth media + 50 ng/ml IGF-I + 0.1mM
mercaptoethanol EXPRES 12 H9P30 Day 6 Growth media + 50 ng/ml IGF-I + 0.1mM
mercaptoethanol Table IV Expression of cell surface markers by EXPRES 01 and 02 lines Marker EXPRES 01- % Expression EXPRES 02- % Expression SSEA-3 100 86 (85-88) SSEA-4 100 87 (83-88) CD56 (NCAM) <1 38 (35-40) CXCR4 <1 20 (10-25) SSEA-1 <1 26 (9-32) E-cadherin 90 (85-95) 75 (72-79) CD9 99 66 (62-68) CD30 _ 97 (96-98) 43 (40-46) LIF-receptor <1 20 (15-21) CD117 92 (90-95) 73 (67-75) Table V DIFFERENTIAL EXPRESSION OF GENES BETWEEN
UNDIFFERENTIATED EMBRYONIC STEM CELLS CULTURED ON
MATRIGELTm AND EXPRES 01(A) AND 02 (B) CELLS CULTURED ON
TCPS
A) ES vs EXPRES 01- Intensity values are in Log2 format.
ES EXPRES Ratio Direction adj. p- Gene Gene Name 01 value Identifier -5.03662 3.037629 269.52 Up 8.34E-05 BG09943 ESTs -2.82645 3.094183 60.57 Up 3.88E-03 NM_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF178853.1 gb:BC002815.1 .4.71714 0.961816 51.23 Up 6.59E-05 A1796169 GATA-binding protein 3 IFL=gb:NM 002051.1 gb:M69106-.1 gb:BC003070.1 -1.57973 4.092731 51 Up 6.13E-03 AL513917 solute carrier family 16 (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 -2.24566 3.409815 50.4 Up 1.19E-03 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM 016588.1 gb:BC0026-8-3.1 gb:AF136631.1 -0.66473 4.897427 47.25 Up 1.97E-04 R06655 ESTs, Moderately similar to AF078844 1 hqp0376 protein (H.sapiens) -2.96204 2.589425 46.9 Up 1.79E-03 NM_0013 Homo sapiens cysteine-11 rich protein 1 (intestinal) (CRIP1), mRNA.
/PROD=cysteine-rich protein 1 (intestinal) /FL=gb:U58630.1 gb:BC002738.1 gb:NM 001311.1 gb:U06-770.1 -0.08298 5.388254 44.36 Up 2.48E-04 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 421525 1.240929 43.9 Up 4.36E-04 Nhl_0081 Homo sapiens fibrobiast 19 growth factor (androgen-induced) (FGF8), mRNA.
/PROD=fibroblast growth factor 8 (androgen-induced) /FL=gb:U36223.1 gb:U46212.1 gb:NM._006119.1 -3.11273 2.306225 42.78 Up 5.07E-03 AW44476 ESTs -4.05111 1.075159 34.93 Up 1.19E-03 J03580 Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 -1.81534 3.025351 28.65 Up 7.00E-04 AW59092 ESTs -2.36335 2.448218 28.08 Up 1.62E-02A1189359 mevalonate (diphospho) decarboxylase /FL=gb:NM 002461.1 gb:BC000011.1 gb:U49260.1 -3.00328 1.794842 27.82 Up 7.77E-03 A1571798 Rho GDP dissociation inhibitor (GDI) alpha -4.17258 0.510307 25.69 Up 2.29E-04 A1040887 ESTs -0.11332 4.420733 23.17 Up 8.78E-05 NM_0036 Homo sapiens basic helix-70 loop-helix domain containing, class B, 2 (BHLHB2), mRNA.
/PROD=differentiated embryo chondrocyte expressed gene1 /FL=gb:AB004066.1 gb:NM_003670.1 -1.94 2.590871 23.12 Up 3.90E-03 NM_0165 Homo sapiens TBX3-iso 69 protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF21670.1 -2.18113 2.33099 22.82 Up 1.12E-02 NM_0040 Homo sapiens arrestin, 41 beta 1 (ARRB1), transcript variant 1, mRNA.
/PROD=arrestin beta 1, isoform A
/FL=gb:BC003636.1 gb:AF084040.1 gb:NM_004041.2 -2.85963 1.609384 22.15 Up 6.37E-03 BC005961 Homo sapiens, parathyroid hormone-like hormone, clone MGC:14611, mRNA, complete cds.
/PROD=parathyroid hormone-like hormone /FL=gb:BC005961.1 0.044298 4.505436 22.03 Up 4.17E-05 W57613 ESTs -3.65051 0.757197 21.23 Up 7.11E-04 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M8394171 gb:AF213459.1 -1.25226 2.990178 18.93 Up 2.70E-04 NM_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF1788-5-3.1 gb:BC002815.1 -0.63516 3.41866 16.61 Up 1.05E-03 AA149250 ESTs, Weakly similar to PROTEIN PRECURSOR
(R.norvegicus) -0.14916 3.880272 16.33 Up 8.45E-04 NM_0025 Homo sapiens natriuretic 21 peptide precursor B
(NPPB), mRNA.
/PROD=natriuretic peptide precursor B
/FL=gb:NM 002521.1 gb:M25296.1 -2.88485 1.143234 16.31 Up 2.83E-03 BF437711 ESTs -2.7136 1.194285 15.01 Up 2.14E-02 NM_0018 Homo sapiens cystatin SN
98 (CST1), mRNA.
/PROD=cystatin SN
/FL=gb:J03870.1 gb:NM_001898.1 -0.07353 3.816817 14.83 Up 1.62E-02 AF116616 Homo sapiens PR00998 mRNA, complete cds.
/PROD=PR00998 /FL=gb:AF116616.1 -1.44577 2.422113 14.6 Up 1.34E-02 AL544576 ESTs 2.301255 6.091008 13.83 Up 6.50E-05 BCO20935 Homo sapiens, Similar to otoconin 90, clone IMAGE:4277593, mRNA.
3.006559 6.79047 13.77 Up 8.80E-05 A1263909 ras homolog gene family, member B
/FL=gb:NM_004040.1 -0.512 3.268087 13.74 Up 2.96E-03 AF345910 Homo sapiens NYD-SP14 mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 3.484047 7.24746 13.58 Up 4.12E-04 NM_0035 Homo sapiens transgelin 2 64 (TAGLN2), mRNA.
/PROD=transgelin 2 /FL=gb:D21261.1 gb:NM_003564.1 2.623145 6.382732 13,54 Up 7.32E-05 A1050866 nodal, mouse, homolog 2.91184 6.66195 13.46 Up 1.44E-04 BC002616 Homo sapiens, transgelin 2, clone MGC:2989, mRNA, complete cds.
/PROD=transgelin 2 /FL=gb:BC002616.1 -1.18027 2.546953 13.24 Up 1.42E-02A1123555 ESTs -0.92213 2.770179 12.93 Up 1.08E-04 AK000345 Homo sapiens cDNA
FLJ20338 fis, clone HEP12179.
-1.85154 1.840613 12.93 Up 6.40E-03 A1949760 ESTs, Weakly similar to unnamed protein product (H.sapiens) 0.899321 4.507212 12.19 Up 1.08E-04 AW19694 ESTs 1.651788 5.252439 12.13 Up 5.58E-05 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb:L19182.71 -1.20347 2.387268 12.05 Up 2.76E-02 BF063186 ESTs 3.669215 7.251816 11.98 Up 2.01E-05 NM 0007 Homo sapiens annexin Al 00 (ANXA1), mRNA.
/PROD=annexin I
/FL=gb:BC001275.1 gb:NM_000700.1 -3.52039 0.041471 11.81 Up 1.58E-02 AW16221 Homo sapiens cDNA
0 FLJ11490 fis, clone 3.006317 6.564471 11.78 Up 2.04E-04 NM_0061 Homo sapiens 83 neurotensin (NTS), mRNA.
/PROD=neurotensin precursor /FL=gb:NM 006183.2 gb:U91618.1 3.227575 6.777916 11.72 Up 2.01E-05 U15174 Homo sapiens BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus E1B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U15174.1 1.869893 5.411751 11.65 Up 2.01E-05 NM_0018 Homo sapiens collagen, 54 type XI, alpha 1 (COL11A1), mRNA.
/PROD=collagen, type XI, alpha 1 /FL=gb:J04177.1 gb:NM_001854.1 2.851479 6.371229 11.47 Up 3.61E-05 A1950472 ESTs -0.1081 3.393761 11.33 Up 1.39E-03 BG02859 ESTs 0.41954 3.911282 11.25 Up 1.42E-04 A1670948 ESTs -1.71451 1.771584 11.21 Up 7.77E-03 BI254089 Homo sapiens full length insert cDNA clone -1.66293 1.80547 11.07 Up 2.68E-02 NM_0008 Homo sapiens glutamate 17 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD67, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 000817.1 gb:M818831 gb:L16888.1 0.451086 3.904705 10.96 Up 5.45E-04 NM_0070 Homo sapiens a 38 disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2) (ADAMTS5), mRNA.
/PROD=a disintegrin and metalloprotease withthrombospondin motifs-5 preproprotein /FL=gb:NM 007038.1 gb:AF1420g -1.44798 1.988376 10.83 Up 1.07E-02 AW37686 ESTs 1.19822 4.633038 10.81 Up 1.22E-04 NM_0169 Homo sapiens NADPH
31 oxidase 4 (NOX4), mRNA.
/PROD=NADPH oxidase 4 /FL=gb:AF261943.1 gb:NM 016931.1 gb:AF254621.1 gb:AB041035.1 1.552808 4.981033 10.76 Up 3.24E-04 NM_0006 Homo sapiens serine (or 02 cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA.
/PROD=serine (or cysteine) proteinase inhibitor, cladeE (nexin, plasminogen activator inhibitor type 1), membe -0.62725 2.792215 10.7 Up 3.24E-04 BC017942 Homo sapiens, Similar to otoconin 90, clone IMAGE:4285317, mRNA.
-1.22834 2.18828 10.68 Up 2.50E-02 BG40285 ESTs -0.85366 2.55067 10.59 Up 3.53E-04 N36408 hypothetical protein /FL=gb:NM_024530.1 1.55625 4.952105 10.53 Up 1.52E-03 BG16436 microtubule-associated protein 1B
/FL=gb:NM 005909.1 0.93094 4.285883 10.23 Up 4.17E-05 AL038787 6-phosphof-r-ucto-2-kinasefructose-2,6-biphosphatase 4 -3.33551 0.008356 10.15 Up 9.88E-03 BF221850 ESTs -1.97569 1.35098 10.03 Up 2.12E-02 NM 0021 Homo sapiens 49 hippocalcin-like 1 (HPCAL1), mRNA.
/PROD=hippocalcin-like 1 /FL=gb:NM 002149.1 gb:D1622771 0.624024 3.934756 9.92 Up 2.01E-05 AF154054 Homo sapiens DRM
(DRM) mRNA, complete cds. /PROD=DRM
/FL=gb:NM 013372.1 gb:AF110137.2 gb:AF045800.1 gb:AF154054.1 -2.37515 0.931587 9.9 Up 2.83E-02 NM_0251 Homo sapiens 36 hypothetical protein FLJ22187 (FLJ22187), mRNA.
/PROD= hypothetical protein FLJ22187 /FL=gb:BC005059.1 gb:NM_025136.1 0.906004 4.154799 9.51 Up 1.45E-04 NM_0133 Homo sapiens cysteine 72 knot superfamily 1, BMP
antagonist 1 (CKTSF1B1), mRNA. /PROD=cysteine knot superfamily 1, BMP
antagonist 1 /FL=gb:NM 013372.1 gb:AF110137.2 gb:AF045800.1 gb:AF154054.1 1.423659 4.64236 9.31 Up 2.01E-05 AB019695 Homo sapiens mRNA for thioredoxin reductase II
beta, complete cds.
/PROD=thioredoxin reductase II beta /FL=gb:AB019695.1 0.620478 3.822765 9.2 Up 6.53E-05 AL567376 G protein-coupled receptor 39 2.317589 5.509474 9.14 Up 1.02E-05J04177 Cluster Incl.
J04177:Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds=(161,5581) /gb=J04177 /gi=179729 /ug=Hs.82772 /len=6158 -0.01596 3.175621 9.14 Up 9.88E-03 L37033 Cluster Incl.
L37033:Human FK-506 binding protein homologue (FKBP38) mRNA, complete cds /cds=(140,1207) /gb=L37033 /gi=965469 /ug=Hs.173464 /len=1613 3.119777 6.302535 9.08 Up 5.07E-03 A1954041 F-box only protein 9 /FL=gb:NM_012347.1 0.891337 4.058968 8.99 Up 1.66E-04 NM_0003 Homo sapiens paired-like 25 homeodomain transcription factor 2 (PITX2), mRNA.
/PROD=paired-like homeodomain transcription factor 2 /FL=gb:NM 000325.1 gb:U6996171 gb:AF048720.1 2.106895 5.247359 8.82 Up 2.13E-04 NM_0014 Homo sapiens filamin C, 58 gamma (actin-binding protein-280) (FLNC), mRNA. /PROD=gamma filamin /FL=gb:AF089841.1 gb:NM_001458.1 -1.42687 1.693258 8.69 Up 2.43E-02 AF243424 Homo sapiens SG2NA
beta isoform mRNA, partial cds.
/PROD=SG2NA beta isoform 0.657996 3.771559 8.66 Up 2.06E-02 AU158380 Homo sapiens cDNA
FLJ13698 fis, clone 0.23287 3.334996 8.59 Up 2.01E-05 R40917 phosphodiesterase 4D, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E3) /FL=gb:L20969.1 gb:NM 006203.1 gb:UO2-882.1 -0.06159 3.027095 8.51 Up 3.60E-04 U16797 Human LERK-5 (EPLG5) mRNA, complete cds.
/PROD=LERK-5 /FL=gb:U16797.1 gb:NM 004093.1 gb:L38734.1 gb:U81262.1 4.07051 7.149479 8.45 Up 4.86E-05 M10943 Human metallothionein-If gene (hMT-If) -0.35204 2.705807 8.33 Up 1.09E-03 BC004490 Homo sapiens, v-fos FBJ
murine osteosarcoma viral oncogene homolog, clone MGC:11074, mRNA, complete cds. /PROD=v-fos FBJ murine osteosarcoma viral oncogenehomolog /FL=gb:NM 005252.2 gb:BC0044-90.1 -2.0132 1.043139 8.32 Up 3.61E-02 BE328496 hypothetical protein /FL=gb:AF116683.1 gb:NM_018615.1 -0.68954 2.36447 8.31 Up 8.94E-04 NM_0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 -0.00953 3.031935 8.23 Up 9.88E-03 AA831438 Mad4 homolog 3.079271 6.1137 8.19 Up 4.17E-05 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb119182.i 0.788995 3.806044 8.1 Up 6.41E-05 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 0.9926 4.004698 8.07 Up 8.48E-05 A1202327 ESTs 0.051719 3.059444 8.04 Up 6.98E-04 NM_0073 Homo sapiens pleckstrin

50 homology-like domain, family A, member 1 (PHLDA1), mRNA.
/PROD=pleckstrin homology-like domain, family A, member 1 /FL=gb:NM_007350.1 -1.69103 1.312148 8.02 Up 1.82E-03 U32500 Human type 2 neuropeptide Y receptor mRNA, complete cds.
/PROD=type 2 neuropeptide Y receptor /FL=gb:U42766.1 gb:U36269.1 gb:U32500.1 -0.93931 2.060071 8 Up 6.51E-03 AA004300 hypothetical protein DKFZp5661133 1.164666 4.161028 7.98 Up 2.51E-03 BC005807 Homo sapiens, clone MGC:10264, mRNA, complete cds.
/PROD=Unknown (protein for MGC:10264) /FL=gb:BC005807.1 2.462987 5.441963 7.88 Up 1.45E-04 NM_0166 Homo sapiens

51 heptacellular carcinoma novel gene-3 protein (L0051339), mRNA.
/PROD=heptacellular carcinoma novel gene-3 protein /FL=gb:NM 016651.2 gb:AF2510i9.2 0.581498 3.560033 7.88 Up 1.07E-04 U38945 Human hypothetical 18.1 kDa protein (CDKN2A) mRNA, complete cds.
/FL=gb:U38945.1 gb:U26727.1 0.470814 3.417829 7.71 Up 8.26E-03 AF176039 Homo sapiens high mobility group protein-R
mRNA, complete cds.
/PROD.--high mobility group protein-R
/FL=gb:AF176039.1 -1.50663 1.438639 7.7 Up 7.38E-04 BF223214 ESTs -2.43082 0.495104 7.6 Up 1.71E-02 BF508288 ESTs 1.084464 4.009912 7.6 Up 1.16E-03 BC004865 Homo sapiens, cleft lip and palate associated transmembrane protein 1, clone MGC:10593, mRNA, complete cds.
/PROD=cleft lip and palate associated transmembraneprotein 1 /FL=gb:BC004865.1 4.232374 7.152167 7.57 Up 1.54E-03 6E971587 tubulin, beta polypeptide /FL=gb:BC001352.1 0.129315 3.042634 7.53 Up 2.17E-04 NM 0054 Homo sapiens 42 eomesociermin (Xenopus Iaevis) homoiog (EOMES), /PROD=eomesociermin (Xenopus Iaevis) homolog .1FL=gb:AB031038.1 gb:NM_005442.1 -0.20075 2.710846 7.52 Up 2.58E-02 NM_0033 Homo sapiens vascular 77 endothelial growth factor B (VEGFB), mRNA.
/PROD=vascular endothelial growth factor B /FL=gb:NM_003377.1 gb:U43368.1 gb:U52819.1 -0.45681 2.439084 7.44 Up 7.82E-03 AI417362 ESTs, Moderately similar to ALU1 HUMAN ALU
SUBFAMILY J
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H sapiens) 0.155309 3.037724 7.37 Up 8.78E-04 NM_0070 Homo sapiens serum 61 constituent protein (MSE55), mRNA.
/PROD=serum constituent protein /FL=gb:M88338.1 gb:NM_007061.1 1.506057 4.362244 7.24 Up 7.30E-05 NM_0014 Homo sapiens epithelial 25 membrane protein 3 (EMP3), mRNA.
/PROD=epithelial membrane protein 3 /FL=gb:U52101.1 gb:NM 001425.1 gb:U8f947.1 -1.75194 1.091177 7.18 Up 3.15E-02 NM_0215 Homo sapiens BarH-like 70 homeobox 1 (BARX1), mRNA. /PROD=BarH-like homeobox 1 /FL=gb:NM 021570.2 gb:AF2133.5-6.1 2.455614 5.294065 7.15 Up 9.88E-03 AF279899 Homo sapiens PNAS-145 mRNA, complete cds.
/PROD=PNAS-145 /FL=gb:U03105.1 gb:NM_006813.1 gb:AF279899.1 1.422626 4.257559 7.14 Up 2.01E-05 NM_0063 Homo sapiens 65 transcriptional activator of the c-fos promoter (CROC4), mRNA.
/PROD=transcriptional activator of the c-fos promoter /FL=gb:NM 006365.1 gb:U49857.1 -2.40588 0.424388 7.11 Up 1.64E-02 NM_0024 Homo sapiens myelin 33 oligodendrocyte glycoprotein (MOG), mRNA. /PROD=myelin oligodendrocyte glycoprotein /FL=gb:U18798.1 gb:U64564.1 gb:NM_002433.1 -1.86904 0.959227 7.1 Up 4.35E-02 AB033831 Homo sapiens hSCDGF
mRNA for spinal cord-derived growth factor, complete cds.
/PROD=spinal cord-derived growth factor /FL=gb:NM 016205.1 gb:AB03381.1 gb:AF091434.1 gb:AF244813.1 1.811736 4.639749 7.1 Up 1.09E-03 M27830 Human 28S ribosomal RNA gene, complete cds.
-0.54131 2.28595 7.1 Up 3.63E-03 BE504838 ESTs 4.065536 6.887587 7.07 Up 4.08E-04 NM_0057 Homo sapiens nuclear 96 transport factor 2 (placental protein 15) (PP15), mRNA.
/PROD=nuclear transport factor 2 (placental protein15) /FL=gb:BC002348.1 gb:NM 005796.1 gb:U43939.1 -0.4348 2.379408 7.03 Up 4.24E-03 BF686824 death-associated protein kinase 3 /FL=gb:AB007144.1 gb:AB022341.1 gb:NM_001348.1 1.448288 4.255531 7 Up 2.01E-05 AF096296 Homo sapiens thymic stroma chemokine-1 precursor, mRNA, complete cds.
/PROD=thymic stroma chemokine-1 precursor /FL=gb:AF142434.1 gb:AF096296.1 gb:AF124601.1 gb:AB010447.1 gb:NM_006072.1 3.504052 6.307554 6.98 Up 4.05E-05 NM_0066 Homo sapiens serum-22 inducible kinase (SNK), mRNA. /PROD=serum-inducible kinase /FL=gb:AF059617.1 gb:NM 006622.1 gb:AF2-23574.1 2.124541 4.927935 6.98 Up 8.80E-05 J05008 Homo sapiens endothelin-1 (EDN1) gene, complete cds /FL=gb:NM 001955.1 1.872394 4.674078 6.97 Up 1.02E-05 AK022852 Homo sapiens C-DNA
FLJ12790 fis, clone NT2RP2001985, weakly similar to Homo sapiens high-risk human papilloma viruses E6 oncoproteins targeted protein E6TP1 alpha mRNA.
1.764338 4.563535 6.96 Up 1.43E-04 AA909044 tryptase, alpha 1.401293 4.178686 6.86 Up 1.66E-04 NM 0032 Homo sapiens tissue 56 inhibitor of metalloproteinase 4 (TIMP4), mRNA.
/PROD=tissue inhibitor of metalloproteinase 4precursor /FL=gb:NM 003256.1 gb:U7645671 0.767075 3.54116 6.86 Up 1.88E-03 AY029208 Homo sapiens type VI
collagen alpha 2 chain precursor (COL6A2) mRNA, complete cds, alternatively spliced.
/PROD=type VI collagen alpha 2 chain precursor /FL=gb:AY029208.1 -1.94468 0.831091 6.85 Up 1.92E-02 NM_1530 Homo sapiens 36 hypothetical protein FLJ32239 (FLJ32239), mRNA.
/FL=gb:NM_153036.1 0.586923 3.359675 6.83 Up 4.17E-05 NM_0000 Homo sapiens 47 arylsutfatase E
(chondrodysplasia punctata 1) (ARSE), mRNA.
/PROD=arylsulfatase E
precursor /FL=gb:X83573.1 gb:NM_000047.1 1.064878 3.834572 6.82 Up 2.41E-04 NM 0026 Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 1 (PDK1), nuclear gene encoding mitochondrial protein, mRNA. /PROD=pyruvate dehydrogenase kinase, isoenzyme 1 /FL=gb:NM 002610.2 gb:L42450.i -0.11882 2.64743 6.8 Up 6.88E-04A1702438 ESTs -0.34208 2.418198 6.78 Up 2.31E-04 A1860150 ESTs, Weakly similar to A49134 ig kappa chain V-I
region (H.sapiens) 4.156522 6.9125 6.76 Up 6.48E-05 NM 0032 Homo sapiens 40 endometrial bleeding associated factor (left-right determination, factor A;
transforming growth factor beta superfamily) (EBAF), mRNA.
/PROD=transforming growth factor, beta 4 /FL=gb:U81523.1 gb:NM 003240.1 gb:AFCT81513.1 -1.8911 0.860193 6.73 Up 2.83E-03 NM_0011 Homo sapiens BCL2-like 1 91 (BCL2L1), mRNA.
/PROD=BCL2-like 1 /FL=gb:NM_001191.1 -0.53771 2.208449 6.71 Up 1.41E-02 A1806338 T-box 3 (ulnar mammary syndrome) /FL=gb:AF170708.2 gb:NM_005996.1 3.824397 6.568635 6.7 Up 1.66E-04 AL031602 Human DNA sequence from clone RP5-1174N9 on chromosome 1p34.1-35.3. Contains the gene for a novel protein with IBR domain, a (pseudo?) gene for a novel protein similar to MT1E
(metallothionein lE
(functional)), ESTs, STSs, GSSs and two putative Cp...
0.001822 2.741586 6.68 Up 4.44E-05 NM_0049 Homo sapiens CAMP
04 response element-binding protein CRE-BPa (H GS165L15.1), mRNA.
/PFOD=cAMP response element-binding protein CRE-BPa /FL=gb:NM 004904.1 gb105911.-1-0.301216 3.030236 6.63 Up 4.76E-04 AA812232 upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591.1 4.63387 7.360687 6.62 Up 4.17E-05 BF217861 metallothionein 1E
(functional) 0.413191 3.124723 6.55 Up 5.00E-02 AL136925 Homo sapiens mRNA;
cDNA DKEZp586H1320 (from clone DKEZp586H1320);
complete cds.
/PROD=hypothetical protein /FL=gb:AL136925.1 -0.28056 2.427947 6.54 Up 1.39E-03 AW09018 dihydropyrimidinase-like 4 7 /FL=gb:NM 006426.1 gb:AB0067T3.1 1.095892 3.804014 6.53 Up 2.43E-04 NM_0011 Homo sapiens 46 angiopoietin 1 (ANGPT1), mRNA.
/PROD=angiopoietin 1 /FL=gb:NM 001146.1 gb:D13628.1 gb:U83508.1 -0.0845 2.62025 6.52 Up 2.59E-04 AA625683 ESTs 2.13274 4.835771 6.51 Up 2.01E-04 AL574210 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 /FL=gb:NM 000602.1 gb:M1600671 -0.64252 2.055951 6.49 Up 2.10E-04 NM_0010 Homo sapiens ryanodine 35 receptor 2 (cardiac) (RYR2), mRNA.
/PROD=ryanodine receptor 2 (cardiac) /FL=gb:NM_001035.1 4.450364 7.144308 6.47 Up 3.61E-05 BF246115 RNA helicase-related protein 0.405368 3.094055 6.45 Up 6.25E-05 AW18819 tumor necrosis factor, 8 alpha-induced protein 6 /FL=gb:NM_007115.1 -0.34351 2.332751 6.39 Up 5.54E-05 NM_0000 Homo sapiens cyclin-77 dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), mRNA. /PROD=cyclin-dependent kinase inhibitor 2A (melanoma,p16, inhibits CDK4) /FL=gb:NM 000077.1 gb127211.i -0.88122 1.790331 6.37 Up 1.37E-03 AA775681 hypothetical protein 3.508565 6.179917 6.37 Up 8.80E-05 NM_0001 Homo sapiens glucan 58 (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV) (GBE1), mRNA.
/PROD=glucan (1,4-alpha-), branching enzyme 1(glycogen branching enzyme) /FL=gb:L07956.1 gb:NM_000158.1 -1.84589 0.82486 6.37 Up 3.13E-03 AV705309 ESTs -0.18263 2.487276 6.36 Up 1.49E-02 AC006942 Homo sapiens chromosome 19, cosmid 3.759854 6.426778 6.35 Up 2.01E-05 AF313413 Homo sapiens putative small membrane protein NID67 mRNA, complete cds. /PROD=putative small membrane protein /FL=gb:AF313413.1 2.4094 5.066795 6.31 Up 3.61E-05 A1809870 HSKM-B protein -2.08089 0.570296 6.28 Up 7.70E-03 BC016043 Homo sapiens, hypothetical protein MGC2865, clone MGC:20246 IMAGE:4635389, mRNA, complete cds.
/FL=gb:BC016043.1 1.37641 4.004952 6.18 Up 1.20E-04 AU148611 Human pTR7 mRNA for repetitive sequence 1.384716 4.012773 6:18 Up 4.52E-04 NM_0062 Homo sapiens splicing 75 factor, arginineserine-rich 6 (SFRS6), mRNA.
/PROD=splicing factor, arginineserine-rich 6 /FL=gb:U30883.1 gb:NM_006275.1 2.979212 5.604053 6.17 Up 1.52E-04 M27830 Human 28S ribosomal RNA gene, complete cds.
0.310893 2.921559 6.11 Up 3.42E-04 NM_0072 Homo sapiens U2 small 79 nuclear ribonucleoprotein auxiliary factor (65kD) (U2AF65), mRNA.
/PROD=U2 small nuclear ribonucleoprotein auxiliaryfactor (65kD) /FL=gb:NM_007279.1 0.65284 3.256353 6.08 Up 2.49E-04 A1819043 ESTs 1.609773 4.213168 6.08 Up 1.35E-04 M29277 Human isolate JuSo MUC18 glycoprotein mRNA (3 variant), complete cds.
/PROD=MUC18 glycoprotein /FL=gb:M29277.1 -0.62167 1.968272 6.02 Up 4.11E-04 A1963304 ESTs 4.459837 7.047717 6.01 Up 1.02E-04 NM 0040 Homo sapiens

52 BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3), nuclear gene encoding mitochondria]
protein, mRNA.
/PROD=BCL2adenovirus E1B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM_004052.2 gb:U15174.1 3.178404 5.762898 6 Up 1.27E-04 AB037810 Homo sapiens mRNA for KIAA1389 protein, partial cds. /PROD=KIAA1389 protein -1.08931 1.494664 6 Up 2.35E-03 AB020683 Homo sapiens mRNA for KIAA0876 protein, partial cds. /PROD=KIAA0876 protein 1.9194 4.501184 5.99 Up 3.61E-05 AK000162 Homo sapiens cDNA
FLJ20155 fis, clone C0L08754, highly similar to ACSA ECOLI
ACETYL:COENZYME A
SYNTHETASE.
0.671205 3.243641 5.95 Up 2.48E-04 AA463626 ESTs 0.091029 2.660133 5.93 Up 9.55E-04 AF277174 Homo sapiens PNAS-137 mRNA, complete cds.
/PROD=PNAS-137 /FL=gb:AF277174.1 1.479222 4.042679 5.91 Up 6.34E-05 NM_0054 Homo sapiens cerberus 1 54 (Xenopus laevis) homolog (cysteine knot superfamily) (CER1), mRNA. /PROD=cerberus 1 /FL=gb:NM_005454.1 -0.29455 2.259676 5.87 Up 2.79E-03 AF312393 Homo sapiens leucine-zipper protein FKSG13 (FKSG13) mRNA, complete cds.
/PROD=leucine-zipper protein FKSG13 /FL=gb:AF312393.1 -0.81321 1.740607 5.87 Up 3.72E-02 NM_0021 Homo sapiens 60 hexabrachion (tenascin C, cytotactin) (HXB), mRNA.
/PROD=hexabrachion (tenascin C, cytotactin) /FL=gb:M55618.1 gb:NM_002160.1 0.167058 2.720179 5.87 Up 1.02E-04 NM_0212 Homo sapiens myosin 23 light chain 2a (L0058498), mRNA.
/PROD=myosin light chain 2a /FL=gb:NM_021223.1 0.901323 3.451092 5.86 Up 3.05E-05 NM 0057 Homo sapiens purinergic 67 receptor (family A group 5) (P2Y5), mRNA.
/PROD=purinergic receptor (family A group 5) /FL=gb:AF000546.1 gb:NM_005767.1 1.007578 3.543738 5.8 Up 2.13E-04 NM_0019 Homo sapiens endothelin 55 1 (EDN1), mRNA.
/PROD=endothelin 1 /FL=gb:NM_001955.1 1.327779 3.862686 5.8 Up 1.51E-04 NM_0071 Homo sapiens tumor 15 necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA.
/PROD=tumor necrosis factor, alpha-induced protein 6 /FL=gb:NM_007115.1 -0.2077 2.32716 5.8 Up 1.52E-04 AA211909 ESTs 1.304257 3.835269 5.78 Up 3.02E-04 NM_0054 Homo sapiens enigma 51 (LIM domain protein) (ENIGMA), mRNA.
/PROD=enigma protein /FL=gb:BC001093.1 gb:NM 005451.2 gb:AF2-65209.1 -0.30113 2.227329 5.77 Up 4.58E-03 6E968750 Homo sapiens ryanodine receptor 2 (cardiac) (RYR2), mRNA
1.678635 4.204607 5.76 Up 9.75E-05 AA086229 enigma (LIM domain protein) 1.411335 3.932627 5.74 Up 1.58E-02 NM_0033 Homo sapiens vasodilator-70 stimulated phosphoprotein (VASP), mRNA.
/PROD=vasodilator-stimulated phosphoprotein /FL=gb:NM_003370.1 -1.32153 1.183922 5.68 Up 2.72E-02 AF217536 Homo sapiens truncated mevalonate kinase mRNA, partial cds, alternatively spliced. /PROD=truncated mevalonate kinase 1.058988 3.560886 5.66 Up 3.56E-03 H05812 insulin-like growth factor receptor /FL=gb:NM_000875.2 4.435207 6.93459 5.65 Up 3.61E-05 AF078844 Homo sapiens hqp0376 protein mRNA, complete cds. /PROD=hqp0376 protein /FL=gb:AF078844.1 2.418835 4.908301 5.62 Up 3.47E-03 NM_0122 Homo sapiens similar to 68 vaccinia virus HindllIK4L
ORF (HU-K4), mRNA.
/PROD=similar to vaccinia virus HindlIl K4L ORF
/FL=gb:U60644.1 gb:3C000553.1 gb:NM 012268.1 -0.56112 1.927121 5.61 Up 6.37E-03 AL041124 hypothetical protein -1.63462 0.844727 5.58 Up 4.98E-03 A1831874 ESTs -0.34446 2.130828 5.56 Up 3.75E-05 NM 0063 Homo sapiens sema 79 domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 30 (SEMA3C), mRNA.
/PROD=sema domain, immunoglobulin domain (Ig), shortbasic domain, secreted, (semaphorin) 3C
/FL=gb:NM 006379.1 gb:AB00020.1 4.143258 6.618477 5.56 Up 1.18E-05 AU146532 pyruvate dehydrogenase kinase, isoenzyme 1 -0.52233 1.950739 5.55 Up 1.54E-03 A1091047 solute carrier family 2 (facilitated glucose transporter), member 1 /FL=gb:K03195.1 gb:NM_006516.1 0.690529 3.155168 5.52 Up 9.91E-04 BC033088 Homo sapiens, Similar to lamin AC, clone MGC:45654 IMAGE:3623265, mRNA, complete cds.
/PROD=Similar to lamin AC /FL=gb:BC033088.1 -0.00098 2.454314 5.48 Up 2.48E-04 NM_0132 Homo sapiens fibronectin 81 leucine rich transmembrane protein 3 (FLRT3), mRNA.
/PROD=fibronectin leucine rich transmembrane protein3 /FL=gb:AF169677.1 gb:NM_013281.1 -0.87622 1.577138 5.48 Up 1.84E-02 M15329 Human interleukin 1-alpha (IL1A) mRNA, complete cds. /PROD=interleukin 1-alpha /FL=gb:M15329.1 5.117294 7.564809 5.45 Up 6.25E-05 M83248 Human nephropontin mRNA, complete cds.
/PROD=nephropontin /FL=gb:M83248.1 2.352834 4.796495 5.44 Up 4.17E-05 A1653107 ESTs 3.27933 5.719116 5.43 Up 3.24E-04 NM_0166 Homo sapiens type I
39 transmembrane protein Fn14 (FN14), mRNA.
/PROD=type I
transmembrane protein Fn14 /FL=gb:NM 016639.1 gb:BC0027718.1 gb:AB035480.1 gb:AF191148.1 -2.06232 0.368788 5.39 Up 6.40E-03 AA148534 pregnancy-associated plasma protein A
/FL=gb:NM 002581.1 gb:U2872771 3.982825 6.413408 5.39 Up 7.48E-05 AA678241 stearoyl-CoA desaturase (delta-9-desaturase) /FL=gb:AB032261.1 gb:AF097514.1 gb:NM_005063.1 0.399566 2.809822 5.32 Up 7.81E-04 AF144103 Homo sapiens NJAC
protein (NJAC) mRNA, complete cds.
/PROD=NJAC protein /FL=gb:AF144103.1 gb:AF106911.1 gb:AF073957.1 gb:BC003513.1 gb:NM_004887.1 4.15299 6.560926 5.31 Up 6.59E-05 NM 0009 Homo sapiens 35 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 (PLOD2), mRNA.

/PROD=procollagen-lysine, 2-oxoglutarate 5-dioxygenase(lysine hydroxylase) 2 /FL=gb:NM 000935.1 gb:U8457371 0.319769 2.724257 5.29 Up 8.94E-04 AL552534 Human mRNA for CD44 antigen, 5UTR (sequence from the 5cap to the start codon).
3.347359 5.750515 5.29 Up 5.27E-03 AF047002 Homo sapiens transcriptional coactivator ALY mRNA, partial cds.
/PROD=transcriptional coactivator ALY
4.571448 6.973787 5.29 Up 3.53E-04 A1631159 solute carrier family 2 (facilitated glucose transporter), member 3 /FL=gb:NM 006931.1 gb:M2068171 1.93843 4.333496 5.26 Up 1.21E-04 NM_0198 Homo sapiens 86 carbohydrate (N-acetylglucosamine 6-0) sulfotransferase 7 (CHST7), mRNA.
/PROD=carbohydrate (N-acetylglucosamine 6-0)sulfotransferase 7 /FL=gb:NM 019886.1 gb:AB0371d7.1 gb:AB040711.1 -0.3185 2.064012 5.21 Up 1.55E-03 U83508 Human angiopoietin-1 mRNA, complete cds.
/PROD=angiopoietin-1 /FL=gb:NM 001146.1 gb:D1362871 gb:U83508.1 1.484424 3.866551 5.21 Up 3.49E-04 BC000076 Homo sapiens, cyclin D1 (PRAD1: parathyroid adenomatosis 1), clone MGC:2316, mRNA, complete cds.
/PROD=cyclin D1 (PRAD1: parathyroid adenomatosis 1) /FL=gb:M73554.1 gb:BC000076.1 4.465458 6.844763 5.2 Up 1.52E-04 AF003114 Homo sapiens CYR61 mRNA, complete cds.
/FL=gb:AF003114.1 -1.33756 1.041706 5.2 Up 8.51E-03 BF196010 ESTs 3.747557 6.125638 5.2 Up 4.52E-04 AA554833 neuroendocrine secretory protein 55 -0.24196 2.129273 5.17 Up 2.80E-04 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 2.657439 5.023981 5.16 Up 1.66E-04 NM 0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.

/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S7359171 1.275689 3.642133 5.16 Up 1.65E-04 BF982289 ESTs, Weakly similar to elastin like protein (D.melanogaster) 2.11271 4.458591 5.08 Up 1.97E-04 H15920 ESTs, Weakly similar to RTA RAT PROBABLE G
PROTEIN-COUPLED
RECEPTOR RTA
(R.norvegicus) 2.624088 4.968498 5.08 Up 1.45E-04 M28882 Human MUC18 glycoprotein mRNA, complete cds.
/PROD=MUC18 glycoprotein /FL=gb:M28882.1 4.046173 6.388326 5.07 Up 6.34E-05 NM_0156 Homo sapiens testin 41 (DKFZP58662022), mRNA. /PROD=testin /FL=gb:BC001451.1 gb:AF245357.1 gb:AF245356.1 gb:NM_015641.1 0.946455 3.284436 5.06 Up 5.46E-04 BM97693 Homo sapiens cDNA
9 FLJ31611 fis, clone NT2R12002923.
1.389207 3.725552 5.05 Up 1.08E-04 AL136805 Homo sapiens mRNA;
cDNA DKFZp434J1521 (from clone DKFZp434J1521);
complete cds.
/PROD=hypothetical protein /FL=gb:AL136805.1 0.710433 3.041407 5.03 Up 1.08E-03 NM_0044 Homo sapiens forkhead 72 box D1 (FOXD1), mRNA.
/PROD=forkhead box D1 /FL=gb:U59832.1 gb:NM_004472.1 2.800881 5.127991 5.02 Up 6.53E-05 NM_0178 Homo sapiens 17 hypothetical protein FLJ20429 (FLJ20429), mRNA.
/PROD=hypothetical protein FLJ20429 /FL=gb:NM_017817.1 0.432778 2.759117 5.02 Up 2.50E-03 A1692523 ESTs -0.94056 1.385676 5.01 Up 4.17E-03 A1927458 Homo sapiens mRNA;
cDNA DKFZp434A196 (from clone DKFZp434A196);
complete cds 0.224112 2.550074 5.01 Up 4.11E-04 BF060767 ESTs -0.47823 1.845598 5.01 Up 2.75E-03 AA489100 ESTs 4.590104 -3.36994 249.01 Down 2.26E-04 AA167449 nuclear receptor subfamily 1, group!, member 3 6.024741 -1.32044 162.6 Down 1.79E-03 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 gb:ART17987.1 gb:AF001900.1 1.940449 -5.04898 127.07 Down 3.05E-05 8E644917 nuclear receptor subfamily 1, group I, member 3 2.68759 -3.61621 79 Down 1.25E-03 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds 5.005827 -1.03397 65.79 Down 1.30E-04 NM 0030 Homo sapiens secretory 20 granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM_003020.1 0.357833 -5.67924 65.67 Down 2.26E-03 BG38978 Human mRNA
9 upregulated during camptothecin-induced apoptosis of U937 cells.
6.500961 0.756526 53.61 Down 4.17E-05 NM_0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
/PROD=secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AFC17987.1 gb:AF001900.1 2.077151 -3.59883 51.13 Down 3.75E-03 BF223193 nuclear receptor subfamily 1, group I, member 3 3.29779 -2.3376 49.71 Down 3.05E-05 U17496 Human proteasome subunit LMP7 (allele LMP7B) mRNA, complete cds. /PROD=proteasome subunit LMP7 /FL=gb:U17497.1 gb:U17496.1 4.803291 -0.78667 48.17 Down 3.75E-05 AA628440 nuclear receptor subfamily 1, group I, member 3 4.124115 -1.42293 46.75 Down 7.16E-04 AW26231 ESTs 2.437935 -3.10907 46.75 Down 2.41E-04 BE672557 ESTs 4.276201 -1.19736 44.43 Down 9.47E-04 AV699347 nuclear receptor subfamily 1, group I, member 3 1.710253 -3.7619 44.39 Down 8.66E-05 NM_0161 Homo sapiens transient 79 receptor potential channel 4 (TRPC4), mRNA.
/PROD=transient receptor potential 4 /FL=g b:NM 016179.1 gb:AF175466.1 2.313549 -3.12747 43.44 Down 5.45E-04 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H.sapiens) 2.835599 -2.26295 34.26 Down 2.50E-03 A1735586 ESTs 0.588183 -4.50758 34.2 Down 2.89E-04 AU118882 endothelin receptor type A
/FL=gb:NM 001957.1 gb:L06622.1 0.349102 -4.73558 33.93 Down 2.50E-02 BM68235 Homo sapiens cDNA
2 FLJ37204 fis, clone BRALZ2006976.
-0.10303 -5.00884 29.98 Down 1.97E-04 NM_0221 Homo sapiens melanoma 68 differentiation associated protein-5 (MDA5), mRNA.
/PROD=melanoma differentiation associated protein-5 /FL=gb:AY017378.1 gb:NM 022168.1 gb:ART95844.1 2.325274 -2.506 28.47 Down 1.35E-04 AW19369 DKFZP566K1924 protein 0.252976 -4.55112 27.94 Down 2.54E-02 NM_0180 Homo sapiens 43 hypothetical protein FLJ10261 (FLJ10261), mRNA.
/PROD=hypothetical protein FLJ10261 /FL=gb:NM_018043.1 2.719388 -2.08299 27.9 Down 1.72E-02 NM 0020 Homo sapiens growth 48 arrest-specific 1 (GAS1), mRNA. /PROD-growth arrest-specific 1 /FL=gb:NM 002048.1 gb:L13698.1 3.257726 -1.54343 27.88 Down 6.25E-05 NM_0043 Homo sapiens bone 35 marrow stromal cell antigen 2 (BST2), mRNA.
/PROD=bone marrow stromal cell antigen 2 /FL=gb:NM 004335.2 gb:D28137.1 4.353788 -0.41404 27.24 Down 4.72E-04 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:ART17987.1 gb:AF001900.1 4.387855 -0.27888 25.4 Down 6.82E-05 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 0.027478 -4.62508 25.15 Down 9.89E-03 NM_1526 Homo sapiens 47 hypothetical protein FLJ32800 (FLJ32800), mRNA.
/FL=gb:NM_152647.1 1.767203 -2.80617 23.81 Down 4.44E-04 A1742043 ESTs 1.665643 -2.69521 20.55 Down 1.08E-04 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 0.414323 -3.84422 19.14 Down 3.42E-04 AF283777 Homo sapiens clone TCBAP0702 mRNA
sequence.
3.779853 -0.4664 18.98 Down 4.72E-04 AV646597 ESTs, Weakly similar to SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.995324 -2.233 18.74 Down 1.01E-03 NM_0148 Homo sapiens 62 gene product (KIAA0307), mRNA. /PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM 014862.1 1.946332 -2.24096 18.22 Down 2.40E-03 BG16670 small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-activating peptide 78) 1.179963 -2.9904 18.01 Down 2.13E-04 U96136 Homo sapiens delta-catenin mRNA, complete cds. /PROD=delta-catenin /FL=gb:NM 001332.1 gb:U72665.1 gb:AB013805.1 gb:U96136.1 gb:AF035302.1 2.060687 -2.07873 17.62 Down 1.01E-03 A1269290 solute carrier family 18 (vesicular monoamine), member 2 /FL=gbil 4269.1 gb:L23205.1 gb:L09118.1 gb:NM_003054.1 2.480221 -1.64839 17.49 Down 1.22E-03 NM_0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U6108371 0.971941 -3.12304 17.09 Down 1.07E-02 NM_0180 Homo sapiens 18 hypothetical protein FLJ10191 (FLJ10191), mRNA.
/PROD=hypothetical protein FLJ10191 /FL=gb:NM_018018.1 2.263194 -1.81469 16.89 Down 2.69E-03 AF052108 Homo sapiens clone 23687 mRNA sequence.

2.115848 -1.84267 15.55 Down 3.89E-02 AF213678 Homo sapiens HAI-2 related small protein (HAI-2) mRNA, complete cds.
/PROD=HAI-2 related small protein /FL=gb:AB038317.1 gb:AF213678.1 2.348373 -1.56046 15.02 Down 7.77E-03 NM 0163 Homo sapiens solute 54 carrier family 21 (organic anion transporter), member 12 (SLC21Al2), mRNA. /PROD=organic anion transporter OATP-E
/FL=gb:AB031051.1 gb:NM 016354.1 gb:AF205072.1 gb:AF187817.1 1.910263 -1.99418 14.97 Down 3.77E-04 NM_0069 Homo sapiens 94 butyrophilin, subfamily 3, member A3 (BTN3A3), mRNA.
/PROD=butyrophilin, subfamily 3, member A3 /FL=gb:U90548.1 gb:NM_006994.2 2.699795 -1.16113 14.53 Down 5.07E-03 NM_0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB0289-6-7.1 gb:AF121104.1 2.172559 -1.66608 14.31 Down 7.83E-03 BE673445 Homo sapiens chromosome 19, cosmid 0.265765 -3.53873 13.97 Down 2.21E-03 A1675836 Human DNA sequence from clone RP11-446H13 on chromosome 10.
Contains the 3 end of the gene for a novel protein similar to KIAA1059 (ortholog of mouse VPS10 domain receptor protein SORCS), an RPL23A
(60S ribosmal protein 23A) pseudogene, ESTs, STSs an 5.440506 1.644236 13.89 Down 6.34E-05 M34455 Human interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mRNA, complete cds.
/FL=gb:NM 002164.1 gb:M3445571 0.330556 -3.45471 13.79 Down 5.46E-04 6E972639 ESTs 0.437404 -3.31877 13.51 Down 4.52E-04 H05254 ESTs 1.32524 -2.42314 13.44 Down 1.57E-02 H29627 ESTs 1.673028 -2.06656 13.36 Down 5.30E-03 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 1.319614 -2.39234 13,1 Down 1.43E-02 NM 0043 Homo sapiens catenin 89 (cadherin-associated protein), alpha 2 (CTNNA2), mRNA.
/PROD=catenin (cadherin-associated protein), alpha 2 /FL,---gb:NM_004389.1 gb:M94151.2 1.708627 -1.98647 12.95 Down 1.75E-02 NM_0175 Homo sapiens KIAA0449 96 protein (KIAA0449), mRNA.
/PROD=hypothetical protein DKFZp434J212 /FL=gb:NM_017596.1 2.777148 -0.8902 12.71 Down 4.36E-04 NM_0220 Homo sapiens estrogen 34 regulated gene 1 (ERG-1), mRNA. /PROD=estrogen regulated gene 1 /FL=gb:AF305835.1 gb:NM_022034.1 1.982765 -1.67669 12.64 Down 6.88E-04 BE672659 ESTs 0.457009 -3.18081 12.45 Down 3.30E-04 AW44981 KIAA0918 protein 0.510314 -3.12055 12.39 Down 1.71E-02 AW78000 ESTs 0.536704 -3.05382 12.05 Down 1.92E-02 AL049250 Homo sapiens mRNA;
cDNA DKFZp564D113 (from clone DKFZp564D113).
2.294336 -1.27392 11.86 Down 1.66E-02 U11058 Homo sapiens large conductance calcium- and voltage-dependent potassium channel alpha subunit (MaxiK) mRNA, complete cds.
/PROD=large conductance calcium- and voltage-dependentpotassium channel alpha subunit /FL=gb:U23767.1 gb:NM 002247.1 gb:AF025999 2.177763 -1.38062 11.78 Down 8.80E-05 NM_0025 Homo sapiens 90 protocadherin 8 (PCDH8), mRNA.
/PROD=protocadherin 8 /FL=gb:NM 002590.2 gb:AF0615-i3.2 -0.48821 -4.01809 11.55 Down 2.29E-02 AB040812 Homo sapiens mRNA for protein kinase PAK5, complete cds.
/PROD=protein kinase PAK5 /FL=gb:AB040812.1 1.785431 -1.74236 11.53 Down 2.18E-03 R15072 ESTs 1.459269 -2.00069 11 Down 3.74E-04 NM 0002 Homo sapiens 77 phenylalanine hydroxylase (PAH), mRNA.
/PROD=phenylalanine hydroxylase /FL=gb:U49897.1 gb:NM_000277.1 1.995493 -1.44407 10.85 Down 7.11E-03 U91903 Human Fritz mRNA, complete cds.
/PROD=Fritz /FL=gb:U24163.1 gb:U68057.1 gb:NM 001463.1 gb:U91903.1 0.679665 -2.7484 10.76 Down 5.57E-03 BC000568 Homo sapiens, clone MGC:3040, mRNA, complete cds.
/PROD=Unknown (protein for MGC:3040) /FL=gb:BC000568.1 1.841888 -1.57619 10.69 Down 1.16E-03 AW07279 contactin 1 -0.42571 -3.8118 10.45 Down 1.58E-02 AK023699 Homo sapiens cDNA
FLJ13637 fis, clone PLACE1011165.
1.923237 -1.4606 10.44 Down 4.11E-04 AW07210 Homo sapiens mRNA;
2 cDNA DKFZp434H205 (from clone DKFZp434H205) 0.931661 -2.45074 10.43 Down 1.07E-02 AW14940 neurexin 1 /FL=gb:AB035356.1 0.781816 -2.56699 10.19 Down 2.50E-02 NM_0006 Homo sapiens 98 arachidonate 5-lipoxygenase (ALOX5), mRNA.
/PROD=arachidonate 5-lipoxygenase /FL=gb:NM 000698.1 gb:J03600.T gb:J03571.1 1.939598 -1.40726 10.17 Down 2.29E-03 AB014737 Homo sapiens mRNA for SMAP-2b, complete cds.
/PROD=SMAP-2b /FL=gb:AB014737.1 0.874376 -2.46854 10.15 Down 1.59E-02 U82671 Homo sapiens chromosome Xq28 melanoma antigen family A2a (MAGEA2A), melanoma antigen family Al2 (MAGEA12), melanoma antigen family A2b (MAGEA2B), melanoma antigen family A3 (MAGEA3), caltractin (CALT), NAD(P)H
dehydrogenase-like protein (NSDHL), a...
3.315768 0.011663 9.88 Down 7.33E-04 AK098525 Homo sapiens cDNA

FLJ25659 fis, clone TST00427, highly similar to Mus musculus hedgehog-interacting protein (Hip) mRNA.
0.121165 -3.1782 9.84 Down 4.65E-03 A1985987 ESTs, Moderately similar to ALU1 HUMAN ALU
SUBFAMILY J
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.686587 -2.59339 9.71 Down 2.72E-02 NM_0004 Homo sapiens proprotein 39 convertase subtilisinkexin type 1 (PCSK1), mRNA.
/PROD=proprotein convertase subtilisinkexin type 1 /FL=gb:NM 000439.2 gb:M9075371 3.113317 -0.0881 9.2 Down 7.30E-05 AL565745 ESTs, Weakly similar to 2108402A carnitine palmitoyltransferase 1 (H.sapiens) 2.890305 -0.29832 9.12 Down 3.24E-04 NM 0154 Homo sapiens 74 DKFZP564A032 protein (DKFZP564A032), mRNA.
/PROD=DKFZP564A032 protein /FL=gb:AF228421.1 gb:AL050267.1 gb:AB013847.1 gb:NM_015474.1 0.447048 -2.73882 9.1 Down 4.19E-02 BE645435 ESTs 3.142124 -0.03564 9.05 Down 3.76E-03 AL832535 Homo sapiens mRNA;
cDNA DKFZp547J1816 (from clone DKFZp547J1816).
0.767101 -2.38787 8.91 Down 1.92E-02 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) 4.315048 1.168713 8.85 Down 7.92E-04 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:BC003079.1 -0.47937 -3.61302 8.78 Down 2.49E-02 BE968773 Homo sapiens mRNA;
cDNA DKFZp56401262 (from clone DKFZp56401262) 3.26376 0.151239 8.65 Down 1.74E-04 BE644809 ESTs 0.384182 -2.72567 8.63 Down 3.02E-02 NM_0058 Homo sapiens RAS
25 guanyl releasing protein 2 (calcium and DAG-regulated) (RASGRP2), mRNA. /PROD=RAS
guanyl releasing protein 2 (calcium andDAG-regulated) /FL=gb:AF043723.1 gb:NM_005825.1 2.363587 -0.72928 8.53 Down 7.38E-04 NM_0246 Homo sapiens 45 hypothetical protein FLJ13842 (FLJ13842), mRNA.
/PROD=hypothetical protein FLJ13842 /FL=gb:NM 024645.1 4.756657 1.668488 8.5 Down 1.30E-04 AV715309 ESTs, Weakly similar to SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.995551 -2.07915 8.43 Down 3.01E-02 NM_0053 Homo sapiens neuronatin 86 (N NAT), mRNA.
/PROD=neuronatin /FL=gb:NM 005386.1 gb:BC001768.1 gb:AB002392.1 gb:U25033.1 2.380226 -0.68921 8.39 Down 8.34E-05 NM_0165 Homo sapiens 46 complement C1r-like proteinase precursor, (L0051279), mRNA.
/PROD=complement C1r-like proteinase precursor, /FL=gb:AF178985.1 gb:NM 016546.1 2.598916 -0.46577 8.37 Down 6.59E-05 AW05159 ESTs, Moderately similar 1 to unnamed protein product (H.sapiens) 1.045717 -2.01579 8.35 Down 1.44E-02A1937060 K1AA1151 protein 3.009579 -0.04543 8.31 Down 7.08E-04 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=KIAA1309 protein 1.440541 -1.60998 8.29 Down 1.58E-02 BE503640 ESTs 0.4785 -2.56291 8.23 Down 2.46E-02 BG53269 integrin, alpha 4 (antigen 0 CD49D, alpha 4 subunit of VLA-4 receptor) 5.84374 2.812887 8.17 Down 6.34E-05 BC000069 Homo sapiens, retinoic acid receptor responder (tazarotene induced) 2, clone MGC:1544, mRNA, complete cds.
/PROD=retinoic acid receptor responder (tazaroteneinduced) 2 /FL=gb:BC000069.1 gb:NM 002889.2 gb:ABCT15632.1 gb:U77594.1 1.110683 -1.89628 8.04 Down 8.48E-04 AA557324 ESTs, Weakly similar to fatty acid omega-hydroxylase (H.sapiens) 1.386384 -1.61585 8.01 Down 3.53E-04 AF196571 Homo sapiens Delta-like-protein (DLL1) mRNA, complete cds.
/PROD=Delta-like-1 protein /FL=gb:NM 005618.2 gb:AF1965-7-1.1 5.363884 2.372618 7.95 Down 7.30E-05 NM 0070 Homo sapiens 15 chondromodulin I
precursor (CHM-I), mRNA.
/PROD=chondromodulin I
precursor /FL=gb:NM 007015.1 gb:AB0060-6-0.1 1.364581 -1.62447 7.94 Down 2.16E-02 NM_1452 Homo sapiens similar to 80 hepatocellular carcinoma-associated antigen HCA557b (LOCI 51194), mRNA.
/FL=gb:BC009462.1 gb:NM_145280.1 2.628136 -0.35867 7.93 Down 1.22E-04 NM_0019 Homo sapiens endothelin 57 receptor type A (EDNRA), mRNA.
/PROD=endothelin receptor type A
/FL=gb:NM 001957.1 gb:L06622.-1-1.712212 -1.25121 7.8 Down 8.48E-04 R62432 Cluster Incl.
R62432:yg52e11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-36023 /clone enc1=3 /gb=R-62432 /gi=834311 /ug=Hs.12321 /len=487 1.443731 -1.51616 7.78 Down 4.37E-03 AJ272267 Homo sapiens partial mRNA for choline dehydrogenase (chdh gene). /PROD=choline dehydrogenase 3.106596 0.148375 7.77 Down 1.23E-02 NM_0023 Homo sapiens Iectin, 05 galactoside-binding, soluble, 1 (galectin 1) (LGALS1), mRNA.
/PROD=beta-galactosidase binding lectin precursor /FL=gb:NM 002305.2 gb:BC001693.1 gb:J04456.1 1.961633 -0.98665 7.72 Down 8.93E-03 NM_0014 Homo sapiens frizzled-63 related protein (FRZB), mRNA. /PROD=frizzled-related protein /FL=gb:U24163.1 gb:U68057.1 gb:NM 001463.1 gb:U91-903.1 2.38092 -0.54428 7.6 Down 6.34E-04 AF053712 Homo sapiens osteoprotegerin ligand mRNA, complete cds.
/PROD=osteoprotegerin ligand /FL=gb:AF053712.1 gb:AF019047.1 0.685413 -2.22507 7.52 Down 2.98E-02 NM 0183 Homo sapiens 83 hypothetical protein FLJ11294 (FLJ11294), mRNA.
/PROD=hypothetical protein FLJ11294 /FL=gb:NM_018383.1 -0.24717 -3.14972 7.48 Down 3.67E-04 AF429305 Homo sapiens C23up NCRMS mRNA, partial sequence; alternatively spliced.
3.893148 0.997757 7.44 Down 1.29E-04 AU144892 Homo sapiens cDNA
FLJ11569 fis, clone 0.82553 -2.06523 7.42 Down 4.10E-02 BC041933 Homo sapiens, clone IMAGE:5300703, mRNA.
0.728978 -2.13318 7.27 Down 1.25E-03 AL573058 complement component 1, r subcomponent 1.033324 -1.8148 7.2 Down 5.93E-03 N80918 Novel human gene mapping to chomosome 2.858719 0.013383 7.19 Down 4.37E-03 L10374 Human (clone CTG-A4) mRNA sequence.
2.260317 -0.57539 7.14 Down 1.02E-03A1138603 ESTs 2.003902 -0.82254 7.09 Down 8.00E-03 8E109660 ESTs 3.85985 1.037668 7.07 Down 2.70E-04 R40892 ESTs 3.921983 1.12675 6.94 Down 3.53E-04 AA206141 ESTs -0.17018 -2.96268 6.93 Down 2.08E-02 AV741130 ESTs, Moderately similar to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.610685 -1.16078 6.83 Down 9.82E-04 AA886335 Homo sapiens serologically defined breast cancer antigen NY-BR-20 mRNA, partial cds 2.859538 0.089114 6.82 Down 2.22E-03 AW01473 ESTs 3.212409 0.467551 6.7 Down 2.69E-04 BG43417 Homo sapiens cDNA
4 FLJ13555 fis, clone 2.116702 -0.60252 6.59 Down 3.35E-03 AF107846 Homo sapiens neuroendocrine-specific Golgi protein p55 (XLalphas) gene, exon XL2 and complete cds 3.179908 0.462842 6.58 Down 3.24E-04 U82811 Human homeodomain-containing protein (HANF) mRNA, complete cds.

=
/PROD=HANF
/FL=gb:U82811.1 gb:NM_003865.1 2.509452 -0.20066 6.54 Down 1.04E-03 NM_0016 Homo sapiens acyl-09 Coenzyme A
dehydrogenase, shortbranched chain (ACADSB), nuclear gene encoding mitochondrial protein, mRNA.
/PROD=acyl-Coenzyme A
dehydrogenase, shortbranchedchain precursor /FL=gb:U12778.1 gb:NM_001609.1 2.596054 -0.10733 6.51 Down 1.39E-03 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) 0.559211 -2.13754 6.48 Down 2.20E-02 BF000203 ESTs 4.534853 1.872557 6.33 Down 9.75E-05 R38389 olfactomedin related ER
localized protein 2.068166 -0.59258 6.32 Down 1.69E-03 BF698797 ESTs 2.168796 -0.49174 6.32 Down 2.44E-04 NM_0025 Homo sapiens neuronal 22 pentraxin I (NPTX1), mRNA. /PROD=neuronal pentraxin I precursor /FL=gb:NM 002522.1 gb:U6184971 -0.10024 -2.75761 6.31 Down 3.60E-02 BC033812 Homo sapiens, Similar to LOCI 55399, clone MGC:45477 IMAGE:5181460, mRNA, complete cds.
/PROD=Similar to /FL=gb:BC033812.1 0.994947 -1.65385 6.27 Down 7.39E-03 NM_0240 Homo sapiens 34 hypothetical protein MGC3129 similar to ganglioside-induced differentiation-associated protein (MGC3129), mRNA.
/PROD=hypothetical protein MGC3129 similar toganglioside-induced differentiation-associated protein /FL=gb:NM_024034.1 gb:BCO
3.758058 1.109291 6.27 Down 4.39E-04 NM_0053 Homo sapiens 56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 1.553207 -1.09181 6.26 Down 2.54E-02 A1653050 ESTs, Weakly similar to HYDROXYPHENYLPYRU
VATE DIOXYGENASE
(H.sapiens) 3.702164 1.060081 6.24 Down 4.08E-04 U26662 Human neuronal pentraxin II (NPTX2) mRNA, partial cds. /PROD=neuronal pentraxin II
4.260791 1.638346 6.16 Down 6.25E-05 AA603344 ESTs, Weakly similar to SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 2.172331 -0.44991 6.16 Down 2.44E-04 NM_0038 Homo sapiens tumor 39 necrosis factor receptor superfamily, member 11a, activator of NFKB
(TNFRSF11A), mRNA.
/PROD=tumor necrosis factor receptor superfamily,member 11a, activator of NFKB
/FL=gb:NM 003839.1 gb:AF018253.1 4.981307 2.359848 6.15 Down 4.17E-05 NM_0051 Homo sapiens 03 fasciculation and elongation protein zeta 1 (zygin I) (FEZ1), transcript variant 1, mRNA.
/PROD=zygin 1, isoform 1 /FL=gb:U60060.1 gb:U69139.1 gb:NM_005103.2 3.826815 1.207679 6.14 Down 6.48E-05 BG40156 Homo sapiens mRNA;
8 cDNA DKFZp434H1235 (from clone DKFZp434H1235); partial cds 1.027188 -1.59055 6.14 Down 8.40E-03 BG16983 adenylate kinase 5 2 /FL=gb:NM 012093.1 gb:AF062565.1 2.054962 -0.54704 6.07 Down 2.86E-03 NM_0028 Homo sapiens 00 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional protease 2) (PSMB9), mRNA.
/PROD=proteasome (prosome, macropain) subunit, betatype, 9 (large multifunctional protease 2) /FL=gb:U01025.1 gb:NM_002800.1 5.372736 2.7744 6.06 Down 8.80E-05 AA669799 Cluster Incl.
AA669799:ag36c04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1118886 /clone_end=3 /gb=AA669799 /gi=2631298 /ug=Hs.6315 /len=679 0.24636 -2.3444 6.02 Down 1.31E-03 AW05758 ESTs 1.145878 -1.44369 6.02 Down 9.46E-03 A1056877 Human DNA sequence from clone RP4-530I1 5 on chromosome 20. Contains the 3 end of the PTPN1 gene for protein tyrosine phosphatase, non-receptor type 1 (EC
3.1.3.48), the gene for a novel protein similar to placental protein DIFF40, an RPL36 (60S Ribos 0.976009 -1.61054 6.01 Down 5.39E-03 AW26420 ESTs 0.497515 -2.08762 6 Down 2.83E-02 AF052117 Homo sapiens clone 23809 mRNA sequence.
0.381933 -2.20139 5.99 Down 8.66E-04 A1913749 ESTs 0.528494 -2.05438 5.99 Down 4.17E-02 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 3.795925 1.232161 5.91 Down 2.20E-04 NM_0046 Homo sapiens N-myc (and 88 STAT) interactor (NMI), mRNA. /PROD=N-myc and STAT interactor /FL=gb:BC001268.1 gb:NM 004688.1 gb:U32849.1 1.934415 -0.62283 5.89 Down 4.93E-04 NM_0013 Homo sapiens deleted in 51 azoospermia-like (DAZL), mRNA. /PROD=deleted in azoospermia-like /FL=gb:U66726.2 gb:NM 001351.1 gb:U66-918.1 gb:U66078.1 1.805448 -0.75007 5.88 Down 1.88E-03A1681917 ESTs, Highly similar to CLASS HOMEODOMAIN

(M.musculus) 2.788534 0.237692 5.86 Down 7.40E-03 AW45092 heterogeneous nuclear 9 ribonucleoprotein Al 2.99034 0.457208 5.79 Down 5.23E-04 NM 0029 Homo sapiens small 93 inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) (SCYB6), mRNA.
/PROD=small inducible cytokine subfamily B(Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) /FL=gb:U81234.1 gb:NM_00299 0.362564 -2.17012 5.79 Down 1.28E-02 AB018580 Homo sapiens mRNA for hluPGFS, complete cds.
/PROD=h1uPGFS
/FL=gb:NM 003739.2 gb:AF1494T6.2 gb:AB018580.1 gb:D17793.1 1.673874 -0.85315 5.76 Down 8.93E-03 NM_0059 Homo sapiens myosin, 65 light polypeptide kinase (MYLK), mRNA.
/PROD=myosin, light polypeptide kinase /FL=gb:AB037663.1 gb:AF069601.2 gb:NM_005965.1 1.858219 -0.66565 5.75 Down 2.13E-04 NM_0050 Homo sapiens 84 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), mRNA.
/PROD=phospholipase A2, group VII (platelet-activatingfactor acetylhydrolase, plasma) /FL=gb:U20157.1 gb:U24577.1 gb:NM_005084.1 3.016209 0.501482 5.71 Down 6.48E-05 AW02637 ESTs 3.692792 1.179422 5.71 Down 1.52E-04 N21096 ESTs 1.28245 -1.23083 5.71 Down 3.20E-04 AF063824 Homo sapiens trp-related protein 4 truncated variant delta mRNA, complete cds. /PROD=trp-related protein 4 truncated variant delta /FL=gb:AF063824.1 3.772564 1.260638 5.7 Down 3.53E-04 AA404269 ESTs 2.016986 -0.49385 5.7 Down 6.37E-03 A1741439 ESTs 2.453774 -0.04433 5.65 Down 1.01E-03 NM 0071 Homo sapiens Wnt 91 inhibitory factor-1 (WIF-1), mRNA. /PROD=Wnt inhibitory factor-1 /FL=gb:AF122922.1 gb:NM_007191.1 5.545158 3.061783 5.59 Down 1.71E-04 BF057809 ESTs 5.219258 2.740374 5.57 Down 1.08E-04 AA974416 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform 2.913327 0.434686 5.57 Down 2.99E-04 NM_0124 Homo sapiens regulator of 19 G-protein signalling 17 (RGS17), mRNA.
/PROD=regulator of G-protein signalling 17 /FL=gb:AF202257.2 gb:NM_012419.2 1.651332 -0.81962 5.54 Down 1.35E-02 NM_0071 Homo sapiens mitogen-81 activated protein kinase kinase kinase kinase 1 (MAP4K1), mRNA.
/PROD=mitogen-activated protein kinase kinase kinasekinase 1 /FL=gb:U66464.1 gb:NM_007181.1 1.293775 -1.16956 5.51 Down 1.15E-02 6E593660 ESTs 1.417933 -1.04305 5.51 Down 4.93E-04 NM_0027 Homo sapiens protein 38 kinase C, beta 1 (PRKCB1), mRNA.
/PROD=protein kinase C, beta 1 /FL=gb:NM_002738.1 3.66812 1.207732 5.5 Down 1.97E-04 NM_1333 Homo sapiens potassium 29 voltage-gated channel, subfamily G, member 3 (KCNG3), transcript variant 1, mRNA.
/PROD=potassium voltage-gated channel, subfamily G,member 3 isoform 1 /FL=gb:AF454548.1 gb:AF348982.1 gb:AB070604.1 gb:NM_133329.4 3.002731 0.549124 5.48 Down 4.89E-04 R54042 ESTs 5.276628 2.824048 5.47 Down 6.48E-05 BC005127 Homo sapiens, adipose differentiation-related protein, clone MGC:10598, mRNA, complete cds.
/PROD=adipose differentiation-related protein /FL=gb:BC005127.1 gb:NM_001122.1 3.380946 0.937118 5.44 Down 1.22E-04 AU151342 Homo sapiens cDNA
FLJ12935 fis, clone 2.01577 -0.42783 5.44 Down 1.92E-0313E220341 casein kinase 2, alpha 1 polypeptide 1.307387 -1.12824 5.41 Down 1.08E-04 AK021452 Homo sapiens cDNA
FLJ11390 fis, clone HEMBA1000561, weakly similar to ZINC FINGER
PROTEIN 91.
0.36507 -2.02151 5.23 Down 4.98E-03 BF062244 ESTs 0.756663 -1.62346 5.21 Down 1.69E-03 BG53358 ESTs 3.876819 1.518834 5.13 Down 4.76E-04 A1651212 ESTs 0.619594 -1.73795 5.12 Down 1.18E-03 BE467611 ESTs 0.482843 -1.87385 5.12 Down 1.04E-03 BG28489 ESTs 1.048359 -1.30538 5.11 Down 8.93E-03 AA464273 ESTs 3.527039 1.198446 5.02 Down 2.69E-03 BG28379 ESTs 2.522705 0.194248 5.02 Down 3.09E-03 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds. /PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM005356.1 gb:M36881.1 2.356401 0.028606 5.02 Down 6.23E-04 NM_0248 Homo sapiens 93 hypothetical protein FLJ14220 (FLJ14220), mRNA.
/PROD=hypothetical protein FLJ14220 /FL=gb:NM 024893.1 4.587367 2.264046 5 Down 2.70E-04 AL049589 Human DNA sequence from clone 570L12 on chromosome Xq13.1-21.1.
Contains the PGK1 gene for phosphoglycerate kinase 1, the gene for a novel protein similar to TAF2G (TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD) (TAF...
B) ES vs EXPRES 02- Intensity values are in Log2 format.
ES EXPRES 02 Ratio Direction adj. p- Gene Gene Name value Identifier -2.7136 7.077563 886 Up 9.62E-04 NM 0018 Homo sapiens cystatin 98 SN (CST1), mRNA.
/PROD=cystatin SN
/FL=gb:J03870.1 gb:NM 001898.1 -2.3713 6.959692 644.03 Up 6.55E-05 R72286 microfil3rillar-associated protein 4 -3.78394 5.172093 496.63 Up 1.06E-04 AW15754 insulin-like growth 8 factor binding protein 5 /FL=gb:M65062.1 gb:M62782.1 gb:NM 000599.1 gb:AF6-55033.1 -4.79257 3.432794 299.28 Up 1.81E-03 AA352113 ESTs -5.16453 3.053666 297.8 Up 5.30E-03 NM_0023 Homo sapiens lumican 45 (LUM), mRNA.
/PROD=Iumican /FL=gb:NM_002345.1 gb:U18728.1 gb:U21128.1 -2.55753 5.625595 290.65 Up 1.79E-04 087811 Homo sapiens mRNA
for GATA-6, complete cds.
IPR00=GATA-6 IFIL=gb:U66075.1 gb:Nfv1 005257.1 oh:DV-811.1 -5.03662 3.030028 268.1 Up 7.79E-05 BG09943 ESTs -2.97296 4.901727 234.7 Up 5.95E-05 A1821586 ESTs, Moderately similar to JE0284 Mm-1 cell derived transplantability-associated protein lb (H.sapiens) -3.06613 4.772945 228.98 Up 2.57E-03 A1422986 ESTs -4.37538 3.399327 218.99 Up 7.01E-05 AA552969 ESTs -3.47045 4.200612 203.81 Up 4.26E-03 NM_0251 Homo sapiens 40 hypothetical protein FLJ22471 (FLJ22471), mRNA.
/PROD=hypothetical protein FLJ22471 /FL=gb:NM_025140.1 -4.82833 2.813842 199.77 Up 1.40E-04 BF064262 ESTs -5.1127 2.479359 192.95 Up 1.06E-04 NM_0026 Homo sapiens paired-

53 like homeodomain transcription factor 1 (PITX1), mRNA.
/PROD=paired-like homeodomain transcription factor 1 /FL=gb:NM_002653.1 -3.4841 4.092799 190.93 Up 4.34E-04 BM12843 Homo sapiens full 2 length insert cDNA
clone YA81B05 -4.64254 2.721466 164.74 Up 2.38E-05 AY177407 Homo sapiens homeobox protein goosecold mRNA, complete cds.
/PROD=homeobox protein goosecoid IFL=gb:AY177407.1 gb:NNI_173849.1 -3.40132 3.923976 160.37 Up 1.34E-02 BF589787 ESTs -1.20324 6.071574 154.86 Up 2.23E-04 NM_0016 Homo sapiens 43 apolipoprotein A-II
(AP0A2), mRNA.
/PROD=apolipoprotein A-II precursor /FL=gb:M29882.1 gb:NM 001643.1 gb:BC005282.1 -3.4292 3.808106 150.89 Up 4.62E-04 AB02802 Cluster Incl.
1 AB028021:HOITIO
sapiens liNF-3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds Icdst(196.1569) /9b=AB028021 /91=4958949 /ugr-Hs.155651 Ilen=1944 -4.71714 2.374201 136.37 Up 6.98E-05 A1796169 GAM-binding protein 3 /FL=gb; NM_ 802051.1 gb:N169186.1 gb:BC083078.1 -2.26798 4.781861 132.5 Up 9.04E-05 NM_0013 Homo sapiens cystatin 22 SA (CST2), mRNA.
/PROD=cystatin SA
/FL=gb:NM_001322.1 -0.81321 6.174771 126.94 Up 1.57E-03 NM_0021 Homo sapiens 60 hexabrachion (tenascin C, cytotactin) (HXB), mRNA.
/PROD=hexabrachion (tenascin C, cytotactin) /FL=gb:M55618.1 gb:NM_002160.1 -2.38522 4.594021 126.17 Up 6.89E-05 AA502609 Homo sapiens ankyrin-like with transmembrane domains 1 (ANKTM1), mRNA
-3.75387 3.204091 124.32 Up 2.13E-04 A1991459 ESTs -4.21525 2.671776 118.36 Up 1.99E-04 NM 0061 Homo sapiens 19 fibroblast growth factor 8 (androgen-induced) (FGF8), mRNA.
/PROD=fibroblast growth factor 8 (androgen-induced) IFL=gb:U36223.1 gbU46212.1 gb:NM..906119.1 -2.02474 4.768631 110.92 Up 7.31E-03 NM 0218 Homo sapiens 27 hypothetical protein FLJ23514 (FLJ23514), mRNA.
/PROD=hypothetical protein FLJ23514 /FL=gb:NM 021827.1 -2.38432 4.381798 108.84 Up 1.01E-03 AL534095 hypothetical protein -2.25187 4.311095 94.55 Up 7.26E-03 AL136944 Homo sapiens mRNA;
cDNA
DKFZp586J0624 (from clone DKFZp586J0624);
complete cds.
/PROD=hypothetical protein /FL=gb:AF215636.1 gb:NM 014585.1 gb:AF -2.31121.1 gb:AF226614.1 gb:AL136944.1 -1.92189 4.619888 93.17 Up 9.02E-04 AV700724 GATA-binding protein 4 1FL=gb:NM 002052.1 0:L34357,71 gb:078260.1 -3.42725 2.997778 85.93 Up 2.95E-03 NM_0224 Homo sapiens 69 hypothetical protein FLJ21195 similar to protein related to DAC
and cerberus (FLJ21195), mRNA.
/PROD=hypothetical protein FLJ21195 similar to proteinrelated to DAC
and cerberus /FL=gb:NM_022469.1 -3.14404 3.270152 85.28 Up 6.55E-05 AB028021 Homo sapiens HNF-3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds.
/PROD=hepatocyte nuclear factor-3 beta /FL=gb:AB028021.1 gb:NM 021784.1 -0.88122 5.526622 84.91 Up 1.25E-04 AA775681 hypothetical protein -2.96204 3.439168 84.52 Up 1.08E-03 NM_0013 Homo sapiens 11 cysteine-rich protein 1 (intestinal) (CRIP1), mRNA.
/PROD=cysteine-rich protein 1 (intestinal) /FL=gb:U58630.1 gb:BC002738.1 gb:NM 001311.1 gb:U06-770.1 -3.42819 2.876705 79.06 Up 2.31E-04 AL121722 Human DNA sequence from clone RP4-788L20 on chromosome 20 Contains the HNF3B
(hepatocyte nuclear factor 3, beta) gene. a novel gene based on ESTs, ESTs, STSs, GSSs and CpG
Islands -1.01231 5.27686 78.2 Up 1.85E-04 NM_0016 Homo sapiens 43 apolipoprotein A-II
(AP0A2), mRNA.
/PROD=apolipoprotein A-II precursor /FL=gb:M29882.1 gb:NM 001643.1 gb:BC005282.1 -2.13331 4.095704 75.01 Up 2.99E-04 4M )038 Homo sapiens 07 fibroblast growth factor 17 (FGF17), mRNA.
/PROD=fibroblast growth factor 17 /F1..="---gb;NM 003867.1 gb:AB009249.1 -0.14916 6.052967 73.63 Up 2.30E-04 NM_0025 Homo sapiens 21 natriuretic peptide precursor B (NPPB), mRNA.
/PROD=natriuretic peptide precursor B
/FL=gb:NM 002521.1 gb:M25296..-1 -2.9139 3.274181 72.91 Up 9.48E-04 NM_0051 Homo sapiens 43 haptoglobin (HP), mRNA.
/PROD=haptoglobin /FL=gb:K00422.1 gb:L29394.1 gb:NM_005143.1 -2.33028 3.85605 72.82 Up 2.04E-04 X02162 Human mRNA for apolipoprotein Al (apo Al).
/PROD=preproapolipo protein Al -4.75249 1.427636 72.51 Up 8.97E-04 AJ276395 Homo sapiens mRNA
for MSF-FN70 (FN
gene).
/PROD=migration stimulation factor -1.50663 4.672617 72.47 Up 9.82E-05 BF223214 ESTs -4.40099 1.778003 72.45 Up 8.87E-05 A1733179 ESTs -2.56553 3.594638 71.51 Up 4.24E-04 D31771 Homo sapiens mRNA
for MSX-2, complete cds. /PROD=MSX-2 /FL=gb:NM 002449.2 gb:031771.1 -3.67415 2.447201 69.62 Up 1.97E-02 BC042378 Homo sapiens, clone IMAGE:5277693, mRNA.
-1.33141 4.770833 68.7 Up 2.36E-04 A1640307 protocadherin 10 -2.41293 3.673615 67.96 Up 8.00E-04 NM_0008 Homo sapiens 46 glutathione S-transferase A2 (GSTA2), mRNA.
/PROD=glutathione S-transferase A2 /FL=gb:BC002895.1 gb:M25627.1 gb:M16594.1 gb:M14777.1 gb:M15872.1 gb: M21758.1 gb:NM_000846.1 -2.95346 3.079949 65.5 Up 7.93E-05 NM 0004 Homo sapiens Kell 20 blood group (KEL), mRNA. /PROD=Kell blood group antigen /FL=gb:BC003135.1 gb:NM_000420.1 -3.41755 2.612638 65.35 Up 1.03E-02A1808090 ESTs -4.08201 1.927438 64.42 Up 5.56E-04 AK000680 Homo sapiens cDNA
FLJ20673 fis, clone KAIA4464.
/FL=gb:AF240634.1 gb:NM_018440.1 -0.1416 5.830942 62.79 Up 6.89E-05 NM_0224 Homo sapiens

54 hypothetical protein FLJ22252 similar to SRY-box containing gene 17 (FLJ22252), mRNA.
/PROD=hybothetical protein FLJ22252 similar to SRY-boxcontaining gene 17 /FL=gb:NM_022454.1 -1.79329 4.15609 61.79 Up 7.58E-04 AL575177 noggin /FL=gb:NM_005450.1 -0.88683 5.039046 60.79 Up 8.36E-05 A1821669 ESTs -3.76697 2.141612 60.07 Up 2.25E-04 NM 0011 Homo sapiens 47 angiopoietin 2 (ANGPT2), mRNA.
/PROD=angiopoietin 2 /FL=gb:AB009865.1 gb:AF004327.1 gb:NM_001147.1 0.720535 6.617979 59.61 Up 5.95E-05 AW00753 Human insulin-like 2 growth factor binding protein 5 (IGEBP5) mRNA
-1.03589 4.784337 56.5 Up 2.23E-04 A1242583 Homo sapiens cDNA
FLJ11550 fis, clone -2.28856 3,531402 56.49 Up 4.54E-04 AF211891 Homo sapiens Mix-like homeobox protein 1 (MILD1) mRNA, complete cds. IPROD=Mix-like horneobox protein 1 IFL=gb:AF211891.1 -2.04403 3.759502 55.85 Up 2.17E-03 NM 0000 Homo sapiens 39 apolipoprotein A-I
(AP0A1), mRNA.
/PROD=apolipoprotein A-I precursor /FL=gb:M27875.1 gb:M11791.1 gb:NM 000039.1 gb:BCCT05380.1 0.129315 5.920102 55.36 Lip 6.89E-05 NM 0054 Homo sapiens 42 eomesoderrnin (Xenopus Isevis) homolog (EOMES), mRNA.
/PROD=eornesoderrni n (Xenopus leevis) hornolog IFL=gbA13031038.1 gb:NM_005442,1 -1.57973 4.207564 55.23 Up 5.25E-03 AL513917 solute carrier family (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 -4.11172 1.670966 55.05 Up 4.57E-04 BG25667 interferon, gamma-7 inducible protein 16 /FL=gb:AF208043.1 -0.28789 5.482347 54.58 Up 6.89E-05 AW77219 Homo sapiens clone 2 23736 mRNA
sequence -1.44577 4.307421 53.94 Up 3.59E-03 AL544576 ESTs -3.9513 1.76416 52.54 Up 7.33E-05 NM 0163 Homo sapiens 41 pancreas-enriched phospholipase C
(L0051196), mRNA.
/PROD=pancreas-enriched phospholipase C
/FL=gb:AF117948.1 gb:NM 016341.1 gb:AF1-90642.2 0.05538 5.762108 52.23 Up 7.33E-05 AI817041 G protein-coupled receptor -3.52376 2.14189 50.76 Up 8.23E-05 AW30021 ESTs, Moderately 7 similar to C212 HUMAN 28.3 KD P OTEIN
C210RF2 (H.sapiens) -3.18877 2.469472 50.5 Up 7.47E-03 AF260333 Homo sapiens AD036 mRNA, complete cds.
/PROD=AD036 /FL=gb:AF260333.1 -1.973 3.674867 50.14 Up 1.91E-04 AA772920 ESTs -2.30094 3.341814 49.96 Up 7.23E-03 A1806174 transcription factor 8 (represses interleukin 2 expression) -2.25531 3.356433 48.9 Up 6.63E-03 A1380207 ESTs -2.71676 2.892681 48.82 Up 5.25E-04 AU144167 Homo sapiens cDNA
FLJ11428 us, clone HEMBA1001071, highly similar to PROCOLLAGEN
ALPHA 1(111) CHAIN
PRECURSOR
-0.16429 5.442379 48.73 Up 6.83E-04 L01639 Human (clone HSY3RR) neuropeptide Y
receptor (NPYR) mRNA, complete cds.
/PROD=neuropeptide Y receptor /FL=gb:L06797.1 gb:NM 003467.1 gb:AF6-25375.1 gb:AF147204.1 gb:M99293.1 gb:L01639.1 -4.03477 1.563749 48.45 Up 1.19E-02 U12170 Human zinc finger homeodomain protein mRNA, complete cds.
/PROD=zinc finger homeodomain protein /FL=gb:U12170.1 -0.08298 5.493663 47.72 Up 2.19E-04 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 -2.99405 2.552238 46.73 Up 4.78E-04 A1767388 Human DNA sequence from clone RP5-1024N4 on chromosome 1p32.1-33. Contains the gene for a novel Sodium:solute symporter family member similar to SLC5A1 (SGLT1), a pseudogene similar to part of butyrophilin family members, a novel gene, ESTs, STSs, GS
-4.61432 0.925434 46.52 Up 2.53E-04 NM_0052 Homo sapiens distal-21 less homeo box 5 (DLX5), mRNA.
/PROD=distal-less homeo box 5 /FL=gb:NM_005221.3 -3.22309 2.302183 46.05 Up 4.60E-03 AW20724 ESTs -2.82645 2.655384 44.69 Up 4.60E-03 NM_0134 Homo sapiens 45 glutamate decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform GAD25 /FL=gb:NM 013445.1 gb:AF17883.1 gb:BC002815.1 0.533443 5.958927 42.98 Up 6.55E-05 NM_0018 Homo sapiens cystatin 99 S (CST4), mRNA.
/PROD=cystatin S
/FL=gb:NM_001899.1 0.116207 5.518477 42.29 Up 1.27E-04 NM 0005 Homo sapiens insulin-99 like growth factor binding protein 5 (IGFBP5), mRNA.
/PROD=insulin-like growth factor binding protein 5 /FL=gb:M65062.1 gb:M62782.1 gb:NM 000599.1 gb:AF0-55033.1 -2.1675 3.230235 42.16 Up 1.53E-04 NM_0218 Homo sapiens 04 angiotensin I
converting enzyme (peptidyl-dipeptidase A) 2 (ACE2), mRNA.
/PROD=angiotensin I
converting enzyme(peptidyl-dipeptidase A) 2 /FL=gb:NM 021804.1 gb:AF2412-5-4.1 gb:AB046569.1 gb:AF291820.1 -0.61985 4.752547 41.42 Up 3.54E-04 NM_0019 Homo sapiens 63 epidermal growth factor (beta-urogastrone) (EGF), mRNA.
/PROD=epidermal growth factor (beta-urogastrone) /FL=gb:NM_001963.2 -1.73746 3.627971 41.22 Up 3.35E-04 NM_0143 Homo sapiens cardiac 91 ankyrin repeat protein (CARP), mRNA.
/PROD=cardiac ankyrin repeat protein /FL=gb:NM014391.1 -3.68848 1.657514 40.67 Up 2.86E-03 NM_0185 Homo sapiens low 57 density lipoprotein-related protein 1B
(deleted in tumors) (LRP1B), mRNA.
/PROD=low density lipoprotein-related protein 1B(deleted in tumors) /FL=gb:AF176832.1 gb:NM_018557.1 -3.11273 2.220281 40.31 Up 5.02E-03 AW44476 ESTs -2.78886 2.517881 39.58 Up 7.89E-03 NM 0011 Homo sapiens 15 adenylate cyclase 8 (brain) (ADCY8), mRNA.
/PROD=adenylate cyclase 8 /FL=gb:NM_001115.1 -1.93668 3.348112 38.98 Up 7.23E-03 BE670361 G protein-coupled receptor 72 /FL=gb:NM 016540.1 gb:AF236081.1 -3.65051 1.595241 37.94 Up 3.80E-04 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M8394171 gb:AF213459.1 0.767075 5.998268 37.56 Up 2.55E-04 AY029208 Homo sapiens type VI
collagen alpha 2 chain precursor (COL6A2) mRNA, complete cds, alternatively spliced.
/PROD=type VI
collagen alpha 2 chain precursor /FL=gb:AY029208.1 -2.34732 2.874499 37.32 Up 6.51E-03 A1240545 glycophorin B
(includes Ss blood group) -2.41622 2.773394 36.49 Up 6.29E-04 NM_0019 Homo sapiens 77 glutamyl aminopeptidase (aminopeptidase A) (ENPEP), mRNA.
/PROD=glutamyl aminopeptidase (aminopeptidase A) /FL=gb:L12468.1 gb:NM 001977.1 gb:L14-721.1 -1.58875 3.588854 36.19 Up 2.45E-03 NM 1525 Homo sapiens 06 hypothetical protein FLJ32835 (FLJ32835), mRNA.
/FL=gb:NM 152506.1 -0.93849 4.238505 36.18 Up 1.38E-02 8E222344 splicing factor, arginineserine-rich 5 1.479222 6.611842 35.08 Up 5.95E-05 NM_0054 Homo sapiens 54 cerberus 1 (Xenopus laevis) homolog (cysteine knot superfamily) (CER1), mRNA.
/PROD=cerberus 1 /FL=gb:NM 005454.1 -0.46494 4.666106 35.04 Up 2.90E-04 A1141603 collagen, type VI, alpha 1 -2.23021 2.897749 34.97 Up 4.92E-04 NM_0017 Homo sapiens cytidine 85 deaminase (CDA), mRNA.
/PROD=cytidine deaminase /FL=gb:L27943.1 gb:NM_001785.1 -3.12836 1.991299 34.77 Up 8.63E-04 NM_0027 Homo sapiens 70 protease, serine, 2 (trypsin 2) (PRSS2), mRNA.
/PROD=protease, serine, 2 (trypsin 2) /FL=gb:M27602.1 gb:NM_002770.1 -0.98659 4.115782 34.35 Up 1.19E-04 M65062 Human insulin-like growth factor binding protein 5 (IGFBP-5) mRNA, complete cds.
/PROD=insulin-like growth factor binding protein 5 /FL=gb:M65062.1 gb:M62782.1 gb:NM 000599.1 gb:ART55033.1 -2.50194 2.569744 33.63 Up 4.84E-03 AJ277914 Homo sapiens partial LHX9 gene for LIM-homeobox 9, 3UTR.
-1.27526 3.792158 33.53 Up 1.12E-03 A1688418 plexin A2 -3.34034 - 1.708137 33.09 Up 2.46E-03 M781795 ESTs 1,339655 6.36612 32.59 Up __ 7.93E-05 AJ224869 Homo sapiens CXCR4 gene encoding receptor -0.6944 4.326307 32.46 Up 7.33E-05 R73554 Human insulin-like growth factor binding protein 5 (IGFBP5) mRNA
-0.67187 4.337831 32.22 Up 7.54E-05 A1692659 heat shock 90kD
protein 1, alpha -0.46298 4.533319 31.92 Up 3.96E-04 S69738 MCP-1=monocyte chemotactic protein (human, aortic endothelial cells, mRNA, 661 nt).
/PROD=MCP-1 -2.56712 2.414446 31.59 Up 1.67E-03A1813758 collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant) /FL=gb:NM_000090.1 -0.31684 4.651259 31.3 Up 7.83E-04 BF130943 ESTs -2.78124 2.184054 31.24 Up __ 8.36E-05 NM_0209 Homo sapiens 95 haptoglobin-related protein (HPR), mRNA.
/PROD=haptoglobin-related protein /FL=gb:NM 020995.1 -1.24179 3.719223 31.15 Up 4.92E-04 AL534095 hypothetical -0.35003 4.606618 31.05 Up 6.88E-03 NM 0017 Homo sapiens CD48 78 antigen (B-cell membrane protein) (CD48), mRNA.
/PROD=CD48 antigen (B-cell membrane protein) /FL=gb:NM 001778.1 gb:M3776671 gb:M59904.1 -1.81534 3.141104 31.05 Up 5.86E-04 AW59092 ESTs -1.93655 3.000448 30.63 Up 5.42E-03 NM_0133 Homo sapiens DNA
69 (cytosine-5-)-methyltransferase 3-like (DNMT3L), mRNA.
/PROD=DNA
(cytosine-5-)-methyltransferase 3-like /FL=gb:BC002560.1 gb:NM 013369.1 gb:AF1-94032.1 1.122063 6.03378 30.1 Up 7.33E-05 X58851 Human MLC1emb gene for embryonic myosin alkaline light chain, promoter and exon 1 -0.4721 4.436335 30.03 Up 7.93E-05 D89377 Homo sapiens mRNA
for MSX-2, complete cds. /PROD=MSX-2 /FL=gb:D89377.1 0.044298 4.952379 30.02 Up 6.89E-05 W57613 ESTs -0.59928 4.305866 29.96 Up 1.03E-03 AF020769 Homo sapiens cardiac ventricular troponin C
mRNA, complete cds.
/PROD=cardiac ventricular troponin C
/FL=gb:NM 003280.1 gb:AF020769.1 -1.04571 3.857701 29.93 Up 4.57E-03 NM_0013 Homo sapiens 62 deiodinase, iodothyronine, type 111 (D103), mRNA.
/PROD=thyroxine deiodinase type III
/FL=gb:NM 001362.1 gb:S79854.1 -3.24802 1.648226 29.78 Up 1.47E-03 A1694325 ESTs -2.50665 2.356234 29.1 Up 8.64E-03 BE222668 ESTs -2.27119 2.568908 28.64 Up 2.53E-03 NM_0026 Homo sapiens platelet-08 derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog) (PDGFB), mRNA.
/PROD=platelet-derived growth factor beta polypeptide(simian sarcoma viral (v-sis) oncogene homolog) /FL=gb:M12783.1 gb:NM_002 -4.34018 0.485509 28.36 Up 7.34E-05 AU144247 Homo sapiens cDNA
FLJ13443 fis, clone -1.02297 3.794799 28.2 Up 3.36E-03 AF208043 Homo sapiens IF116b (IF116b) mRNA, complete cds.
/PROD=IFI16b /FL=gb:AF208043.1 -2.79469 2.013598 28.02 Up 9.94E-05 A1700341 ESTs -2.73255 2.070789 27.92 Up 1.35E-03 X89271 H.sapiens mRNA
for HG11 orphan receptor.
/PROD=HG11 orphan receptor /FL=gb:NM_005161.1 -3.05797 1.724772 27.53 Up 3.48E-04 A1801626 ESTs, Moderately similar to SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) -2.83953 1.922194 27.13 Up 5.16E-04 BG29019 hypothetical protein /FL=gb:NM_025069.1 -4.60716 0.149736 27.04 Up 1.22E-02 NM_0046 Homo sapiens solute 96 carrier family 16 (monocarboxylic acid transporters), member 4 (SLC16A4), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 4 /FL=gb:U59185.1 gb:NM_004696.1 -1.57919 3.174205 26.97 Up 5.94E-04 AL524520 G protein-coupled receptor 49 -1.36626 3.37132 26.68 Up 2.16E-03 A1824037 ESTs, Weakly similar to FCE2 MOUSE LOW
AFFINITY
IMMUNOGLOBULIN
EPSILON FC
RECEPTOR
(M.musculus) 0.167058 4.895371 26.51 Up 6.90E-05 NM 0212 Homo sapiens myosin 23 light chain 2a (L0058498), mRNA.
/PROD=myosin light chain 2a /FL=gb:NM_021223.1 -1.4009 3.316905 26.31 Up 6.35E-04 BCO29835 Homo sapiens, clone IMAGE:5169759, mRNA.
-2.16518 2.549789 26.26 Up 1.77E-03 A1521166 ESTs, Moderately similar to MYOTUBULARIN-(H.sapiens) -3.32235 1.375121 25.95 Up 2.00E-04 BC039433 Homo sapiens, clone IMAGE:5303550, mRNA.
-5.7338 -1.05152 25.67 Up 8.80E-03 NM_0201 Homo sapiens 30 chromosome 8 open reading frame 4 (C8ORF4), mRNA.
/PROD=chromosome 8 open reading frame /FL=gb:NM 020130.1 gb:AF268637.1 1.214325 5.878585 25.36 Up 7.93E-05 M36172 Human embryonic myosin alkali light chain (MLC1) mRNA, complete cds.
/FL=gb:M36172.1 gb:M24121.1 gb:NM_002476.1 -2.20104 2.461597 25.33 Up 4.67E-03 NM_0009 Homo sapiens 39 proopiomelanocortin (adrenocorticotropin beta-lipotropin alpha-melanocyte stimulating hormone beta-melanocyte stimulating hormone beta-endorphin) (POMC), mRNA.
/PROD=proopiomelan ocortin (adrenocorticotropinbe ta-lipotropin alpha-melanocyt -0.2674 4.336009 24.31 Up 9.18E-05 N48299 ESTs, Moderately similar to NFY-C
(H.sapiens) 1.367677 5.968973 24.27 Up 1.00E-04 AF116676 Homo sapiens PR01957 mRNA, complete cds.
/PROD=PRO1957 /FL=gb:AF116676.1 -0.62697 3.974228 24.27 Up 4.69E-04 NM_0055 Homo sapiens 31 interferon, gamma-inducible protein 16 (IF116), mRNA.
/PROD=interferon, gamma-inducible protein 16 /FL=gb:M63838.1 gb:NM_005531.1 -3.90861 0.686447 24.17 Up 3.72E-03 BCO22531 Homo sapiens, olfactomedin 3, clone MGC:26675 IMAGE:4812035, mRNA, complete cds.
/PROD=olfactomedin 3 /FL=gb:AF397394.1 gb:BCO22531.1 -2.75089 1.840723 24.11 Up 2.60E-04 AL365343 Homo sapiens mRNA
full length insert cDNA
clone EUROIMAGE
32539.
-0.6097 3.975428 24 Up 1.05E-04 L12468 Homo sapiens aminopeptidase A
mRNA, complete cds.
/PROD=aminopeptidas e A /FL=gbil 2468.1 gb:NM 001977.1 gb:L14-7-21.1 -3.18285 1.397334 23.92 Up 3.32E-04 BC041441 Homo sapiens, clone IMAGE:5167131, mRNA.
-1.92796 2.645248 23.81 Up 1.20E-02 6E551416 ESTs, Weakly similar to KIAA1330 protein (H.sapiens) -4.05111 0.51291 23.65 Up 1.05E-03 J03580 Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 -2.79378 1.767388 23.61 Up 3.68E-02 AW29140 ESTs -2.80173 1.752943 23.5 Up 7.26E-03 AW08823 ESTs 0.422022 4.975085 23.48 Up 1.38E-04 D49958 Homo sapiens mRNA
for membrane glycoprotein M6, complete cds.
/PROD=membrane glycoprotein M6 /FL=gb:D49958.1 -1.20314 3.343061 23.36 Up 3.63E-04 M60721 Human homeobox gene, complete cds.
/FL=gb:M60721.1 gb:NM_021958.1 1.932439 6.477785 23.35 Up 7.33E-05 H92988 tyrosine 3-monooxygenasetrypto phan 5-monooxygenase activation protein, eta polypeptide -3.00328 1.524799 23.07 Up 8.50E-03 A1571798 Rho GDP dissociation inhibitor (GDI) alpha 0.526605 5.052252 23.03 Up 7.01E-05 N71923 fibronectin leucine rich transmembrane protein 3 /FL=gb:AF169677.1 gb:NM_013281.1 -1.26047 3.239318 22.62 Up 5.12E-03 NM_0072 Homo sapiens 50 Kruppel-like factor 8 (KLF8), mRNA.
/PROD=Kruppel-like factor 8 /FL=gb:U28282.1 gb:NM_007250.1 -1.93118 2.556654 22.44 Up 2.34E-04 L33477 Human (clone 8B1) Br-cadherin mRNA, complete cds.
/PROD=Br-cadherin /FL=gb:L34057.1 gb:L33477.1 gb:NM_004061.1 0.005876 4.456564 21.87 Up 6.89E-05 AK023621 Homo sapiens cDNA
FLJ13559 fis, clone PLACE1007852, highly similar to Homo sapiens mRNA for KIAA0878 protein.
-1.94 2.509492 21.85 Up 4.29E-03 NM_0165 Homo sapiens TBX3-69 iso protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF2167-5-0.1 -3.44347 1.001698 21.78 Up 1.61E-02 AF187858 Homo sapiens angiopoietin-2 isoform-1 mRNA, complete cds, alternatively spliced.
/PROD=angiopoietin-2 isoform-1 /FL=gb:AF187858.1 0.586923 5.027737 21.72 Up 6.55E-05 NM_0000 Homo sapiens 47 arylsulfatase E
(chondrodysplasia punctata 1) (ARSE), mRNA.
/PROD=arylsulfatase E precursor /FL=gb:X83573.1 gb:NM_000047.1 1.422626 5.860875 21.68 Up 5.95E-05 NM_0063 Homo sapiens 65 transcriptional activator of the c-fos promoter (CROC4), mRNA.
/PROD=transcriptional activator of the c-fos promoter /FL=gb:NM 006365.1 gb:U4985771 -4.18575 0.241573 21.52 Up 7.54E-03 NM_0017 Homo sapiens 36 complement component 5 receptor 1 (C5a ligand) (C5R1), mRNA.
/PROD=complement component 5 receptor 1 (C5a ligand) /FL=gb:M62505.1 gb:NM_001736.1 2.301255 6.712959 21.28 Up 7.68E-05 BCO20935 Homo sapiens, Similar to otoconin 90, clone IMAGE:4277593, mRNA.
-3.61192 0.788317 21.12 Up 1.71E-03 R37101 ESTs -0.62474 3.768383 21.01 Up 6.55E-05 NM 0003 Homo sapiens protein 13 S (alpha) (PROS1), mRNA.
/PROD=protein S
(alpha) /FL=gb:M15036.1 gb:NM_000313.1 -0.62725 3.760374 20.93 Up 1.52E-04 BC017942 Homo sapiens, Similar to otoconin 90, clone IMAGE:4285317, mRNA.
-1.52261 2.858274 20.83 Up 2.98E-03 NM_0026 Homo sapiens PDZ
14 domain containing 1 (PDZK1), mRNA.
/PROD=PDZ domain containing 1 /FL=gb:NM 002614.1 gb:AF012261.1 -1.11347 3.25087 20.6 Up 4.26E-03 N69091 ESTs -0.11332 4.231933 20.33 Up 1.05E-04 NM_0036 Homo sapiens basic 70 helix-loop-helix domain containing, class B, 2 (BHLHB2), mRNA.
/PROD=differentiated embryo chondrocyte expressed gene1 /FL=gb:AB004066.1 gb:NM_003670.1 -1.69238 2.643704 20.2 Up 3.73E-03 W05495 ESTs -2.18113 2.138504 19.97 Up 1.23E-02 NM_0040 Homo sapiens 41 arrestin, beta 1 (ARRB1), transcript variant 1, mRNA.
/PROD=arrestin beta 1, isoform A
/FL=gb:BC003636.1 gb:AF084040.1 gb:NM_004041.2 1.306329 5.625069 19.96 Up 6.90E-05 NM_0012 Homo sapiens bone 00 morphogenetic protein 2 (BMP2), mRNA.
/PROD=bone morphogenetic protein 2 precursor /FL=gb:NM_001200.1 -1.23777 3.066156 19.75 Up 6.27E-04 A1917371 ESTs -0.00098 4.266076 19.25 Up 9.82E-05 NM 0132 Homo sapiens 81 fibronectin leucine rich trans membrane protein 3 (FLRT3), mRNA.
/PROD=fibronectin leucine rich transmembrane protein3 /FL=gb:AF169677.1 gb:NM_013281.1 -2.0132 2.250432 19.21 Up 1.37E-02 6E328496 hypothetical protein /FL=gb:AF116683.1 gb:NM 018615.1 1.758844 6.008618 19.02 Up 6.55E-05 N21138 K1AA0878 protein /FL=gb:NM 014899.1 gb:AB020685.1 0.095309 4.341668 18.98 Up 8.55E-04 AA524250 deleted in liver cancer -0.96212 3.265791 18.74 Up 2.04E-04 AY113699 Homo sapiens presenilin stabilization factor b (PSF) mRNA, complete cds;
alternatively spliced.
/PROD=presenilin stabilization factor b /FL=gb:AY113699.1 0.502339 4.722511 18.64 Up 1.04E-04 A1676059 ESTs -1.74369 2.474001 18.61 Up 7.33E-05 NM 0018 Homo sapiens 82 corticotropin releasing hormone-binding protein (CRHBP), mRNA.
/PROD=corticotropin releasing hormone-binding protein /FL=gb:NM_001882.2 0.70975 4.924051 18.56 Up 1.64E-04 BF939489 glycoprotein M6A
/FL=gb:D49958.1 -2.40752 1.7892 18.34 Up 4.46E-03 A1738662 homeo box HB9 /FL=gb:NM_005515.1 -1.34609 2.844235 18.26 Up 7.33E-05 NM_0183 Homo sapiens 88 hypothetical protein FLJ11316 (FLJ11316), mRNA.
/PROD=hypothetical protein FLJ11316 /FL=gb:NM_018388.1 -0.74044 3.448679 18.24 Up 7.33E-05 N63706 ESTs -1.55229 2.611591 17.92 Up 4.34E-04 AU158444 Homo sapiens cDNA
FLJ14216 fis, clone NT2RP3003672, weakly similar to 1-CELL SURFACE

PRECURSOR
0.082922 4.230149 17.72 Up 1.63E-04 A1632223 hypothetical protein DKFZp434F2322 -1.66293 2.482886 17.7 Up 1.56E-02 NM_0008 Homo sapiens 17 glutamate decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD67, mRNA.
/PROD=glutamate decarboxylase 1, isoform GAD67 /FL=gb:NM 000817.1 gb:M81883.1 gb:L16888.1 -1.82505 2.319685 17.69 Up 7.89E-03 T16257 G
protein-coupled receptor 37 (endothelin receptor type B-like) /FL=gb:NM 005302.1 gb:AF017262.1 -3.11387 1.027176 17.64 Up 9.68E-03 U70370 Human hindlimb expressed homeobox protein backfoot (Bft) mRNA, complete cds.
/PROD=hindlimb expressed homeobox protein backfoot /FL=gb:U70370.1 gb:BC003685.1 -0.98938 3.143558 17.54 Up 6.04E-03 AF190725 Homo sapiens beta-site APP cleaving enzyme (BACE) mRNA, complete cds.
/PROD=beta-site APP
cleaving enzyme /FL=gb:AF200343.1 gb:AF204943.1 gb:AF190725.1 gb:AF201468.1 gb:NM_012104.1 -0.74839 3.363245 17.29 Up 5.33E-03 M17955 Human MHC class!!
HLA-DQ-beta mRNA, complete cds.
/FL=gb:M33907.1 gb:M17955.1 gb:M16996.1 gb:M17563.1 gb:M20432.1 gb:M26042.1 2.851479 6.958929 17.24 Up 5.95E-05 A1950472 ESTs -2.85963 1.242896 17.18 Up 7.55E-03 BC005961 Homo sapiens, parathyroid hormone-like hormone, clone MGC:14611, mRNA, complete cds.
/PROD=parathyroid hormone-like hormone /FL=gb:BC005961.1 -1.18027 2.905057 16.97 Up 1.03E-02 A1123555 ESTs -1.53522 2.547506 16.94 Up 2.58E-03 NM_0064 Homo sapiens 56 sialyltransferase (STHM), mRNA.
/PROD=sialyltransfera se /FL=gb:U14550.1 gb:NM_006456.1 1.620279 5.700292 16.91 Up 1.08E-04 A1583173 major histocompatibility complex, class 11, DQ
beta 1 1.446234 5.516116 16.79 Up -- 6.55E-05 AF348491 Homo sapiens chemokine receptor CXCR4 mRNA, complete cds.
/PROD=chemokine receptor CXCR4 /FL=gb:AF348491.1 0.880085 4.948285 16.77 Up -- 6.90E-05 NM_0060 Homo sapiens N-myc 96 downstream regulated (NDRG1), mRNA.
/PROD=N-myc downstream regulated /FL=gb:AF004162.1 gb:BC003175.1 gb:D87953.1 gb:NM_006096.1 -1.11823 2.945099 16.72 Up 1.28E-02 NM_0021 Homo sapiens 00 glycophorin B
(includes Ss blood group) (GYPB), mRNA.
/PROD=glycophorin B
precursor /FL=gb:J02982.1 gb:NM_002100.2 -1.68075 2.377232 16.66 Up 4.35E-03 NM_0124 Homo sapiens sema 31 domain, immunoglobulin domain (1g), short basic domain, secreted, (semaphorin) 3E
(SEMA3E), mRNA.
/PROD=sema domain, immunoglobulin domain (1g), shortbasic domain, secreted, (semaphorin) 3E
/FL=gb:NM 012431.1 gb:AB0023-9.1 0.70158 4.759011 16.65 Up 1.07E-04 U46768 Human stanniocalcin mRNA, complete cds.
/PROD=stanniocalcin /FL=gb:U25997.1 gb:NM 003155.1 gb:U48-768.1 2.429693 6.487025 16.65 Up 6.89E-05 AA284532 tyrosine 3-monooxygenasetrypto phan 5-monooxygenase activation protein, eta polypeptide 1.964573 6.018949 16.61 Up 1.18E-04 NM_0307 Homo sapiens 81 scavenger receptor with C-type lectin (SRCL), mRNA.
/PROD=scavenger receptor with C-type lectin /FL=gb:NM_030781.1 0.399566 4.451136 16.58 Up 1.57E-04 AF144103 Homo sapiens NJAC
protein (NJAC) mRNA, complete cds.
/PROD=NJAC protein /FL=gb:AF144103.1 gb:AF106911.1 gb:AF073957.1 gb:BC003513.1 gb:NM_004887.1 4.590104 -3.21322 223.38 Down 7.77E-05 AA167449 nuclear receptor subfamily 1, group I, member 3 1.940449 -5.370717 158.81 Down 8.36E-05 BE644917 nuclear receptor subfamily 1, group I, member 3 3.29779 -3.911445 147.98 Down 2.38E-05 U17496 Human proteasome subunit LMP7 (allele LMP7B) mRNA, complete cds.
/PROD=proteasome subunit LMP7 /FL=gb:U17497.1 gb:U17496.1 4.124115 -2.85548 126.2 Down 2.99E-03 AW26231 ESTs 3.702164 -2.970402 102.01 Down 2.53E-03 U26662 Human neuronal pentraxin II (NPTX2) mRNA, partial cds.
/PROD=neuronal pentraxin II
1.785431 -4.509786 78.53 Down 1.45E-03 R15072 ESTs 5.545158 -0.710745 76.42 Down 7.01E-05 BF057809 ESTs 1.946332 -3.865792 56.19 Down 7.43E-04 BG16670 small inducible cytokine subfamily B
(Cys-X-Cys), member 5 (epithelial-derived neutrophil-activating peptide 78) 1.717184 -3.902593 49.17 Down 1.30E-04 AF237813 Homo sapiens NPD009 mRNA, complete cds.
/PROD=NPD009 /FL=gb:NM 020686.1 gb:AF2378T3.1 3.179908 -2.381796 47.23 Down 9.96E-04 U82811 Human homeodomain-containing protein (HANF) mRNA, complete cds.
/PROD=HANF
/FL=gb:U82811.1 =

gb:NM_003865.1 2.359289 -3.177031 46.41 Down 1.72E-04 NM_0063 Homo sapiens 34 neuroblastoma (nerve tissue) protein (AMY), mRNA.
/PROD=neuroblastom a (nerve tissue) protein /FL=gb:NM 006334.1 gb:D82343-.71 4.276201 -1.247561 46.01 Down 7.33E-05 AV699347 nuclear receptor subfamily 1, group I, member 3 2.435058 -2.963261 42.18 Down 1.36E-04 BF056204 Homo sapiens, clone IMAGE:3603836, mRNA, partial cds 2.348373 -2.98029 40.19 Down 7.34E-05 NM_0163 Homo sapiens solute 54 carrier family 21 (organic anion transporter), member 12 (SLC21Al2), mRNA.
/PROD=organic anion transporter OATP-E
/FL=gb:AB031051.1 gb:NM_016354.1 gb:AF205072.1 gb:AF187817.1 4.315048 -0.819678 35.13 Down 3.33E-03 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA.
/PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:BC003079.1 2.348717 -2.72835 33.76 Down 9.42E-04 NM 0018 Homo sapiens 77 complement component (3dEpstein Barr virus) receptor 2 (CR2), mRNA.
/PROD=complement component (3dEpstein Barr virus)receptor 2 /FL=gb:NM 001877.1 gb:M260041 3.342331 -1.710595 33.2 Down 6.55E-05 AA876372 Homo sapiens mRNA;
cDNA DKFZp667D095 (from clone DKFZp667D095) 1.995324 -3.045119 32.91 Down 4.60E-03 NM_0148 Homo sapiens 62 KIAA0307 gene product (KIAA0307), mRNA.
/PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM_014862.1 2.890305 -2.133881 32.54 Down 1.71E-03 NM_0154 Homo sapiens protein (DKFZP564A032), mRNA.
/PROD=DKFZP564A0 32 protein /FL=gb:AF228421.1 gb:AL050267.1 gb:AB013847.1 gb:NM_015474.1 2.443445 -2.518495 31.17 Down 7.43E-03 NM_1523 Homo sapiens 32 chromosome 14 open reading frame 47 (C14orf47), mRNA.
/FL=gb:NM_152332.1 3.692792 -1.250743 30.77 Down 8.80E-04 N21096 ESTs 2.266312 -2.653405 30.27 Down 7.22E-03 NM 0030 Homo sapiens 26 domain GRB2-like 2 (SH3GL2), mRNA.
/PROD=SH3-domain GRB2-like 2 /FL=gb:AF036268.1 gb:NM_003026.1 2.453774 -2.402069 28.96 Down 7.93E-05 NM_0071 Homo sapiens Wnt 91 inhibitory factor-1 (WIF-1), mRNA.
/PROD=Wnt inhibitory factor-1 /FL=gb:AF122922.1 gb:NM 007191.1 2.325274 -2.512615 28.6 Down 3.19E-05 AW19369 3 protein 1.982765 -2.836916 28.24 Down 1.21E-04 6E672659 ESTs 0.997895 -3.793735 27.7 Down 3.97E-03 AW02592 ESTs, Weakly similar 8 to 138588 reverse transcriptase homolog (H.sapiens) 4.756657 0.005012 26.94 Down 6.55E-05 AV715309 ESTs, Weakly similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 4.803291 0.085342 26.32 Down 7.34E-05 AA628440 nuclear receptor subfamily 1, group I, member 3 1.124153 -3.582082 26.1 Down 5.42E-03 W52934 ESTs, Weakly similar to similar to serinethreonine kinase (C.elegans) 0.874376 -3.810554 25.72 Down 2.24E-02 U82671 Homo sapiens chromosome Xq28 melanoma antigen family A2a (MAGEA2A), melanoma antigen family Al2 (MAGEA12), melanoma antigen family A2b (MAGEA2B), melanoma antigen family A3 (MAGEA3), caltractin (CALT), NAD(P)H
dehydrogenase-like protein (NSDHL), a...
0.621075 -4.029928 25.12 Down 5.18E-03 BCO28721 Homo sapiens, Similar to solute carrier family 1 (high affinity aspartateglutamate transporter), member 6, clone MGC:33092 IMAGE:5269300, mRNA, complete cds.
/PROD=Similar to solute carrier family 1 (highaffinity aspartateglutamate transporter), memb 1.49883 -3.130556 24.75 Down 7.87E-04 BF057784 ESTs 2.074855 -2.552806 24.72 Down 1.87E-03 A1420156 ESTs 3.2597 -1.357805 24.55 Down 1.05E-03 NM_0176 Homo sapiens 71 hypothetical protein FLJ20116 (FLJ20116), mRNA.
/PROD=hypothetical protein FLJ20116 /FL=gb:NM_017671.1 -0.10303 -4.717227 24.49 Down 7.33E-05 NM_0221 Homo sapiens 68 melanoma differentiation associated protein-5 (MDA5), mRNA.
/PROD=melanoma differentiation associated protein-5 /FL=gb:AY017378.1 gb:NM 022168.1 gb:AF6-95844.1 2.688175 -1.908993 24.2 Down 2.73E-04 NM_0141 Homo sapiens 78 HSPC156 protein (HSPC156), mRNA.
/PROD=HSPC156 protein /FL=gb:NM 014178.1 gb:AF161565.1 1.24677 -3.309288 23.52 Down 2.54E-02 BCO28359 Homo sapiens, clone IMAGE:4828836, mRNA.
0.686587 -3.862863 23.42 Down 1.28E-03 NM_0004 Homo sapiens 39 proprotein convertase subtilisinkexin type 1 (PCSK1), mRNA.
/PROD=proprotein convertase subtilisinkexin type 1 /FL=gb:NM_000439.2 gb:M90753.1 5.363884 0.82261 23.28 Down 7.68E-05 NM_0070 Homo sapiens 15 chondromodulin 1 precursor (CHM-I), mRNA.
/PROD=chondromodul in 1 precursor /FL=gb:NM 007015.1 gb:AB006050.1 3.962328 -0.577927 23.27 Down 6.90E-05 AL533416 axonal transport of synaptic vesicles 2.086969 -2.410461 22.59 Down 9.65E-03 AL359055 Homo sapiens mRNA
full length insert cDNA
clone EUROIMAGE
2344436.
0.536704 -3.939442 22.26 Down 4.78E-03 AL049250 Homo sapiens mRNA;
cDNA DKFZp564D113 (from clone DKFZp564D113).
4.260791 -0.214844 22.25 Down 6.89E-05 AA603344 ESTs, Weakly similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.121165 -4.34837 22.15 Down 1.36E-04 A1985987 ESTs, Moderately similar to SUBFAMILY J
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.437404 -4.019211 21.96 Down 2.48E-02 H05254 ESTs 2.263194 -2.16575 21.54 Down 7.34E-04 AF052108 Homo sapiens clone 23687 mRNA
sequence.
4.055226 -0.3701 21.49 Down 1.16E-04 NM_0013 Homo sapiens claudin 07 7 (CLDN7), mRNA.
/PROD=claudin 7 /FL=gb:BC001055.1 gb:NM_001307.1 5.440506 1.023282 21.37 Down 1.02E-04 M34455 Human interferon-gamma-inducible indoleamine 2,3-dioxygenase (IDO) mRNA, complete cds.
/FL=gb:NM 002164.1 gb:M3445571 2.169025 -2.207268 20.77 Down 3.41E-03 NM_0224 Homo sapiens N-67 acetylgalactosamine-4-0-sulfotransferase (GALNAC-4-ST1), mRNA. /PROD=N-acetylgalactosamine-4-0-sulfotransferase /FL=gb:NM 022467.1 gb:AF3006T2.1 0.252976 -4.116368 20.67 Down 3.36E-03 NM 0180 Homo sapiens 43 hypothetical protein FLJ10261 (FLJ10261), mRNA.
/PROD=hypothetical protein FLJ10261 /FL=gb:NM_018043.1 1.353776 -3.010836 20.6 Down 2.85E-02 AF147427 Homo sapiens full length insert cDNA
clone YP80A10.
2.437935 -1.918781 20.49 Down 1.70E-03 6E672557 ESTs 2.46341 -1.870689 20.17 Down 4.16E-04 NM_0031 Homo sapiens 82 tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, neurokinin alpha, neuropeptide K,neuropeptide gamma) (TAC1), transcript variant beta, mRNA.
/PROD=tachykinin 2 precursor, isoform beta /FL=gb:U3 2.294336 -2.028037 20.01 Down 7.10E-03 U11058 Homo sapiens large conductance calcium-and voltage-dependent potassium channel alpha subunit (MaxiK) mRNA, complete cds.
/PROD=large conductance calcium-and voltage-dependentpotassium channel alpha subunit /FL=gb:U23767.1 gb:NM 002247.1 gb:AR:125999 4.534853 0.221559 19.88 Down 7.68E-05 R38389 olfactomedin related ER localized protein 3.142124 -1.136699 19.41 Down 1.73E-02 AL832535 Homo sapiens mRNA;
cDNA
DKFZp547J1816 (from clone DKFZp547J1816).
3.85985 -0.410223 19.29 Down 7.34E-05 R40892 ESTs 4.557488 0.304559 19.07 Down 1.43E-04 AK026546 Homo sapiens cDNA:
FLJ22893 fis, clone KAT04792.
5.966394 1.719122 18.99 Down 1.99E-04 AL117612 Homo sapiens mRNA;
cDNA
DKFZp564B1264 (from clone DKFZp564B1264).
1.212373 -3.013161 18.71 Down 5.22E-04A1564075 ESTs 2.27629 -1.932316 18.49 Down 1.09E-04 BC044830 Homo sapiens, Similar to RIKEN cDNA

1700011F14 gene, clone MGC:35062 IMAGE:5166167, mRNA, complete cds.
/PROD=Similar to RIKEN cDNA
1700011F14 gene /FL=gb:BC044830.1 3.18092 -1.007603 18.23 Down 1.29E-03 AJ011712 Homo sapiens TNNT1 gene, exons 1-11 (and joined CDS) 2.598916 -1.553059 17.78 Down 2.46E-03 AW05159 ESTs, Moderately 1 similar to unnamed protein product (H.sapiens) 2.003902 -2.139208 17.67 Down 4.71E-03 BF109660 ESTs 1.905278 -2.229324 17.56 Down 5.05E-04 NM_0189 Homo sapiens solute 64 carrier family 37 (glycerol-3-phosphate transporter), member 1 (SLC37A1), mRNA.
/PROD=solute carrier family 37 (glycerol-3-phosphatetransporter), member 1 /FL=gb:NM_018964.1 0.330556 -3.792993 17.43 Down 3.26E-04 BE972639 ESTs 1.044277 -3.067425 17.29 Down 1.23E-02 AL529104 ESTs 0.733534 -3.349221 16.94 Down 4.39E-03 BF061389 ESTs, Weakly similar to JC1405 6-pyruvoyltetrahydropteri n synthase (H.sapiens) 2.684281 -1.394654 16.9 Down 2.91E-04 BF449063 collagen, type XIV, alpha 1 (undulin) 4.572354 0.512428 16.68 Down 5.89E-04 BF437747 ESTs, Weakly similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 2.313549 -1.734907 16.55 Down 6.84E-03 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K protein A
(H.sapiens) 0.679665 -3.355919 16.4 Down 1.43E-03 BC000568 Homo sapiens, clone MGC:3040, mRNA, complete cds.
/PROD=Unknown (protein for MGC:3040) /FL=gb:BC000568.1 4.099873 0.092088 16.09 Down 6.90E-05 A1057619 ESTs, Highly similar to T42654 hypothetical protein DKFZp434G1115.1 (H.sapiens) 1.459269 -2.519 15.76 Down 6.26E-03 NM_0002 Homo sapiens 77 phenylalanine hydroxylase (PAH), mRNA.
/PROD=phenylalanine hydroxylase /FL=gb:U49897.1 gb:NM_000277.1 2.220936 -1.733714 15.5 Down 1.34E-04 AF237813 Homo sapiens NPD009 mRNA, complete cds.
/PROD=NPD009 /FL=gb:NM 020686.1 gb:AF2378T3.1 2.81177 -1.140906 15.48 Down 6.89E-05 NM 0025 Homo sapiens 93 procollagen C-endopeptidase enhancer (PCOLCE), mRNA.
/PROD=procollagen C-endopeptidase enhancer /FL=gb:BC000574.1 gb:NM 002593.2 gb:ABC708549.1 gb:L33799.1 1.529971 -2.399749 15.24 Down 2.29E-02 NM_0247 Homo sapiens 89 hypothetical protein FLJ22529 (FLJ22529), mRNA.
/PROD=hypothetical protein FLJ22529 /FL=gb:NM_024789.1 0.255558 -3.655262 15.04 Down 4.26E-03 BC039509 Homo sapiens, clone IMAGE:5578073, mRNA.
0.970967 -2.921559 14.85 Down 4.46E-03 A1144156 ESTs 2.38092 -1.504443 14.78 Down 4.36E-04 AF053712 Homo sapiens osteoprotegerin ligand mRNA, complete cds.
/PROD=osteoprotegeri n ligand /FL=gb:AF053712.1 gb:AF019047.1 3.779853 -0.095194 14.67 Down 3.22E-04 AV646597 ESTs, Weakly similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.651332 -2.189895 14.33 Down 3.45E-03 NM_0071 Homo sapiens 81 mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1), mRNA.
/PROD=mitogen-activated protein kinase kinase kinasekinase 1 /FL=gb:U66464.1 gb:NM_007181.1 3.786136 -0.030985 14.1 Down 1.49E-04 BF057731 ESTs 3.257726 -0.553697 14.04 Down 4.48E-04 NM_0043 Homo sapiens bone 35 marrow stromal cell antigen 2 (BST2), mRNA. /PROD=bone marrow stromal cell antigen 2 /FL=gb:NM 004335.2 gb:D28137-.71 -0.33527 -4.146199 14.03 Down 4.21E-03 BE968806 ESTs, Weakly similar to ALU4 HUMAN ALU

SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.349102 -3.450633 13.93 Down 1.30E-02 BM68235 Homo sapiens cDNA
2 FLJ37204 fis, clone BRALZ2006976.
2.172559 -1.624126 13.9 Down 2.32E-03 BE673445 Homo sapiens chromosome 19, cosmid R28379 0.381933 -3.390833 13.67 Down 1.84E-02 AI913749 ESTs 1.120467 -2.648498 13.63 Down 1.85E-03 BE672607 ESTs 1.924097 -1.801676 13.23 Down 8.92E-03 AW24292 ESTs 1.491527 -2.224633 13.14 Down 7.01E-05 BG25813 ESTs 2.060687 -1.652733 13.12 Down 5.63E-03 A1269290 solute carrier family 18 (vesicular monoamine), member 2 /FL=gb114269.1 gb:L23205.1 gb:L09118.1 gb:NM_003054.1 2.886142 -0.811762 12.98 Down 4.93E-04 U83115 Human non-lens beta gamma-crystallin like protein (AIM1) mRNA, partial cds.
/PROD=non-lens beta gamma-crystallin like protein 0.626797 -3.063928 12.91 Down 4.51E-02 AF393369 Homo sapiens sigma 1C adaptin (AP1S3) mRNA, complete cds.
/PROD=sigma 1C
adaptin /FL=gb:AF393369.1 1.575227 -2.112834 12.89 Down 1.85E-03 BE856544 hypothetical protein 0.4785 -3.197824 12.78 Down 1.72E-04 BG53269 integrin, alpha 4 0 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 1.707178 -1.969084 12.78 Down 1.84E-02 AF043179 Homo sapiens T cell receptor beta chain (TCRBV13S1-TCRBJ2S1) mRNA, complete cds.
/PROD=T cell receptor beta chain /FL=gb:AF043179.1 0.47298 -3.177323 12.56 Down 8.00E-03 AF311324 Homo sapiens ubiquitin-like fusion protein mRNA, complete cds.
/PROD=ubiquitin-like fusion protein /FL=gb:AF311324.1 2.641731 -0.985721 12.36 Down 1.49E-04 AL133653 Homo sapiens mRNA;
cDNA
DKFZp434M2415 (from clone DKFZp434M2415).
2.913327 -0.707745 12.3 Down 3.70E-03 NM 0124 Homo sapiens 19 regulator of G-protein signalling 17 (RGS17), mRNA.
/PROD=regulator of G-protein signalling 17 /FL=gb:AF202257.2 gb:NM_012419.2 2.127724 -1.49095 12.28 Down 1.49E-03 NM_0012 Homo sapiens 75 chromogranin A
(parathyroid secretory protein 1) (CHGA), mRNA.
/PROD=chromogranin A /FL=gb:BC001059.1 gb:NM 001275.2 gb:J03- 15.1 gb:J03483.1 0.80034 -2.81487 12.25 Down 4.62E-03 AW00310 ESTs 2.11511 -1.494168 12.2 Down 1.27E-03 NM_0005 Homo sapiens ATP-93 binding cassette, sub-family B (MDRTAP), member 2 (ABCB2), mRNA. /PROD=ATP-binding cassette, sub-family B, member 2 /FL=gb:NM 000593.2 gb:L21205.-T
gb:L21206.1 gb:L21207.1 gb:L21204.1 gb:L21208.1 3.690675 0.086414 12.16 Down 1.85E-03 AW27401 ESTs 1.283746 -2.317044 12.13 Down 4.10E-03 NM_0140 Homo sapiens VLCS-31 H1 protein (VLCS-H1), mRNA. /PROD=very long-chain acyl-CoA
synthetase homolog 1 /FL=gb:AF064254.1 gb:NM_014031.1 0.467003 -3.132847 12.12 Down 4.39E-02 AL117530 Homo sapiens mRNA;

cDNA DKFZp434B172 (from clone DKFZp434B172);
partial cds.
/PROD=hypothetical protein 2.6402 -0.955567 12.09 Down 3.80E-02 NM_0132 Homo sapiens breast 67 cell glutaminase (GA), mRNA. /PROD=breast cell glutaminase /FL=gb:AF110331.1 gb:AF110330.1 gb:AF223944.1 gb:NM_013267.1 1.858597 -1.724557 11.98 Down 5.91E-04 AA757457 ESTs 0.945333 -2.635993 11.97 Down 2.41E-03 BC040959 Homo sapiens, clone IMAGE:5242616, mRNA.
3.795925 0.223304 11.9 Down 1.71E-03 NM_0046 Homo sapiens N-myc 88 (and STAT) interactor (NMI), mRNA.
/PROD=N-myc and STAT interactor /FL=gb:BC001268.1 gb:NM_004688.1 gb:U32849.1 2.074972 -1.490898 11.84 Down 2.94E-03 NM_0179 Homo sapiens 33 hypothetical protein FLJ20701 (FLJ20701), mRNA.
/PROD=hypothetical protein FLJ20701 /FL--zgb:NM_017933.1 -0.42571 -3.975429 11.71 Down 1.54E-03 AK023699 Homo sapiens cDNA
FLJ13637 fis, clone PLACE1011165.
3.742964 0.195658 11.69 Down 1.19E-04 T62571 microtubule-associated protein 7 /FL=gb:NM_003980.1 1.621518 -1.924672 11.68 Down 2.63E-02 NM_0037 Homo sapiens 25 oxidative 3 alpha hydroxysteroid dehydrogenase; retinol dehydrogenase; 3-hydroxysteroid epimerase (RODH), mRNA.
/PROD=oxidative 3 alpha hydroxysteroid dehydrogenase;retinol dehydrogenase; 3-hydroxysteroid epimerase /FL=gb:AF016509.1 gb:A
6.076777 2.566425 11.4 Down 6.90E-05 AF229180 Homo sapiens alpha-aminoadipate semialdehyde synthase mRNA, complete cds.
/PROD=alpha-aminoadipate semialdehyde synthase /FL=gb:AF229180.1 3.758058 0.25238 11.36 Down 1.89E-04 NM_0053 Homo sapiens 56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-spectfic protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 3.797019 0.297284 11.31 Down 2.69E-04A1871745 ESTs 2.469508 -1.020673 11.24 Down 9.14E-04 W63754 Homo sapiens mRNA
for gycosyltransferase (ORF1) 1.048359 -2.438018 11.21 Down 1.39E-02 AA464273 ESTs 3.146674 -0.339455 11.21 Down 1.26E-04 BF435773 cortactin SH3 domain-binding protein 1.627801 -1.848139 11.13 Down 3.70E-03 L39833 Homo sapiens (clone hKvBeta3) K+ channel beta subunit mRNA, complete cds.
/PROD=K+ channel beta-subunit /FL=gb:U16953.1 gb:L39833.1 1.594689 -1.879508 11.11 Down 4.03E-02 AJ236915 Homo sapiens mRNA
for pak5 protein.
/PROD=pak5 protein /FL=gb:NM 020168.1 gb:AF2768-9-3.1 2.806504 -0.6571 11.03 Down 1.21E-04 NM_0036 Homo sapiens fatty-45 acid-Coenzyme A
ligase, very long-chain 1 (FACVL1), mRNA.
/PROD=very long-chain fatty-acid-Coenzyme A ligase 1 /FL=gb:AF096290.1 gb:D88308.1 gb:NM_003645.1 3.826815 0.364324 11.02 Down 6.55E-05 8G40156 Homo sapiens mRNA;
8 cDNA
DKFZp434H 1235 (from clone DKFZp434H1235);
partial cds 2.99034 -0.471936 11.02 Down 7.16E-04 NM 0029 Homo sapiens small 93 inducible cytokine subfamily B (Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) (SCYB6), mRNA.

/PROD=small inducible cytokine subfamily B(Cys-X-Cys), member 6 (granulocyte chemotactic protein 2) /FL=gb:U81234.1 gb:NM_00299 3.788599 0.329467 11 Down 8.58E-05 NM 0022 Homo sapiens 52 potassium voltage-gated channel, delayed-rectifier, subfamily S. member 3 (KCNS3), mRNA.
/PROD=potassium voltage-gated channel,delayed-rectifier, subfamily S, member 3 /FL=gb:AF043472.1 gb:NM 002252.1 gb:BCCT04987.1 gb:BC004148.1 4.397278 0.939176 10.99 Down 1.22E-04 NM_0216 Homo sapiens 14 potassium intermediatesmall conductance calcium-activated channel, subfamily N, member 2 (KCNN2), mRNA.
/PROD=potassium intermediatesmall conductancecalcium-activated channel, subfamily N, member /FL=gb:NM 021614.1 gb:AF2396T3.1 1.027188 -2.423197 10.93 Down 1.22E-03 BG16983 adenylate kinase 5 2 /FL=gb:NM_012093.1 gb:AF062595.1 1.022495 -2.421211 10.88 Down 2.47E-02 BC002832 Homo sapiens, Similar to butyrophilin, subfamily 3, member A2, clone MGC:3790, mRNA, complete cds.
/PROD=Similar to butyrophilin, subfamily 3, member A2 /FL=gb:U90144.1 gb:NM 007047.1 gb:U90546.1 gb:BC002832.1 0.311203 -3.122447 10.81 Down 1.70E-03 A1964053 ESTs 1.673874 -1.728682 10.57 Down 2.25E-03 NM_0059 Homo sapiens myosin, 65 light polypeptide kinase (MYLK), mRNA.
/PROD=myosin, light polypeptide kinase /FL=gb:AB037663.1 gb:AF069601.2 gb:NM_005965.1 1.443731 -1.955774 10.55 Down 1.43E-03 AJ272267 Homo sapiens partial mRNA for choline dehydrogenase (chdh gene). /PROD=choline dehydrogenase 0.383563 -3.004508 10.47 Down 2.48E-02 A1377688 ESTs 0.995551 -2.39165 10.46 Down 5.14E-03 NM 0053 Homo sapiens 86 neuronatin (N NAT), mRNA.
/PROD=neuronatin /FL=gb:NM 005386.1 gb:BC001768.1 gb:AB002392.1 gb:U25033.1 3.45531 0.070626 10.44 Down 1.94E-04 AV733308 integrin, alpha 6 3.527039 0.143408 10.44 Down 5.95E-05 BG28379 ESTs 2.950823 -0.418278 10.33 Down 1.38E-03 NM_0036 Homo sapiens fatty-45 acid-Coenzyme A
ligase, very long-chain 1 (FACVL1), mRNA.
/PROD=very long-chain fatty-acid-Coenzyme A ligase 1 /FL=gb:AF096290.1 gb:D88308.1 gb:NM_003645.1 1.55078 -1.80799 10.26 Down 3.70E-03 H28597 thymopoietin 5.005827 1.649812 10.24 Down 1.90E-04 NM_0030 Homo sapiens 20 secretory granule, neuroendocrine protein 1 (782 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM_003020.1 0.760646 -2.590248 10.2 Down 2.29E-02 AW58979 ESTs 2.209313 -1.126222 10.09 Down 5.95E-05 AA747379 calcitonin-related polypeptide, beta /FL=gb:NM_000728.1 -0.10418 -3.43217 10.04 Down 4.66E-03 NM_0176 Homo sapiens

55 hypothetical protein FLJ20075 (FLJ20075), mRNA.
/PROD=hypothetical protein FLJ20075 /FL=gb:NM_017655.1 2.598488 -0.722855 10 Down 2.03E-03 L08599 Human uvomorulin (E-cadherin) (UVO) mRNA, complete cds.
/PROD=uvomorulin /FL=gb:NM 004360.1 gb:L08599.-1-1.858219 -1.457169 9.95 Down 1.81E-03 NM 0050 Homo sapiens 84 phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7), mRNA.
/PROD=phospholipase A2, group VII (platelet-activatingfactor acetylhydrolase, plasma) /FL=gb:U20157.1 gb:U24577.1 gb:NM_005084.1 1.910263 -1.3945 9.88 Down 1.27E-03 NM_0069 Homo sapiens 94 butyrophilin, subfamily 3, member A3 (BTN3A3), mRNA.
/PROD=butyrophilin, subfamily 3, member A3 /FL=gb:U90548.1 gb:NM_006994.2 2.001097 -1.297629 9.84 Down 1.19E-03 BCO28721 Homo sapiens, Similar to solute carrier family 1 (high affinity aspartateglutamate transporter), member 6, clone MGC:33092 IMAGE:5269300, mRNA, complete cds.
/PROD=Similar to solute carrier family 1 (highaffinity aspartateglutamate transporter), memb 5.020283 1.723791 9.83 Down 1.63E-04 AK025084 Homo sapiens cDNA:
FLJ21431 fis, clone C0L04214, highly similar to HSU80736 Homo sapiens CAGF9 mRNA.
2.474373 -0.811562 9.75 Down 5.94E-03 NM_0132 Homo sapiens solute 72 carrier family 21 (organic anion transporter), member 11 (SLC21A11), mRNA. /PROD=solute carrier family 21 (organic aniontransporter), member 11 /FL=gb:NM 013272.2 gb:AF20507f4.1 gb:AB031050.2 gb:AF187816.1 2.116702 -1.16308 9.71 Down 4.40E-02 AF107846 Homo sapiens neuroendocrine-specific Golgi protein p55 (XLalphas) gene, exon XL2 and complete cds 2.472358 -0.803312 9.68 Down 2.33E-03 NM_0003 Homo sapiens 63 troponin I, cardiac (TNNI3), mRNA.
/PROD=troponin I, cardiac /FL=gb:M64247.1 gb:NM_000363.1 0.384182 -2.880367 9.61 Down 4.26E-03 NM_0058 Homo sapiens RAS
25 guanyl releasing protein 2 (calcium and DAG-regulated) (RASGRP2), mRNA.
/PROD=RAS guanyl releasing protein 2 (calcium andDAG-=
regulated) /FL=gb:AF043723.1 gb:NM 005825.1 2.394742 -0.866876 9.59 Down 1.57E-04 A1733027 ESTs, Weakly similar to RET2 HUMAN
RETINOI-BINDING
PROTEIN II, CELLULAR
(H.sapiens) 1.319792 -1.930717 9.52 Down 5.95E-05 M18767 Human complement subcomponent Cis, alpha- and beta-chains, complete cds.
/FL=gb:J04080.1 gb:M18767.1 gb:NM_001734.1 3.859451 0.610002 9.51 Down 5.73E-04 AJ242502 Homo sapiens mRNA
for E-MAP-115105 (MAP gene).
/PROD=epithelial microtubule-associated protein 3.009579 -0.239729 9.51 Down 5.22E-04 AB037730 Homo sapiens mRNA
for KIAA1309 protein, partial cds.
/PROD=KIAA1309 protein 2.600702 -0.646217 9.49 Down 1.43E-02 AA740186 biliverdin reductase A
/FL=gb:NM 000712.1 gb:U34877-...1 0.971941 -2.274152 9.49 Down 7.72E-04 NM_0180 Homo sapiens 18 hypothetical protein FLJ10191 (FLJ10191), mRNA.
/PROD=hypothetical protein FLJ10191 /FL=gb:NM_018018.1 0.414323 -2.829854 9.48 Down 6.30E-03 AF283777 Homo sapiens clone TCBAP0702 mRNA

sequence.
6.139688 2.900659 9.44 Down 4.48E-04 BC036488 Homo sapiens, clone MGC:43145 1MAGE:5261574, mRNA, complete cds.
/PROD=Unknown (protein for MGC:43145) /FL=gb:BC036488.1 1.569503 -1.668679 9.44 Down 1.24E-03 BF195118 ESTs, Weakly similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.665643 -1.567308 9.4 Down 8.63E-04 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 4.319584 1.104655 9.29 Down 5.53E-04 AA618420 Homo sapiens cDNA:
FLJ23597 fis, clone 4.436354 1.227541 9.25 Down 2.94E-04 AI912275 B-cell CLLIymphoma 11A (zinc finger protein) /FL=gb:NM 022893.1 gb:NM_018-014.1 1.923237 -1.283751 9.23 Down 3.70E-03 AW07210 Homo sapiens mRNA;
2 cDNA DKFZp434H205 (from clone DKFZp434H205) 2.59299 -0.613677 9.23 Down 1.94E-04 NM_0038 Homo sapiens 87 development and differentiation enhancing factor 2 (DDEF2), mRNA.
/PROD=ADP-ribosylation factor(ail)-directed GTPaseactivating protein /FL=gb:AB007860.1 gb:NM_003887.1 3.20248 0.002668 9.19 Down 5.80E-04 AF220153 Homo sapiens four and a half LIM
domains 1 protein isoform C (FHL1) mRNA, complete cds, alternatively spliced.
/PROD=four and a half LIM domains 1 protein isoform C
/FL=gb:AF220153.1 1.689335 -1.505873 9.16 Down 2.46E-03 NM_0312 Homo sapiens testis 72 expressed sequence 14 (TEX14), mRNA.
/PROD=testis expressed sequence /FL=gb:NM_031272.1 3.026209 -0.167981 9.15 Down 6.90E-05 BC032302 Homo sapiens, similar to UDP-glucose ceramide glucosyltransferase-like 2, clone MGC:40268 IMAGE:5169731, mRNA, complete cds.
/PROD=similar to UDP-glucose ceramideglucosyltransf erase-like 2 /FL=gb:BC032302.1 3.116245 -0.070826 9.11 Down 7.93E-05 NM 0179 Homo sapiens 47 hypothetical protein FLJ20733 (FLJ20733), mRNA.
/PROD=hypothetical protein FLJ20733 /FL=gb:NM_017947.1 2.91664 -0.26326 9.06 Down 1.68E-03 AW00336 Homo sapiens clone 7 25237 mRNA
sequence 4.453662 1.27718 9.04 Down 7.33E-05 AV681807 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 3.454075 0.278604 9.03 Down 1.86E-04 AV691491 Homo sapiens mRNA;
cDNA
DKFZp564D1462 (from clone DKFZp564D1462) 1.883578 -1.291525 9.03 Down 2.67E-02 BF970287 Human DNA sequence from clone RP1-310013 on chromosome 20q11.2.
Contains (part of) four novel genes, ESTs, STSs, GSSs and four putative CpG islands 2.326737 -0.838174 8.97 Down 2.61E-03 NM_0159 Homo sapiens germ 82 cell specific Y-box binding protein (L0051087), mRNA.
/PROD=germ cell specific Y-box binding protein /FL=gb:NM 015982.1 gb:AF09685-4.1 0.392456 -2.771428 8.96 Down 2.73E-02 NM_0030 Homo sapiens 07 semenogelin I
(SEMG1), mRNA.
/PROD=semenogelin I
/FL=gb:J04440.1 gb:NM_003007.1 3.116953 -0.041715 8.93 Down 3.90E-04 AA469071 Cluster Incl.

AA469071:ne17f11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-881517 /clone end=3 /gb=AA46907:1-/gi=2195605 /ug=Hs.180479 /len=758 3.113317 -0.040507 8.9 Down 2.36E-03 AL565745 ESTs, Weakly similar to 2108402A carnitine palmitoyltransferase 1 (H.sapiens) 5.010828 1.86984 8.82 Down 3.28E-04 AK027006 Homo sapiens cDNA:
FLJ23353 fis, clone HEP14321, highly similar to HSU80736 Homo sapiens CAGF9 mRNA.
3.249727 0.113464 8.79 Down 2.14E-04 BC001745 Homo sapiens, clone MGC:3328, mRNA, complete cds.
/PROD=Unknown (protein for MGC:3328) /FL=gb:BC001745.1 gb:NM_014392.1 1.532208 -1.601117 8.77 Down 3.19E-03 A1796813 advillin 5.063502 1.934512 8.75 Down 1.01E-04 AB018289 Homo sapiens mRNA
for KIAA0746 protein, partial cds.
/PROD=KIAA0746 protein 1.934415 -1.192238 8.73 Down 3.13E-03 NM_0013 Homo sapiens deleted 51 in azoospermia-like (DAZL), mRNA.
/PROD=deleted in azoospermia-like /FL=gb:U66726.2 gb:NM 001351.1 gb:U65-918.1 gb:U66078.1 2.522705 -0.592752 8.67 Down 9.13E-03 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gbiU07236.1 gb:NM 005356.1 gb:M3881.1 3.995648 0.881994 8.66 Down 6.55E-05 A1961231 KIAA0808 gene product /FL=gbiAB018351.1 gb:NM_014729.1 2.077151 -1.020617 8.56 Down 7.33E-05 BF223193 nuclear receptor subfamily 1, group I, member 3 6.650173 3.554864 8.55 Down 8.55E-04 NM_0043 Homo sapiens 60 cadherin 1, type 1, E-cadherin (epithelial) (CDH1), mRNA.
/PROD=cadherin 1, type 1, E-cadherin (epithelial) /FL=gb:NM 004360.1 gb:L08599.*-T
1.440541 -1.650241 8.52 Down 1.11E-03 BE503640 ESTs 1.344522 -1.721548 8.37 Down 1.97E-02 AW07170 dipeptidylpeptidase VI
4.319671 1.253603 8.37 Down 1.05E-04 AF063002 Homo sapiens LIM
protein SLIMMER
mRNA, complete cds.
/PROD=LIM protein SLIMMER
/FL=gb:AF063002.1 gb:AF098518.1 2.575606 -0.489298 8.37 Down 1.24E-03 BC016785 Homo sapiens, Similar to hypothetical protein PR01722, clone IMAGE:4096414, mRNA.
1.070412 -1.992167 8.35 Down 7.29E-04 AF070642 Homo sapiens clone 24488 mRNA
sequence.
3.083054 0.021788 8.35 Down 2.33E-03 BCO26969 Homo sapiens, clone IMAGE:5116073, mRNA, partial cds.
6.075972 3.015223 8.34 Down 1.35E-04 NM_0014 Homo sapiens four 49 and a half LIM
domains 1 (FHL1), mRNA. /PROD=four and a half LIM
domains 1 /FL=gb:U60115.1 gb:NM 001449.1 gb:U26538.1 0.779095 -2.27952 8.33 Down 1.58E-02 AF497717 Homo sapiens tissue-type lung unknown mRNA.
4.227241 1.173625 8.3 Down 3.47E-04 A1193252 ESTs, Weakly similar to AF133270 1 SLIT2 (H sapiens) 1.139113 -1.908335 8.27 Down 1.40E-02A!741469 ESTs 3.120689 0.079671 8.23 Down 6.27E-04 U01874 Human me20m mRNA, complete cds.
/PROD=me20m /FL=gb:NM 006928.1 gb:BC0014714.1 gb:U01874.1 3.499377 0.460367 8.22 Down 2.16E-03 NM 0245 Homo sapiens 72 hypothetical protein FLJ12691 (FLJ12691), mRNA.
/PROD=hypothetical protein FLJ12691 /FL=gb:NM_024572.1 2.568736 -0.463022 8.18 Down 4.78E-03 AA531287 ESTs Table VI DIFFERENTIAL EXPRESSION OF GENES BETWEEN
UNDIFFERENTIATED EMBRYONIC STEM CELLS CULTURED ON
MATRIGELTm AND EXPRES 01(A) AND 02(B) CELLS CULTURED ON
TCPS
A) 119P39 at 2 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.
EXPRES 2 HR DE Ratio Direction adj. p- Gene Gene Name 01 value Identifier -3.61621 3.301718 120.92 Up 0.001179 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -1.32044 4.320344 49.89 Up 0.005081 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF617987.1 gb:AF001900.1 -3.12747 2.331072 43.97 Up 0.000718 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H.sapiens) -2.3376 2.787516 34.9 Up 0.000229 U17496 Human proteasome subunit LMP7 (allele LMP7B) mRNA, complete cds. /PROD=proteasome subunit LMP7 /FL=gb:U17497.1 gb:U17496.1 -0.27888 4.715023 31.86 Up 0.000339 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -1.56608 3.343812 30.06 Up 0.009753 NM_0007 Homo sapiens cytochrome 67 P450, subfamily 1113 (phenobarbital-inducible), polypeptide 6 (CYP2B6), mRNA.
/PROD=cytochrome P450, subfamily IIB(phenobarbital-inducible), polypeptide 6 /FL=gb:NM 000767.2 gb:AF1822T7.1 gb:M29874.1 0.756526 5.558453 27.89 Up 0.000271 NM 0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
IPROD:r.seoreted frizzied-related protein 1 iFi..=0:AF056087.1 gb:NM._003012.2 gb:AF017987.1 gb:AF001900.1 -1.03397 3.688335 26.4 Up 0.000308 NM 0030 Homo sapiens secretory 20 granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM_003020.1 -1.64839 2.654165 19.73 Up 0.000963 NM 0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U61083:1 -0.41404 3.88291 19.66 Up 0.00068 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF017987.1 gb:AF001900.1 -4.55112 -0.49607 16.62 Up 0.040292 NM 0180 Homo sapiens 43 hypothetical protein FLJ10261 (FLJ10261), mRNA.
/PROD=hypothetical protein FLJ10261 /FL=gb:NM_018043.1 -2.38787 1.639634 16.31 Up 0.010236 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) -2.506 1.482042 15.87 Up 0.000737 AW19369 DKFZP566K1924 protein -1.89835 2.076299 15.72 Up 0.000308 AL122010 Human DNA sequence from clone RP5-997D16 on chromosome 1p34.1-35.3 Contains part of the gene for DAP-1 protein, STSs, GSSs and a CpG
island -2.80061 1.027087 14.2 Up 0.005931 NM_0146 Homo sapiens S100 24 calcium-binding protein A6 (calcyclin)(S100A6), mRNA. /PROD=S100 calcium-binding protein A6 /FL=gb:NM 014624.2 gb:BC001L1Th .1 -1.56046 2.251934 14.05 Up 0.009772 NM_0163 Homo sapiens solute 54 carrier family 21 (organic anion transporter), member 12 (SLC21Al2), mRNA. /PROD=organic anion transporter OATP-E
/FL=gb:AB031051.1 gb:NM 016354.1 gb:AF205072.1 gb:AF187817.1 1.109291 4.853054 13.4 Up 0.000308 NM_0053 Homo sapiens

56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 -2.69521 1.04038 13.32 Up 0.000271 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 1.168713 4.897416 13.26 Up 0.001059 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:BC003079.1 -3.05488 0.645316 13 Up 0.001719A1569804 ESTs -0.10733 3.574485 12.83 Up 0.001042 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for 1MAGE:3840937) -3.12055 0.460578 11.97 Up 0.018849 AW78000 ESTs -0.8902 2.675714 11.84 Up 0.001172 NM_0220 Homo sapiens estrogen 34 regulated gene 1 (ERG-1), mRNA. /PROD=estrogen regulated gene 1 /FL=gb:AF305835.1 gb:NM_022034.1 -2.233 1.292642 11.52 Up 0.002196 NM_0148 Homo sapiens KIAA0307 62 gene product (KIAA0307), mRNA. /PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM_014862.1 -1.16113 2.362911 11.5 Up 0.007894 NM 0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB0289-6-7.1 gb:AF121104.1 -2.7484 0.710709 11 Up 0.006544 BC000568 Homo sapiens, clone MGC:3040, mRNA, complete cds.
/PROD=Unknown (protein for MGC:3040) /FL=gb:BC000568.1 -2.89467 0.509405 10.59 Up 0.010729 AW97120 ESTs -1.66608 1.669381 10.09 Up 0.01208 BE673445 Homo sapiens chromosome 19, cosmid -1.38062 1.947029 10.04 Up 0.000277 NM_0025 Homo sapiens 90 protocadherin 8 (PCDH8), mRNA.
/PROD=protocadherin 8 /FL=gb:NM 002590.2 gb:AF0615-7-3.2 1.12675 4.40089 9.67 Up 0.000277 AA206141 ESTs -0.04543 3.208344 9.54 Up 0.000875 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=K1AA1309 protein -3.12304 0.081126 9.22 Up 0.025215 NM_0180 Homo sapiens 18 hypothetical protein F1110191 (FLJ10191), mRNA.
/PROD=hypothetical protein FLJ10191 /FL=gb:NM_018018.1 -2.26295 0.940715 9.21 Up 0.013376 A1735586 ESTs 3.061783 6.265115 9.21 Up 0.000149 BF057809 ESTs -1.57619 1.598447 9.03 Up 0.001707 AW07279 contactin 1 1.260638 4.356898 8.55 Up 0.000408 AA404269 ESTs -1.79406 1.19242 7.93 Up 0.023768 NM_0047 Homo sapiens solute 31 carrier family 16 (monocarboxylic acid transporters), member 7 (SLC16A7), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 7 /FL=gb:AF058056.1 gb:NM_004731.1 -1.25121 1.703716 7.75 Up 0.000875 R62432 Cluster Incl.
R62432:yg52e11.s1 Homo sapiens cDNA, 3 end /clone=1MAGE-36023 /clone end=3 /gb=R-6-2432 /gi=834311 /ug=Hs.12321 /len=487 -2.01579 0.901094 7.55 Up 0.014339 A1937060 KIAA1151 protein 0.194248 3.083487 7.41 Up 0.002413 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds. /PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36881.1 -2.17012 0.714641 7.39 Up 0.011075 AB018580 Homo sapiens mRNA for hluPGFS, complete cds.
/PROD=h1uPGFS
/FL=gb:NM 003739.2 gb:AF149416.2 gb:AB018580.1 gb:D17793.1 1.872557 4.741366 7.3 Up 0.000311 R38389 olfactomedin related ER
localized protein -1.81469 1.042382 7.25 Up 0.007408 AF052108 Homo sapiens clone 23687 mRNA sequence.
-1.51616 1.329372 7.19 Up 0.007084 AJ272267 Homo sapiens partial mRNA for choline dehydrogenase (chdh gene). /PROD=choline dehydrogenase -0.54428 2.289592 7.13 Up 0.000308 AF053712 Homo sapiens osteoprotegerin ligand mRNA, complete cds.
/PROD=osteoprotegerin ligand /FL=gb:AF053712.1 gb:AF019047.1 -3.17826 -0.38807 6.92 Up 0.040995 A1798098 ESTs -1.88254 0.903098 6.9 Up 0.007894 BF694956 Human DNA sequence from clone RP1-187J11 on chromosome 6q11.1-22.33. Contains the gene for a novel protein similar to S. pombe and S.
cerevisiae predicted proteins, the gene for a novel protein similar to protein kinase C inhibitors, the 3 end of the -1.27392 1.501511 6.85 Up 0.036787 U11058 Homo sapiens large conductance calcium- and voltage-dependent potassium channel alpha subunit (MaxiK) mRNA, complete cds.
/PROD=large conductance calcium- and voltage-dependentpotassium channel alpha subunit /FL=gb:U23767.1 gb:NM 002247.1 gb:AF6-25999 -1.89628 0.858329 6.75 Up 0.001372 AA557324 ESTs, Weakly similar to fatty acid omega-hydroxylase (H.sapiens) -2.62694 0.10781 6.66 Up 0.017924 NM_0000 Homo sapiens 55 butyrylcholinesterase (BCHE), mRNA.
/PROD=butyrylcholinester ase precursor /FL=gb:M16541.1 gb:M16474.1 gb:NM_000055.1 -0.69028 2.041376 6.64 Up 0.001589 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DQw1-beta, complete cds.
/FL=gb:NM 002123.1 gb:M1627671 gb:M60028.1 gb:M17564.1 gb:M81141.1 gb:M81140.1 1.037668 3.763873 6.62 Up 0.00068 R40892 ESTs -1.4606 1.25243 6.56 Up 0.001042 AW07210 Homo sapiens mRNA;
2 cDNA DKFZp434H205 (from clone DKFZp434H205) -2.07873 0.629421 6.53 Up 0.006819 A1269290 solute carrier family 18 (vesicular monoamine), member 2 /FL=gb:L14269.1 gb:L23205.1 gb:L09118.1 gb:NM_003054.1 -1.17422 1.532018 6.53 Up 0.009466 A1962169 ESTs -1.85153 0.844198 6.48 Up 0.022892 AL359062 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076.
-0.32746 2.355449 6.42 Up 0.000657 L39833 Homo sapiens (clone hKvBeta3) K+ channel beta subunit mRNA, complete cds. /PROD=K+
channel beta-subunit /FL=gb:U16953.1 gb:L39833.1 -0.62283 2.054006 6.39 Up 0.000522 NM_0013 Homo sapiens deleted in 51 azoospermia-like (DAZL), mRNA. /PROD=deleted in azoospermia-like /FL=gb:U66726.2 gb:NM 001351.1 gb:1J65-918.1 gb:U66078.1 -0.04433 2.61928 6.34 Up 0.001042 NM 0071 Homo sapiens Wnt 91 inhibitory factor-1 (WIF-1), mRNA. /PROD=Wnt inhibitory factor-1 IFL=gb:AF122922.1 gb:NM_007191.1 0.462867 3.108247 6.26 Up 0.006847 A1807026 ESTs 1.37261 4.006097 6.21 Up 0.000311 BC040605 Homo sapiens, clone IMAGE:5271039, mRNA.
0.997757 3.610644 6.12 Up 0.000246 AU144892 Homo sapiens cDNA
FLJ11569 fis, clone 2.214091 4.82397 6.1 Up 0.000277 N98595 ESTs -0.58317 2.018483 6.07 Up 0.000412 AL563460 GATA-binding protein 2 /FL.=gb:M68891.1 -3.21441 -0.62151 6.03 Up 0.033157 NM_0219 Homo sapiens pre-TNK
81 cell associated protein (1D12A), mRNA.
/PROD=pre-TNK cell associated protein /FL=gb:L17325.1 gb:NM_021981.1 -1.61054 0.964359 5.96 Up 0.005872 AW26420 ESTs -0.46577 2.083834 5.85 Up 0.00021 AW05159 ESTs, Moderately similar 1 to unnamed protein product (H.sapiens) -1.09181 1.45367 5.84 Up 0.027071 A1653050 ESTs, Weakly similar to HYDRoXYPHENYLPYRU
VATE DIOXYGENASE
(H.sapiens) -1.64801 0.893628 5.82 Up 0.000875 AW77991 ESTs -0.49174 2.041917 5.79 Up 0.005081 NM 0025 Homo sapiens neuronal 22 pentraxin I (NPTX1), mRNA. /PROD=neuronal pentraxin I precursor /FL=gb:NM 002522.1 gb:U6134971 -0.7841 1.740263 5.75 Up 0.00111 BF672975 lipoprotein lipase /FL=gb:M15856.1 gb:NM_000237.1 -0.75335 1.769582 5.75 Up 0.01551 AK023900 Homo sapiens cDNA
FLJ13838 fis, clone THYR01000756, weakly similar to ALPHA-N-ACETYLGALACTOSAMIN
IDE ALPHA-2,6-SIALYLTRANSFERASE
(EC 2.4.99.-).
/FL=gb:NM 013443.1 gb:AB035173.1 1.174608 3.695562 5.74 Up 0.001082 A1659533 ArgAbl-interacting protein ArgBP2 -2.3444 0.162277 5.68 Up 0.00079 AW05758 ESTs -1.70607 0.798713 5.68 Up 0.006868 BC040321 Homo sapiens, Similar to LIM homeobox protein 8, clone IMAGE:4839343, mRNA.
-1.11642 1.371492 5.61 Up 0.016088 BC000185 Homo sapiens, Similar to c,arnitine palmitoyltransferase I, liver, clone MGC:1772, mRNA, complete cds.
/PROD=Similar to carnitine palmitoyltransferase !Jiver /FL=gb:BC000185.1 2.631289 5.118301 5.61 Up 0.002033 AK026546 Homo sapiens cDNA:
FLJ22893 fis, clone KAT04792.
-1.99418 0.464132 5.5 Up 0.002048 NM_0069 Homo sapiens 94 butyrophilin, subfamily 3, member A3 (BTN3A3), mRNA.
/PROD=butyrophilin, subfamily 3, member A3 /FL=gb:U90548.1 gb:NM_006994.2 -2.05438 0.400672 5.48 Up 0.047179 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) -0.0881 2.345496 5.4 Up 0.001106 AL565745 ESTs, Weakly similar to 2108402A carnitine palmitoyltransferase 1 (H.sapiens) -1.67442 0.753821 5.38 Up 0.004073 AW11745 neurotrimin -0.2823 2.124629 5.3 Up 0.006868 NM_0165 Homo sapiens peptide 82 transporter 3 (L0051296), mRNA. /PROD=peptide transporter 3 /FL=gb:NM 016582.1 gb:AB020598.1 -0.08433 2.303971 5.24 Up 0.003841 NM_0007 Homo sapiens cytochrome 67 P450, subfamily IIB
(phenobarbital-inducible), polypeptide 6 (CYP2B6), mRNA.
/PROD=cytochrome P450, subfamily IIB(phenobarbital-inducible), polypeptide 6 /FL=gb:NM 000767.2 gb:AF1822i7.1 gb:M29874.1 -0.49385 1.890277 5.22 Up 0.005872 A1741439 ESTs 2.372618 4.749882 5.2 Up 0.000339 NM_0070 Homo sapiens 15 chondromodulin I
precursor (CHM-I), mRNA.
/PROD=chondromodulin 1 precursor /FL=gb:NM 007015.1 gb:AB006050.1 0.650035 3.011594 5.14 Up 0.011507 NM_0047 Homo sapiens lecithin 44 retinol acyltransferase (phosphatidylcholine--retinol 0-acyltransferase) (LRAT), mRNA.
/PROD=lecithin retinol acyltransferase(phosphati dylcholine-retinol 0-acyltransferase) /FL=gb:NM 004744.1 gb:AF0715'10.1 -1.60594 0.753467 5.13 Up 0.027018 AL050090 Homo sapiens mRNA;
cDNA DKFZp586F1018 (from clone DKFZp586F1018).
/PROD=hypothetical protein 4.239108 6.593362 5.11 Up 0.001589 BG54252 pyruvate dehydrogenase 1 phosphatase /FL=gb:NM 018444.1 gb:AF155661.1 0.040412 2.375678 5.05 Up 0.00034 AA960844 Homo sapiens, clone IMAGE:4081483, mRNA
1.986226 4.31181 5.01 Up 0.000576 NM_0184 Homo sapiens pyruvate 44 dehydrogenase phosphatase (PDP), mRNA. /PROD=pyruvate dehydrogenase phosphatase /FL=gb:NM 018444.1 gb:AF155661.1 3.409815 -3.01948 86.18 Down 0.000948 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM 016588.1 gb:BC0026-8-3.1 gb:AF136631.1 5.388254 -0.10197 44.95 Down 0.000308 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 3.094183 -2.07205 35.91 Down 0.000277 NM_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF1788'5-3.1 gb:BC002815.1 4.092731 -0.56561 25.25 Down 0.000149 AL513917 solute carrier family (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 2.990178 -1.65945 25.1 Down 0.012588 NA/1_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant 0AD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF178853.1 gb:BC002815.1 6.777916 2.398415 20.81 Down 0.000465 U15174 Homo sapiens BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus E1B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U157174.1 2.469646 -1.82868 19.68 Down 0.035416 N76327 ESTs, Highly similar to 1011297A transferrin receptor (H.sapiens) 2.306111 -1.98162 19.53 Down 0.000324 A1632223 hypothetical protein DKFZp434F2322 3.834572 -0.18549 16.22 Down 0.001082 NM_0026 Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 1 (PDK1), nuclear gene encoding mitochondrial protein, mRNA. /PROD=pyruvate dehydrogenase kinase, isoenzyme 1 /FL=gb:NM 002610.2 gb:L42450.7I
1.790331 -2.19355 15.82 Down 0.001383 AA775681 hypothetical protein 2.770179 -1.16728 15.32 Down 0.000149 AK000345 Homo sapiens cDNA
FLJ20338 fis, clone HEP12179.
3.025351 -0.90644 15.26 Down 0.000718 AW59092 ESTs 4.505436 0.7876 13.16 Down 0.000277 W57613 ESTs 4.749034 1.283923 11.04 Down 0.001992 NM_0021 Homo sapiens 3-hydroxy-30 3-methylglutaryl-Coenzyme A synthase 1 (soluble) (HMGCS1), mRNA. /PROD=3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1(soluble) /FL=gb:NM 002130.1 gb:L25798.1 gb:BC000297.1 2.792215 -0.63797 10.78 Down 0.000308 BC017942 Homo sapiens, Similar to otoconin 90, clone IMAGE:4285317, mRNA.
1.80547 -1.58337 10.47 Down 0.003516 NM_0008 Homo sapiens glutamate 17 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD67, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 000817.1 gb:M8188371 gb:L16888.1 5.095598 1.712881 10.43 Down 0.003841 NM_0055 Homo sapiens insulin 42 induced gene 1 (INSIG1), mRNA. /PROD=insulin induced gene 1 /FL=gb:NM_005542.1 3.268087 -0.094 10.28 Down 0.000308 AF345910 Homo sapiens NYD-SP14 mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 4.161028 0.812032 10.19 Down 0.01551 BC005807 Homo sapiens, clone MGC:10264, mRNA, complete cds.
/PROD=Unknown (protein for MGC:10264) /FL=gb:BC005807.1 2.62025 -0.70119 10 Down 0.002196 AA625683 ESTs 1.840613 -1.45068 9.79 Down 0.004024 A1949760 ESTs, Weakly similar to unnamed protein product (H.sapiens) 1.389794 -1.83973 9.38 Down 0.001383 BG49869 ESTs 1.075159 -2.15236 9.37 Down __ 0.002413 J03580 __ Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 0.757197 -2.44574 9.21 Down 0.036787 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M83941.1 gb:AF213459.1 0.831091 -2.3635 9.16 Down 0.026606 NM_1530 Homo sapiens 36 hypothetical protein FLJ32239 (FLJ32239), mRNA.
/FL=gb:NM_153036.1 4.507212 1.314761 9.14 Down 0.000772 AW19694 ESTs 1.194285 -1.99568 9.13 Down 0.018647 NM_0018 Homo sapiens cystatin SN
98 (CST1), mRNA.
/PROD=cystatin SN
/FL=gb:J03870.1 gb:NM 001898.1 3.030236 -0.13469 8.97 Down 0.001421 AA812232 upreguTated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591.71 2.422113 -0.73175 8.9 Down 0.012832 AL544576 ESTs 6.091008 2.976341 8.66 Down 0.000149 BCO20935 Homo sapiens, Similar to otoconin 90, clone IMAGE:4277593, mRNA.
5.023981 1.92526 8.57 Down 0.000702 NM_0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.
/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591:i 4.285883 1.193881 8.53 Down 0.000308 AL038787 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 4 6.371229 3.380355 7.95 Down 0.000277 A1950472 ESTs 3.953402 0.998399 7.75 Down 0.000728 BC005369 Homo sapiens, chromosome 1 open reading frame 12, clone MGC:12484, mRNA, complete cds.
/PROD=chromosome 1 open reading frame 12 /FL=gb:AF277176.1 gb:NM_022051.1 gb:AF229245.1 gb:BC005369.1 2.759117 -0.13047 7.41 Down 0.000277 A1692523 ESTs 1.143234 -1.73889 7.37 Down 0.018647 BF437711 ESTs 2.36447 -0.49577 7.26 Down 0.000358 NM 0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 2.514693 -0.33184 7.19 Down 0.000412 NM_1450 Homo sapiens 32 hypothetical protein MGC21636 (MGC21636), mRNA.
/FL=gb:BCO20572.1 gb:NM_145032.2 1.956681 -0.85067 7 Down 0.045693 NM_0052 Homo sapiens coagulation 42 factor II (thrombin) receptor-like 1 (F2RL1), mRNA.
/PROD=coagulation factor II (thrombin) receptor-like lprecursor /FL=gb:U34038.1 gb:NM_005242.2 4.103964 1.313863 6.92 Down 0.000149 M579773 ESTs 4.501184 1.716877 6.89 Down 0.000149 AK000162 Homo sapiens cDNA
FLJ20155 fis, clone C0L08754, highly similar to ACSA ECOLI
ACETYL=COENZYME A
SYNTHETASE.
2.660133 -0.12206 6.88 Down 0.000412 AF277174 Homo sapiens PNAS-137 mRNA, complete cds.
/PROD=PNAS-137 /FL=gb:AF277174.1 4.560288 1.812725 6.72 Down 0.049122 BF979497 squalene epoxidase 0.300578 -2.4423 6.69 Down 0.047414 A1110886 prothymosin, alpha (gene sequence 28) 3.816817 1.093203 6.61 Down 0.008646 AF116616 Homo sapiens PR00998 mRNA, complete cds.
/PROD=PR00998 /FL=gb:AF116616.1 7.047717 4.332472 6.57 Down 6.33E-05 NM_0040 Homo sapiens 52 BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3), nuclear gene encoding mitochondria, protein, mRNA.
/PROD=BCL2adenovirus El B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U15-174.1 4.897427 2.262649 6.21 Down 0.000149 R06655 ESTs, Moderately similar to AF078844 1 hqp0376 protein (H.sapiens) 4.424942 1.790634 6.21 Down 0.010942 AF493929 Homo sapiens regulator of G protein signalling 5 (RGS5) mRNA, complete cds. /PROD=regulator of G protein signalling 5 /FL=gb:AF493929.1 2.28595 -0.34058 6.18 Down 0.001421 BE504838 ESTs 2.276913 -0.33923 6.13 Down 0.045179 AK025909 Homo sapiens cDNA:
FLJ22256 fis, clone HRCO2860.
2.33099 -0.27829 6.1 Down 0.020405 NM_0040 Homo sapiens arrestin, 41 beta 1 (ARRB1), transcript variant 1, mRNA.
/PROD=arrestin beta 1, isoform A
/FL=gb:BC003636.1 gb:AF084040.1 gb:NM_004041.2 5.319714 2.718977 6.07 Down 0.00034 AL117352 Human DNA sequence from clone RP5-876B10 on chromosome 1q42.12-43. Contains the 3 end of the GNPAT gene for glyceronephosphate 0-acyltransferase (DHAPAT, DAPAT, dihydroxyacetone phosphate acyltransferase, EC
2.3.1.42), the gene for a novel protei...
6.618477 4.029022 6.02 Down 0.000267 AU146532 pyruvate dehydrogenase kinase, isoenzyme 1 2.658828 0.094296 5.92 Down 0.000277 NM_0246 Homo sapiens 03 hypothetical protein FLJ11588 (FLJ11588), mRNA.
/PROD=hypothetical protein FLJ11588 /FL=gb:NM_024603.1 3.806044 1.246883 5.89 Down 0.001383 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 4.782763 2.225157 5.89 Down 0.000229 NM_0041 Homo sapiens 99 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II (P4HA2), mRNA.

/PROD=procollagen-proline, 2-oxoglutarate4-dioxygenase (proline 4-hydroxylase), alpha polypeptidell /FL=gb:NM_004199.1 gb:U904 2.350127 -0.15742 5.69 Down 0.001603 AK026106 Homo sapiens cDNA:
FLJ22453 fis, clone HRC09679, highly similar to AF059516 Homo sapiens tolloid-like 2 protein (TLL2) mRNA.
5.979532 3.475949 5.67 Down 0.038914 U18197 Human ATP:citrate lyase mRNA, complete eds.
/PROD=ATP:citrate lyase /FL=gb:U18197.1 2.322104 -0.13595 5.49 Down 0.001082 AW29136 ESTs 2.951696 0.4944 5.49 Down 0.004024 AB019562 Homo sapiens mRNA
expressed only in placental villi, clone SMAP41.
2.265595 -0.17155 5.42 Down 0.00303 NM_0221 Homo sapiens myodulin 44 protein (L0064102), mRNA. /PROD=myodulin protein /FL=gb:AB055421.1 gb:AF191770.1 gb:NM 022144.1 gb:AFi34259.1 5.606506 3.176643 5.39 Down 0.000149 NM_0134 Homo sapiens follistatin 09 (FST), transcript variant FST344, mRNA.
/PROD=follistatin isoform FST344 precursor /FL=gb:NM 013409.1 gb:BC0041i57.1 4.03305 1.617698 5.33 Down 0.000512 6E300521 insulin induced gene 1 /FL=gb:NM_005542.1 5.294065 2.87892 5.33 Down 0.01743 AF279899 Homo sapiens PNAS-145 mRNA, complete cds.
/PROD=PNAS-145 /FL=gb:U03105.1 gb:NM_006813.1 gb:AF279899.1 5.807319 3.40016 5.3 Down 0.000277 NM_0180 Homo sapiens 04 hypothetical protein FLJ10134 (FLJ10134), mRNA.
/PROD=hypothetical protein FLJ10134 /FL=gb:NM_018004.1 2.64743 0.242871 5.29 Down 0.00111 A1702438 ESTs 4.257559 1.873346 5.22 Down 0.00021 NM_0063 Homo sapiens 65 transcriptional activator of the c-fos promoter (CROC4), mRNA.
/PROD=transcriptional activator of the c-fos promoter /FL=gb:NM 006365.1 gb:U4985771 B) H9P39 at 6 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.
EXPRES 6 HR DE Ratio Direction adj. p- Gene Gene Name 01 value Identifier -3.61621 3.039489 100.82 Up 0.001521 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -1.32044 4.397292 52.63 Up 0.005415 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 ge:AF6-17987.1 gb:AF001900.1 -3.12747 2.554429 51.34 Up 0.000785 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H.sapiens) -1.56608" 3.285259 28.87 Up 0.010886 NM_0007 Homo sapiens cytochrome 67 P450, subfamily IIB
(phenobarbital-inducible), polypeptide 6 (CYP2B6), mRNA.
/PROD=cytochrome P450, subfamily IIB(phenobarbital-inducible), polypeptide 6 /FL=gb:NM 000767.2 gb:AF1822-77.1 gb:M29874.1 0,756526 5.442022 25.73 Up 0.000181 NM 0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
IPRODr-secreted frizzled-related protein 1 IFL=gb:AF056087.1 gb:NM 003012.2 gb:AF0-17987.1 gb:AF001900.1 -1.03397 3.570137 24.32 Up 0.000451 NM_0030 Homo sapiens secretory 20 granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM_003020.1 -0.27888 4.229001 22.75 Up 0.000262 AF225513 Homo sapiens CAMP-dependent protein kinase inhibitor beta mRNA, complete cds.

/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -0.41404 4.064841 22.3 Up 0.000713 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF0-17987.1 gb:AF001900.1 -1.64839 2.511027 17.87 Up 0.001081 NM_0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U6108371 -0.10733 3.921888 16.33 Up 0.001963 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) -1.89835 2.08573 15.82 Up 0.000268 AL122010 Human DNA sequence from clone RP5-997D16 on chromosome 1p34.1-35.3 Contains part of the gene for DAP-1 protein, STSs, GSSs and a CpG
island -2.38787 1.510394 14.91 Up 0.012419 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) 1.168713 4.97383 13.98 Up 0.000908 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:BC003079.1 1.109291 4.713388 12.16 Up 0.000639 NM_0053 Homo sapiens 56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36881.1 -0.69028 2.890465 11.96 Up 0.001335 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DQw1-beta, complete cds.
/FL=gb:NM 002123.1 gb:Ml 62761 gb:M60028.1 gb:M17564.1 gb:M81141.1 gb:M81140.1 -2.89467 0.604102 11.3 Up 0.009629 AW97120 ESTs -1.66608 1.816524 11.18 Up 0.011253 BE673445 Homo sapiens chromosome 19, cosmid 3.061783 6.476101 10.66 Up 0.000192 BF057809 ESTs 1.495888 4.907617 10.64 Up 0.000719 NM 0021 Homo sapiens heme 33 oxygenase (decycling) 1 (HMOX1), mRNA.
/PROD=heme oxygenase (decyclizing) 1 /FL=gb:NM_002133.1 -3.05488 0.24579 9.85 Up 0.002819 A1569804 ESTs -2.233 1.058708 9.79 Up 0.002994 NM 0148 Homo sapiens KIAA0307 62 gene product (KIAA0307), mRNA. /PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM_014862.1 -3.588 -0.31418 9.67 Up 0.048375 A1743261 ESTs -2.01579 1.241268 9.56 Up 0.012905 A1937060 KIAA1151 protein -2.16864 1.08358 9.53 Up 0.053176 NM_0014 Homo sapiens galanin 80 receptor 1 (GALR1), mRNA. /PROD=galanin receptor 1 /FL=gb:NM 001480.2 gb:U2385471 gb:L34339.1 gb:U53511.1 -1.39784 1.792634 9.13 Up 0.006895 BE222344 splicing factor, arginineserine-rich 5 -1.79406 1.292814 8.5 Up 0.025849 NM_0047 Homo sapiens solute 31 carrier family 16 (monocarboxylic acid transporters), member 7 (SLC16A7), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 7 /FL=gb:AF058056.1 gb:NM_004731.1 -0.04543 3.025604 8.4 Up 0.001481 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=KIAA1309 protein -2.62694 0.426879 8.3 Up 0.015097 NM_0000 Homo sapiens 55 butyrylcholinesterase (BCHE), mRNA.
/PROD=butyrylcholinester ase precursor /FL=gb:M16541.1 gb:M16474.1 gb:NM_000055.1 -3.17826 -0.15901 8.11 Up 0.032029A1798098 ESTs 1.875596 4.86264 7.93 Up 0.052512 M10098 Human 18S rRNA gene, complete.
-2.87679 0.053356 7.62 Up 0.045164 A1378647 ESTs -2.39234 0.513238 7.49 Up 0.032932 NM_0043 Homo sapiens catenin 89 (cadherin-associated protein), alpha 2 (CTNNA2), mRNA.
/PROD=catenin (cadherin-associated protein), alpha 2 /FL=gb:NM 004389.1 gb:M94151.2--1.16113 1.724952 7.39 Up 0.016804 NM_0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB0289-67.1 gb:AF121104.1 0.194248 3.078427 7.38 Up 0.002349 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds. /PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 -1.57619 1.300336 7.34 Up 0.003836 AW07279 contactin 1 2.284174 5.158015 7.33 Up 0.031092 M10098 Human 18S rRNA gene, complete.
-1.51992 1.341829 7.27 Up 0.008657 AA460960 H.sapiens mRNA (clone ICRFp507L1876) 0.462867 3.324494 7.27 Up 0.005747 A1807026 ESTs -2.05438 0.78321 7.15 Up 0.031227 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 0.997757 3.818432 7.06 Up 0.000204 AU144892 Homo sapiens cDNA
FLJ11569 fis, clone 2.013831 4.834052 7.06 Up 0.044501 M10098 Human 18S rRNA gene, complete.
-2.26295 0.550594 7.03 Up 0.018367 A1735586 ESTs -1.51616 1.294636 7.02 Up 0.005536 AJ272267 Homo sapiens partial mRNA for choline dehydrogenase (chdh gene). /PROD=choline dehydrogenase -2.13754 0.667215 6.99 Up 0.022696 BF000203 ESTs 0.466394 3.270039 6.98 Up 0.000736 NM 0031 Homo sapiens Spi-B
21 transcription factor (Spi-1PU.1 related) (SPIB), mRNA. /PROD=Spi-B
transcription factor (Spi-1PU.1 related) /FL=gb:NM_003121.1 -2.17012 0.632675 6.98 Up 0.0112 AB018580 Homo sapiens mRNA for hluPGFS, complete cds.
/PROD=h1uPGFS
/FL=gb:NM 003739.2 gb:AF1494T6.2 gb:AB018580.1 gb:D17793.1 -2.45074 0.326451 6,86 Up 0.021849 AW14940 neurexin 1 /FL=gb:AB035356.1 -0.8902 1.856598 6.71 Up 0.001423 NM_0220 Homo sapiens estrogen 34 regulated gene 1 (ERG-1), mRNA. /PROD=estrogen regulated gene 1 /FL=gb:AF305835.1 gb:NM_022034.1 -1.25121 1.488908 6.68 Up 0.001035 R62432 Cluster Incl.
R62432:yg52e11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-36023 /clone end=3 /gb=R-6-2432 /gi=834311 /ug=Hs.12321 /len=487 -1.42062 1.315517 6.66 Up 0.053176A1830490 glycerol kinase -1.85153 0.876867 6.63 Up 0.021533 AL359062 Homo sapiens mRNA
full length insert cDNA clone EUROIMAGE 1913076.
-3.12055 -0.40125 6.59 Up 0.044501 AW78000 ESTs 1.037668 3.7519 6.56 Up 0.000736 R40892 ESTs -2.07873 0.630876 6.54 Up 0.00724 A1269290 solute carrier family (vesicular monoamine), member 2 /FL=gb:L14269.1 gb:L23205.1 gb:L09118.1 gb:NM_003054.1 -1.88254 0.821519 6.52 Up 0.006908 BF694956 Human DNA sequence from clone RP1-187J11 on chromosome 6q11.1-22.33. Contains the gene for a novel protein similar to S. pombe and S.
cerevisiae predicted proteins, the gene for a novel protein similar to protein kinase C inhibitors, the 3 end of the -0.5392 2.15739 6.48 Up 0.00126 AA769438 ESTs, Moderately similar to ALU1 HUMAN ALU
SUBFAMILY J
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.872557 4.557858 6.43 Up 0.000315 R38389 olfactomedin related ER
localized protein -2.06656 0.610015 6.39 Up 0.01711 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 -1.4606 1.189801 6.28 Up 0.001394 AW07210 Homo sapiens mRNA;
2 cDNA DKFZp434H205 (from clone DKFZp434H205) -1.17422 1.42382 6.05 Up 0.007542A1962169 ESTs -1.27392 1.293844 5.93 Up 0.042956 U11058 Homo sapiens large conductance calcium- and voltage-dependent potassium channel alpha subunit (MaxiK) mRNA, complete cds.
/PROD=large conductance calcium- and voltage-dependentpotassium channel alpha subunit /FL=gb:U23767.1 gb:NM 002247.1 gb:AF6-25999 -0,04433 2,486339 5.78 Up 0.001511 Mil_0071 Homo sapiens Writ 91 inhibitory factor-1 (WW-1), mRNA. /PROD=Wni:
inhibitory factor-1 iFL=gb:AF122922.1 gb:NM...007191,1 -1.38062 1.126483 5.68 Up 0.003297 NM_0025 Homo sapiens 90 protocadherin 8 (PCDH8), mRNA.
/PROD=protocadherin 8 /FL=gb:NM 002590.2 gb:AF0615T3.2 1.37261 3.87602 5.67 Up 0.000713 BC040605 Homo sapiens, clone IMAGE:5271039, mRNA.
-2.3444 0.156063 5.66 Up 0.002001 AW05758 ESTs -1.60594 0.882381 5.61 Up 0.016783 AL050090 Homo sapiens mRNA;
cDNA DKFZp586F1018 (from clone DKFZp586F1018).
/PROD=hypothetical protein -1.09181 1.384319 5.56 Up 0.030796A1653050 ESTs, Weakly similar to HYDR-oXYPHENYLPYRU
VATE DIOXYGENASE
(H.sapiens) -0.32746 2.147256 5.56 Up 0.001039 L39833 Homo sapiens (clone hKvBeta3) K+ channel beta subunit mRNA, complete cds. /PROD=K+
channel beta-subunit /FL=gb:U16953.1 gb:L39833.1 -0.46577 2.00387 5.54 Up 0.000262 AW05159 ESTs, Moderately similar 1 to unnamed protein product (H.sapiens) -2.19527 0.241495 5.41 Up 0.017156 NM_0133 Homo sapiens EH
33 domain-binding mitotic phosphoprotein (EPSIN), mRNA. /PROD=EH
domain-binding mitotic phosphoprotein /FL=gb:NM 013333.1 gb:AF07372-7.1 1.684042 4.109252 5.37 Up 0.000924 BE504979 Wiskott-Aldrich syndrome-like /FL=gb:D88460.1 gb:NM_003941.1 2.7744 5.196982 5.36 Up 0.001859 1AA669799 Cluster Incl.
AA669799:ag36c04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1118886 /clone_end=3 /g b=AA669799 /gi=2631298 Jug=Hs.6315 /len=679 0.623369 3.023579 5.28 Up 0.000791 NM_0063 Homo sapiens 34 neuroblastoma (nerve tissue) protein (AMY), mRNA.
/PROD=neuroblastoma (nerve tissue) protein /FL=gb:NM 006334.1 gb:D8234371 -0.0881 2.307249 5.26 Up 0.000742 AL565745 ESTs, Weakly similar to 2108402A carnitine palmitoyltransferase I
(H.sapiens) 0.225505 2.619908 5.26 Up 0.000552 A1968440 ESTs -1.67442 0.713629 5.23 Up 0.008409 AW11745 neurotrimin 0.040412 2.394979 5.11 Up 0.000552 AA960844 Homo sapiens, clone IMAGE:4081483, mRNA
1.638346 3.992456 5.11 Up 0.000281 AA603344 ESTs, Weakly similar to ALU7_HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.923146 4.275361 5.11 Up 0.000799 BF057731 ESTs 1.398961 3.745146 5.08 Up 0.000972 NM_0240 Homo sapiens 36 hypothetical protein MGC3103 (MGC3103), mRNA.
/PROD=hypothetical protein MGC3103 /FL=gb:NM 024036.1 gb:BC000267.1 -0.2823 2.040956 5 Up 0.007542 NM 0165 Homo sapiens peptide 82 transporter 3 (L0051296), mRNA. /PROD=peptide transporter 3 /FL=gb:NM 016582.1 gb:AB020548.1 3.409815 -2.62843 65.72 Down 0.0112 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM_016588.1 gb:BC002683.1 gb:AF136631.1 5.388254 0.009545 41.61 Down 0.000281 NM 0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 3.094183 -1.98643 33.84 Down 0.012905 NM_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF178853.1 gb:BC002815.1 3.025351 -1.81749 28.7 Down 0.004056 AW59092 ESTs 4.092731 -0.55563 25.08 Down 0.000627 AL513917 solute carrier family (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 6.777916 2.149128 24.74 Down 0.000281 U15174 Homo sapiens BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus El B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U15174.1 0.959227 -3.66704 24.7 Down 0.001627 AB033831 Homo sapiens hSCDGF
mRNA for spinal cord-derived growth factor, complete cds.
/PROD=spinal cord-derived growth factor /FL=gb:NM 016205.1 gb:AB0338-3-1 .1 gb:AF091434.1 gb:AF244813.1 1.470435 -3.07409 23.34 Down 0.029826 L49506 Homo sapiens cyclin G2 mRNA, complete cds.
/PROD=cyclin G2 /FL=gb:L49506.1 4.161028 -0.3587 22.94 Down 0.006316 BC005807 Homo sapiens, clone MGC:10264, mRNA, complete cds.
/PROD=Unknown (protein for MGC:10264) /FL=gb:BC005807.1 2.446762 -1.7919 18.88 Down 0.029145 NM 0059 Homo sapiens S-phase 83 kinase-associated protein 2 (p45) (SKP2), mRNA.
/PROD=S-phase kinase-associated protein 2 (p45) /FL=gb:U33761.1 gb:NM 005983.1 1.790331 -2.43995 18.77 Down 0.001074 AA775681 hypothetical protein 4.505436 0.27614 18.76 Down 0.000281 W57613 ESTs 2.792215 -1.38592 18.1 Down 0.013563 BC017942 Homo sapiens, Similar to otoconin 90, clone IMAGE:4285317, mRNA.
4.507212 0.470029 16.42 Down 0.000262 AW19694 ESTs 2.469646 -1.56158 16.35 Down 0.000649 N76327 ESTs, Highly similar to 1011297A transferrin receptor (H.sapiens) 2.770179 -1.16077 15.25 Down 0.000181 AK000345 Homo sapiens cDNA
FLJ20338 fis, clone HEP12179.
3.834572 -0.07465 15.02 Down 0.000272 NM_0026 Homo sapiens pyruvate dehydrogenase kinase, isoenzyme 1 (PDK1), nuclear gene encoding mitochondrial protein, mRNA. /PROD=pyruvate dehydrogenase kinase, isoenzyme 1 /FL=gb:NM 002610.2 gb:L42450.71 2.306111 -1.49375 13.93 Down 0.004398 A1632223 hypothetical protein DKFZp434F2322 3.030236 -0.72689 13.52 Down 0.006371 AA812232 upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591.1 3.268087 -0.40455 12.75 Down 0.000114 AF345910 Homo sapiens NYD-SP14 mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 5.294065 1.68926 12.17 Down 0.001199 AF279899 Homo sapiens PNAS-145 mRNA, complete cds.
/PROD=PNAS-145 /FL=gb:U03105.1 gb:NM 006813.1 gb:AF2-79899.1 0.173113 -3.3673 11.64 Down 0.006169 NM_1524 Homo sapiens 90 hypothetical protein MGC39558 (MGC39558), mRNA.
/FL=gb:BCO29564.1 gb:NM_152490.1 0.432613 -3.10597 11.62 Down 0.013508 BC004884 Homo sapiens, clone MGC:11141, mRNA, complete cds.
/PROD7--Unknown (protein for MGC:11141) /FL=gb:BC004884.1 6.371229 2.841928 11.55 Down 0.000432 A1950472 ESTs 5.023981 1.496597 11.53 Down 0.000207 NM_0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.
/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591-.:I
2.036188 -1.4564 11.26 Down 0.023936 U55936 Human SNAP-23 mRNA, complete cds.
/PROD=SNAP-23 /FL=gb:U55936.1 gb:BC000148.2 gb:BC003686.1 gb:Y09567.1 1.075159 -2.41498 11.24 Down 0.004979 J03580 Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 6.091008 2.605414 11.2 Down 0.000741 BCO20935 Homo sapiens, Similar to otoconin 90, clone IMAGE:4277593, mRNA.
0.783065 -2.6827 11.05 Down 0.030265 AB014486 Homo sapiens mRNA for RA70, complete cds.
/PROD=RA70 /FL=gb:AF051323.1 gb:BC002893.1 gb:AB014486.1 gb:AF072166.1 gb:NM 003930.1 2.505869 -0.95096 10.98 Down 0.001627 AV721177 phosp1-atidylinositol binding clathrin assembly protein 4.749034 1.297636 10.94 Down 0.000464 NM 0021 Homo sapiens 3-hydroxy-30 3-methylglutaryl-Coenzyme A synthase 1 (soluble) (HMGCS1), mRNA. /PROD=3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1(soluble) /FL=gb:NM 002130.1 gb125798.-1-gb:BC000297.1 1.840613 -1.60133 10.87 Down 0.015976A1949760 ESTs, Weakly similar to unnamed protein product (H.sapiens) 2.060071 -1.36259 10.72 Down 0.003053 AA004300 hypothetical protein DKFZp5661133 2.990178 -0.3979 10.47 Down 0.000924 NM_0134 Homo sapiens glutamate 45 decarboxylase 1 (brain, 67kD) (GAD1), transcript variant GAD25, mRNA.
/PROD=glutamate decarboxylase 1, isoform /FL=gb:NM 013445.1 gb:AF178853.1 gb:BC002815.1 1.143234 -2.23959 10.43 Down 0.00724 BF437711 ESTs 0.680039 -2.65005 10.06 Down 0.005452 AW26835 ESTs, Highly similar to antigen (H.sapiens) 0.757197 -2.55666 9.94 Down 0.012419 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M8394171 gb:AF213459.1 3.953402 0.655224 9.84 Down 0.000312 BC005369 Homo sapiens, chromosome 1 open reading frame 12, clone MGC:12484, mRNA, complete cds.
/PROD=chromosome 1 open reading frame 12 /FL=gb:AF277176.1 gb:NM 022051.1 gb:AF2-29245.1 gb:BC005369.1 2.660133 -0.625 9.75 Down 0.000281 AF277174 Homo sapiens PNAS-137 mRNA, complete cds.
/PROD=PNAS-137 /FL=gb:AF277174.1 2.370141 -0.82549 9.16 Down 0.011076 BCO20691 Homo sapiens, Similar to pre-B-cell colony-enhancing factor, clone MGC:22427 IMAGE:4717726, mRNA, complete cds.
/PROD=Similar to pre-B-cell colony-enhancing factor /FL=gb:BCO20691.1 1.250277 -1.93752 9.11 Down 0.02358 BC035744 Homo sapiens, hypothetical protein HSPC129, clone MGC:46091 IMAGE:5744745, mRNA, complete cds.
/FL=gb:8C035744.1 2.62025 -0.48479 8.6 Down 0.002377 AA625683 ESTs 4.560288 1.479495 8.46 Down 0.000799 BF979497 squalene epoxidase 1.609384 -1.40302 8.07 Down 0.03374 BC005961 Homo sapiens, parathyroid hormone-like hormone, clone MGC:14611, mRNA, complete cds.
/PROD=parathyroid hormone-like hormone /FL=gb:BC005961.1 2.422113 -0.58962 8.07 Down 0.035909 AL544576 ESTs 4.285883 1.280326 8.03 Down 0.000262 AL038787 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 4 1.194285 -1.77245 7.82 Down 0.029849 NM 0018 Homo sapiens cystatin SN
98 (CST1), mRNA.
/PROD=cystatin SN
/FL=gb:J03870.1 gb:NM_001898.1 0.885541 -2.07053 7.76 Down 0.025326 AV721958 ESTs 4.501184 1.559254 7.68 Down 0.000103 AK000162 Homo sapiens cDNA
FLJ20155 fis, clone C0L08754, highly similar to ACSA ECOLI
ACETYL-COENZYME A
SYNTHETASE.
2.264785 -0.65782 7.58 Down 0.000552 AF005037 Homo sapiens secretory carrier membrane protein (SCAMPI) mRNA, complete cds.
/PROD=secretory carrier membrane protein /FL=gb:AF038966.1 gb:AF005037.1 gb:NM_004866.1 5.095598 2.21166 7.38 Down 0.001394 NM_0055 Homo sapiens insulin 42 induced gene 1 (INSIGI ), mRNA. /PROD=insulin induced gene 1 /FL=gb:NM 005542.1 5.979532 3.098176 7.37 Down 0.003586 U18197 Human ATi5:citrate lyase mRNA, complete cds.
/PROD=ATP:citrate lyase /FL=gb:U18197.1 4.782763 1.929757 7.23 Down 0.000451 NM_0041 Homo sapiens 99 procollagen-proline, 2-oxogiutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II (P4HA2), mRNA.
/PROD=procollagen-proline, 2-oxoglutarate4-dioxygenase (proline 4-hydroxylase), alpha polypeptidell /FL=gb:NM_004199.1 gb:U904 5.356771 2.540614 7.04 Down 0.000587 W92036 ESTs 1.41468 -1.38083 6.94 Down 0.017389 NM_0184 Homo sapiens 70 uncharacterized hypothalamus protein HT009 (HT009), mRNA.
/PROD=uncharacterized hypothalamus protein /FL=gb:AF220183.1 gb:NM_018470.1 7.047717 4.25951 6.91 Down 0.000431 NM_0040 Homo sapiens 52 BCL2adenovirus ElB
19kD-interacting protein 3 (BNIP3), nuclear gene encoding mitochondrial protein, mRNA.
/PROD=BCL2adenovirus El B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U15174.1 1.815339 -0.96912 6.89 Down 0.011253 13E206621 Homo sapiens mRNA;
cDNA DKFZp434P228 (from clone DKFZp434P228) 5.319714 2.54291 6.85 Down 0.000213 AL117352 Human DNA sequence from clone RP5-876B10 on chromosome 1q42.12-43. Contains the 3 end of the GNPAT gene for glyceronephosphate 0-acyltransferase (DHAPAT, DAPAT, dihydroxyacetone phosphate acyltransferase, EC
2.3.1.42), the gene for a novel protei...
4.010007 1.2423 6.81 Down 0.00398 NM 0065 Homo sapiens beta-1,3-N-77 acetylglucosaminyltransfer ase (BETA3GNT), mRNA.
/PROD= beta-1,3-N-acetylglucosaminyltransfer ase /FL=gb:NM_006577.2 gb:AF288208.1 gb:AF092051.2 1.390174 -1.34692 6.67 Down 0.014402 BC001224 Homo sapiens, clone MGC:982 IMAGE:3354306, mRNA, complete cds.
/PROD=Unknown (protein for MGC:982) /FL=gb:BC001224.1 0.831091 -1.89825 6.63 Down 0.025217 NM 1530 Homo sapiens 36 hypothetical protein FLJ32239 (FLJ32239), mRNA.
/FL=gb:NM_153036.1 2.33099 -0.39642 6.62 Down 0.000103 NM_0040 Homo sapiens arrestin, 41 beta 1 (ARRB1), transcript variant 1, mRNA.
/PROD=arrestin beta 1, isoform A
/FL=gb:BC003636.1 gb:AF084040.1 gb:NM_004041.2 1.389794 -1.32346 6.56 Down 0.006908 BG49869 ESTs 4.424942 1.717072 6.53 Down 0.000627 AF493929 Homo sapiens regulator of G protein signalling 5 (RGS5) mRNA, complete cds. /PROD=regulator of G protein signalling 5 /FL=gb:AF493929.1 1.987876 -0.71603 6.52 Down 0.032029 D84105 Human CD46 mRNA, complete cds.
/PROD=CD46 /FL=gb:D84105.1 2.224696 -0.43842 6.33 Down 0.003781 NM_0156 Homo sapiens 01 DKFZP564G092 protein (DKFZP564G092), mRNA.
/PROD=DKFZP564G092 protein /FL=gb:NM_015601.1 0.366041 -2.27572 6.24 Down 0.017238 A1242583 Homo sapiens cDNA
FLJ11550 fis, clone 0.899011 -1.74189 6.24 Down 0.031092 NM 0028 Homo sapiens parathyroid 20 hormone-like hormone (PTHLH), mRNA.
/PROD=parathyroid hormone-like hormone /FL=gb:J03802.1 gb:NM_002820.1 -0.00139 -2.64223 6.24 Down 0.045323 NM_0028 Homo sapiens protein 37 tyrosine phosphatase, receptor type, B (PTPRB), mRNA. /PROD=protein tyrosine phosphatase, receptor type, B
/FL=gb:NM_002837.1 0.81216 -1.82788 6.23 Down 0.021836 NM_0177 Homo sapiens 63 hypothetical protein FLJ20315 (FLJ20315), mRNA.
/PROD=hypothetical protein FLJ20315 /FL=gb:NM 017763.1 5.600865 2.995377 6.09 Down 0.000713 A1183997 regulator of-G-protein signalling 5 /FL=gb:AB008109.1 gb:NM 003617.1 gb:AF159570.1 2.350127 -0.2504 6.07 Down 0.030265 AK026106 Homo sapiens cDNA:
FLJ22453 fis, clone HRC09679, highly similar to AF059516 Homo sapiens tolloid-like 2 protein (TLL2) mRNA.
3.732985 1.134619 6.06 Down 0.001697 A1459194 early growth response 1 2.36447 -0.20141 5.92 Down 0.000552 NM_0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 3.621319 1.058823 5.91 Down 0.001394 AY072911 Homo sapiens coxsackie-adenovirus-receptor isoform CAR37 (CXADR) mRNA, complete cds;
alternatively spliced.
/PROD=coxsackie-adenovirus-receptor isoform CAR37 /FL=gb:AY072911.1 3.816817 1.261309 5.88 Down 0.000279 AF116616 Homo sapiens PR00998 mRNA, complete cds.
/PROD=PR00998 /FL=gb:AF116616.1 2.003811 -0.52279 5.76 Down 0.012377 AK001291 Homo sapiens cDNA
FLJ10429 fis, clone NT2RP1000413, highly similar to Homo sapiens mRNA for KIAA0587 protein.
2.951696 0.463484 5.61 Down 0.000268 AB019562 Homo sapiens mRNA
expressed only in placental villi, clone SMAP41.
4.654166 2.17714 5.57 Down 0.006161 H09085 Homo sapiens clone mRNA, complete cds 2.590871 0.126582 5.52 Down 0.00106 NM_0165 Homo sapiens TBX3-iso 69 protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF2167g0.1 2.432066 -0.0298 5.51 Down 0.005455 NM_0070 Homo sapiens DnaJ-like 34 heat shock protein 40 (HLJ1), mRNA.
/PROD=DnaJ-like heat shock protein 40 /FL=gb:NM 007034.2 gb:U40992 5.807319 3.352042 5.48 Down 0.000612 NM_0180 Homo sapiens 04 hypothetical protein FLJ10134 (FLJ10134), mRNA.
/PROD=hypothetical protein FLJ10134 /FL=gb:NM_018004.1 2.006604 -0.43301 5.42 Down 0.000713 NM 0040 Homo sapiens discs, large 87 (Drosophila) homolog 1 (DLG1), mRNA.
/PROD=discs, large (Drosophila) homolog 1 /FL=gb:NM 004087.1 gb:U13896:1 0.72592 -1.71056 5.41 Down 0.014643 AB050856 Homo sapiens beta3GaINAcT-1 mRNA
for globoside synthase, complete cds, clone:type 2. /PROD=globoside synthase /FL=gb:AB050856.1 3.805066 1.369345 5.41 Down 0.001099 BG33007 Human alpha-catenin 6 mRNA, partial cds.
3.70002 1.279892 5.35 Down 0.014262 NM_0065 Homo sapiens SEC10 (S.
44 cerevisiae)-like 1 (SEC10L1), mRNA.
/PROD=SEC10 (S.
cerevisiae)-like 1 /FL=gb:U85946.1 gb:NM_006544.1 0.873551 -1.53444 5.31 Down 0.031228 AW29337 ESTs 5.850582 3.443167 5.31 Down 0.008657 AF394735 Homo sapiens MAD2 mitotic arrest deficient-like 1 variant (MAD2L1) mRNA, complete cds.
/PROD=MAD2 mitotic arrest deficient-like 1 variant /FL=gb:AF394735.1 5.252439 2.850969 5.28 Down 0.000192 NM 0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb:L19182.1 1.275104 -1.11616 5.25 Down 0.031092 AU146738 Homo sapiens cDNA
FLJ11985 fis, clone 4.255531 1.866771 5.24 Down 0.001003 AF096296 Homo sapiens thymic stroma chemokine-1 precursor, mRNA, complete cds.
/PROD=thymic stroma chemokine-1 precursor /FL=gb:AF142434.1 gb:AF096296.1 gb:AF124601.1 gb:AB010447.1 gb:NM 006072.1 4.075321 1.687619 5.23 Down 0.000791 A1652662 branched chain aminotransferase 1, cytosolic 3.806044 1.418363 5.23 Down 0.010886 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 2.276913 -0.10568 5.21 Down 0.042222 AK025909 Homo sapiens cDNA:
FLJ22256 fis, clone HRCO2860.
3.264799 0.883433 5.21 Down 0.001003 NM_0160 Homo sapiens CGI-146 76 protein (L0051029), mRNA. /PROD=CGI-146 protein /FL=gb:NM 016076.1 gb:AF151964.1 -0.70217 -3.08122 5.2 Down 0.046444 AV735100 ESTs, Weakly similar to SUBFAMILY J
SEQUENCE

CONTAMINATION
WARNING ENTRY
(H.sapiens) 2.28595 -0.08329 5.17 Down 0.001394 BE504838 ESTs 0.424388 -1.93597 5.13 Down 0.039624 NM_0024 Homo sapiens myelin 33 oligodendrocyte glycoprotein (MOG), mRNA. /PROD=myelin oligodendrocyte glycoprotein /FL=gb:U18798.1 gb:U64564.1 gb:NM_002433.1 5.450694 3.100148 5.1 Down 0.000281 AF095771 Homo sapiens PTH-responsive osteosarcoma B1 protein (B1) mRNA, complete cds.
/PROD=PTH-responsive osteosarcoma B1 protein /FL=gb:AF095771.1 2.176455 -0.15806 5.04 Down 0.000603 AB033281 Homo sapiens BTRCP2 mRNA for F-box and WD-repeats protein isoform C, complete cds. /PROD=F-box and WD-repeats protein beta-TRCP2 isoformC
/FL=gb:AF176022.1 gb:AB033281.1 4.103964 1.770836 5.04 Down 0.000114 AA579773 ESTs 4.970228 2.637225 5.04 Down 0.005013 AF450454 Homo sapiens putative zinc finger protein 42 (ZFP42) mRNA, complete cds. /PROD=putative zinc finger protein 42 /FL=gb:AF450454.1 1.951234 -0.37257 5.01 Down 0.032802 NM_0162 Homo sapiens RAB23, 77 member RAS oncogene family (RAB23), mRNA.
/PROD=RAB23 protein /FL=gb:NM 016277.1 gb:AB03424-4.1 C) H9P39 at 24 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.
EXPRES 24 HRS Ratio Direction adj. p- Gene Gene Name 01 DE value Identifier -3.61621 3.252949 116.9 Up 1.09E-03 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -3.12747 2.81955 61.69 Up 5.09E-04 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H.sapiens) -0.27888 4.796134 33.71 Up 2.25E-04 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -3.26893 1.684842 30.99 Up 1.95E-04 NM_0017 Homo sapiens cytidine 85 deaminase (CDA), mRNA.
/PROD=cytidine deaminase /FL=gb:L27943.1 gb:NM_001785.1 -3.88742 0.690893 23.89 Up 2.83E-03 AA180985 ESTs -1.32044 3.115913 21.65 Up 9.44E-03 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF6-17987.1 gb:AF001900.1 1.168713 5.393939 18.7 Up 4.05E-04 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:BC003079.1 -2.69521 1.432079 17.48 Up 7.06E-05 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 -2.506 1.523432 16.33 Up 2.66E-04 AW19369 DKFZP566K1924 protein -0.10733 3.827249 15.29 Up 5.09E-04 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) -3.62742 0.232422 14.52 Up 1.32E-02 AA772920 ESTs -0.69028 3.077263 13.62 Up 8.84E-04 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DQw1-beta, complete cds.
/FL=gb:NM 002123.1 gb:M1627671 gb:M60028.1 gb:M17564.1 gb:M81141.1 gb:M81140.1 -2.38787 1.308962 12.97 Up 1.24E-02 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) -1.03397 2.650732 12.86 Up 4.41E-04 NM_0030 Homo sapiens secretory 20 granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM 003020.1 -2.05438 1.576656 12.39 Up 1.46E-02 6G29090 ESTs,Tmoderately similar to ALIN HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(11.sapiens) 0.756526 4.2504 11.27 Up 1.84E-04 NM 0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
/PROD=secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:ARS-17987.1 gb:AF001900.1 -1.39784 2.037775 10.82 Up 4.58E-03 BE222344 splicing factor, arginineserine-rich 5 -3.12304 0.280186 10.58 Up 1.86E-02 NM_0180 Homo sapiens 18 hypothetical protein FLJ10191 (FLJ10191), mRNA.
/PROD=hypothetical protein FLJ10191 /FL=gb:NM_018018.1 -2.01579 1.387151 10.58 Up 7.46E-03A1937060 KIAA1151 protein -2.19527 1.171426 10.32 Up 2.14E-03 NM_0133 Homo sapiens EH
33 domain-binding mitotic phosphoprotein (EPSIN), mRNA. /PROD=EH
domain-binding mitotic phosphoprotein /FL=gb:NM 013333.1 gb:AF07372-7.1 -1.16113 2.202477 10.29 Up 8.90E-03 NM_0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB0289-6-7.1 gb:AF121104.1 1.109291 4.425076 9.96 Up 3.72E-04 NM_0053 Homo sapiens 56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36881.1 -1.66608 1.62119 9.76 Up 1.29E-02 6E673445 Homo sapiens chromosome 19, cosmid -2.233 1.032915 9.62 Up 4.41E-03 NM 0148 Homo sapiens KIAA0307 62 gene product (KIAA0307), mRNA. /PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM_014862.1 -3.17826 0.063512 9.46 Up 2.56E-02 A1798098 ESTs 3.042634 6.275162 9.4 Up 1.84E-04 NM 0054 Homo sapiens 42 eomesodermin (Xenopus laevis) homolog (EONIES), mRNA.
/PROD=eomesodermin (Xenopus laevis) homolog /FL=gb:AB031038.1 gb:NNI_005442.1 -2.62694 0.564089 9.13 Up 1.08E-02 NM_0000 Homo sapiens 55 butyrylcholinesterase (BCHE), mRNA.
/PROD=butyrylcholinester ase precursor /FL=gb:M16541.1 gb:M16474.1 gb:NM_000055.1 -3.588 -0.42279 8.97 Up 5.08E-02 A1743261 ESTs -1.75731 1.403919 8.95 Up 3.72E-02 BC008992 Homo sapiens, clone MGC:16926 IMAGE:4183000, mRNA, complete cds.
/PROD=Unknown (protein for MGC:16926) /FL=gb:BC008992.1 -1.56608 1.492453 8.33 Up 3.48E-02 NM_0007 Homo sapiens cytochrome 67 P450, subfamily IIB
(phenobarbital-inducible), polypeptide 6 (CYP2B6), mRNA.
/PROD=cytochrome P450, subfamily 11B(phenobarbital-inducible), polypeptide 6 /FL=gb:NM 000767.2 gb:AF1822T7.1 gb:M29874.1 -1.64839 1.373964 8.12 Up 2.63E-03 NM_0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U61083.1 -2.85395 0.154004 8.04 Up 3.89E-02 AY063451 Homo sapiens D21S2088E mRNA
sequence.

-1.61054 1.380575 7.95 Up 3.70E-03 AW26420 ESTs -3.12055 -0.14826 7.85 Up 3.16E-02 AW78000 ESTs -0.48291 2.475412 7.77 Up 6.01E-04 NM_0002 Homo sapiens ocular 73 albinism 1 (Nettleship-Falls) (0A1), mRNA.
/PROD=ocular albinism 1 (Nettleship-Falls) protein /FL=gb:NM_000273.1 -0.01122 2.91624 7.61 Up 5.09E-04 A1356398 butyrate response factor 2 (EGF-response factor 2) /FL=gb:BC005010.1 gb:NM 006887.1 -0.41404 2.492138 7.5 Up 1.22E-03 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 g b:AF6-17987.1 gb:AF001900.1 -0.04543 2.826104 7.32 Up 8.38E-04 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=KIAA1309 protein 3.061783 5.932074 7.31 Up 2.39E-04 BF057809 ESTs 1.750623 4.603127 7.22 Up 3.35E-04 AA176289 ESTs 1.37261 4.224545 7.22 Up 2.56E-04 BC040605 Homo sapiens, clone IMAGE:5271039, mRNA.
0.194248 2.977224 6.88 Up 1.76E-03 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds. /PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 -2.17012 0.571059 6.69 Up 1.11E-02 AB018580 Homo sapiens mRNA for hluPGFS, complete cds.
/PROD=h1uPGFS
/FL=gb:NM 003739.2 gb:AF1494i6.2 gb:AB018580.1 gb:D17793.1 0.270429 2.998558 6.63 Up 2.01E-02 AF493872 Homo sapiens guanine nucleotide binding protein gamma 4 (GNG4) mRNA, complete cds.
/PROD=guanine nucleotide binding protein gamma 4 /FL=gb:AF493872.1 0.462867 3.188675 6.62 Up 5.56E-03 A1807026 ESTs -2.3444 0.379948 6.61 Up 5.18E-04 AW05758 ESTs -2.06656 0.644395 6.55 Up 1.48E-02 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 -1.88254 0.823917 6.53 Up 5.94E-03 BF694956 Human DNA sequence from clone RP1-187J11 on chromosome 6q11.1-22.33. Contains the gene for a novel protein similar to S. pombe and S.
cerevisiae predicted proteins, the gene for a novel protein similar to protein kinase C inhibitors, the 3 end of the -2.14678 0.54813 6.48 Up 2.59E-02 AA143060 ESTs, Highly similar to 138945 melanoma ubiquitous mutated protein (H.sapiens) -1.09181 1.594917 6.44 Up 2.17E-02 A1653050 ESTs, Weakly similar to HYDRoXYPHENYLPYRU
VATE DIOXYGENASE
(H.sapiens) -1.57619 1.107388 6.42 Up 2.44E-03 AW07279 contactin 1 -1.42062 1.262234 6.42 Up 5.27E-02 A1830490 glycerol kinase -1.51992 1.159662 6.41 Up 4.58E-03 AA460960 H.sapiens mRNA (clone ICRFp507L1876) 0.828954 3.501807 6.38 Up 9.79E-04 AK026659 Homo sapiens cDNA:
FLJ23006 fis, clone LNG00414.
0.040412 2.69519 6.3 Up 3.16E-04 AA960844 Homo sapiens, clone IMAGE:4081483, mRNA
-0.0881 2.555378 6.25 Up 1.84E-04 AL565745 ESTs, Weakly similar to 2108402A carnitine palmitoyltransferase 1 (H.sapiens) -0.66924 1.971531 6.24 Up 1.10E-02 A1986120 latent transforming growth factor beta binding protein 1 /FL=gb:M34057.1 gb:NM_000627.1 -1.25121 1.36043 6.11 Up 8.84E-04 R62432 Cluster Incl.
R62432:yg52e11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-36023 /clone end=3 /gb=R2432 /g1=834311 /ug=Hs.12321 /len=487 1.285793 3.892769 6.09 Up 1.84E-04 A1949827 ESTs -1.4606 1.131857 6.03 Up 1.46E-03 AW07210 Homo sapiens mRNA;
2 cDNA DKFZp434H205 (from clone DKFZp434H205) 1.037668 3.589262 5.86 Up 3.89E-04 R40892 ESTs -2.13754 0.412333 5.86 Up 2.35E-02 BF000203 ESTs 1.470195 4.017332 5.84 Up 1.93E-04 A1676059 ESTs 0.780689 3.30524 5.75 Up 2.66E-04 A1016316 ESTs -1.41031 1.100005 5.7 Up 2.17E-02 A1832477 serologically defined colon cancer antigen 43 -0.68225 1.819364 5.66 Up 3.04E-03 N48299 ESTs, Moderately similar to NFY-C (H.sapiens) 0.937118 3.415706 5.57 Up 2.66E-04 AU151342 Homo sapiens cDNA
FLJ12935 fis, clone -0.41626 2.0614 5.57 Up 1.39E-03 BF110534 ESTs 2.167442 4.632856 5.52 Up 2.19E-04 NM_0015 Homo sapiens insulin-like 52 growth factor-binding protein 4 (IGFBP4), mRNA. /PROD=insulin-like growth factor-binding protein 4 /FL=gb:M62403.1 gb:NM 001552.1 -0.46577 1.990737 5.49 Up 1.62E-04 AW05159 ESTs, Moderately similar 1 to unnamed protein product (H.sapiens) -1.98038 0.474231 5.48 Up 1.22E-02 NM_0024 Homo sapiens Musashi 42 (Drosophila) homolog 1 (MSI1), mRNA.
/PROD=Musashi (Drosophila) homolog 1 /FL=gb:AB012851.1 gb:NM_002442.1 0.466394 2.917466 5.47 Up 6.01E-04 NM_0031 Homo sapiens Spi-B
21 transcription factor (Spi-1PU.1 related) (SPIB), mRNA. /PROD=Spi-B
transcription factor (Spi-1PU.1 related) /FL=gb:NM_003121.1 -2.73733 -0.30853 5.38 Up 1.36E-03 L41944 Homo sapiens interferon receptor ifnar2-1 (splice variant IFNAR2-1) mRNA, complete cds.
/PROD=interferon receptor /FL=gb:NM 000874.1 gb:L41944.71 0.923781 3.31197 5.23 Up 2.23E-04 8E897866 ESTs 1.198446 3.56619 5.16 Up 3.79E-03 BG28379 ESTs 0.013383 2.37551 5.14 Up 7.45E-03 L10374 Human (clone CTG-A4) mRNA sequence.
-1.39667 0.965049 5.14 Up 2.75E-03 A1018174 ESTs -3.38515 -1.06056 5.01 Up 3.31E-02 NM 1723 Homo sapiens putative 68 protein LG30 (G30), mRNA. /PRODz--putative protein LG30 /FL=gb:AY138548.1 gb:NM_172368.1 3.409815 -1.99672 42.42 Down 8.38E-04 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM 016588.1 gb:BC0026-8-3.1 gb:AF136631.1 4.092731 -0.75499 28.79 Down 3.57E-04 AL513917 solute carrier family 16 (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 5.388254 0.591477 27.8 Down 4.11E-05 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 2.306225 -2.24414 23.43 Down 1.14E-03 AW44476 ESTs 2.306111 -1.93483 18.91 Down 7.20E-04 A1632223 hypothetical protein DKFZp434F2322 3.025351 -1.21304 18.87 Down 6.42E-03 AW59092 ESTs 0.757197 -3.40795 17.94 Down 7.19E-03 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M8394171 gb:AF213459.1 0.959227 -3.03425 15.93 Down 1.27E-02 AB033831 Homo sapiens hSCDGF
mRNA for spinal cord-derived growth factor, complete cds.
/PROD=spinal cord-derived growth factor /FL=gb:NM 016205.1 gb:AB0338-3-1.1 gb:AF091434.1 gb:AF244813.1 4.505436 0.524918 15.79 Down 1.36E-04 W57613 ESTs 0.942774 -2.97701 15.13 Down 8.44E-04 AW95778 ESTs, Weakly similar to 6 S51797 vasodilator-stimulated phosphoprotein (H.sapiens) 1.1136 -2.73154 14.37 Down 1.61E-02 Z70519 H.sapiens FASApo 1 mRNA for FAS soluble protein (clone FAS
Exo4Del). /PROD=FAS
soluble protein 1.389794 -2.42829 14.1 Down 1.11E-02 BG49869 ESTs 1.312148 -2.42325 13.32 Down 5.09E-04 U32500 Human type 2 neuropeptide Y receptor mRNA, complete cds.
/PROD=type 2 neuropeptide Y receptor /FL=gb:U42766.1 gb:U36269.1 gb:U32500.1 2.62025 -1.04008 12.64 Down 1.04E-03 AA625683 ESTs 3.268087 -0.32148 12.04 Down 1.86E-04 AF345910 Homo sapiens NYD-SP14 mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 4.152765 0.57732 11.92 Down 3.06E-04 AW00317 stanniocalcin 1 6.777916 3.231028 11.69 Down 3.37E-05 U15174 Homo sapiens BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus El B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb :U15-174 .1 1.143234 -2.39818 11.64 Down 6.01E-04 BF437711 ESTs 2.36447 -1.1716 11.6 Down 3.57E-04 NM_0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 4.285883 0.804811 11.17 Down 3.89E-04 AL038787 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 4 5.023981 1.567701 10.98 Down 2.66E-04 NM_0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.
/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S7359171 2.590871 -0.83277 10.73 Down 2.00E-03 NM_0165 Homo sapiens TBX3-iso 69 protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF21670.1 2.332751 -1.07983 10.65 Down 2.06E-02 NM_0000 Homo sapiens cyclin-77 dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), mRNA. /PROD=cyclin-dependent kinase inhibitor 2A (melanoma,p16, inhibits CDK4) /FL=gb:NM 000077.1 gb:L27211.-1-1.577138 -1.83389 10.64 Down 3.70E-03 M15329 Human interleukin 1-alpha (IL1A) mRNA, complete cds. /PROD=interleukin 1-alpha /FL=gb:M15329.1 0.831091 -2.57623 10.61 Down 1.77E-02 NM_1530 Homo sapiens 36 hypothetical protein FLJ32239 (FLJ32239), mRNA.
/FL=gb:NM_153036.1 2.350127 -1.04844 10.55 Down 2.83E-03 AK026106 Homo sapiens cDNA:

FLJ22453 fis, clone HRC09679, highly similar to AF059516 Homo sapiens tolloid-like 2 protein (TLL2) mRNA.
4.927935 1.558948 10.33 Down 6.84E-04 J05008 Homo sapiens endothelin-1 (EDN1) gene, complete cds /FL=gb:NM_001955.1 2.951696 -0.34119 9.8 Down 5.52E-04 AB019562 Homo sapiens mRNA
expressed only in placental villi, clone SMAP41.
-0.42962 -3.66853 9.44 Down 3.14E-02 D28364 Human mRNA for annexin II, 5UTR (sequence from the 5cap to the start codon).
3.030236 -0.19682 9.36 Down 3.06E-04 AA812232 upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S7359171 4.528627 1.33908 9.12 Down 1.86E-04 NM_0031 Homo sapiens 55 stanniocalcin 1 (STC1), mRNA.
/PROD=stanniocalcin 1 /FL=gb:U25997.1 gb:NM 003155.1 gb:U46-768.1 2.660133 -0.51613 9.04 Down 3.37E-05 AF277174 Homo sapiens PNAS-137 mRNA, complete cds.
/PROD=PNAS-137 /FL=gb:AF277174.1 2.422113 -0.74259 8.97 Down 6.51E-03 AL544576 ESTs 3.806044 0.684261 8.7 Down 3.17E-04 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 3.953402 0.872354 8.46 Down 1.12E-03 BC005369 Homo sapiens, chromosome 1 open reading frame 12, clone MGC:12484, mRNA, complete cds.
/PROD=chromosome 1 open reading frame 12 /FL=gb:AF277176.1 gb:NM 022051.1 gb:AF09245.1 gb:BC005369.1 3.437271 0.406885 8.17 Down 1.28E-04 AB029025 Homo sapiens mRNA for KIAA1102 protein, partial cds. /PROD=KIAA1102 protein 2.469646 -0.53314 8.02 Down 1.95E-03 N76327 ESTs, Highly similar to 1011297A transferrin receptor (H.sapiens) 4.255531 1.305501 7.73 Down 2.22E-03 AF096296 Homo sapiens thymic stroma chemokine-1 precursor, mRNA, complete cds.
/PROD=thymic stroma chemokine-1 precursor /FL=gb:AF142434.1 gb:AF096296.1 gb:AF124601.1 gb:AB010447.1 gb:NM_006072.1 1.609384 -1.3385 7.72 Down 3.57E-04 BC005961 Homo sapiens, parathyroid hormone-like hormone, clone MGC:14611, mRNA, complete cds.
/PROD=parathyroid hormone-like hormone /FL=gb:BC005961.1 5.356771 2.475735 7.37 Down 2.39E-04 W92036 ESTs 4.055862 1.176103 7.36 Down 1.54E-04 AK026815 Homo sapiens cDNA:
FLJ23162 fis, clone LNG09734.
4.782763 1.926881 7.24 Down 2.56E-04 NM_0041 Homo sapiens 99 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II (P4HA2), mRNA.
/PROD=procollagen-proline, 2-oxoglutarate4-dioxygenase (proline 4-hydroxylase), alpha polypeptidell /FL=gb:NM_004199.1 gb:U904 4.749034 1.911794 7.15 Down 6.01E-04 NM_0021 Homo sapiens 3-hydroxy-30 3-methylglutaryl-Coenzyme A synthase 1 (soluble) (HMGCS1), mRNA. /PROD=3-hydroxy-3-methylgiutaryl-Coenzyme A synthase 1(soluble) /FL=gb:NM 002130.1 gb125798.i gb:BC000297.1 4.501184 1.674786 7.09 Down 3.37E-05 AK000162 Homo sapiens cDNA
FLJ20155 fis, clone C0L08754, highly similar to ACSA ECOLI
ACETYL-COENZYME A
SYNTHETASE.
4.103964 1.279587 7.08 Down 1.86E-04 M579773 ESTs 5.294065 2.498324 6.94 Down 3.17E-04 AF279899 Homo sapiens PNAS-145 mRNA, complete cds.
/PROD=PNAS-145 /FL=gb:U03105.1 gb:NM 006813.1 gb:AF09899.1 6.179917 3.394324 6.9 Down 2.56E-04 NM_0001 Homo sapiens glucan 58 (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV) (GBE1), mRNA.
/PROD=glucan (1,4-alpha-), branching enzyme 1(glycogen branching enzyme) /FL=gb:L07956.1 gb:NM_000158.1 3.880272 1.125517 6.75 Down 2.25E-04 NM 0025 Homo sapiens natriuretic 21 peptide precursor B
(NPPB), mRNA.
/PROD=natriuretic peptide precursor B
/FL=gb:NM 002521.1 g b:M252961 1.075159 -1.64214 6.58 Down 2.88E-03J03580 Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 0.031255 -2.68323 6.56 Down 1.26E-02 AU142380 Homo sapiens cDNA
FLJ34825 fis, clone NT2NE2008785, weakly similar to ANTER-SPECIFIC PROLINE-RICH PROTEIN APG.
5.252439 2.540223 6.55 Down 1.93E-04 NM 0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb:L19182.7I
1.58166 -1.12925 6.55 Down 3.72E-02 AF207990 Homo sapiens fer-1 like protein 3 (FER1L3) mRNA, complete cds.
/PROD=fer-1 like protein 3 /FL=gb:AF207990.1 3.732985 1.022527 6.55 Down 8.08E-04 A1459194 early growth response 1 6.1137 3.411176 6.51 Down 2.56E-04 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb119182.i 4.507212 1.810296 6.48 Down 1.84E-04 AW19694 ESTs 2.770179 0.094942 6.39 Down 7.20E-04 AK000345 Homo sapiens cDNA
FLJ20338 fis, clone HEP12179.
4.633038 1.983552 6.27 Down 5.56E-04 NM_0169 Homo sapiens NADPH
31 oxidase 4 (NOX4), mRNA.
/PROD=NADPH oxidase 4 /FL=gb:AF261943.1 gb:NM_016931.1 gb:AF254621.1 gb:AB041035.1 5.099016 2.450575 6.27 Down 4.88E-04 NM_0181 Homo sapiens 92 hypothetical protein FLJ10718 (FLJ10718), mRNA.
/PROD=hypothetical protein FLJ10718 /FL=gb:NM 018192.1 3.41866 0.772516 6.26 Down 1.05E-03 AA149250 ESTs, Weakly similar to PROTEIN PRECURSOR
(R.norvegicus) 4.506475 1.891343 6.13 Down 2.83E-04 A1300520 stanniocalcin 1 /FL=gb:U25997.1 gb:NM 003155.1 gb:U46768.1 0.060743 -2.53505 6.05 Down 3.08E-02 NM 0147 Homo sapiens zinc finger 95 homeobox 1B (ZFHX1B), mRNA. /PROD=zinc finger homeobox 18 /FL=gb:NM 014795.1 gb:AB011141.1 1.470435 -1.11845 6.02 Down 1.04E-03 L49506 Homo sapiens cyclin G2 mRNA, complete cds.
/PROD=cyclin G2 /FL=gb:L49506.1 7.564809 4.992443 5.95 Down 2.36E-04 M83248 Human nephropontin mRNA, complete cds.
/PROD=nephropontin /FL=gb:M83248.1 3.508683 0.95049 5.89 Down 3.89E-04 AK027231 Homo sapiens cDNA:
FLJ23578 fis, clone LNG12709.
3.543738 0.987655 5.88 Down 4.67E-04 NM_0019 Homo sapiens endothelin 55 1 (EDN1), mRNA.
/PROD=endothelin 1 /FL=gb:NM_001955.1 0.279226 -2.24474 5.75 Down 3.73E-02 AF278532 Homo sapiens beta-netrin mRNA, complete cds.
/PROD=beta-netrin /FL=gb:AF119916.1 gb:AF297711.1 gb:NM 021229.1 gb:AFZ78532.1 1.771584 -0.72454 5.64 Down 1.63E-03 B1254089 Homo sapiens full length insert cDNA clone 5.450694 2.958035 5.63 Down 1.84E-04 AF095771 Homo sapiens PTH-responsive osteosarcoma 61 protein (B1) mRNA, complete cds.
/PROD=PTH-responsive osteosarcoma B1 protein /FL=gb:AF095771.1 2.648874 0.166558 5.59 Down 1.84E-04 AW00753 Human insulin-like growth 2 factor binding protein 5 (IGFBP5) mRNA
4.420733 1.940312 5.58 Down 1.95E-04 NM_0036 Homo sapiens basic helix-70 loop-helix domain containing, class B, 2 (BHLHB2), mRNA.
/PROD=differentiated embryo chondrocyte expressed genel /FL=gb:AB004066.1 gb:NM_003670.1 1.659275 -0.81556 5.56 Down 6.51E-03 L16895 Human lysyl oxidase (LOX) gene, exon 7 3.334996 0.86328 5.55 Down 8.21E-04 R40917 phosphodiesterase 4D, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E3) /FL=gb:L20969.1 gb:NM_006203.1 gb:U02882.1 2.886643 0.429864 5.49 Down 1.63E-03 NM_0220 Homo sapiens G protein-36 coupled receptor, family C, group 5, member C
(GPRC5C), transcript variant 1, mRNA.
/PROD=G protein-coupled receptor, family C, group 5,member C, isoform a, precursor /FL=gb:AF207989.1 gb:NM_022036.1 5.319714 2.870709 5.46 Down 1.84E-04 AL117352 Human DNA sequence from clone RP5-876810 on chromosome 1q42.12-43. Contains the 3 end of the GNPAT gene for glyceronephosphate 0-acyltransferase (DHAPAT, DAPAT, dihydroxyacetone phosphate acyltransferase, EC
2.3.1.42), the gene for a novel protei...
5.398488 2.949509 5.46 Down 3.37E-05 NM_0011 Homo sapiens alpha-34 fetoprotein (AFP), mRNA.
/PROD=alpha-fetoprotein /FL=gb:NM 001134.1 gb:J00077.1 3.904705 1.46154 5.44 Down 4.81E-04 NM_0070 Homo sapiens a 38 disintegrin-like and metal loprotease (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2) (ADAMTS5), mRNA.
/PROD=a disintegrin and metalloprotease withthrombospondin motifs-5 preproprotein /FL=gb:NM 007038.1 gb:AF1420 -2.001263 -0.41849 5.35 Down 2.30E-03 U46768 Human stanniocalcin mRNA, complete cds.
/PROD=stanniocalcin /FL=gb:U25997.1 gb:NM 003155.1 gb:U46.768.1 5.095598 2.679984 5.34 Down 3.06E-04 NM_0055 Homo sapiens insulin 42 induced gene 1 (INSIG1), mRNA. /PROD=insulin induced gene 1 /FL=gb:NM_005542.1 0.899011 -1.48844 5.23 Down 7.45E-03 NM_0028 Homo sapiens parathyroid 20 hormone-like hormone (PTHLH), mRNA.
/PROD=parathyroid hormone-like hormone /FL=gb:J03802.1 gb:NM_002820.1 2.933166 0.546859 5.23 Down 1.54E-04 NM_0057 Homo sapiens lipoma 80 HMGIC fusion partner (LHFP), mRNA.
/PROD=lipoma HMGIC
fusion partner /FL=gb:NM 005780.1 gb:AF0988-67.1 2.454314 0.080053 5.18 Down 3.37E-05 NM_0132 Homo sapiens fibronectin 81 leucine rich transmembrane protein 3 (FLRT3), mRNA.
/PROD=fibronectin leucine rich transmembrane protein3 /FL=gb:AF169677.1 gb:NM_013281.1 4.981033 2.626098 5.12 Down 1.14E-03 NM_0006 Homo sapiens serine (or 02 cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA.
/PROD=serine (or cysteine) proteinase inhibitor, cladeE (nexin, plasminogen activator inhibitor type 1), membe 5.209052 2.857021 5.11 Down 2.66E-04 A1754404 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 /FL=gb:NM 000935.1 gb:U8457371 7.251816 4.921229 5.03 Down 5.18E-04 NM 0007 Homo sapiens annexin Al 00 (ANXA1), mRNA.
/PROD=annexin I
/FL=gb:BC001275.1 gb:NM_000700.1 D) II.9P39 at 30 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.

EXPRES 30 HR DE Ratio Direction adj. p- Gene Gene Name 01 value Identifier -3.61621 3.085829 104.12 Up 1.25E-03 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -3.12747 2.633618 54.23 Up 5.47E-04 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H sapiens) -3.26893 2.480892 53.81 Up 3.52E-04 NM_0017 Homo sapiens cytidine 85 deaminase (CDA), mRNA.
/PROD=cytidine deaminase /FL=gb:L27943.1 gb:NM_001785.1 -3.62742 1.93392 47.22 Up 3.24E-03 AA772920 ESTs -0.27888 4.672575 30.94 Up 2.20E-04 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -3.88742 0.719139 24.36 Up 2.32E-03 AA180985 ESTs 1.168713 5.535315 20.63 Up 4.09E-04 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF0788Z15.1 gb:BC003079.1 -2.05438 2.234331 19.54 Up 9.02E-03 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H sapiens) -0.69028 3.350018 16.45 Up 8.76E-04 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DQw1-beta, complete cds.
/FL=gb:NM_002123.1 -1.32044 2.675867 15.96 Up 1.31E-02 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 3.042634 6.981126 15.33 Up 2.51E-04 NM 0054 Homo sapiens 42 eornesodermin (Xenopus laevis) homolog (EOMES), mRNA.
/PROD=eomesodermin (Xenopus laevis) homolog IFL=gb:AB031036.1 gb:NMõ.005442,1 -0.41626 3.4773 14.86 Up 5.42E-04 BF110534 ESTs -2.69521 1.031628 13.24 Up 7.80E-05 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 -2.38787 1.314022 13.01 Up 1.37E-02 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) -2.45311 1.22951 12.84 Up 4.18E-02 BC042378 Homo sapiens, clone IMAGE:5277693, mRNA.
-0.68225 2.956253 12.45 Up 2.72E-04 N48299 ESTs, Moderately similar to NFY-C (H.sapiens) -0.18256 3.454591 12.44 Up 2.72E-04 A1583173 major histocompatibility complex, class II, DQ beta -0.26005 3.330481 12.05 Up 1.37E-03 R72286 microfibrillar-associated protein 4 -1.75731 1.805232 11.81 Up 2.70E-02 BC008992 Homo sapiens, clone MGC:16926 IMAGE:4183000, mRNA, complete cds.
/PROD=Unknown (protein for MGC:16926) /FL=gb:BC008992.1 -3.76077 -0.22572 11.59 Up 2.57E-02 A1040305 ESTs 0.758526 4.287575 11.56 Up 4.69E-04 NM 0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
/PROD:zseereted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF617987.1 gb:AF001900.1 -1.61054 1.918985 11.55 Up 2.71E-03 AW26420 ESTs -2.30432 1.221219 11.52 Up 3.31E-02 BC017958 Homo sapiens, clone IMAGE:4607409, mRNA.
-1.16113 2.306767 11.06 Up 6.77E-03 NM_0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB028967.1 gb:AF121104.1 -1.03397 2.369328 10.58 Up 5.45E-04 NM_0030 Homo sapiens secretory 20 granule, neuroendocrine protein 1 (7B2 protein) (SGNE1), mRNA.
/PROD=secretory granule, neuroendocrine protein 1 (7B2protein) /FL=gb:BC005349.1 gb:NM_003020.1 -0.80043 2.583204 10.44 Up 9.08E-04 D87811 Homo sapiens mRNA for GATA-6, complete cds.
/PROD=GATA-6 IFL=gb:U66075.1 ob:NM 005257,1 gb:D87-811,1 -1.16952 2.129685 9.84 Up 4.80E-02 NM_0013 Homo sapiens disabled 43 (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) (DAB2), mRNA. /PROD=disabled (Drosophila) homolog 2 /FL=gb:U39050.1 gb:NM 001343.1 gb:U5446.1 gb:BC003064.1 -0.10733 3.157091 9.61 Up 2.31E-03 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) -0.70855 2.511903 9.32 Up 2.13E-03 AI917371 ESTs 1.109291 4.227073 8.68 Up 1.36E-03 NM_0053 Homo sapiens 56 lymphocyte-specific protein tyrosine kinase (LCK), mRNA.
/PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M36-881.1 -1.39784 1.697082 8.54 Up 1.04E-02 BE222344 splicing factor, arginineserine-rich 5 -2.23133 0.840905 8.41 Up 8.31E-03 AA044140 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta -1.64839 1.38707 8.2 Up 2.49E-03 NM_0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U6108371 0.502333 3.532743 8.17 Up 1.88E-03 AF211891 Home sapiens Mix-like homeobox protein 1 (WW1) mRNA, complete cds.
IPROD=Mix-like homeobox protein 1 IFL=gb:AF211891.1 1.470195 4.487924 8.1 Up 4.48E-04 A1676059 ESTs -1.66608 1.305765 7.85 Up 1.61E-02 6E573445 Homo sapiens chromosome 19, cosmid -2.17012 0.717557 7.4 Up 8.40E-03 AB018580 Homo sapiens mRNA for hluPGFS, complete cds.
/PROD=h1uPGFS
/FL=gb:NM 003739.2 gb:AF1494-1-6.2 gb:AB018580.1 gb:D17793.1 -3.17826 -0.30252 7.34 Up 3.88E-02 A1798098 ESTs -2.62694 0.235765 7.27 Up 1.61E-02 NM_0000 Homo sapiens 55 butyrylcholinesterase (BCHE), mRNA.
/PROD=butyrylcholinester ase precursor /FL=gb:M16541.1 gb:M16474.1 gb:NM_000055.1 -2.13754 0.709615 7.2 Up 1.59E-02 BF000203 ESTs 1.750623 4.592477 7.17 Up 3.86E-04 AA176289 ESTs 0.923781 3.753533 7.11 Up 5.45E-04 BE897866 ESTs -1.51616 1.306468 7.07 Up 3.70E-03 AJ272267 Homo sapiens partial mRNA for choline dehydrogenase (chdh gene). /PROD=choline dehydrogenase -3.12304 -0.30584 7.05 Up 3.13E-02 NM_0180 Homo sapiens 18 hypothetical protein FLJ10191 (FLJ10191), mRNA.
/PROD=hypothetical protein FLJ10191 /FL=gb:NM_018018.1 0.828954 3.642692 7.03 Up 1.53E-03 AK026659 Homo sapiens cDNA:
FLJ23006 fis, clone LNG00414.
3.061783 5.870643 7.01 Up 1.32E-04 BF057809 ESTs -0.20066 2.598953 6.96 Up 8.90E-04 NM_0016 Homo sapiens acyl-09 Coenzyme A
dehydrogenase, shortbranched chain (ACADSB), nuclear gene encoding mitochondrial protein, mRNA.
/PROD=acyl-Coenzyme A
dehydrogenase, shortbranchedchain precursor /FL=gb:U12778.1 gb:NM_001609.1 -0.5777 2.186912 6.8 Up 2.34E-03 BC036592 Homo sapiens, clone IMAGE:4814184, mRNA.
-2.20139 0.556645 6.76 Up 1.88E-03A1913749 ESTs -2.19527 0.555455 6.73 Up 3.02E-03 NM_0133 Homo sapiens EH
33 domain-binding mitotic phosphoprotein (EPSIN), mRNA. /PROD=EH
domain-binding mitotic phosphoprotein /FL=gb:NM 013333.1 gb:AF0737-2-7.1 0.194248 2.884093 6.45 Up 3.02E-03 U07236 Human mutant lymphocyte-specific protein tyrosine kinase (LCK) mRNA, complete cds. /PROD=Iymphocyte-specific protein tyrosine kinase /FL=gb:U07236.1 gb:NM 005356.1 gb:M38-881.1 -1.4606 1.195222 6.3 Up 1.88E-03 AW07210 Homo sapiens mRNA;
2 cDNA DKEZp434H205 (from clone DKEZp434H205) -0.41404 2.208672 6.16 Up 1.88E-03 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:ART17987.1 gb:AF001900.1 -1.98038 0.627155 6.09 Up 9.18E-03 NM_0024 Homo sapiens Musashi 42 (Drosophila) homolog 1 (MSII), mRNA.
/PROD=Musashi (Drosophila) homolog 1 /FL=gb:AB012851.1 gb:NM_002442.1 -3.12055 -0.51875 6.07 Up 4.51E-02 AW78000 ESTs 2,428694 5.011314 5.99 Up 8.90E-04 8E510715 fibroblast growth factor 4 (heparin secretory transforming protein I, Kaposi sarcoma oncogene) IFL=gb;IV117446.1 gb:WM_002007.1 -2.06656 0.511613 5.97 Up 1.81E-02 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 -1.18368 1.389404 5.95 Up 1.12E-03 AB011152 Homo sapiens mRNA for KIAA0580 protein, partial cds. /PROD=KIAA0580 protein 0.884916 3.44953 5.92 Up 2.61E-04 NM_0001 Homo sapiens cytochrome 04 P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile) (CYP1I31), mRNA.
/PROD=cytochrome P450, subfamily I (dioxin-inducible),polypeptide 1 /FL=gb:U03688.1 gb:NM_000104.2 1.380324 3.936779 5.88 Up 4.48E-04 NM_0068 Homo sapiens histamine 95 N-methyltransferase (HNMT), mRNA.
/PROD=histamine N-methyltransferase /FL=gb:NM 006895.1 gb:D16224.1 gb:U08092.1 0.937118 3.476237 5.81 Up 5.45E-04 AU151342 Homo sapiens cDNA
FLJ12935 fis, clone -2.3444 0.189019 5.79 Up 3.32E-03 AW05758 ESTs -1.09181 1.43832 5.78 Up 2.62E-02 A1653050 ESTs, Weakly similar to HYDRoXYPHENYLPYRU
VATE DIOXYGENASE
(H.sapiens) 0.270429 2.788184 5.73 Up 2.50E-02 AF493872 Homo sapiens guanine nucleotide binding protein gamma 4 (GNG4) mRNA, complete cds.
/PROD=guanine nucleotide binding protein gamma 4 /FL=gb:AF493872.1 2.453593 4.950008 5.64 Up 4.67E-04 NM_0054 Homo sapiens selenoprotein P, plasma, 1 (SEPP1), mRNA.
/PROD=selenoprotein P
precursor /FL=gb:NM 005410.1 -1.88254 0.61166 5.63 Up 6.09E-03 BF694956 Human DNA sequence from clone RP1-187J11 on chromosome 6q11.1-22.33. Contains the gene for a novel protein similar to S. pombe and S.
cerevisiae predicted proteins, the gene for a novel protein similar to protein kinase C inhibitors, the 3 end of the 0.462867 2.940232 5.57 Up 8.05E-03 A1807026 ESTs -0.04543 2.430022 5.56 Up 1.88E-03 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=KIAA1309 protein -0.01122 2.462282 5.55 Up 2.31E-03 A1356398 butyrate response factor 2 (EGF-response factor 2) /FL=gb:BC005010.1 gb:NM_006887.1 1.285793 3.745524 5.5 Up 2.58E-03 A1949827 ESTs 1.37261 3.832097 5.5 Up 4.48E-04 BC040605 Homo sapiens, clone IMAGE:5271039, mRNA.
-0.67823 1.780805 5.5 Up 3.24E-04 AA040057 protocadherin 20 -1.41031 1.030229 5.43 Up 1.98E-02 A1832477 serologically defined colon cancer antigen 43 1.076427 3.500322 5.37 Up 1.17E-03 A1640307 protocadherin 10 -0.35323 2.051621 5.3 Up 2.59E-03 BM66601 Homo sapiens cDNA
0 FLJ23803 fis, clone HEP22811.
0.040412 2.442774 5.29 Up 3.56E-04 AA960844 Homo sapiens, clone IMAGE:4081483, mRNA

-1.51992 0.881919 5.28 Up 6.04E-03 AA460960 H.sapiens mRNA (clone ICRFp507L1876) -2.32443 0.069216 5.25 Up 3.43E-03 BC035759 Homo sapiens, clone IMAGE:5557641, mRNA.
4.072718 6.466193 5.25 Up 1.53E-03 AU144598 cell recognition molecule Caspr2 /FL=gb:AF193613.1 gb:NM_014141.1 0.143628 2.506522 5.14 Up 1.36E-02 AB037763 Homo sapiens mRNA for KIAA1342 protein, partial cds. /PROD=KIAA1342 protein /FL=gb:AF299075.1 -0.46577 1.883396 5.1 Up 6.92E-04 AW05159 ESTs, Moderately similar 1 to unnamed protein product (H.sapiens) 0.780689 3.126868 5.08 Up 7.58E-04 A1016316 ESTs 3.409815 -2.82988 75.57 Down 1.48E-02 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM_016588.1 gb:BC002683.1 gb:AF136631.1 0.757197 -4.3571 34.64 Down 4.81E-03 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M83941.1 gb:AF213459.1 5.388254 0.288621 34.29 Down 4.14E-05 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 4.092731 -0.8862 31.54 Down 7.12E-04 AL513917 solute carrier family 16 (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM 004207.1 2.306111 -2.22732 23.16 Down 8.51E-04 A1632223 hypothetical protein DKFZp434F2322 3.030236 -1.2974 20.08 Down 8.31E-03 AA812232 upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591:71 4.505436 0.504147 16.01 Down 1.23E-04 W57613 ESTs 3.025351 -0.90728 15.27 Down 2.53E-04 AW59092 ESTs 3.268087 -0.54228 14.03 Down 2.76E-05 AF345910 Homo sapiens NYD-mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 2.62025 -1.1154 13.32 Down 1.12E-03 AA625683 ESTs 6.777916 3.123818 12.59 Down 6.00E-05 U15174 Homo sapiens BCL2adenovirus El B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus El B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U1174.1 2.590871 -1.03729 12.36 Down 1.53E-03 NM_0165 Homo sapiens TBX3-iso 69 protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF2167-5-0.1 4.152765 0.533234 12.29 Down 2.53E-04 AW00317 stanniocalcin 1 4.528627 0.921256 12.19 Down 7.80E-05 NM_0031 Homo sapiens 55 stanniocalcin 1 (STC1), mRNA.
/PROD=stanniocalcin 1 /FL=gb:U25997.1 gb:NM_003155.1 gb:U46768.1 1.544409 -1.9767 11.48 Down 4.92E-02 NM_0005 Homo sapiens insulin-like 99 growth factor binding protein 5 (IGFBP5), mRNA. /PROD=insulin-like growth factor binding protein 5 /FL=gb:M65062.1 gb:M62782.1 gb:NM 000599.1 gb:ART55033.1 5.023981 1.530419 11.26 Down 2.80E-04 NM_0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.
/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591-.:1 2.36447 -1.00627 10.34 Down 1.88E-03 NM_0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 4.285883 0.94478 10.13 Down 7.80E-05 AL038787 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 4 4.782763 1.624946 8.92 Down 4.14E-05 NM_0041 Homo sapiens 99 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide It (P4HA2), mRNA.
/PROD=procollagen-proline, 2-oxoglutarate4-dioxygenase (proline 4-hydroxylase), alpha polypeptidell /FL=gb:NM_004199.1 gb:U904 2.660133 -0.48383 8.84 Down 3.01E-04 AF277174 Homo sapiens PNAS-137 mRNA, complete cds.
/PROD=PNAS-137 /FL=gb:AF277174.1 1.99849 -1.11713 8.67 Down 1.48E-02 NM_0023 Homo sapiens lysyl 17 oxidase (LOX), mRNA.
/PROD=lysyl oxidase /FL=gb:AF039291.1 gb:NM 002317.1 gb:M9i17054.1 4.927935 1.83445 8.54 Down 4.77E-04 J05008 Homo sapiens endothelin-1 (EDN1) gene, complete cds /FL=gb:NM_001955.1 5.356771 2.317383 8.22 Down 1.92E-05 W92036 ESTs 3.806044 0.77917 8.15 Down 1.32E-04 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 2.350127 -0.67445 8.14 Down 1.86E-02 AK026106 Homo sapiens cDNA:
FLJ22453 fis, clone HRC09679, highly similar to AF059516 Homo sapiens tolloid-like 2 protein (TLL2) mRNA.
5.450694 2.473087 7.88 Down 2.35E-04 AF095771 Homo sapiens PTH-responsive osteosarcoma B1 protein (B1) mRNA, complete cds.
/PROD=PTH-responsive osteosarcoma B1 protein /FL=gb:AF095771.1 2.208449 -0.76852 7.87 Down 5.20E-03 A1806338 T-box 3 (ulnar mammary syndrome) /FL=gb:AF170708.2 gb:NM_005996.1 2.951696 -0.00873 7.78 Down 4.48E-04 AB019562 Homo sapiens mRNA
expressed only in placental villi, clone SMAP41.
3.953402 0.998843 7.75 Down 2.51E-04 BC005369 Homo sapiens, chromosome 1 open reading frame 12, clone MGC:12484, mRNA, complete cds.
/PROD=chromosome 1 open reading frame 12 /FL=gb:AF277176.1 gb:NM 022051.1 gb:AF2.-29245.1 gb:BC005369.1 4.507212 1.576505 7.62 Down 2.04E-04 AW19694 ESTs 4.055862 1.195121 7.26 Down 5.45E-04 AK026815 Homo sapiens cDNA:
FLJ23162 fis, clone LNG09734.
4.103964 1.24922 7.23 Down 8.28E-05 AA579773 ESTs 2.001263 -0.84882 7.21 Down 3.24E-03 U46768 Human stanniocalcin mRNA, complete cds.
/PROD=stanniocalcin /FL=gb:U25997.1 gb:NM 003155.1 gb:U46-768.1 1.1136 -1.73388 7.2 Down 3.21E-04 Z70519 H.sapiens FASApo 1 mRNA for FAS soluble protein (clone FAS
Exo4Del). /PROD=FAS
soluble protein 2.332751 -0.46123 6.94 Down 1.69E-04 NM 0000 Homo sapiens cyclin-77 dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), mRNA. /PROD=cyclin-dependent kinase inhibitor 2A (melanoma,p16, inhibits CDK4) /FL=gb:NM 000077.1 gb:L272111 5.187988 2.402941 6.89 Down 3.52E-04 AA074145 proline oxidase homolog 4.255531 1.471522 6.89 Down 3.24E-04 AF096296 Homo sapiens thymic stroma chemokine-1 precursor, mRNA, complete cds.
/PROD=thymic stroma chemokine-1 precursor /FL=gb:AF142434.1 gb:AF096296.1 gb:AF124601.1 gb:AB010447.1 gb:NM_006072.1 4.501184 1.72274 6.86 Down 7.80E-05 AK000162 Homo sapiens cDNA
FLJ20155 fis, clone C0L08754, highly similar to ACSA ECOLI
ACETYL-COENZYME A
SYNTHETASE.
2.770179 0.000064 6.82 Down 2.31E-03 AK000345 Homo sapiens cDNA
FLJ20338 fis, clone HEP12179.
6.1137 3.356776 6.76 Down 2.20E-04 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGEBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb:L19182.7f 4.506475 1.751272 6.75 Down 2.53E-04 A1300520 stanniocalcin 1 /FL=gb:U25997.1 gb:NM 003155.1 gb:U46-768.1 3.404056 0.670009 6.65 Down 4.14E-05 A1623211 lymphocyte-specific protein 1 2.469646 -0.26027 6.63 Down 4.40E-03 N76327 ESTs, Highly similar to 1011297A transferrin receptor (H.sapiens) 5.252439 2.542675 6.54 Down 3.24E-04 NM 0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGEBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=g b:NM 001553.1 gb:L19182.1 5.294065 2.607826 6.44 Down 1.45E-03 AF279899 Homo sapiens PNAS-145 mRNA, complete cds.
/PROD=PNAS-145 /FL=gb:U03105.1 gb:NM 006813.1 gb:AF79899.1 1.312148 -1.30796 6.15 Down 2.85E-04 U32500 Human type 2 neuropeptide Y receptor mRNA, complete cds.
/PROD=type 2 neuropeptide Y receptor /FL=gb:U42766.1 gb:U36269.1 gb:U32500.1 6.179917 3.561259 6.14 Down 3.24E-04 NM 0001 Homo sapiens glucan 58 (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV) (GBE1), mRNA.
/PROD=glucan (1,4-alpha-), branching enzyme 1(glycogen branching enzyme) /FL=gb:L07956.1 gb:NM_000158.1 0.959227 -1.64817 6.09 Down 2.57E-02 AB033831 Homo sapiens hSCDGF
mRNA for spinal cord-derived growth factor, complete cds.
/PROD=spinal cord-derived growth factor /FL=gb:NM 016205.1 gb:AB03381.1 gb:AF091434.1 gb:AF244813.1 0.579765 -1.99563 5.96 Down 2.00E-02 A1393930 ESTs 3.508683 0.978051 5.78 Down 4.14E-05 AK027231 Homo sapiens cDNA:
FLJ23578 fis, clone LNG12709.
1.577138 -0.9435 5.74 Down 1.09E-02 M15329 Human interleukin 1-alpha (IL1A) mRNA, complete cds. /PROD=interleukin 1-alpha /FL=gb:M15329.1 2.982965 0.463474 5.73 Down 5.03E-04 AK026829 Homo sapiens cDNA:

FLJ23176 fis, clone LNG10452.
3.86075 1.347537 5.71 Down 7.64E-04 U85995 Cluster Incl.
U85995:Human clone IMAGE-22181 unknown protein mRNA, partial cds /cds=(0,1291) /gb=U85995 /gi=1835749 /ug=Hs.79340 /len=1696 2.64743 0.138623 5.69 Down 2.04E-04 A1702438 ESTs 3.437271 0.928673 5.69 Down 5.45E-04 AB029025 Homo sapiens mRNA for KIAA1102 protein, partial cds. /PROD=K1AA1102 protein 2.886643 0.386181 5.66 Down 1.25E-03 NM_0220 Homo sapiens G protein-36 coupled receptor, family C, group 5, member C
(GPRC5C), transcript variant 1, mRNA.
/PROD=G protein-coupled receptor, family C, group 5,member C, isoform a, precursor /FL=gb:AF207989.1 gb:NM_022036.1 5.099016 2.60798 5.62 Down 4.48E-04 NM_0181 Homo sapiens 92 hypothetical protein FLJ10718 (FLJ10718), mRNA.
/PROD=hypothetical protein FLJ10718 /FL=gb:NM_018192.1 5.807319 3.321529 5.6 Down 3.21E-04 NM_0180 Homo sapiens 04 hypothetical protein FLJ10134 (FLJ10134), mRNA.
/PROD=hypothetical protein FLJ10134 /FL=gb:NM 018004.1 1.659275 -0.80393 5.51 Down 2.08E-03 L16895 Human lystioxidase (LOX) gene, exon 7 2.060071 -0.40069 5.51 Down 5.45E-04 AA004300 hypothetical protein DKFZp566I133 3.094055 0.633797 5.5 Down 6.17E-04 AW18819 tumor necrosis factor, 8 alpha-induced protein 6 /FL=gb:NM_007115.1 1.865674 -0.57364 5.42 Down 1.88E-03 AU156421 Homo sapiens cDNA
FLJ13457 fis, clone 5.207569 2.775215 5.4 Down 1.32E-04 AA083478 Homo sapiens mRNA full length insert cDNA clone 2.322104 -0.10923 5.39 Down 1.89E-03 AW29136 ESTs 3.862686 1.433656 5.39 Down 1.88E-03 NM_0071 Homo sapiens tumor 15 necrosis factor, alpha-induced protein 6 (INFAIP6), mRNA.
/PROD=tumor necrosis factor, alpha-induced protein 6 /FL=gb:NM_007115.1 4.881197 2.470702 5.32 Down 1.33E-03 NM 0019 Homo sapiens enolase 2, 75 (gamma, neuronal) (EN02), mRNA.
/PROD=enolase 2, (gamma, neuronal) /FL=gb:NM 001975.1 gb:BC0027-45.1 gb:M22349.1 5.318139 2.908344 5.31 Down 4.67E-04 U87408 Cluster Incl.
U87408:Human clone IMAGE-74593 unknown protein mRNA, partial cds /cds=(0,1362) /gb=U87408 /gi=1842104 /ug=Hs.79340 /len=1982 3.41866 1.024231 5.26 Down 1.40E-03M149250 ESTs, Weakly similar to PROTEIN PRECURSOR
(R.norvegicus) 2.28595 -0.10789 5.26 Down 1.74E-03 BE504838 ESTs 1.143234 -1.2451 5.24 Down 2.07E-03 BF437711 ESTs 2.164901 -0.22261 5.23 Down 2.00E-03 A1559300 ESTs 0.38149 -2.00456 5.23 Down 1.36E-02 Z25433 H.sapiens protein-serinethreonine kinase gene, complete CDS.
/PROD=protein-serinethreonine kinase /FL=gb:Z25433.1 2.271332 -0.11134 5.22 Down 1.88E-03 NM_0151 Homo sapiens KIAA0633 98 protein (COBL), mRNA.
/PROD=KIAA0633 protein /FL=gb:NM_015198.1 2.933166 0.558335 5.19 Down 1.04E-03 NM_0057 Homo sapiens lipoma 80 HMGIC fusion partner (LHFP), mRNA.
/PROD=lipoma HMGIC
fusion partner /FL=gb:NM 005780.1 gb:AF098867.1 3.77776 1.406437 5.17 Down 3.24E-04 BU729850 hypothetical protein 3.113698 0.751705 5.14 Down 7.12E-04 NM_0021 Homo sapiens insulinoma-96 associated 1 (INSM1), mRNA.
/PROD=insulinoma-associated 1 /FL=gb:NM 002196.1 gb:M931191 7.564809 5.218561 5.09 Down 5.70E-04 M83248 Human nephropontin mRNA, complete cds.
/PROD=nephropontin /FL=gb:M83248.1 5.209052 2.875305 5.04 Down 3.17E-04 A1754404 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 /FL=gb:NM 000935.1 gb:U84573-.7I
1.639038 -0.68383 5 Down 2.00E-03 AW02787 ESTs, Weakly similar to 9 NBHUC8 decorin precursor (H.sapiens) E) H9P39 at 48 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.
EXPRES 48 HRS Ratio Direction adj. p- Gene Gene Name 01 DE value Identifier -3.62742 4.403382 261.52 Up 9.26E-04 AA772920 ESTs -3.26893 4.712617 252.75 Up 7.47E-05 NM_0017 Homo sapiens cytidine 85 deaminase (CDA), mRNA.
/PROD=cytidine deaminase /FL=gb:L27943.1 gb:NM_001785.1 -4.01441 3.67249 206.06 Up 1.83E-04 AB028021 Cluster Incl.
AB028021:Homo sapiens HNF-3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds /cds=(196,1569) /gb=AB028021 /gi=4958949 /ug=Hs.155651 /1en=1944 -4.29896 3.38304 205.36 Up 6.25E-05 AY177407 Homo sapiens nomeobox protein goosecoid mRNA, complete cds.
/PROD=homeobox protein goosecold IFL=gb:AY177407.1 g b:N N1_173849.1 -0.80043 6.55024 163.22 Up 7.98E-05 087611 Homo sapiens mRNA for GATA-6, complete cds.
IPROD=GATA-6 fFL=gb:U66075,1 gb:NIVI 005257,1 gb:D87i311.1 -2.178 4.977566 142.57 Up 5.92E-04 NM_0144 Homo sapiens dickkopf 20 (Xenopus laevis) homolog 4 (DKK4), mRNA. IPROD=dickkopf (Xenopus laevis) hornolog 4 IFL=gb:AB017788.1 gb:AF177397.1 gb:NIVI_014420.1 -3.61621 3.360873 125.98 Up 8.64E-04 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -3.8752 2,947466 113,19 Up 8,92E-05 AB02802 Homo sapiens HNF-1 3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds. 1PROD=nepatocyte nuclear factor-3 beta iFi...-zgb:A8028021.1 gb:NM_021784.1 -0.62093 5.956038 95.47 Up 7.47E-05 NM 0224 Homo sapiens 54 hypothetical protein Fl.-.122252 similar to SRY-box containing gene 17 (FL.J22252), mRNA.
/PROD=hypothetical protein FL-122252 similar to SRY-boxcontaining gene 17 IFL=gb;NM_022454.1 -1.11159 5.388499 90.52 Up 1.05E-04 NM_0038 Homo sapiens fibroblast 67 growth factor 17 (FGF17), mRNA.
IPRODrzfibroblast growth factor 17 IF1.9b:NIO 003867,1 gb:AB009249.1 -3.7558 2.70012 87.79 Up 1.88E-03 AW47365 ESTs -0.83997 5.315997 71.31 Up 2.36E-04 A1821669 ESTs -0.26005 5.721539 63.19 Up 1.82E-04 R72286 microfibrillar-associated protein 4 -1.32044 4.378147 51.93 Up 4.06E-03 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF6-17987.1 gb:AF001900.1 -3.12747 2.481837 48.82 Up 4.18E-04 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H.sapiens) -0.69028 4.779809 44.33 Up 1.82E-04 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DC)wl-beta, complete cds.
/FL=gb:NM 002123.1 gb:M1627671 gb:M60028.1 gb:M17564.1 gb:M81141.1 gb:M81140.1 -4.79201 0.661683 43.83 Up 3.06E-04 NM_0124 Homo sapiens sema 31 domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E
(SEMA3E), mRNA.
/PROD=sema domain, immunoglobulin domain (Ig), shortbasic domain, secreted, (semaphorin) 3E
/FL=gb:NM_012431.1 gb:AB002329.1 -1.55323 3.862277 42.68 Up 1.26E-04 A1821586 ESTs, Moderately similar to JE0284 Mm-1 cell derived transplantability-associated protein lb (H.sapiens) -5.25658 0.098569 40.93 Up 1.11E-03 AW00557 putative 47 kDa protein -2.45311 2.87165 40.08 Up 1.40E-02 BC042378 Homo sapiens, clone IMAGE:5277693, mRNA.
-3.10357 2.19103 39.25 Up 6.25E-05 NM 0014 Homo sapiens forkhead 53 box Cl (FOXC1), mRNA.
/PROD=forkhead box Cl /FL=gb:NM_001453.1 -0.27888 4.97765 38.23 Up 7.98E-05 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -0.81978 4.345795 35.89 Up 3.86E-04 A1824037 ESTs, Weakly similar to AFFINITY
IMMUNOGLOBULIN
EPSILON FC RECEPTOR
(M.musculus) -2.4051 2.697137 34.35 Up 6.25E-05 NM_0210 Homo sapiens 20 F37Esophageal cancer-related gene-coding leucine-zipper motrf (FEZ1), mRNA.
/PROD=F37Esophageal cancer-related gene-codingleucine-zipper motif /FL=gb:AF123659.1 gb:NM_021020.1 0.756526 5.856918 34.31 Up 7.98E-05 NM_0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
/PROD=secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF017987.1 gb:AF001900.1 -0.41626 4.620452 32.82 Up 2.24E-04 BF110534 ESTs 0.502333 5.516306 32.31 Up 1.26E-04 AF211691 Homo sapiens Mix-like homeobox protein 1 (MILD1) mRNA, complete cds, /PROD=Mix-like homeobox protein 1 /FL=gb:AF211891.1 -2.39338 2.604622 31.96 Up 3.59E-03 M17955 Human MHC class II HLA-DQ-beta mRNA, complete cds. /FL=gb:M33907.1 gb:Ml 7955.1 gb:M16996.1 gb:M17563.1 gb:M20432.1 gb:M26042.1 -0.5292 4.348346 29.4 Up 1.25E-03 A1127440 ESTs -4.15276 0.716875 29.24 Up 1.59E-04 AA129444 Homo sapiens mRNA for KIAA1263 protein, partial cds -0.18256 4.556137 26.7 Up 5.90E-05 A1583173 major histocompatibility complex, class 11, DQ beta -3.47945 1.255979 26.64 Up 2.39E-04 NM_0008 Homo sapiens glutathione 54 S-transferase theta 2 (GSTT2), mRNA.
/PROD=glutathione S-transferase theta 2 /FL=gb:L38503.1 gb:BC002415.1 gb:NM_000854.2 -3.39007 1.340459 26.55 Up 9.26E-03 NM 0066 Homo sapiens cell 14 adhesion molecule with homology to Li CAM
(close homologue of L1) (CHL1), mRNA.
/PROD=cell adhesion molecule with homology to L1CAM(close homologue of L1) /FL=gb:AF002246.1 gb:NM_006614.1 -1.61054 3.073011 25.7 Up 6.48E-04 AW26420 ESTs -0.68225 3.994036 25.57 Up 8.92E-05 N48299 ESTs, Moderately similar to NFY-C (H.sapiens) -2.69284 1.94677 24.93 Up 1.03E-02 R33964 Homo sapiens cDNA
FLJ11022 fis, clone -3.3099 1.316389 24.7 Up 4.00E-03 NM_1720 Homo sapiens retinol 37 dehydrogenase 10 (all-trans) (RDH10), mRNA.
/PROD=retinol dehydrogenase 10 /FL=gb:NM 172037.1 gb:AF456765.1 -2.23941 2.381967 24.61 Up 2.32E-03 NM_0054 Homo sapiens sine oculis 13 homeobox (Drosophila) homolog 3 (SIX3), mRNA.
/PROD=sine oculis homeobox (Drosophila) homolog 3 /FL=gb:NM_005413.1 -2.6422 1.964075 24.36 Up 8.92E-05 BF589787 ESTs -2.05438 2.54631 24.26 Up 6.59E-03 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.168713 5.686572 22.91 Up 2.60E-04 NM 0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078811-5.1 gb:BC003079.1 -0.77864 3.712574 22.49 Up 5.77E-04 NM 0220 Homo sapiens reserved 55 (KCNK12), mRNA.
/PROD=tandem pore domain potassium channel THIK-2 /FL=gb:NM_022055.1 gb:AF287302.1 -0.70855 3.762307 22.17 Up 7.67E-04 A1917371 ESTs -2.06656 2.392721 22 Up 2.94E-03 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 3.042634 7.476267 21.61 Up 5.90E-05 NM_0054 Homo sapiens 42 eomesodermin (Xenopus laevis) homolog (EOMES), mRNA.
/PROD=eomesodermin (Xenopus laevis) homolog /FL=gb:AB031038.1 gb:NM_005442.1 -1.28224 3.131936 21.32 Up 2.22E-04 NM 0055 Homo sapiens LIM
68 homeobox protein 1 (LHX1), mRNA.
/PROD=LIM homeobox protein 1 /FL=gb:NM 005568.1 gb:U14755:1 -2.83906 1.564539 21.16 Up 4.15E-04 T15545 ESTs -0.5777 3.802538 20.82 Up 8.57E-04 BC036592 Homo sapiens, clone IMAGE:4814184, mRNA.
-3.88742 0.452273 20.25 Up 2.18E-03 AA180985 ESTs -1.95127 2.384447 20.19 Up 2.26E-03 L12468 Homo sapiens aminopeptidase A mRNA, complete cds.
/PROD=aminopeptidase A
/FL=gb:L12468.1 gb:NM 001977.1 gb1147721.1 -4.63418 -0.31383 19.98 Up 2.41E-02 8F112218 ESTs -2.30432 1.94413 19.01 Up 1.88E-02 BC017958 Homo sapiens, clone IMAGE:4607409, mRNA.
-2.9769 1.2531 18.77 Up 1.55E-02 AW61211 ESTs 0.420056 4.641313 18.65 Up 7.47E-05 NM 0122 Homo sapiens dickkopf 42 (Xenopus laevis) homolog 1 (DKK1), mRNA.
/PROD=dickkopf (Xenopus laevis) homolog 1 /FL=gb:AF177394.1 gb:NM 012242.1 gb:AFT27563.1 -0.41404 3.780442 18.31 Up 4.24E-04 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM_003012.2 gb:AF017987.1 gb:AF001900.1 -2.90798 1.272589 18.13 Up 1.07E-04 NM_0016 Homo sapiens 43 apolipoprotein A-II
(AP0A2), mRNA.
/PROD=apolipoprotein A-ll precursor /FL=gb:M29882.1 gb:NM_001643.1 gb:BC005282.1 -3.84662 0.311955 17.86 Up 2.27E-02 BF445031 ESTs -0.48487 3.656098 17.64 Up 7.98E-05 BG15053 ESTs 0.442286 4.570914 17.49 Up 1.50E-04 NM_0017 Homo sapiens CD48 78 antigen (B-cell membrane protein) (CD48), mRNA.
/PROD=CD48 antigen (B-cell membrane protein) /FL=gb:NM 001778.1 gb:M37766.1 gb:M59904.1 -2.0457 2.013773 16.67 Up 9.72E-04 A1422986 ESTs -1.37391 2.670539 16.5 Up 1.44E-02 NM_0066 Homo sapiens ret finger 05 protein-like 2 (RFPL2), mRNA. /PROD=ret finger protein-like 2 /FL=gb:NM_006605.1 -3.51429 0.527621 16.47 Up 2.50E-03 AA352113 ESTs -0.15629 3.869435 16.29 Up 4.57E-04 A1799018 ESTs -0.81856 3.176308 15.94 Up 8.74E-05 A1129628 ESTs -2.38787 1.575045 15.59 Up 9.00E-03 BC003517 Homo sapiens, clone IMAGE:3542589, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3542589) -1.39784 2.47691 14.67 Up 2.38E-03 6E222344 splicing factor, arginineserine-rich 5 -2.20139 1.663866 14.57 Up 7.98E-05A1913749 ESTs -3.18081 0.676419 14.49 Up 2.33E-04 AW44981 KIAA0918 protein -2.14545 1.70837 14.46 Up 3.27E-03 NM_0158 Homo sapiens 31 acetylcholinesterase (YT
blood group) (ACHE), transcript variant E4-E5, mRNA.
/PROD=acetylcholinestera se P1-linked form precursor /FL=gb:NM_015831.1 -2.233 1.502044 13.32 Up 1.33E-03 NM_0148 Homo sapiens KIAA0307 62 gene product (KIAA0307), mRNA. /PROD=KIAA0307 gene product /FL=gb:AB002305.1 gb:NM_014862.1 -0.21464 3.518576 13.3 Up 5.92E-04 NM_0050 Homo sapiens reelin 45 (RELN), mRNA.

/PROD=reelin /FL=gb:U79716.1 gb:NM_005045.1 -0.96765 2.760723 13.25 Up 1.83E-04 NM_0244 Homo sapiens Wilms 26 tumor 1 (WT1), transcript variant D, mRNA.
/PROD=Wilms tumor 1 isoform D
/FL=gb:NM 024424.1 gb:NM 024426.1 1.076427 4.796662 13.18 Up 6.25E-05 A1640307 protoca-dherin 10 1.197921 4.916826 13.17 Up 6.25E-05 AW15072 hypothetical protein 0.366041 4.082294 13.14 Up 1.82E-04 A1242583 Homo sapiens cDNA
FLJ11550 fis, clone -0.13396 3.581638 13.14 Up 5.99E-04 NM 0062 Homo sapiens platelet-06 derived growth factor receptor, alpha polypeptide (PDGERA), mRNA. /PROD=platelet-derived growth factor receptor, alphapoiypeptide IFL=gh:101.. 006206,1 gb:M21574..1 -2.08299 1.631534 13.13 Up 3.64E-02 NM_0020 Homo sapiens growth 48 arrest-specific 1 (GAS1), mRNA. /PROD=growth arrest-specific 1 /FL=gb:NM_002048.1 gb:L13698.1 0.502235 4.214192 13.1 Up 2.47E-04 NM_0148 Homo sapiens KIAA0878 99 protein (KIAA0878), mRNA. /PROD=KIAA0878 protein /FL=gb:NM 014899.1 gb:AB0206-8-5.1 0.500662 4.2088 13.07 Up 4.57E-04 AB043703 Homo sapiens FZD8 mRNA for seven-transmembrane receptor Frizzled-8, complete cds.
/PROD=seven-transmembrane receptor Frizzled-8 /FL=gb:A6043703.1 -1.80959 1.846066 12.6 Up 2.72E-03 6E447246 KIAA0960 protein 0.804491 4.446299 12.48 Up 2.36E-04 AA583044 bone morphogenetic protein 2 /FL=gb:NM_001200.1 0.937118 4.57509 12.45 Up 7.47E-05 AU151342 Homo sapiens cDNA
FLJ12935 fis, clone 2.428694 6.062052 12.41 Up 7.98E-05 8E510715 fibroblast growth factor 4 (heparin secretory transforming protein 1, Kaposi sarcoma oncogene) /EL=gh:M17446,1 gb:NM_002007.1 -4.25059 -0.61821 12.4 Up 2.17E-02 AL834407 Homo sapiens mRNA;
cDNA DKFZp547H074 (from clone DKFZp547H074).
-2.64131 0.98784 12.37 Up 4.22E-02 AU157303 ESTs 1.370117 4.998653 12.37 Up 2.02E-04 M33653 Human (clones HT-(125,133)) alpha-2 type IV
collagen (COL4A2) mRNA, complete cds.
/PROD=alpha-2 type IV
collagen /FL=gb:M33653.1 -0.05814 3.523836 11.98 Up 5.01E-04 BF308645 KIAA1415 protein 0.85401 4.424822 11.88 Up 3.70E-04 NM 0017 Homo sapiens calcitonin 42 receptor (CALCR), mRNA.
/PROD=calcitonin receptor /FL=gb:AB022177.1 gb:NM 001742.1 gb:U26553.1 gb:U26554.1 -0.4843 3.086083 11.88 Up 1.07E-04 NM_0017 Homo sapiens CD1D
66 antigen, d polypeptide (CD1D), mRNA.
/PROD=CD1D antigen, d polypeptide /FL=gb:NM 001766.1 gb:J04142.1 -3.03319 0.529885 11.82 Up 3.86E-02 A1378026 ESTs -0.45718 3.095926 11.74 Up 2.21E-04 BF939489 glycoprotein M6A
/FL=gb:D49958.1 -1.35345 2.18761 11.64 Up 3.72E-03 AW15757 ESTs, Weakly similar to 1 100331 hypothetical protein KIM0555 (H.sapiens) 1.829497 5.364987 11.6 Up 2.65E-04 AA534817 ESTs, Weakly similar to SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H sapiens) 0.828954 4.325235 11.28 Up 4.08E-04 AK026659 Homo sapiens cDNA:
FLJ23006 fis, clone LNG00414.
-1.68521 1.795916 11.17 Up 5.31E-03 NM_0027 Homo sapiens protease, 70 serine, 2 (trypsin 2) (PRSS2), mRNA.
/PROD=protease, serine, 2 (trypsin 2) /FL=gb:M27602.1 gb:NM_002770.1 -1.75731 1.71717 11.12 Up 2.72E-02 BC008992 Homo sapiens, clone MGC:16926 IMAGE:4183000, mRNA, complete cds.
/PROD=Unknown (protein for MGC:16926) /FL=gb:BC008992.1 -0.33264 3.138536 11.09 Up 2.48E-04 NM_0203 Homo sapiens 53 phospholipid scramblase 4 (L0057088), mRNA.
/PROD=phospholipid scramblase 4 /FL=gb:NM 020353.1 gb:AF19903.1 -2.84061 0.614927 10.97 Up 1.85E-03 A1123532 ESTs -0.11092 3.32528 10.82 Up 1.51E-04 BF591483 ESTs -2.87916 0.555292 10.81 Up 6.20E-03 BF529886 Homo sapiens cDNA
FLJ39329 fis, clone OCBBF2015751.
0.378586 3.8114 10.8 Up 6.60E-05 BF109231 ESTs 0.53123 3.962218 10.79 Up 5.00E-04 BF112171 DKFZP56400423 protein -1.82351 1.607197 10.78 Up 1.13E-03 AA603467 ribosomal protein S11 -2.56291 0.847807 10.63 Up 1.68E-02 8053269 integrin5 alpha 4 (antigen 0 CD49D. alpha 4 subunit of VLA:4 receptor) 0.1187 3.529403 10.63 Up 1.31E-04 N21184 Cluster Incl.
N21184:yx41a1 0.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-264282 /clone_end=3 /gb=N21184 /gi=1126354 /ug=Hs.93605 /len=619 -3.12055 0.266255 10.46 Up 1.87E-02 AW78000 ESTs -0.27888 3.087584 10.31 Up 1.05E-04 NM_0030 Homo sapiens SWISNF
78 related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 (SMARCD3), mRNA. /PROD=SWISNF
related, matrix associated, actindependent regulator of chromatin, subfamily d, member 3 /FL=gb:NM 003078.1 gb 1.223968 4.582504 10.26 Up 1.32E-04 AL574912 ESTs, Weakly similar to serine protease (H sapiens) -0.52859 2.828373 10.25 Up 6.20E-03 AW59061 ESTs -1.20714 2.140319 10.18 Up 1.22E-03 BC042378 Homo sapiens, clone IMAGE:5277693, mRNA.
1.59762 4.944335 10.17 Up 1.33E-03 NM 0186 Homo sapiens core 49 histone macroH2A2.2 (MACROH2A2), mRNA.
/PROD=core histone macroH2A2.2 /FL=gb:AF151534.1 gb:NM_018649.1 -0.75724 2.582097 10.12 Up 5.49E-03 AL445192 Human DNA sequence from clone RP11-269H4 on chromosome 20 Contains the 3 end of the KIAA1415 gene similar to T-Lymphona invasion and metastasis inducing protein 1, ESTs, STSs and GSSs 0.884916 4.219652 10.09 Up 9.57E-05 NM_0001 Homo sapiens cytochrome 04 P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile) (CYP1B1), mRNA.
/PROD=cytochrome P450, subfamily I (dioxin-inducible),polypeptide 1 /FL=gb:U03688.1 gb:NM_000104.2 -2.62694 0.700178 10.04 Up 8.15E-03 NM_0000 Homo sapiens 55 butyrylcholinesterase (BCHE), mRNA.
/PROD=butyrylcholinester ase precursor /FL=gb:M16541.1 gb:M16474.1 gb:NM_000055.1 1.388898 4.709109 9.99 Up 1.48E-04 BE620739 ESTs 0.345528 3.6261,19 9.72 Up 6.25E-05 AW27618 major histocompatibility 6 complex, class II, DO beta 1.563993 4.835093 9.65 Up 7.47E-05 NM_0024 Homo sapiens microsomal 13 glutathione S-transferase 2 (MGST2), mRNA.
/PROD=microsomal glutathione S-transferase 2 /FL=gb:NM_002413.1 gb:U77604.1 0.923781 4.188917 9.61 Up 7.47E-05 BE897866 ESTs -1.64839 1.585806 9.41 Up 1.44E-03 NM_0049 Homo sapiens phorbolin 00 (similar to apolipoprotein B
mRNA editing protein) (DJ742C19.2), mRNA.
/PROD=phorbolin (similar to apolipoprotein B
mRNAediting protein) /FL=gb:NM 004900.1 gb:U61083:1 0.829254 4.053354 9.34 Up 1.19E-04 AV697515 hypothetical protein -0.62897 2.594105 9.34 Up 2.12E-02 A1694545 ESTs 1.040647 4.25749 9.3 Up 6.25E-05 A1348094 K1AA0882 protein -2.10316 1.110711 9.28 Up 1.17E-02H49805 ESTs -0.67823 2.5328 9.26 Up 1.82E-04 AA040057 protocadherin 20 -0.27302 2.923702 9.17 Up 3.58E-04 NM_0142 Homo sapiens interleukin 71 1 receptor accessory protein-like 1 (IL1RAPL1), mRNA. /PROD=interleukin 1 receptor accessory protein-like 1 /FL=gb:AF284435.1 gb:NM 014271.1 gb:AF1-81284.1 0.205308 3.376912 9.01 Up 1.73E-04 BF509230 ESTs -0.13427 3.027131 8.95 Up 1.71E-04 D49958 Homo sapiens mRNA for membrane glycoprotein M6, complete cds.
/PROD=membrane glycoprotein M6 /FL=gb:D49958.1 -0.95386 2.202339 8.91 Up 5.60E-04 AF312769 Homo sapiens cryptic mRNA, complete cds.
/PROD=cryptic /FL=gb:AF312769.1 -1.39976 1.747599 8.86 Up 1.07E-04 NM_0052 Homo sapiens mitogen-04 activated protein kinase kinase kinase 8 (MAP3K8), mRNA.
/PROD=mitogen-activated protein kinase kinase kinase8 /FL=gb:NM 005204.1 gb:D1449771 -1.12824 2.007285 8.79 Up 9.57E-05 AK021452 Homo sapiens cDNA
FLJ11390 fis, clone HEMBA1000561, weakly similar to ZINC FINGER
PROTEIN 91.
4.042679 7.170301 8.74 Up 2.33E-04 NM_0054 Homo sapiens cerberus 1 54 (Xenopus laevis) homolog (cysteine knot superfamily) (CER1), mRNA. /PROD=cerberus 1 /FL=gb:NM_005454.1 2.430238 5.551898 8.7 Up 7.47E-05 NM_0049 Homo sapiens calbindin 1, 29 (28kD) (CALB1), mRNA.
/PROD=calbindin 1 /FL=gb:NM_004929.2 -3.17826 -0.07573 8.59 Up 2.88E-02 A1798098 ESTs 0.424882 3.515001 8.52 Up 1.13E-03 A1692659 heat shock 90kD protein 1, alpha 2.19676 5.285103 8.51 Up 6.25E-05 AW26410 ESTs -1.16113 1.925599 8.5 Up 9.58E-03 NM 0122 Homo sapiens potassium 81 voltage-gated channel, Shal-related subfamily, member 2 (KCND2), mRNA. /PROD=potassium voltage-gated channel, Shal-relatedsubfamily, member 2 /FL=gb:NM 012281.1 gb:AB0289-67.1 gb:AF121104.1 1.071985 4.144927 8.41 Up 9.57E-05 NM_0045 Homo sapiens receptor 60 tyrosine kinase-like orphan receptor 2 (ROR2), mRNA.
/PROD=receptor tyrosine kinase-like orphan receptor 2 /FL=gb:M97639.1 gb:NM_004560.1 1.750623 4.809696 8.33 Up 2.20E-04 M176289 ESTs -1.25995 1.783805 8.25 Up 1.48E-03 AK026607 Homo sapiens cDNA:
FLJ22954 fis, clone KAT09813, highly similar to AF010315 Homo sapiens Pig11 (PIG11) mRNA.
0.828899 3.847136 8.1 Up 6.55E-04 NM_0012 Homo sapiens bone 00 morphogenetic protein 2 (BMP2), mRNA.
/PROD=bone morphogenetic protein 2 precursor /FL=gb:NM_001200.1 1.690321 4.701963 8.06 Up 1.26E-04 NM 0140 Homo sapiens 45 DKFZP564C1940 protein (DKFZP564C1940), mRNA.
/PROD=DKFZP564C1940 protein /FL=gb:BC000424.1 gb:AF131760.1 gb:NM_014045.1 1.979568 4.987789 8.05 Up 7.98E-05 M17565 Human MHC class II DQ-beta associated with DRw6, DQw1 protein, complete cds.
/FL=gb:M17565.1 -0.75007 2.251382 8.01 Up 1.88E-03A1681917 ESTs, Highly similar to CLASS HOMEODOMAIN

(M.musculus) 2.109037 5.094219 7.92 Up 5.90E-05 AW01492 calbindin 1, (28kD) 7 /FL=gb:NM_004929.2 1.380324 4.364081 7.91 Up 2.74E-04 NM 0068 Homo sapiens histamine 95 N-methyltransferase (HNMT), mRNA.
/PROD=histamine N-methyltransferase /FL=gb:NM 006895.1 gb:D1622471 gb:U08092.1 0.143628 3.121397 7.88 Up 7.94E-03 AB037763 Homo sapiens mRNA for KIAA1342 protein, partial cds. /PROD=KIAA1342 protein /FL=gb:AF299075.1 -0.20066 2.775234 7.87 Up 4.95E-04 NM_0016 Homo sapiens acyl-09 Coenzyme A
dehydrogenase, shortbranched chain (ACADSB), nuclear gene encoding mitochondrial protein, mRNA.
/PROD=acyl-Coenzyme A
dehydrogenase, shortbranchedchain precursor /FL=gb:U12778.1 g b:NM_001609.1 -2.16611 0.806244 7.85 Up 2.70E-02 NM_0019 Homo sapiens glutamyl 77 aminopeptidase (aminopeptidase A) (ENPEP), mRNA.
/PROD=glutamyl aminopeptidase (aminopeptidase A) /FL=gb:L12468.1 gb:NM_001977.1 gb:L14721.1 0.007601 2.978021 7.84 Up 3.96E-04 N63706 ESTs 1.186033 4.154093 7.82 Up 1.02E-04 A1627704 ESTs, Weakly similar to T17346 hypothetical protein DKFZp58601624.1 (H.sapiens) 1.207341 4.163803 7.76 Up 7.98E-05 M31213 Human papillary thyroid carcinoma-encoded protein mRNA, complete cds. /FL=gb:M31213.1 0.106425 3.062268 7.76 Up 1.05E-04 NM_0183 Homo sapiens 71 hypothetical protein FLJ11264 (FLJ11264), mRNA.
/PROD=hypothetical protein FLJ11264 /FL=gb:NM_018371.1 1.997597 4.940494 7.69 Up 8.49E-05 BC005997 Homo sapiens, clone MGC:14801, mRNA, complete cds.
/PROD=Unknown (protein for MGC:14801) /FL=gb:BC005997.1 -0.29145 2.648165 7.67 Up 8.78E-04 A1197932 ESTs -1.20098 1.732939 7.64 Up 8.76E-03 NM_0017 Homo sapiens cadherin 4, 94 type 1, R-cadherin (retinal) (CDH4), mRNA.
/PROD=cadherin 4, type 1, R-cadherin (retinal) /FL=gb:L34059.1 gb:NM_001794.1 -0.96106 1.954749 7.55 Up 3.03E-04 AU153412 Homo sapiens cDNA
FLJ13136 fis, clone 4.072718 6.987624 7.54 Up 3.42E-04 AU144598 cell recognition molecule Caspr2 IFL=gb:AF193613.1 gb:NM_014141.1 1.754933 4.669573 7.54 Up 1.40E-04 NM_0132 Homo sapiens fibronectin 31 leucine rich transmembrane protein 2 (FLRT2), mRNA.
/PROD=fibronectin leucine rich transmembrane protein2 /FL=gb:AB007865.1 gb:AF169676.1 gb:NM_013231.1 -2.81405 0.095993 7.52 Up 9.09E-03 A1694325 ESTs -1.80965 1.082014 7.42 Up 2.00E-02 NM_1525 Homo sapiens 06 hypothetical protein FLJ32835 (FLJ32835), mRNA.
/FL=gb:NM_152506.1 0.360809 3.246455 7.39 Up 7.76E-03 N47315 protein kinase C and casein kinase substrate in neurons 1 -0.10733 2.776046 7.38 Up 2.10E-03 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) -1.44407 1.430083 7.33 Up 1.37E-02 U91903 Human Fritz mRNA, complete cds.
/PROD=Fritz /FL=gb:U24163.1 gb:U68057.1 gb:NM 001463.1 gb:U91-903.1 2.383898 5.242759 7.25 Up 9.57E-05 BF476502 hypothetical protein -1.74597 1.112559 7.25 Up 3.28E-02 AW26981 hypothetical protein /FL=gb:NM_022068.1 -2.26295 0.569202 7.12 Up 1.70E-02 A1735586 ESTs -1.6164 1.213758 7.11 Up 2.52E-02X00452 Human mRNA for DC
classll histocompatibility antigen alpha-chain.
/PROD=DC class II
histocompatibility antigenalpha-chain -0.13959 2.687835 7.1 Up 3.70E-04 BG10985 Homo sapiens clone TUA8 Cri-du-chat region mRNA
-0.88175 1.936253 7.05 Up 3.50E-03 A1650874 ESTs -1.37453 1.440655 7.04 Up 1.15E-02 AF126966 Homo sapiens voltage-dependent calcium channel alpha 1G subunit a isoform (CACNA1G) mRNA, complete cds.
/PROD=voltage-dependent calcium channel alpha 1Gsubunit a isoform /FL=gb:AF190860.1 gb:AF126966.1 -3.09265 -0.28152 7.02 Up 9.07E-03 A1093492 ESTs -0.54935 2.252035 6.97 Up 1.12E-03 NM 0068 Homo sapiens guanosine 77 monophosphate reductase (GMPR), mRNA.
/PROD=guanosine monophosphate reductase /FL=gb:M24470.1 gb:NM_006877.1 1.956109 4.750668 6.94 Up 2.21E-04 A1332979 potassium voltage-gated channel, subfamily G, member 1 /FL=gb:NM 002237.1 gb:AF033363.1 -1.26967 1.520668 6.92 Up 7.48E-03 AW16671 KIAA0403 protein -0.23726 2.551912 6.91 Up 3.23E-04 AA912476 Homo sapiens cDNA
FLJ13221 fis, clone 2.093848 4.875184 6.87 Up 5.90E-05 AC004010 Human BAG clone GS1--0.96264 1.812987 6.85 Up 6.20E-03 AB028998 Homo sapiens mRNA for K1AA1075 protein, partial cds. /PROD=K1AA1075 protein -2.33994 0.434528 6.84 Up 3.67E-02 AL134708 ESTs -2.08762 0.681751 6.82 Up 2.01E-02 AF052117 Homo sapiens clone 23809 mRNA sequence.
0.323675 3.088394 6.8 Up 8.50E-03 M32577 Human MHC HLA-DQ
beta mRNA, complete cds. /FL=gb:M32577.1 3.287037 6.047807 6.78 Up 5.77E-04 A1633559 ESTs -2.02151 0.737644 6.77 Up 3.93E-03 BF062244 ESTs -1.66608 1.08864 6.75 Up 1.86E-02 6E673445 Homo sapiens chromosome 19, cosmid 0.449168 3.190138 6.69 Up 1.96E-04A1688418 plexin A2 0.798972 3.539942 6.69 Up 4.35E-04 A1082827 hypothetical protein 0.83572 3.564527 6.63 Up 1.99E-03 N21138 K1AA0878 protein /FL=gb:NM 014899.1 gb:AB0206-85.1 1.231172 3.958844 6.62 Up 2.36E-04A1949419 ESTs -2.31389 0.411671 6.61 Up 1.05E-02 AF302494 Homo sapiens voltage-gated K+ channel subunit MIRP2 (KCNE3) mRNA, complete cds.
/PROD=voltage-gated K+
channel subunit M1RP2 /FL=gb:NM 005472.1 gb:AF07651.1 gb:AF302494.1 1.415513 4.132936 6.58 Up 3.18E-04 A1692703 potassium voltage-gated channel, lsk-related family, member 3 0.631332 3.346113 6.56 Up 5.92E-04A1130705 ESTs, Weakly similar to A46302 PTB-associated splicing factor, long form (H.sapiens) 3.954335 6.666275 6.55 Up 7.98E-05 AB020675 Homo sapiens mRNA for KIAA0868 protein, partial cds. /PROD=KIAA0868 protein /FL=gb:AF193613.1 gb:NM 014141.1 -1.09181 1.620124 6.55 Up 2.00E-02 A1653050 ESTs, VNeakly similar to HYDRoXYPHENYLPYRU

(H.sapiens) 1.888188 4.581731 6.47 Up 3.37E-04 AW34031 ESTs -1.83503 0.855966 6.46 Up 6.85E-03 AA552969 ESTs -2.08627 0.604316 6.46 Up 1.75E-03 N50714 ESTs -1.2719 1.416234 6.44 Up 4.00E-03 NM_0204 Homo sapiens 06 polycythemia rubra vera 1;
cell surface receptor (PRV1), mRNA.
/PROD=polycythemia rubra vera 1; cell surfacereceptor /FL=gb:NM 020406.1 gb:AF1467,T7.1 2.444644 5.126622 6.42 Up 2.48E-04 AA789332 ESTs, Moderately similar to K1AA1215 protein (H.sapiens) -1.10551 1.574234 6.41 Up 1.76E-02 AL136859 Homo sapiens mRNA;
cDNA DKFZp434P1735 (from clone DKFZp434P1735);
complete cds.
/PROD=hypothetical protein /FL=gb:AL136859.1 -1.30127 1.354641 6.3 Up 4.69E-04 A1003579 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 /FL=gb:NM_003042.1 -0.22337 2.432405 6.3 Up 5.31E-03 NM_0218 Homo sapiens phorbolin-22 like protein MDS019 (MDS019), mRNA.
/PROD=phorbolin-like protein MDS019 /FL=gb:AF182420.1 gb:NM_021822.1 -1.25121 1.403996 6.3 Up 1.13E-03 R62432 Cluster Incl.
R62432:yg52e11.s1 Homo sapiens cDNA, 3 end /clone=1MAGE-36023 /clone end=3 /gb=R-6-2432 /gi=834311 /ug=Hs.12321 /len=487 -1.55104 1.102459 6.29 Up 7.99E-04 AU157716 Homo sapiens cDNA
FLJ13585 fis, clone -2.47063 0.175591 6.26 Up 1.53E-02 H09657 ESTs 0.373467 3.018454 6.25 Up 1.79E-03 AU151239 Homo sapiens cDNA
FLJ12927 fis, clone 1.861693 4.496649 6.21 Up 3.70E-04 A1374739 ESTs -1.73396 0.890885 6.17 Up 1.62E-02 AU145336 Homo sapiens cDNA
FLJ11655 fis, clone 1.586056 4.195825 6.1 Up 4.67E-04 Z83851 Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a novel gene, ESTs, GSSs and four putative CpG
islands 0.569298 3.178582 6.1 Up 3.18E-04 NM 0003 Homo sapiens tissue 62 inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), mRNA.
/PROD=tissue inhibitor of metalloproteinase 3precursor /FL=gb:NM 000362.2 gb:U1439471 gb:U67195.1 gb:U02571.1 -2.13754 0.46922 6.09 Up 2.02E-02 BF000203 ESTs 0.013383 2.617624 6.08 Up 5.42E-03 L10374 Human (clone CTG-A4) mRNA sequence.
1.250788 3.85327 6.07 Up 1.09E-04 AF077040 Homo sapiens SIH003 mRNA, complete cds.
/PROD=SIH003 /FL=gb:AF077040.1 -1.09421 1.502221 6.05 Up 2.38E-03 AK023621 Homo sapiens cDNA
FLJ13559 fis, clone PLACE1007852, highly similar to Homo sapiens mRNA for KIAA0878 protein.
0.466394 3.059875 6.04 Up 5.79E-04 NM_0031 Homo sapiens Spi-B
21 transcription factor (Spi-1PU.1 related) (SPIB), mRNA. /PROD=Spi-B
transcription factor (Spi-1PU.1 related) /FL=gb:NM_003121.1 -0.18863 2.401303 6.02 Up 3.85E-03 AV700724 GATA-binding protein 4 /FL=gb:NM 002052.1 gb:L34357.71 gb:D78260.1 =
2.182526 4.77117 6.02 Up 8.49E-05 NM_0040 Homo sapiens dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272 (DMD), transcript variant Dp427p2, mRNA.
/PROD=dystrophin Dp427p2 isoform /FL=gb:NM_004010.1 1.08211 3.666711 6 Up 9.72E-04 AF010314 Homo sapiens Pig10 (PIG10) mRNA, complete cds. /PROD=Pig10 /FL=gb:AF059611.1 gb:AF010314.1 gb:NM 003633.1 gb:BC600418.1 gb:AF005381.1 -1.4606 1.112751 5.95 Up 1.20E-03 AW07210 Homo sapiens mRNA;

on chromosome 6q11.1-22.33. Contains the gene for a novel protein similar to S. pombe and S.
cerevisiae predicted proteins, the gene for a novel protein similar to protein kinase C inhibitors, the 3 end of the -0.68545 1.817815 5.67 Up 5.99E-03 BC035640 Homo sapiens, clone IMAGE:5547405, mRNA.
-1.92555 0.569805 5.64 Up 1.75E-03 BE856597 ESTs 3.313759 5.801354 5.61 Up 1.18E-04 AB020657 Homo sapiens mRNA for KIAA0850 protein, complete cds.
/PROD=KIAA0850 protein /FL=gb:AB020657.1 gb:AF161553.1 gb:AF205218.1 gb:NM_016389.1 4.49505 6.977964 5.59 Up 6.25E-05 AK093435 Homo sapiens cDNA
FLJ36116 fis, clone TESTI2022338.
0.618056 3.100379 5.59 Up 1.33E-04 BG16533 ESTs -1.12392 1.354596 5.57 Up 2.50E-03 T82147 ESTs -1.17289 1.304294 5.57 Up 6.03E-03 AW02598 ESTs, Weakly similar to 0 A47582 B-cell growth factor precursor (H.sapiens) -0.66753 1.784294 5.47 Up 9.05E-04 AF284435 Homo sapiens TIGIRR-2 mRNA, complete cds.
/PROD=TIGIRR-2 /FL=gb:AF284435.1 gb:NM 014271.1 gb:AF181284.1 -0.04543 2.399112 5.44 Up 1.46E-03 AB037730 Homo sapiens mRNA for KIAA1309 protein, partial cds. /PROD=KIAA1309 protein -2.47478 -0.03132 5.44 Up 8.96E-03 NM_1526 Homo sapiens 87 hypothetical protein FLJ33641 (FLJ33641), mRNA.
/FL=gb:NM_152687.1 -1.89695 0.545787 5.44 Up 3.46E-03 ALI 36944 Homo sapiens mRNA;
cDNA DKFZp586J0624 (from clone DKFZp586J0624);
complete cds.
/PROD=hypothetical protein /FL=gb:AF215636.1 gb:NM 014585.1 gb:AF2-31121.1 gb:AF226614.1 g b:AL136944.1 1.095538 3.529324 5.4 Up 1.59E-04 AF319520 Homo sapiens ARG99 mRNA, complete cds.

/PROD=ARG99 /FL=gb:AF319520.1 2.130365 4.562488 5.4 Up 8.49E-05 BC005047 Homo sapiens, clone MGC:12852, mRNA, complete cds.
/PROD=Unknown (protein for MGC:12852) /FL=gb:NM_001946.1 gb:AB013382.1 gb:BC003562.1 gb:BC003143.1 gb:BC005047.1 3.686635 6.118029 5.39 Up 1.82E-04 AF205218 Homo sapiens NS1-binding protein-like protein mRNA, complete cds.
/PROD=NS1-binding protein-like protein /FL=gb:AB020657.1 gb:AF161553.1 gb:AF205218.1 gb:NM_016389.1 1.298769 3.727597 5.38 Up 2.76E-04 A1123815 ESTs 1.182358 3.610132 5.38 Up 1.82E-04 AW27013 Homo sapiens mRNA for 8 KIAA1729 protein, partial cds -1.39667 1.02491 5.36 Up 6.51E-03 A1018174 ESTs -0.47241 1.946888 5.35 Up 6.80E-03 NM_0066 Homo sapiens ret finger 04 protein-like 3 (RFPL3), mRNA. /PROD=ret finger protein-like 3 /FL=gb:NM_006604.1 -0.68921 1.725879 5.33 Up 1.34E-04 NM_0165 Homo sapiens 46 complement C1r-like proteinase precursor, (L0051279), mRNA.
/PROD=complement C1r-like proteinase precursor, /FL=gb:AF178985.1 gb:NM_016546.1 -0.17505 2.238912 5.33 Up 1.05E-04 AA995925 Homo sapiens clone 23741 mRNA sequence -0.20099 2.21229 5.33 Up 1.55E-03 BF984830 retinoic acid induced 1 2.377335 4.79048 5.33 Up 4.69E-04 NM_0053 Homo sapiens hyaluronan 28 synthase 2 (HAS2), mRNA.
/PROD=hyaluronan synthase 2 /FL=gb:U54804.1 gb:NM_005328.1 -0.98665 1.425455 5.32 Up 1.34E-02 NM 0014 Homo sapiens frizzled-63 related protein (FRZB), mRNA. /PROD=frizzled-related protein /FL=gb:U24163.1 gb:U68057.1 gb:NM 001463.1 gb:U91-903.1 2.264046 4.672118 5.31 Up 1.25E-04 AL049589 Human DNA sequence from clone 570L12 on chromosome Xq13.1-21.1.
Contains the PGK1 gene for phosphoglycerate kinase 1, the gene for a novel protein similar to TAF2G (TATA box binding protein (TBP)-associated factor, RNA polymerase II, G, 32kD) (TAF...
-0.35323 2.046488 5.28 Up 2.37E-03 BM66601 Homo sapiens cDNA
0 FLJ23803 us, clone HEP22811.
3.472109 5.867303 5.26 Up 7.98E-05 AW06972 Homo sapiens mRNA;
9 cDNA DKFZp434132119 (from clone DKFZp43462119); partial cds 0.977201 3.368558 5.25 Up 7.47E-05 A1656807 ESTs 2.732975 5.121756 5.24 Up 6.52E-04 AC005378 Homo sapiens PAC clone RP5-1137M13 from 7q33-q35 1.592667 3.976725 5.22 Up 6.48E-04 A1978754 ESTs 1.008383 3.391251 5.22 Up 8.23E-04 6E397715 pre-B-cell leukemia transcription factor 2 /FL=gb:NM 002586.1 0.134434 2.516313 5.21 Up 3.13E-04 AV758821 ESTs, Weakly similar to (H.sapiens) 1.496791 3.877324 5.21 Up 8.49E-05 BF338045 calumenin 0.329872 2.705019 5.19 Up 1.05E-04 A1652899 ESTs -0.39856 1.964554 5.14 Up 1.29E-03 BC019064 Homo sapiens, Similar to hypothetical protein FLJ14743, clone MGC:29781 IMAGE:4590587, mRNA, complete cds.
/PROD=Similar to hypothetical protein /FL=gb:BC019064.1 0.462867 2.81993 5.12 Up 8.02E-03 A1807026 ESTs 0.385307 2.742224 5.12 Up 4.37E-04 BF435123 bromodonnain and PHD
finger containing, 3 -1.10371 1.252512 5.12 Up 9.04E-04 NM_0059 Homo sapiens snail 1 85 (drosophila homolog), zinc finger protein (SNA11), mRNA. /PROD=snail 1 (drosophila homolog), zinc fingerprotein /FL=gb:AF125377.1 gb:NM_005985.1 1.094591 3.449692 5.12 Up 1.02E-04 NM_0240 Homo sapiens 64 hypothetical protein MGC5363 (MGC5363), mRNA.
/PROD=hypothetical protein MGC5363 /FL=gb:BC001000.2 gb:NM_024064.1 2.167442 4.520183 5.11 Up 4.37E-04 NM_0015 Homo sapiens insulin-like 52 growth factor-binding protein 4 (IGFBP4), mRNA. /PROD=insulin-like growth factor-binding protein 4 /FL=gb:M62403.1 gb:NM_001552.1 2.49682 4.845096 5.09 Up 2.00E-04 NM_0149 Homo sapiens KIAA0854 43 protein (KIAA0854), mRNA. /PROD=KIAA0854 protein /FL=gb:NM 014943.1 gb:AB0206-6-1.1 0.089114 2.430633 5.07 Up 5.31E-03 AW01473 ESTs 0.208844 2.544219 5.05 Up 4.90E-04 H09780 Human (clone CTG-A4) mRNA sequence 1.38879 3.721503 5.04 Up 1.05E-04 D21254 Human mRNA for OB-cadherin-1, complete cds.
/PROD=0B-cadherin-1 /FL=gb:L34056.1 gb:NM 001797.1 gb:D21-254.1 -0.07494 2.251273 5.01 Up 8.04E-04 NM 0013 Homo sapiens dual 94 specificity phosphatase 4 (DUSP4), mRNA.
/PROD=dual specificity phosphatase 4 /FL=gb:NM 001394.2 gb:BC002671.1 gb:U48807.1 gb:U21108.1 2.115363 4.439619 5.01 Up 1.50E-04 NM_0187 Homo sapiens zinc-00 binding protein Rbcc728 (Rbcc728), mRNA.
/PROD=zinc-binding protein Rbcc728 /FL=gb:NM_018700.1 1.361153 -4.07391 43.26 Down 4.28E-04 NM_0143 Homo sapiens POU
52 transcription factor (OCT11), mRNA.
/PROD=POU transcription factor /FL=gb:NM 014352.1 gb:AF133895.1 gb:AF162278.1 1.312148 -3.67593 31.74 Down 2.15E-02 U32500 Human type 2 neuropeptide Y receptor mRNA, complete cds.
/PROD=type 2 neuropeptide Y receptor /FL=gb:U42766.1 gb:U36269.1 gb:U32500.1 3.409815 -1.40094 28.07 Down 4.88E-03 NM_0165 Homo sapiens neuritin 88 (L0051299), mRNA.
/PROD=neuritin /FL=gb:NM 016588.1 gb:BC0026-63.1 gb:AF136631.1 0.757197 -4.01309 27.29 Down 5.31E-03 AF213459 Homo sapiens ephrin receptor EPHA3 complete form (EPHA3) mRNA, complete cds.
/PROD=ephrin receptor EPHA3 complete form /FL=gb:NM 005233.1 gb:M8394171 gb:AF213459.1 5.187988 0.925716 19.19 Down 1.82E-04 AA074145 praline oxidase homolog 3.862686 -0.33976 18.41 Down 1.79E-03 NM_0071 Homo sapiens tumor 15 necrosis factor, alpha-induced protein 6 (TNFAIP6), mRNA.
/PROD=tumor necrosis factor, alpha-induced protein 6 /FL=gb:NM_007115.1 0.579765 -3.61266 18.28 Down 1.63E-03 A1393930 ESTs 3.77776 -0.38219 17.88 Down 4.99E-04 BU729850 hypothetical protein 2.951696 -1.16992 17.41 Down 5.31E-03 AB019562 Homo sapiens mRNA
expressed only in placental villi, clone SMAP41.
1.143234 -2.96901 17.29 Down 1.60E-04 BF437711 ESTs 3.268087 -0.81338 16.93 Down 1.82E-04 AF345910 Homo sapiens NYD-SP14 mRNA, complete cds.
/PROD=NYD-SP14 /FL=gb:AF345910.1 3.113698 -0.8325 15.41 Down 6.25E-05 NM_0021 Homo sapiens insulinoma-96 associated 1 (INSM1), mRNA.
/PROD=insulinoma-associated 1 /FL=gb:NM 002196.1 gb:M93119.1 4.927935 1.009599 15.12 Down 1.75E-04 J05008 Homo sapiens endothelin-1 (EDN1) gene, complete cds /FL=gb:NM 001955.1 4.897427 1.053368 14.36 Down 6.25E-05 R06655 ESTs, Moderately similar to AF078844 1 hqp0376 protein (H sapiens) 2.271332 -1.54277 14.07 Down 1.21E-02 NM_0151 Homo sapiens KIAA0633 98 protein (COBL), mRNA.
/PROD=KIAA0633 protein /FL=gb:NM_015198.1 3.025351 -0.68158 13.06 Down 6.25E-05 AW59092 ESTs 0.961816 -2.64027 12.14 Down 1.38E-02A1796169 GATA-binding protein 3 /FL=gb:NM 002051.1 gb:M6910671 gb:BC003070.1 1.840613 -1.75619 12.1 Down 1.31E-02A1949760 ESTs, Weakly similar to unnamed protein product (H.sapiens) 2.350127 -1.16435 11.43 Down 1.75E-03 AK026106 Homo sapiens cDNA:
FLJ22453 fis, clone HRC09679, highly similar to AF059516 Homo sapiens tolloid-like 2 protein (TLL2) mRNA.
2.36447 -1.11975 11.19 Down 1.26E-04 NM_0051 Homo sapiens carbonic 81 anhydrase III, muscle specific (CA3), mRNA.
/PROD=carbonic anhydrase III
/FL=gb:BC004897.1 gb:NM_005181.2 3.806044 0.35797 10.91 Down 5.32E-04 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 5.023981 1.579769 10.88 Down 1.50E-04 NM_0064 Homo sapiens 72 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1), mRNA.
/PROD=upregulated by 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S73591 7.564809 4.126951 10.84 Down 6.52E-04 M83248 Human nephropontin mRNA, complete cds.
/PROD=nephropontin /FL=gb:M83248.1 4.055862 0.664604 10.49 Down 9.57E-05 AK026815 Homo sapiens cDNA:
FLJ23162 fis, clone LNG09734.
3.437271 0.12475 9.94 Down 3.82E-04 AB029025 Homo sapiens mRNA for KIAA1102 protein, partial cds. /PROD=KIAA1102 protein 2.129273 -1.1448 9.67 Down 1.66E-04 AV734646 DNA segment on chromosome X (unique) 9928 expressed sequence 4.847114 1.573515 9.67 Down 1.73E-04 NM 0064 Homo sapiens lung type-I
74 cell membrane-associated glycoprotein (Ti A-2), transcript variant 2, mRNA. /PROD=lung type-! cell membrane-associatedglycoprotein, isoform 2 precursor /FL=gb:NM 006474.1 gb:AF03042.8.1 1.577138 -1.67271 9.51 Down 7.76E-03 M15329 Human interleukin 1-alpha (ILIA) mRNA, complete cds. /PROD=interleukin 1-alpha /FL=gb:M15329.1 4.505436 1.287267 9.31 Down 9.57E-05 W57613 ESTs 3.508683 0.294832 9.28 Down 1.97E-04 AK027231 Homo sapiens cDNA:
FLJ23578 fis, clone LNG12709.
2.62025 -0.53251 8.89 Down 5.60E-04 AA625683 ESTs 1.659275 -1.48435 8.84 Down 9.40E-04 L16895 Human lysyl oxidase (LOX) gene, exon 7 5.207569 2.064859 8.83 Down 2.72E-04 M083478 Homo sapiens mRNA full length insert cDNA clone 2.306225 -0.8129 8.69 Down 2.76E-04 AW44476 ESTs 2.000419 -1.10961 8.63 Down 5.03E-03 NM_0312 Homo sapiens testis 72 expressed sequence 14 (TEX14), mRNA.
/PROD=testis expressed sequence 14 /FL=gb:NM_031272.1 5.450694 2.394209 8.32 Down 9.84E-05 AF095771 Homo sapiens PTH-responsive osteosarcoma B1 protein (B1) mRNA, complete cds.
/PROD=PTH-responsive osteosarcoma B1 protein /FL=gb:AF095771.1 5.252439 2.196404 8.32 Down 1.18E-03 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb119182.i 4.507212 1.458704 8.27 Down 1.26E-04 AW19694 ESTs 3.543738 0.544705 7.99 Down 4.95E-04 NM 0019 Homo sapiens endothelin 55 1 (EDN1), mRNA.
/PROD=endothelin 1 /FL=gb:NM_001955.1 3.334996 0.337521 7.99 Down 1.34E-05 R40917 phosphodiesterase 4D, cAMP-specific (dunce (Drosophila)-homolog phosphodiesterase E3) /FL=gb:L20969.1 gb:NM_006203.1 gb:U02882.1 4.092731 1.098988 7.97 Down 7.83E-04 AL513917 solute carrier family 16 (monocarboxylic acid transporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 3.19487 0.215496 7.89 Down 2.37E-03 NM_1735 Homo sapiens 53 hypothetical protein FLJ25801 (FLJ25801), mRNA.
/FL=gb:NM_173553.1 5.388254 2.421904 7.82 Down 3.23E-04 NM_0042 Homo sapiens solute 07 carrier family 16 (monocarboxylic acid transporters), member 3 (SLC16A3), mRNA.
/PROD=solute carrier family 16 (monocarboxylic acidtransporters), member 3 /FL=gb:U81800.1 gb:NM_004207.1 3.094055 0.128818 7.81 Down 3.00E-04 AW18819 tumor necrosis factor, 8 alpha-induced protein 6 /FL=gb:NM_007115.1 2.332751 -0.63023 7.8 Down 9.35E-05 NM_0000 Homo sapiens cyclin-77 dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) (CDKN2A), mRNA. /PROD=cyclin-dependent kinase inhibitor 2A (melanoma,p16, inhibits CDK4) /FL=gb:NM 000077.1 gb:L27211.-1 1.10782 -1.84525 7.74 Down 3.46E-03 BCO29425 Homo sapiens, Similar to KIAA1275 protein, clone IMAGE:4616553, mRNA.
3.655193 0.705514 7.73 Down 3.18E-04 A1659927 Homo sapiens cDNA:
FLJ22547 fis, clone 5.356771 2.412135 7.7 Down 1.86E-04W92036 ESTs 2.28595 -0.65294 7.67 Down 2.78E-03 BE504838 ESTs 6.1137 3.198978 7.54 Down 2.22E-04 NM_0015 Homo sapiens insulin-like 53 growth factor binding protein 7 (IGFBP7), mRNA. /PROD=insulin-like growth factor binding protein 7 /FL=gb:NM 001553.1 gb:L19182.71 4.738703 1.825888 7.53 Down 1.59E-04 NM_0140 Homo sapiens 33 DKFZP586A0522 protein (DKFZP586A0522), mRNA.
/PROD=DKFZP586A0522 protein /FL=gb:NM_014033.1 4.633038 1.723613 7.51 Down 7.34E-05 NM_0169 Homo sapiens NADPH
31 oxidase 4 (NOX4), mRNA.
/PROD=NADPH oxidase 4 /FL=gb:AF261943.1 gb:NM 016931.1 gb:AFi-54621.1 gb:AB041035.1 0.831091 -2.07313 7.49 Down 1.64E-02 NM_1530 Homo sapiens 36 hypothetical protein FLJ32239 (FLJ32239), mRNA.
/FL=gb:NM 153036.1 3.030236 0.148098 7.37 Down 1.06E-03 AA812232 upreguiateciby 1,25-dihydroxyvitamin D-3 /FL=gb:NM 006472.1 gb:S7359171 5.715937 2.845518 7.31 Down 6.25E-05 U85658 Human transcription factor ERF-1 mRNA, complete cds. /PROD=ERF-1 /FL=gb:NM 003222.1 gb:U8565871 2.597946 -0.264 7.27 Down 1.96E-04 AW13814 ESTs 2.798327 -0.06241 7.26 Down 1.59E-04 BF062943 protocadherin 18 2.590871 -0.2675 7.25 Down 5.03E-03 NM_0165 Homo sapiens TBX3-iso 69 protein (TBX3-iso), mRNA. /PROD=TBX3-iso protein /FL=gb:NM 016569.1 gb:AF2167-5-0.1 2.967768 0.161666 6.99 Down 2.73E-03 AL121753 Human DNA sequence from clone RP4-61404 on chromosome 20q11.1-12 Contains the 3 part of the MMP24 (matrix metalloproteinase 24 (membrane-inserted)) gene, the ITGB4BP
(integrin beta 4 binding protein) gene, the 3 end of a novel gene, the 3 end o...
1.041706 -1.73204 6.84 Down 3.48E-02 BF196010 ESTs 0.424388 -2.34418 6.81 Down 3.04E-03 NM_0024 Homo sapiens myelin 33 oligodendrocyte glycoprotein (MOG), mRNA. /PROD=myelin oligodendrocyte glycoprotein /FL=gb:U18798.1 gb:U64564.1 gb:NM_002433.1 6.307554 3.554438 6.74 Down 3.96E-04 NM 0066 Homo sapiens serum-22 inducible kinase (SNK), mRNA. /PROD=serum-inducible kinase /FL=gb:AF059617.1 gb:NM 006622.1 gb:AF03574.1 3.876749 1.137352 6.68 Down 1.28E-03 AL574184 hydroxyprostaglandin dehydrogenase 15-(NAD) /FL=gb:NM 000860.1 gb:L76465.f:
7.67265 4.935152 6.67 Down 3.86E-04 NM 0029 Homo sapiens S100 66 calcium-binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11)) (S100A10), mRNA.
/PROD=S100 calcium-binding protein A10 /FL=gb:M81457.1 gb:M38591.1 gb:NM_002966.1 3.127666 0.401912 6.62 Down 4.36E-04 NM_0035 Homo sapiens 77 undifferentiated embryonic cell transcription factor 1 (UTF1), mRNA.
/PROD=undifferentiated embryonic cell transcriptionfactor 1 /FL=gb:NM 003577.1 gb:AB0110-i6.1 2.677334 -0.04099 6.58 Down 4.48E-04 NM_0000 Homo sapiens collagen, 94 type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) (COL7A1), mRNA. /PROD=collagen, type VII, alpha 1 (epidermolysisbullosa, dystrophic, dominant and recessive) /FL=gb:L02870.1 gb:NM_000094.1 4.796495 2.100178 6.48 Down 2.14E-05 A1653107 ESTs 1.075159 -1.6205 6.48 Down 2.02E-02 J03580 Human, parathyroid-like protein (associated with humoral hypercalcemia of malignancy) mRNA, complete cds.
/FL=gb:J03580.1 3.86075 1.187353 6.38 Down 1.59E-04 U85995 Cluster Incl.
U85995:Human clone IMAGE-22181 unknown protein mRNA, partial cds /cds=(0,1291) /gb=U85995 /gi=1835749 /ug=Hs.79340 /len=1696 0.300578 -2.35535 6.3 Down 2.44E-02 A1110886 prothymosin, alpha (gene sequence 28) 0.182328 -2.47093 6.29 Down 1.88E-02 BC036917 Homo sapiens, clone MGC:46457 IMAGE:5201433, mRNA, complete cds.
/PROD=Unknown (protein for MGC:46457) /FL=gb:BC036917.1 6.568635 3.918368 6.28 Down 1.51E-04 AL031602 Human DNA sequence from clone RP5-1174N9 on chromosome 1p34.1-35.3. Contains the gene for a novel protein with IBR domain, a (pseudo?) gene for a novel protein similar to MT1E
(metallothionein lE
(functional)), ESTs, STSs, GSSs and two putative Cp...
1.639038 -1.00453 6.25 Down 5.77E-04 AW02787 ESTs, Weakly similar to 9 NBHUC8 decorin precursor (H.sapiens) 4.038177 1.406797 6.2 Down 1.02E-04 BF449053 ESTs 6.008797 3.380703 6.18 Down 1.64E-03 W72516 dihydropyrimidinase-like 3 /FL=gb:NM 001387.1 gb:D7801471 2.098906 -0.52676 6.17 Down 2.78E-03 NM_0039 Homo sapiens cyclin Al 14 (CCNA1), mRNA.
/PROD=cyclin Al /FL=gb:NM 003914.1 gb:U6683871 1.99849 -0.59877 6.05 Down 5.92E-04 NM_0023 Homo sapiens lysyl 17 oxidase (LOX), mRNA.
/PROD=lysyl oxidase /FL=gb:AF039291.1 gb:NM 002317.1 gb:M94:054.1 2.982965 0.397911 6 Down 1.82E-04 AK026829 Homo sapiens cDNA:
FLJ23176 fis, clone LNG10452.
3.08363 0.500579 5.99 Down 1.74E-04 U73778 Human collagen type XII
alpha-1 precursor (COL12A1) mRNA.
/PROD=collagen type XII
alpha-1 /FL=gb:NM_004370.3 0.857744 -1.71151 5.94 Down 4.12E-03 AB085901 Homo sapiens DBL mRNA
for DBL proto-oncogene splicing variant 1, complete cds.
/PROD=DBL proto-oncogene splicing variant 1 /FL=gb:AB085901.1 7.251816 4.700433 5.86 Down 3.86E-04 NM_0007 Homo sapiens annexin Al 00 (ANXA1), mRNA.
/PROD=annexin 1 /FL=gb:BC001275.1 gb:NM_000700.1 5.318139 2.768691 5.85 Down 9.51E-05 U87408 Cluster Incl.
U87408:Human clone IMAGE-74593 unknown protein mRNA, partial cds /cds=(0,1362) /gb=U87408 /gi=1842104 /ug=Hs.79340 /len=1982 0.668218 -1.87886 5.84 Down 1.56E-02 BE048571 ESTs 4.103964 1.558115 5.84 Down 8.74E-05 AA579773 ESTs 0.549053 -1.9953 5.83 Down 4.41E-02 A1825645 ESTs, Weakly similar to HOMEOBOX PROTEIN
GBX-2 (H.sapiens) 2.98904 0.457127 5.78 Down 7.98E-05 AW13814 ESTs 3.280973 0.749482 5.78 Down 2.21E-04 AL139377 Human DNA sequence from clone RP11-251J8 on chromosome 13 Contains ESTs, STSs, GSSs and a CpG island.
Contains two novel genes with two isoforms each and the KIAA0610 gene with two isoforms 2.750597 0.238017 5.71 Down 1.92E-02 NM 0069 Homo sapiens SRY (sex 42 determining region Y)-box 20 (S0X20), mRNA.
/PROD=SRY (sex determining region Y)-box 20 /FL=gb:NM 006942.1 gb:8C000985.71 gb:AB006867.1 3.880272 1.369596 5.7 Down 1.82E-04 NM_0025 Homo sapiens natriuretic 21 peptide precursor B
(NPPB), mRNA.
/PROD=natriuretic peptide precursor B
/FL=gb:NM 002521.1 gb:M2529671 2.324824 -0.18374 5.69 Down 2.00E-04 AL096771 Human DNA sequence from clone RP1-238D15 on chromosome 6q12-14.3 Contains part of COL12A1 (collagen, type XII, alpha 1) gene and STSs 6.179917 3.681421 5.65 Down 6.25E-05 NM_0001 Homo sapiens glucan 58 (1,4-alpha-), branching enzyme 1 (glycogen branching enzyme, Andersen disease, glycogen storage disease type IV) (GBE1), mRNA.
/PROD=glucan (1,4-alpha-), branching enzyme 1(glycogen branching enzyme) /FL=gb:L07956.1 gb:NM_000158.1 6.777916 4.283022 5.64 Down 3.42E-04 U15174 Homo sapiens BCL2adenovirus E1B
19kD-interacting protein 3 (BNIP3) mRNA, complete cds.
/PROD=BCL2adenovirus E1B 19kD-interacting protein 3 /FL=gb:AF002697.1 gb:NM 004052.2 gb:U1174.1 3.560033 1.066273 5.63 Down 4.18E-04 U38945 Human hypothetical 18.1 kDa protein (CDKN2A) mRNA, complete cds.
/FL=gb:U38945.1 gb:U26727.1 2.64743 0.1565 5.62 Down 7.06E-03 A1702438 ESTs 4.981033 2.492173 5.61 Down 7.98E-05 NM 0006 Homo sapiens serine (or 02 cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA.
/PROD=serine (or cysteine) proteinase inhibitor, cladeE (nexin, plasminogen activator inhibitor type 1), membe 5.13621 2.649783 5.6 Down 1.82E-04 BC013944 Homo sapiens, Similar to myosin, heavy polypeptide 7, cardiac muscle, beta, clone IMAGE:4064393, mRNA.
2.648874 0.170587 5.57 Down 2.39E-04 AW00753 Human insulin-like growth 2 factor binding protein 5 (IGFBP5) mRNA
4.285883 1.811154 5.56 Down 1.26E-04 AL038787 6-phosphofructo-2-kinasefructose-2,6-biphosphatase 4 3.41866 0.980192 5.42 Down 3.42E-04 AA149250 ESTs, Weakly similar to PROTEIN PRECURSOR
(R.norvegicus) 3.932141 1.49687 5.41 Down 6.25E-05 NM_0044 Homo sapiens growth 90 factor receptor-bound protein 14 (GRB14), mRNA. /PROD=growth factor receptor-bound protein 14 /FL=gb:L76687.1 gb:NM_004490.1 4.64236 2.208805 5.4 Down 4.99E-04 AB019695 Homo sapiens mRNA for thioredoxin reductase II
beta, complete cds.
/PROD=thioredoxin reductase II beta /FL=gb:AB019695.1 2.256481 -0.17666 5.4 Down 2.51E-03 NM_0184 Homo sapiens NAG22 95 protein (L0055873), mRNA. /PROD=NAG22 protein /FL=gb:AF247820.3 gb:NM_018495.3 2.93223 0.515985 5.34 Down 1.40E-03 J05594 Homo sapiens NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (PDGH) mRNA, complete cds.
/PROD=NAD+-dependent hydroxyprostaglandindehy drogenase /FL=gb:J05594.1 3.557525 1.145962 5.32 Down 1.74E-04 BF514079 Kruppel-like factor 4 (gut) 6.844763 4.45073 5.26 Down 5.92E-04 AF003114 Homo sapiens CYR61 mRNA, complete cds.
/FL=gb:AF003114.1 3.947271 1.57134 5.19 Down 3.82E-04 A1928035 ESTs 4.835771 2.460275 5.19 Down 1.74E-04 AL574210 serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 /FL=gb:NM 000602.1 gb:Ml 6006.1 5.332534 2.96686 5.15 Down 2.34E-04 AW18988 protocadherin 18 5.43052 3.069652 5.14 Down 2.73E-04 AU154455 lung type-I cell membrane-associated glycoprotein 3.041407 0.703421 5.06 Down 1.48E-04 NM_0044 Homo sapiens forkhead 72 box D1 (FOXD1), mRNA.
/PROD=forkhead box D1 /FL=gb:U59832.1 gb:NM_004472.1 F) H9P39 at 72 hr DE stage vs EXPRES 01- Intensity values are in Log2 format.
EXPRES 72 HRS Ratio Direction adj. p- Gene Gene Name 01 DE value Identifier 401441 5.083597 547.99 Up 9,50E-05 A802802 Cluster Incl.
AB028021:Homo sapiens HNE-3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds icds=(196,1569) Igt-nA13028021 igi=4958949 fug=Hs,155651 ilen=1944 -4.79201 3.675687 354.02 Up 7.11E-05 NM_0124 Homo sapiens sema 31 domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E
(SEMA3E), mRNA.
/PROD=sema domain, immunoglobulin domain (Ig), shortbasic domain, secreted, (semaphorin) 3E
/FL=gb:NM 012431.1 gb:AB0023-2-9.1 -5.25658 3.066715 320.3 Up 5.36E-05 AW00557 putative 47 kDa protein -0.80043 7.317513 277.81 Up 3.10E-05 087811 Homo sapiens mRNA for GATA-6, complete cds.
IPRO0=GATA-6 /FL=gb:U56075.1 gb:NM 005257.1 gb:D67-811.1 -3.8752 4.204423 270.53 Up 1.89E-05 AB028021 Homo sapiens HNF-3beta mRNA for hepatocyte nuclear factor-3 beta, complete cds.
/PROD=hepatocyte nuclear factor-3 beta /FL=gb:AB028021.1 gb:NM_021784.1 -3.26893 4.729085 255.65 Up 3.66E-05 NM_0017 Homo sapiens cytidine 85 deaminase (CDA), mRNA.
/PROD=cytidine deaminase /FL=gb:L27943.1 gb:NM_001785.1 429696 3.360647 202.2 Up 1.85E-05 AY177407 Homo sapiens homeobox protein goosecoid mRNA, complete cds.
1PROD=homeobox protein goosecoid /FL=gb:AY177407.1 gb:NM_173849,1 -0.62093 6.953987 190,67 Up 1.85E-05 hitli_0224 Homo sapiens 54 hypothetical protein FLJ22252 similar to SRY-box containing gene 17 (FLJ22252), mRNA.
IPROD=hypothetical protein FLJ22252 similar to SRY-boxcontaining gene 17 IFL=gb:NM_022454.1 -4.50758 2.853368 164.39 Up 5.73E-05 AU118882 endothelin receptor type A
/FL=gb:NM 001957.1 gb:L06622.1 -1.11159 6.244682 163,85 Up 1.85E-05 NM 0038 Homo sapiens fibroblast 67 growth factor 17 (FGF17), mRNA.
1PROD=fibroblast growth factor 17 IFL=gb:NIM 003867.1 0:AS0092-49,1 -0.26005 7.057553 159.52 Up 8.58E-05 R72286 microfibrillar-associated protein 4 -3.62742 3.595825 149.42 Up 1.19E-03 AA772920 ESTs -3.61621 3.595293 148.21 Up 7.06E-04 AL569326 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds -1.32044 5.888668 147.96 Up 1.62E-03 AF017987 Homo sapiens secreted apoptosis related protein 2 (SARP2) mRNA, complete cds. /PROD=secreted apoptosis related protein 2 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AF0-17987.1 gb:AF001900.1 -0.83997 6.288395 139.91 Up 1.06E-04 A1821669 ESTs -1.89695 5.066236 124.78 Up 5.04E-05 AL136944 Homo sapiens mRNA;
cDNA DKFZp586J0624 (from clone DKFZp586J0624);
complete cds.
/PROD=hypothetical protein /FL=gb:AF215636.1 gb:NM 014585.1 gb:AF231121.1 gb:AF226614.1 gb:AL136944.1 -2.90798 4.005677 120.56 Up 7.41E-05 NM_0016 Homo sapiens 43 apolipoprotein A-II
(AP0A2), mRNA.
/PROD=apolipoprotein A-ll precursor /FL=gb:M29882.1 gb:NM 001643.1 gb:BCCT05282.1 -3.39007 3.146077 92.81 Up 2.92E-03 NM 0066 Homo sapiens cell 14 adhesion molecule with homology to LICAM
(close homologue of L1) (CHU), mRNA.
IPROD=cell adhesion molecule with homology to L1CAM(close homologue of LI) IFL=gb:AF002246.1 gb:NIV1_006614.1 -4.63418 1.846961 89.33 Up 5.54E-03 BF112218 ESTs -2.0457 4.332524 83.18 Up 1.95E-04 A1422986 ESTs 0.756526 7.130796 82.96 Up 2.44E-05 NM 0030 Homo sapiens secreted 12 frizzled-related protein 1 (SFRP1), mRNA.
/PROD=secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM_003012.2 gb:AF017987.1 gb:AF001900.1 -3.17056 3.112711 77.88 Up 5.66E-05 A1801626 ESTs, Moderately similar to ALU4 HUMAN ALU

SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) -2.5679 3.691959 76.63 Up 1.85E-05 AL121722 Human DNA sequence from clone RP4-788L20 on chromosome 20 Contains the HNF3B
(hepatocyte nuclear factor 3, beta) gene. a novel gene based on ESTs, ESTs, STSs, GSSs and CpG Islands -3.12184 3.093954 74.33 Up 1.27E-04 A1700341 ESTs -3.51429 2.6835 73.4 Up 7.26E-04 AA352113 ESTs 0.502235 6.679567 72.37 Up 8.17E-06 NM_0148 Homo sapiens KIAA0878 99 protein (KIAA0878), mRNA. /PROD=KIAA0878 protein /FL=gb:NM 014899.1 gb:AB020685.1 -3.7619 2.400862 71.64 Up 4.61E-05 NM_0161 Homo sapiens transient 79 receptor potential channel 4 (TRPC4), mRNA.
/PROD=transient receptor potential 4 /FL=gb:NM 016179.1 gb:AF17540-6.1 -1.66311 4.46486 69.94 Up 3.60E-04 S69738 MCP-1=monocyte chemotactic protein (human, aortic endothelial cells, mRNA, 661 nt).
/PROD=MCP-1 -2.26295 3.775709 65.74 Up 1.21E-03 A1735586 ESTs -3.20091 2.823883 65.11 Up 8.22E-03 NM_0026 Homo sapiens PDZ
14 domain containing 1 (PDZK1), mRNA.
/PROD=PDZ domain containing 1 /FL=gb:NM 002614.1 gb:AF01228-1.1 -0.81978 5.17876 63.94 Up 1.52E-04 A1824037 ESTs, Weakly similar to AFFINITY
IMMUNOGLOBULIN
EPSILON FC RECEPTOR
(M.musculus) -3.10357 2.888163 63.63 Up 1.85E-05 NM_0014 Homo sapiens forkhead 53 box Cl (FOXC1), mRNA.
/PROD=forkhead box Cl /FL=gb:NM_001453.1 -0.41404 5.48675 59.75 Up 1.39E-04 A1332407 secreted frizzled-related protein 1 /FL=gb:AF056087.1 gb:NM 003012.2 gb:AFO-17987.1 gb:AF001900.1 -4.29055 1.60372 59.48 Up 5.86E-05 A1337300 Homo sapiens, clone MGC:4604, mRNA, complete cds /FL=gb:BC004219.1 -1.70149 4.121658 56.62 Up 6.46E-04 AF225426 Homo sapiens HT016 mRNA, complete cds.
/PROD=HT016 /FL=gb:AF225426.1 -2.07937 3.707398 55.21 Up 2.52E-03 NM 0016 Homo sapiens 43 apolipoprotein A-II
(AP0A2), mRNA.
/PROD=apolipoprotein A-ll precursor /FL=gb:M29882.1 gb:NM 001643.1 gb:BCCI05282.1 0.800949 6.56634 54.39 Up 2.72E-07 NM_0307 Homo sapiens scavenger 81 receptor with C-type lectin (SRCL), mRNA.
/PROD=scavenger receptor with C-type lectin /FL=gb:NM_030781.1 -2.72686 2.973219 51.99 Up 1.82E-04 A1692180 PTPRF interacting protein, binding protein 2 (liprin beta 2) -1.55323 4.113731 50.81 Up 2.92E-05 A1821586 ESTs, Moderately similar to JE0284 Mm-1 cell derived transplantability-associated protein lb (H.sapiens) -3.53873 2.127137 50.77 Up 4.17E-04 A1675836 Human DNA sequence from clone RP11-446H13 on chromosome 10.
Contains the 3 end of the gene for a novel protein similar to KIAA1059 (ortholog of mouse VPS10 domain receptor protein SORCS), an RPL23A
(60S ribosmal protein 23A) pseudogene, ESTs, STSs an -2.45311 3.17372 49.41 Up 1.17E-02 BC042378 Homo sapiens, clone IMAGE:5277693, mRNA.
-2.91295 2.704851 49.1 Up 5.98E-03 AW00557 putative 47 kDa protein -1.44407 4.173723 49.1 Up 1.23E-03 U91903 Human Fritz mRNA, complete cds.
/PROD=Fritz /FL=gb:U24163.1 gb:U68057.1 gb:NM_001463.1 gb:U91903.1 -0.77864 4.836717 49.02 Up 2.61E-04 NM_0220 Homo sapiens reserved 55 (KCNK12), mRNA.
/PROD=tandem pore domain potassium channel THIK-2 /FL=gb:NM 022055.1 gb:AF287362.1 -3.90126 1.704039 48.68 Up 2.65E-04 A1004009 ESTs, Moderately similar to ALU7 HUMAN ALU
SUBFAMILY SQ
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) 1.388898 6.98175 48.26 Up 1.85E-05 6E620739 ESTs -3.91992 1.582406 45.33 Up 1.28E-04 AL553774 K1AA1462 protein -2.50168 2.984782 44.83 Up 6.69E-03 X16468 Human mRNA for alpha-1 type II collagen.
-1.71797 3.748284 44.21 Up 2.10E-03 AL524520 G protein-coupled receptor 49 -0.5292 4.934946 44.14 Up 7.15E-04 A1127440 ESTs -0.69028 4.756395 43.61 Up 1.42E-04 M16276 Human MHC class II HLA-DR2-Dw12 mRNA DQw1-beta, complete cds.
/FL=gb:NM 002123.1 gb:M1627671 gb:M60028.1 gb:M17564.1 gb:M81141.1 gb:M81140.1 0.83572 6.263504 43.05 Up 8.83E-05 N21138 K1AA0878 protein /FL=gb:NM 014899.1 gb:AB02065.1 -2.61405 2.778049 41.99 Up 4.08E-05 U71207 Human eyes absent homolog (Eab1) mRNA, complete cds.
/PROD=Eab1 /FL=gb:NM 005244.1 gb:U7120771 -3.54017 1.841563 41.69 Up 9.86E-04 NM_0020 Homo sapiens gastrin-91 releasing peptide (GRP), mRNA. /PROD=gastrin-releasing peptide /FL=gb:NM 002091.1 gb:K02054.1 gb:BC004488.1 -2.39338 2.964195 41 Up 2.62E-03 M17955 Human MHC class II HLA-DQ-beta mRNA, complete cds. /FL=gb:M33907.1 gb:M17955.1 gb:M16996.1 gb:M17563.1 gb:M20432.1 gb:M26042.1 -1.77041 3.564655 40.37 Up 1.48E-03 NM_0039 Homo sapiens sema 66 domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A
(SEMA5A), mRNA.
/PROD=sema domain, seven thrombospondin repeats (type1 and type 1-like), transmem -0.27888 5.053648 40.29 Up 4.00E-05 AF225513 Homo sapiens cAMP-dependent protein kinase inhibitor beta mRNA, complete cds.
/PROD=cAMP-dependent protein kinase inhibitor beta /FL=gb:AF225513.1 -2.4051 2.925248 40.23 Up 2.25E-05 NM_0210 Homo sapiens 20 F37Esophageal cancer-related gene-coding leucine-zipper motif (FEZ1), mRNA.
/PROD=F37Esophageal cancer-related gene-codingleucine-zipper motif /FL=gb:AF123659.1 gb:NM_021020.1 -2.16079 3.152396 39.76 Up 4.00E-05 NM 0005 Homo sapiens von 52 Willebrand factor (VWF), mRNA. /PROD=von Willebrand factor precursor /FL=gb:NM_000552.2 -2.6422 2.666218 39.63 Up 1.85E-05 BF589787 ESTs -1.09421 4.204596 39.36 Up 7.37E-05 AK023621 Homo sapiens cDNA
FLJ13559 fis, clone PLACE1007852, highly similar to Homo sapiens mRNA for KIAA0878 protein.
-3.7558 1.527474 38.94 Up 3.02E-03 AW47365 ESTs -3.21708 2.015336 37.59 Up 1.57E-04 NM_0044 Homo sapiens EphA4 38 (EPHA4), mRNA.

/PROD=EphA4 /FL=gb136645.1 gb:NM 004438.1 -0.18256 5.019816 36.82 Up 1.85E-05 A1583173 major ITistocompatibility complex, class II, DQ beta -0.18863 5.007893 36.67 Up 3.26E-04 AV700724 GATA-binding protein 4 /FL=gb:NM 002052.1 ab:L.34357.71-gb:D78260.1 -2.69284 2.499705 36.57 Up 6.77E-03 R33964 Homo sapiens cDNA
FLJ11022 fis, clone 0.804491 5.966318 35.8 Up 4.00E-05 AA583044 bone morphogenetic protein 2 /FL=gb:NM_001200.1 0.828899 5.985645 35.67 Up 4.40E-05 NM_0012 Homo sapiens bone 00 morphogenetic protein 2 (BMP2), mRNA.
/PROD= bone morphogenetic protein 2 precursor /FL=gb:NM_001200.1 0.663834 5.813725 35.5 Up 7.23E-05 AI817041 G protein-coupled receptor -2.83906 2.291355 35.03 Up 8.28E-05 T15545 ESTs -3.25309 1.849989 34.37 Up 1.65E-03 AL050154 Homo sapiens mRNA;
cDNA DKFZp586L0120 (from clone DKFZp586L0120).
0.713597 5.813528 34.3 Up 2.17E-04 6E508344 ESTs -1.61054 3.372801 31.63 Up 6.80E-04 AW26420 ESTs -3.31261 1.666545 31.54 Up 5.69E-04 BG39785 major histocompatibility 6 complex, class II, DQ
alpha 1 -1.35345 3.621423 31.45 Up 7.05E-04 AW15757 ESTs, Weakly similar to 1 100331 hypothetical protein KIAA0555 (H.sapiens) -0.81856 4.154852 31.42 Up 2.94E-05 A1129628 ESTs -0.45718 4.48679 30.78 Up 6.26E-05 BF939489 glycoprotein M6A
/FL=gb:D49958.1 0.424882 5.366945 30.74 Up 1.58E-04 A1692659 heat shock 90kD protein 1, alpha -0.95386 3.986146 30.7 Up 7.87E-05 AF312769 Homo sapiens cryptic mRNA, complete cds.
/PROD=cryptic /FL=gb:AF312769.1 -1.39784 3.506506 29.95 Up 9.97E-04 6E222344 splicing factor, arginineserine-rich 5 -0.47614 4.408298 29.54 Up 3.38E-05 BF508639 Homo sapiens mRNA;
cDNA DKFZp434E082 (from clone DKFZp434E082) -3.12747 1.716365 28.72 Up 9.08E-04 AV726956 ESTs, Weakly similar to C35826 hypothetical 13K
protein A (H sapiens) -2.81405 2.019329 28.51 Up 9.96E-04 A1694325 ESTs 1.829497 6.661623 28.48 Up 3.89E-05 AA534817 ESTs, Weakly similar to ALU8_HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) -1.42034 3.409373 28.44 Up 4.12E-04 6E737251 Homo sapiens cDNA:
FLJ22482 fis, clone HRC10859, highly similar to IR0180147 Homo sapiens mRNA full length insert cDNA clone 1.563993 6.383462 28.24 Up 1.85E-05 NM_0024 Homo sapiens microsomal 13 glutathione S-transferase 2 (MGST2), mRNA.
/PROD=microsomal glutathione S-transferase 2 /FL=gb:NM_002413.1 gb:U77604.1 1.314051 6.126464 28.1 Up 1.89E-05 BC000740 Homo sapiens, cholecystokinin B
receptor, clone MGC:2199, mRNA, complete cds.
/PROD=cholecystokinin B
receptor /FL=gb:L07746.1 gb:L08112.1 gb:S70057.1 gb:BC000740.1 gb:L04473.1 gb:NM_000731.1 0.420056 5.197721 27.43 Up 1.85E-05 NM_0122 Homo sapiens dickkopf 42 (Xenopus laevis) homolog 1 (DKK1), mRNA.
/PROD=dickkopf (Xenopus laevis) homolog 1 /FL=gb:AF177394.1 gb:NM 012242.1 gb:AF127563.1 -1.54464 3.22856 27.34 Up 5.11E-05 A1743534 Homo sapiens mRNA;
cDNA DKFZp56461162 (from clone DKFZp56461162);
complete cds /FL=gb:AL136646.1 -4.15276 0.598294 26.93 Up 1.83E-04 AA129444 Homo sapiens mRNA for KIAA1263 protein, partial cds -1.83503 2.912585 26.86 Up 8.60E-04 AA552969 ESTs 0.442286 5.16846 26.47 Up 1.85E-05 NM_0017 Homo sapiens CD48 78 antigen (B-cell membrane protein) (CD48), mRNA.
/PROD=CD48 antigen (6-cell membrane protein) /FL=gb:NM 001778.1 gb:M3776671 gb:M59904.1 -2.05438 2.666454 26.37 Up 5.65E-03 BG29090 ESTs, Moderately similar 8 to ALU8 HUMAN ALU
SUBFAMILY SX
SEQUENCE
CONTAMINATION
WARNING ENTRY
(H.sapiens) -3.25961 1.457558 26.3 Up 1.49E-02 NM_0163 Homo sapiens pancreas-41 enriched phospholipase C
(L0051196), mRNA.
/PROD=pancreas-enriched phospholipase C
/FL=gb:AF117948.1 gb:NM 016341.1 gb:AF1-90642.2 -0.68225 4.022195 26.07 Up 4.08E-05 N48299 ESTs, Moderately similar to NFY-C (H.sapiens) -0.37709 4.293707 25.47 Up 5.32E-05 AU152102 Homo sapiens cDNA
FLJ12993 fis, clone -0.13959 4.521681 25.3 Up 5.89E-05 BG10985 Homo sapiens clone TUA8 Cri-du-chat region mRNA
-1.80965 2.799751 24.41 Up 4.74E-03 NM_1525 Homo sapiens 06 hypothetical protein FLJ32835 (FLJ32835), mRNA.
/FL=gb:NM 152506.1 1.275191 5.879425 24.32 Up 3.33E-05 A1587307 hypothetical /FL=gb:NM_024641.1 -3.79684 0.804733 24.28 Up 2.78E-04 AK026720 Homo sapiens cDNA:
FLJ23067 fis, clone LNG04993.
-0.13427 4.467037 24.27 Up 2.87E-05 049958 Homo sapiens mRNA for membrane glycoprotein M6, complete cds.
/PROD=membrane glycoprotein M6 /FL=gb:D49958.1 1.997597 6.595913 24.22 Up 2.84E-05 BC005997 Homo sapiens, clone MGC:14801, mRNA, complete cds.
/PROD=Unknown (protein for MGC:14801) /FL=gb:BC005997.1 -2.9769 1.607498 23.99 Up 1.19E-02 AW61211 ESTs -3.10679 1.463399 23.76 Up 3.41E-04 N59476 ESTs -2.06656 2.502146 23.73 Up 2.55E-03 AF141339 Homo sapiens LYST-interacting protein LIP3 mRNA, partial cds.
/PROD=LYST-interacting protein LIP3 0.007601 4.558709 23.44 Up 1.02E-04 N63706 ESTs -0.15629 4.385668 23.3 Up 2.61E-04 A1799018 ESTs -3.10838 1.4221 23.11 Up 3.43E-04 N50412 ESTs -2.50006 1.997519 22.59 Up 1.83E-03 U66061 Human germline T-cell receptor beta chain TCRBV17S1A1T, TCRBV2S1, TCRBV10S1P, TCRBV29S1P, TCRBV19S1P, TCRBV15S1, TCRBV11S1A1T, HVB
relic, TCRBV28S1P, TCRBV34S1, TCRBV14S1, TCRBV3S1, TCRBV4S1A1T, TRY4, TRY5, TRY6, TRY7, TRY8, TCRBD1, TCRBJ1S1, TCRB...
-0.98665 3.469502 21.95 Up 1.93E-03 NM 0014 Homo sapiens frizzled-63 related protein (FRZB), mRNA. /PROD=frizzled-related protein /FL=gb:U24163.1 gb:U68057.1 gb:NM 001463.1 gb:U91-903.1 -0.62897 3.790333 21.4 Up 7.95E-03 A1694545 ESTs 0.500662 4.91845 21.37 Up 1.92E-04 AB043703 Homo sapiens FZD8 mRNA for seven-transmembrane receptor Frizzled-8, complete cds.
/PROD=seven-transmembrane receptor Frizzled-8 /FL=gb:AB043703.1 -0.10733 4.302037 21.25 Up 2.88E-04 BC005107 Homo sapiens, clone IMAGE:3840937, mRNA, partial cds.
/PROD=Unknown (protein for IMAGE:3840937) -0.70855 3.6919 21.12 Up 4.93E-04A1917371 ESTs -3.53207 0.857843 20.97 Up 1.12E-03 NM_0027 Homo sapiens protease, 69 serine, 1 (trypsin 1) (PRSS1), mRNA.
/PROD=protease, serine, 1 (trypsin 1) /FL=gb:M22612.1 gb:NM_002769.1 1.168713 5.556831 20.94 Up 2.43E-04 NM_0161 Homo sapiens 16.7Kd 39 protein (L0051142), mRNA. /PROD=16.7Kd protein /FL=gb:NM 016139.1 gb:AF078845.1 gb:8C003079.1 -1.68521 2.69622 20.84 Up 2.06E-03 NM 0027 Homo sapiens protease, 70 serine, 2 (trypsin 2) (PRSS2), mRNA.
/PROD=protease, serine, 2 (trypsin 2) /FL=gb:M27602.1 gb:NM_002770.1 -2.14813 2.233148 20.84 Up 2.55E-04 NM_0060 Homo sapiens p53-34 induced protein (PIG11), mRNA. /PROD=p53-induced protein /FL=gb:AF010315.1 gb:BC000443.1 gb:BC003010.1 gb:NM_006034.1 -0.5982 3.780076 20.8 Up 1.63E-02 A1806510 putative 47 kDa protein 0.449168 4.82657 20.78 Up 2.33E-05 A1688418 plexin A2 1.223968 5.565279 20.27 Up 1.85E-05 AL574912 ESTs, Weakly similar to serine protease (H.sapiens) 2,366939 6.691717 20.01 Up 3.09E-05 AJ224869 Homo sapiens CXCR4 gene encoding receptor -1.83333 2.487663 19.99 Up 2.10E-03 NM_0065 Homo sapiens myelin-01 associated oligodendrocyte basic protein (MOBP), mRNA.
/PROD=myelin-associated oligodendrocyte basic protein /FL=gb:D28113.1 gb:NM_006501.1 -2.16064 2.095432 19.11 Up 1.23E-02 NM 0004 Homo sapiens nuclear 75 receptor subfamily 0, group B, member 1 (NROB1), mRNA.
/PROD=adrenal hypoplasia protein /FL=gb:NM_000475.2 1.861693 6.103583 18.92 Up 2.59E-05 A1374739 ESTs -3.47945 0.755598 18.83 Up 5.51E-04 NM_0008 Homo sapiens glutathione 54 S-transferase theta 2 (GSTT2), mRNA.
/PROD=glutathione S-transferase theta 2 /FL=gb:L38503.1 gb:BC002415.1 gb:NM_000854.2 -1.25995 2.973193 18.81 Up 2.98E-04 AK026607 Homo sapiens cDNA:
FLJ22954 fis, clone KA109813, highly similar to AF010315 Homo sapiens Pig11 (P1G11) mRNA.
-0.27888 3.946435 18.7 Up 2.46E-05 NM_0030 Homo sapiens SW1SNF
78 related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3 (SMARCD3), mRNA. /PROD=SW1SNF
related, matrix associated, actindependent regulator of chromatin, subfamily d, member 3 /FL=gb:NM_003078.1 gb 1.740607 5.961556 18.65 Up 2.25E-05 NM_0021 Homo sapiens 60 hexabrachion (tenascin C, cytotactin) (HXB), mRNA.
/PROD=hexabrachion (tenascin C, cytotactin) /FL=gb:M55618.1 gb:NM_002160.1 -2.84061 1.378474 18.62 Up 7.18E-04 A1123532 ESTs 3.042634 7.250084 18.47 Up 2.33E-05 NM_0054 Homo sapiens 42 eomesodermin (Xenopus laevis) homolog (EOMES), mRNA.
/PROD=eomesodermin (Xenopus laevis) homolog /FL=gb:AB031038.1 gb:NM_005442.1 1.192657 5.39941 18.47 Up 1.18E-04 NM_0246 Homo sapiens 41 hypothetical protein FLJ12838 (FLJ12838), mRNA.
/PROD=hypothetical protein FLJ12838 /FL=gb:NM_024641.1 -2.81453 1.375898 18.26 Up 3.27E-02 BC014585 Homo sapiens, clone IMAGE:4047715, mRNA.
0.476688 4.64635 18 Up 1.14E-04 NM_0245 Homo sapiens 81 hypothetical protein FLJ13942 (FLJ13942), mRNA.
/PROD=hypothetical protein FLJ13942 /FL=gb:NM_024581.1 -2.14545 2.018966 17.93 Up 2.47E-03 NM 0158 Homo sapiens 31 acetylcholinesterase (YT
blood group) (ACHE), transcript variant E4-E5, mRNA.
/PROD=acetylcholinestera se P1-linked form precursor /FL=gb:NM_015831.1 -2.24406 1.891442 17.58 Up 4.96E-05 NM_0032 Homo sapiens 75 tropomodulin (TMOD), mRNA.
/PROD=tropomodulin /FL=gb:NM 003275.1 gb:M770161 gb:BC002660.1 -0.5777 3.557171 17.57 Up 5.59E-04 8C036592 Homo sapiens, clone IMAGE:4814184, mRNA.
-0.05814 4.076316 17.56 Up 1.83E-04 BF308645 KIAA1415 protein -1.27748 2.846094 17.43 Up 1.96E-04 D78260 Homo sapiens mRNA for GATA-4 transcription factor, complete cds.
/PROD=GATA-4 transcription factor /FL=gb:NM 002052.1 gb134357.71 gb:D78260.1 -2.64131 1.466395 17.24 Up 2.99E-02 AU157303 ESTs -1.82351 2.283948 17.24 Up 3.95E-04 M603467 ribosomal protein S11 1.59762 5.701737 17.2 Up 5.72E-04 NM_0186 Homo sapiens core 49 histone macroH2A2.2 (MACROH2A2), mRNA.

/PROD=core histone macroH2A2.2 /FL=gb:AF151534.1 gb:NM_018649.1 -0.20099 3.88744 17.01 Up 1.99E-04 BF984830 retinoic acid induced 1 -0.41626 3.652079 16.78 Up 2.69E-04 BF110534 ESTs 2.377335 6.437231 16.68 Up 1.89E-05 NM_0053 Homo sapiens hyaluronan 28 synthase 2 (HAS2), mRNA.
/PROD=hyaluronan synthase 2 /FL=gb:U54804.1 gb:NM_005328.1 -0.29145 3.768186 16.68 Up 2.40E-04 A1197932 ESTs -3.88742 0.162889 16.57 Up 2.95E-03 AA180985 ESTs -0.75724 3.289214 16.52 Up 2.66E-03 AL445192 Human DNA sequence from clone RP11-269H4 on chromosome 20 Contains the 3 end of the KIAA1415 gene similar to T-Lymphona invasion and metastasis inducing protein 1, ESTs, STSs and GSSs -2.30432 1.732166 16.41 Up 2.23E-02 BC017958 Homo sapiens, clone IMAGE:4607409, mRNA.
-3.30412 0.716129 16.23 Up 3.22E-02 AU157224 Homo sapiens cDNA
FLJ11570 fis, clone -3.4744 0.544234 16.21 Up 8.79E-03 L32867 Homo sapiens alpha 2,8-sialyltransferase mRNA, complete cds.
/PROD=alpha 2,8-sialyltransferase /FL=gb:L43494.1 gb:D26360.1 gb:L32867.1 gb:NM_003034.1 -3.09265 0.925475 16.2 Up 2.03E-03 A1093492 ESTs -1.39277 2.622602 16.17 Up 2.73E-04A1629041 ESTs 0.366041 4.354631 15.87 Up 8.71E-05 A1242583 Homo sapiens cDNA
FLJ11550 fis, clone -0.35867 3.62672 15.84 Up 3.71E-05 NM_0019 Homo sapiens endothelin

57 receptor type A (EDNRA), mRNA.
/PROD=endothelin receptor type A
/FL=gb:NM 001957.1 gb:L06622.71 -0.66587 3.318505 15.83 Up 9.18E-05 NM_0013 Homo sapiens deiodinase, 62 iodothyronine, type III
(DI03), mRNA.
/PROD=thyroxine deiodinase type III
/FL=gb:NM 001362.1 gb:S7985471 -1.80959 2.172774 15.81 Up 1.70E-03 BF447246 KIAA0960 protein -3.95752 0.007632 15.62 Up 1.52E-02 NM 0014 Homo sapiens epiregulin 32 (EREG), mRNA.

/PROD=epiregulin precursor /FL=gb:D30783.1 gb:NM_001432.1 -0.22337 3.730539 15.5 Up 9.97E-04 NM_0218 Homo sapiens phorbolin-22 like protein MDS019 (MDS019), mRNA.
/PROD=phorbolin-like protein MDS019 /FL=gb:AF182420.1 gb:NM_021822.1 -2.56291 1.390726 15.49 Up 1.14E-02 BG53269 integrin, alpha 4 (antigen 0 CD49D, alpha 4 subunit of VLA-4 receptor) -2.89467 1.029195 15.18 Up 4.69E-03 AW97120 ESTs -1.16952 2.748825 15.12 Up 2.94E-02 NM_0013 Homo sapiens disabled 43 (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) (DAB2), mRNA. /PROD=disabled (Drosophila) homolog 2 /FL=gb:U39050.1 gb:NM 001343.1 gb:U53-446.1 gb:BC003064.1 0.798972 4.674672 14.68 Up 5.97E-05 A1082827 hypothetical protein -0.33264 3.541617 14.66 Up 3.49E-05 NM_0203 Homo sapiens 53 phospholipid scramblase 4 (L0057088), mRNA.
/PROD=phospholipid scramblase 4 /FL=gb:NM 020353.1 gb:AF1990-2-3.1 -0.88175 2.988123 14.62 Up 1.30E-03 A1650874 ESTs -0.11092 3.758565 14.62 Up 4.96E-05 BF591483 ESTs 1.370117 5.237165 14.59 Up 7.39E-05 M33653 Human (clones HT-(125,133)) alpha-2 type IV
collagen (COL4A2) mRNA, complete cds.
/PROD=alpha-2 type IV
collagen /FL=gb:M33653.1 0.041468 3.902142 14.53 Up 9.62E-04 BF130943 ESTs -0.41994 3.432925 14.45 Up 1.98E-03 A1686957 K1AA1494 protein -3.44709 0.392958 14.32 Up 3.27E-02 H39185 ESTs 1.071985 4.903249 14.23 Up 1.89E-05 NM_0045 Homo sapiens receptor 60 tyrosine kinase-like orphan receptor 2 (ROR2), mRNA.
/PROD=receptor tyrosine kinase-like orphan receptor 2 /FL=gb:M97639.1 gb:NM_004560.1 -0.60671 3.220921 14.2 Up 2.49E-03 NM 0004 Homo sapiens

58 transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor (TCF2), transcript variant a, mRNA.
/PROD=transcription factor 2, isoform a /FL=gb:NM 000458.1 1.186033 5.004503 14.11 Up 5.86E-05 A1627704 ESTs, Weakly similar to T17346 hypothetical protein DKFZp58601624.1 (H.sapiens) -2.69521 1.121263 14.09 Up 5.32E-05 AF282250 Homo sapiens calneuron 1 (CALN1) mRNA, complete cds.
/PROD=calneuron 1 /FL=gb:AF282250.1 -2.70961 1.095539 13.98 Up 2.03E-02 AK055534 Homo sapiens cDNA
FLJ30972 fis, clone HEART2000492.
-0.65009 3.149996 13.93 Up 2.55E-04 NM_0179 Homo sapiens 31 hypothetical protein FLJ20699 (FLJ20699), mRNA.
/PROD=hypothetical protein FLJ20699 /FL=gb:NM 017931.1 -1.6164 2.173017 13.83 Up 9.97E-03X00452 Human mR-IA for DC
class!l histocompatibility antigen alpha-chain.
/PROD=DC class!i histocompatibility antigenalpha-chain -3.47125 0.312463 13.77 Up 3.91E-02 BF114815 ESTs -2.17973 1.59463 13.68 Up 1.03E-03 BE379542 chromodomain helicase DNA binding protein 3 /FL=gb:U91543.1 -1.95127 1.804379 13.51 Up 3.31E-03 L12468 Homo sapiens aminopeptidase A mRNA, complete cds.
/PROD=aminopeptidase A
/FL=gb:L12468.1 gb:NM 001977.1 gb:L14721.1 0,449933 4.203433 13.49 Up 6.43E-04 Z21533 H.sapiens HEX gene encoding homeobox related protein.
/PROD=homeobox related protein 0.502333 4.255116 13.48 Up 3.46E-04 AF211891 Homo sapiens Mix-like homeobox protein 1 (MILD1) mRNA, complete cds. /PROD=Mix-like homeobox protein 1 /FL=gb:AF211891.1 0.151239 3.88836 13.33 Up 5.61E-05 BE644809 ESTs 0.631332 4.364524 13.3 Up 8.23E-05 A1130705 ESTs, Weakly similar to A46302 P18-associated splicing factor, long form (H.sapiens) DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DENIANDE OU CE BREVETS
= COMPREND PLUS D'UN TOME.

NOTE: Pour les tomes additionels, veillez contacter le Bureau Canadien des Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.

NOTE: For additional volumes please contact the Canadian Patent Office.

Claims

1. A method to expand cells expressing markers characteristic of the definitive endoderm lineage, comprising the steps of: culturing cells expressing markers characteristic under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix.

2. The method of claim 1, wherein the cells expressing markers characteristic of the definitive endoderm lineage are derived from pluripotent cells.

3. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum at a concentration from about 0.2% to about 5%.

4. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing serum at a concentration of about 0.5%.

5. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing activin-A at a concentration from about 50ng/ml to about 100ng/ml.

6. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing activin-A at a concentration of about 100ng/ml.

7. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing a Wnt ligand at a concentration from about 10ng/ml to about 20ng/ml.

8. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing a Wnt ligand at a concentration of about 200ng/ml.

9. The method of claim 8, wherein the Wnt ligand is Wnt-3a.

10. The method of claims 1 or 2, wherein the cells are cultured under hypoxic conditions, on a tissue culture substrate that is not pre-treated with a protein or an extracellular matrix, in medium containing a GSK-3B inhibitor.

11. The method of claim 2, wherein the cells expressing markers characteristic are obtained by:
a. Culturing human embryonic stem cells; and b. Differentiating the human embryonic stem cells into cells expressing markers characteristic of definitive endoderm cells.

12. The method of claim 11, wherein the human embryonic stem cells are treated with a Rho kinase inhibitor.

13. The method of claim 11, wherein the human embryonic stem cells are cultured on an extracellular matrix, prior to differentiating the cells.

14. The method of claim 11, wherein the human embryonic stem cells are cultured on a feeder cell layer.

15. The method of claim 11, wherein the human embryonic stem cells are differentiated on an extracellular matrix.

16. The method of claim 11, wherein the human embryonic stem cells are differentiated on a feeder cell layer.

17. The method of claim 11, wherein the human embryonic stem cells are cultured and differentiated in normoxic conditions.

18. The method of claim 11, wherein the human embryonic stem cells are cultured and differentiated in hypoxic conditions.